

# Precision Medicine for PTSD

The National Center for PTSD  
Fiscal Year 2022 Annual Report



# Contents

- [Acronyms Used in the Text](#) ..... 3
- [From the Executive Director](#) ..... 5
- [Precision Medicine for PTSD: The Big Picture](#) ..... 6
- [Major Research Initiatives in 2022](#)..... 12
- [Promoting PTSD Education: Training, Dissemination, and Communication](#)..... 17
- [About the National Center for PTSD](#) ..... 22
- [Leadership in 2022](#) ..... 23
- [Appendix A: Acronyms Used in Appendix B](#) ..... 24
- [Appendix B: Research Narratives by Division](#)..... 27
- [Appendix C: Fiscal Year 2022 Funding](#) ..... 45
- [Appendix D: Publications](#) ..... 57
- [Appendix E: Publications in Press](#)..... 85
- [Appendix F: Scientific Presentations by National Center Staff](#) ..... 99
- [Appendix G: Education Presentations by National Center Staff](#) ..... 108
- [Appendix H: Editorial Board Activities](#)..... 113

# Acronyms Used in the Text

<b>Abbreviation</b>	<b>Definition</b>
BRIDGES	Building Re-Integration from Dreams and Goals to Execution and Success
CAPS-5	Clinician Administered PTSD Scale for DSM-5
CBT	Cognitive Behavioral Therapy
CDC	Centers for Disease Control and Prevention
CHIIPS	Center for Harmonizing and Improving Interventions to Prevent Suicide
CPT	Cognitive Processing Therapy
DNA	Deoxyribonucleic Acid
DoD	Department of Defense
DSM-5	Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
EEG	Electroencephalogram
EHR	Electronic Health Record
EMDR	Eye Movement Desensitization and Reprocessing
FY	Fiscal Year
IPV	Intimate Partner Violence
MD	Medical Doctor
MOUD	Medication for Opioid Use Disorder
MRI	Magnetic Resonance Imaging
MST	Military Sexual Trauma
MVP	Million Veteran Program
NHRVS	National Health and Resilience in Veterans Study
OUD	Opioid Use Disorder
PAI	Personalized Advantage Index
PE	Prolonged Exposure
PET	Positron Emission Tomography
TRACTS	Translational Research Center for Traumatic Brain Injury and Stress Disorders
PTSD-Repository	PTSD Trials Standardized Database
RISE	Recovering from IPV through Strength and Empowerment

**Abbreviation**

**Definition**

SP-CRC

Suicide Prevention Clinical Resource Center

STRONG STAR

South Texas Research Organizational Network Guiding Studies on Trauma and Resilience

TIC

Tech into Care

TMS

Transcranial Magnetic Stimulation

VA

Department of Veterans Affairs

VHA

Veterans Health Administration

VISN

Veterans Integrated Service Network

WET

Written Exposure Therapy

# From the Executive Director

About 80% of Veterans make dramatic improvements with the treatments available today. But what if we could better that number? That is the goal of Precision Medicine for the treatment of PTSD—finding the right treatment for the right individual at the right time, to improve treatment outcomes for all patients.

While maintaining our work across operational priorities, from biomarkers to implementation, the NCPTSD elevated its interest in Precision Medicine for PTSD. Our current work establishes the building blocks of a research program to advance knowledge about a Precision Medicine framework for treating PTSD. The initiative is no doubt a challenging endeavor, but there is an immense opportunity to improve clinical outcomes for all patients. You can read more about our work on page 6.

In parallel, we continued our focus on equity and inclusivity in research, education, and work culture. We have created Spanish versions of web pages and podcasts, completed research exploring disparities and differences in VA mental health care, and have many other ongoing education, research, and work culture efforts to ensure that NCPTSD's work is equitable and inclusive. This work will surely continue into 2023 and beyond.

I'd also like to take this opportunity to formally thank Dr. Matthew Friedman, founding Executive Director of the National Center for PTSD, for his tireless and generous work. Recognized as a world leader in clinical research and treatment of PTSD, Matt originally retired from the NCPTSD in 2015, though he continued working with us part time until March of 2022. I can't imagine a National Center without Matt, but he taught us to persevere, and persevere we will. Thank you, Matt, for everything you've done over the years. Your legacy will continue, I'm sure.

In other news, I'm sad to report that we lost a dear member of the NCPTSD family, Dr. Steve Southwick, one of the world's leading experts on psychological traumatization and human resilience. A longtime senior investigator with NCPTSD, Steve passed away in April 2022. His humor, kindness, and selflessness will be greatly missed by all of us at NCPTSD.

As always, we've learned a lot this year. And we've taken that knowledge and put it to work successfully, treating the thousands of Veterans who count on us to provide them relief from the effects of PTSD.



**Paula P. Schnurr, PhD**

**Paula P. Schnurr, PhD**  
Executive Director

# Precision Medicine for PTSD: The Big Picture

Since its establishment in 1989, the National Center for PTSD has been at the forefront of research and education on PTSD treatment, and on underlying psychological and biological factors of PTSD. In just over three decades, effective treatments for PTSD have been developed and disseminated within and outside of VA. This progress is remarkable, but there is still room to improve PTSD treatment outcomes. In pursuit of this goal, the National Center is turning toward a new goal: Precision Medicine for PTSD.

John Krystal, MD, Director of NCPTSD’s Clinical Neurosciences Division, explains Precision Medicine: “Precision Medicine involves the identification of predictive markers of any kind—molecular, brain imaging, biochemical, clinical, cognitive markers—that can inform the types of treatments that are likely to work most effectively for groups of patients.” Simply stated, it’s finding the right treatment for the right individual at the right time.

## Top 3 Things to Know about Precision Medicine for PTSD

1. There are effective treatments for PTSD, but there is room for improvement.
2. The goal of Precision Medicine is to get the right treatment, to the right patient, at the right time.
3. Precision Medicine for PTSD will be a long-term endeavor, requiring many researchers from across the spectrum of research—from genetics to clinical research to digital specialists.

The National Center for PTSD is taking a particular interest in Precision Medicine for PTSD because some people aren’t responding—or aren’t responding enough—to available treatments, says Paula Schnurr, PhD, Executive Director of the National Center. “There’s a need to improve treatment outcomes for PTSD. We need to make people better, and we need to make them well. Precision Medicine is a strategy that can help us do that.”

“We know a fair amount about predictors—how likely a patient is to respond to treatment, regardless of the treatment,” Schnurr continues, “but we know close to nothing about what treatment is best for any given individual.”

To illustrate, let’s say a single mother with three children and two jobs gets assigned a PTSD treatment that involves daily homework. That treatment might not be effective for her, because doing homework takes time that the patient doesn’t have. After evaluating her social circumstances and preferences, we might suggest a treatment that does not require homework to be effective. This process is called shared decision making (see sidebar, page 7).

But, in the future, when we know more about how the effective treatments for PTSD

work, we might be able to test for certain physiologic or genetic markers, or understand that certain symptoms improve after specific treatments, or know that women do particularly well in a certain treatment. A clinician could then use this information to decide which PTSD treatment is right for an individual patient.



## What Treatments Do We Have Now?

Individual, manualized trauma-focused psychotherapy is recommended as the first-line treatment for PTSD by the VA/DoD. Trauma-focused psychotherapy means that the details of the traumatic event are a focus of the therapy. The most effective trauma-focused psychotherapies for PTSD include Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR). There is also evidence to support the use of medications such as paroxetine, sertraline, and venlafaxine for PTSD, as well as select non-trauma-focused psychotherapy.

The way in which a patient is matched with a treatment varies. In some cases, it has to do with what is available—in other words, what treatments a provider or clinic offers. In other cases, the provider may offer the treatment that they think is best for the patient. In the ideal case, shared decision making occurs. Sonya Norman, PhD, Director of the PTSD Consultation Program, explains.

“We’ll educate the patient about the different effective treatment options and have an informed discussion about what makes sense to them,” she said.

That includes understanding the patient’s values, preferences, and goals, as well as what works with the individual’s schedule. Shared decision making helps the patient invest in their own treatment. The PTSD Decision Aid, developed by the National Center for PTSD, is a tool to help patients understand evidence-based PTSD treatments, as well as their own priorities about treatment.

No matter how we get there, people being treated for PTSD deserve improved outcomes. With our current best treatments, more than half of people improve to the point where they are no longer diagnosed with PTSD, Norman says. “They feel better, their symptoms are less distressing to them, they’re doing better in their job, and they’re having healthy relationships. Treatment sets them on a path to a better quality of life.”



The [PTSD Decision Aid](#) is a tool that helps patients understand evidence-based PTSD treatments, and to work with their provider to choose the best option for them.

## Where We Are Now

To date, there have been many studies done that aim to understand what treatments work best for whom—but they’re relatively small and not necessarily connected. But that’s changing, thanks to the National Center and its diverse group of investigators.

Rather than create more and more interventions, the focus needs to be on how to improve upon and tailor what already exists to make those interventions more effective. Schnurr says the National Center’s main research priority is to design trials aimed at assessing differential treatment response. Its secondary priority is to reanalyze existing data. “Creating a large dataset will allow more sophisticated analyses,” she said. Right now, there isn’t sufficient data to guide individualized treatment selection,

which is one of the factors that makes Precision Medicine such an important topic in terms of PTSD.

Brian Marx, PhD, Deputy Director of the Behavioral Science Division, says the National Center is focused on exploring which studies have been done in Precision Medicine for PTSD specifically, then identifying gaps in the findings and a plan to address those gaps.

“We are actively figuring out what the agenda is, where we need to go from here, what studies need to be done, how we pool our resources, and how we create datasets that help us move the field forward in a revolutionary kind of way,” he said.

Despite these promising building blocks, developing Precision Medicine for PTSD does come with challenges.

## Precision Medicine Has Its Challenges

### Precision Medicine for psychiatric care is still in its infancy

PTSD (and other mental health disorders) is not like cancer; there's no biopsy to confirm its presence. "A lot of these symptoms are variations of a normal response to experiences," said Paul Holtzheimer, MD, Deputy Director for Research. "It's normal to have certain biological and psychological reactions. It's normal to feel grief when somebody dies. What's abnormal is when it doesn't go away."

Going forward, an accurate assessment of PTSD will be key to understanding which treatments are effective for which patients. PTSD is currently best diagnosed through structured clinical interviews such as the [Clinician Administered PTSD Scale for DSM-5 \(CAPS-5\)](#), which relies on clinician judgment. The CAPS-5 is an effective diagnostic tool, but the field is seeking out more biologic signatures of PTSD.



[A training tool developed by NCPTSD uses a "virtual" patient to train clinicians and researchers to administer the CAPS-5.](#)

treatments are likely to work best for an individual patient means that more patients will receive effective PTSD treatment and relief from their symptoms.

The field of Precision Medicine and PTSD is so new that researchers would admit that they don't know a lot about it. But that's changing.

"The assessment, and how we actually assay these various components, whether they're chemicals, brain waves, whatever, has to improve tremendously to get a more meaningful signal," leading to more accurate diagnosis, said Holtzheimer.

These challenges mean that Precision Medicine for PTSD is a complicated endeavor. However, the potential eventual gains are great. Having a better understanding of which

### Big data

Precision Medicine almost necessarily depends on "big data"—having large datasets that allow investigators to understand and compare how differences in clinical, biological, and social characteristics are related to treatment. One area of focus is genetics. The National Center's Clinical Neurosciences Division has created a unique resource for the field of PTSD, where there is large-scale gene discovery from genetics research. This research, led by Joel Gelernter, MD, involves geneticists based at the National Center and affiliated faculty within the Division.

"This gene identification process is really important, as there are genes related to the vulnerability for developing PTSD or related to symptom profiles once it develops," Krystal said. In fact, different kinds of genetic markers have emerged from this research.

NCPTSD investigators are involved with several large-scale collaborations designed to understand the genetic markers of PTSD and other illnesses. [The Million Veteran Program \(MVP\)](#), a national research program to learn how genes, lifestyle, and military exposures affect health and illness, is expressly focused on Precision Medicine. The MVP aims to collect DNA samples from a million Veterans, and is banking those samples and combining them with data gathered from questionnaires and medical records of participants in the MVP with the hope that this data will lead to important discoveries, like how to best treat various kinds of cancer among Veterans. For example, not everyone with breast cancer requires the same treatment or level of treatment. The hope is that the collection of all these DNA samples will lead to discoveries that might lead to better medications and interventions. National Center investigators Gelernter, Robert Pietrzak, PhD, and Mark Logue, PhD, have all contributed to research helping to understand what genetic markers contribute to PTSD risk.

Genetics research is on the cutting edge of Precision Medicine for other disorders and is informing ongoing PTSD work at the Clinical Neurosciences Division.

"We'll take the genes we identify in the postmortem brain tissue of PTSD patients and from the genetics we identified into genetically engineered animals so we can try to understand how these gene changes affect brain circuit function and behavior," Krystal said. These research paradigms can then be used to test novel therapeutics in the animals and identify potential new treatments.




“We can grow neurons derived from people with PTSD and grow these neurons from stem cells, which we can collect in the blood from people with PTSD,” he said. This is just one of the dozens of studies that are currently taking place at the National Center.

Big data is not limited to genetic studies. Schnurr recently completed a study of over 900 Veterans with PTSD, with the goal of better understanding which individuals might be best served by [Cognitive Processing Therapy \(CPT\)](#) and which would be better served by [Prolonged Exposure \(PE\)](#). Those analyses, which utilize a novel analytic technique called the Personalized Advantage Index (PAI), are underway. Built on prior work done by Schnurr and Shannon Wiltsey Stirman, PhD, the PAI is a prognostic index that can shed light on which patients are likely to do better in one treatment versus another.

Often, very large sample sizes are needed in order to have something significant to say. Even the largest psychotherapy trials to date (such as Schnurr’s CPT vs. PE trial) are small, relative to what is needed to perform the kind of analyses needed for Precision Medicine.

Researchers believe big data will help them learn how to choose and tailor treatments for people with PTSD. “We know that people who are more symptomatic may



**The PTSD Brain Bank collects postmortem brain tissue from PTSD patients, and facilitates research that helps understand the genetic and molecular underpinnings of PTSD.**

impact the outcome of treatment, but we don’t know anything about how to match people to the various treatments that are available,” Marx said.

### National PTSD Brain Bank

One approach to understanding how treatments work for PTSD and finding new treatment targets involves understanding how genes (and the proteins they code for) are different in people with PTSD. Under the leadership of Dr. Holtzheimer, the National Center collaborates with academic partners to operate the National PTSD Brain Bank, which is doing this type of research. Last year, the National Center published a groundbreaking transcriptomic analysis of PTSD (i.e., a


study of which genes are expressed in people with PTSD), led by Matthew Girgenti, PhD. This analysis was extremely important in guiding work within the Center, as there were signs that the genes implicated in the risk for PTSD were playing out in changes in gene expression found in the postmortem brain tissue of people who had been diagnosed with PTSD. In addition, work by Girgenti’s group showed differences in the genetics of men and women with PTSD and depression, providing a possible avenue for future Precision Medicine efforts.

The analysis also showed, says Krystal, that there’s only limited overlap between the gene expression pattern in postmortem brain tissue of people with major depression and people with PTSD. There were distinct molecular changes in the brain associated with major depression and with PTSD, also with only limited overlap. So, although PTSD and depression commonly occur together and share many symptoms, they appear to be biologically distinct disorders.

### The power of digital

Precision Medicine for PTSD isn’t limited to large-scale genetic studies like MVP or to psychotherapy trials. Thanks to more than a dozen [mobile apps developed by the National Center](#), we have digital mental health interventions that can be responsive to where the patient is.

“Thanks to smartphones and wearables, as well as the internet, we could gather moment-to-moment data that can be used to discover patient characteristics,” said Eric Kuhn, PhD, investigator at NCPTSD’s Dissemination and Training Division. “We can develop dynamic, personalized interventions in the real world, where people are in need. We can actually be out there in the hands of our patients with powerful interventions that are truly personalized to what that person is experiencing in that moment and what they need.”



**PTSD Coach, and other mobile apps developed by NCPTSD, can be used to track symptoms and handle stress symptoms in the moment.**

For example, the PTSD Coach app has tools for users to screen for PTSD symptoms, learn to handle stress symptoms in the moment, and connect them with more support as needed. These apps provide a low-resource way to provide care to patients who may benefit from a lighter touch. Digital mental health has the potential to vastly expand the potential reach of evidence-based care for PTSD.

“We do not have the resources to deal with everybody in the same way—nor should we,” Marx said. “Some people need more assistance, more services, and more intensive care than others. It makes sense to get the services to the people that need those services—the care they need in order to address their specific concerns. It’s what confronts mental health in general.”

## Looking to the Future

Precision Medicine clearly has a lot of promise, but the field of Precision Medicine for PTSD is still at an early stage. “A lot will be determined by what we learn in the present,” Marx said. And while the National Center doesn’t yet have the data itself, “we are doing a really good job in terms of figuring out how to pool datasets together, create a huge data repository, and produce a set of common data elements that all the investigators in the Center can use in order to provide the opportunity to collect the necessary data,” he said.

## Designing new studies

Investigators are working on new studies that help predict up front which patients can benefit from which

treatments. Dr. Holtzheimer, for instance, is currently working on two complementary studies that use imaging to try to identify brain activity patterns that predict who will respond to transcranial magnetic stimulation (TMS) for patients with depression, many of whom also have PTSD.


The National Center is leveraging a VA-wide program that helps set up TMS clinics that make it possible to collect multiple sessions of EEG and MRI, at baseline, then after several treatments, and at the end point. This allows investigators to look at early changes in brain activity that may predict eventual response.

“This is related to Precision Medicine because the goal is to identify actual biological predictors for who will respond to relatively novel, niche treatment that’s different than medication and different than psychotherapy,” Holtzheimer said.

## Positioned for success

A focused mission, a multidisciplinary research program, organization around translation from science to clinical practice, strong partnerships within and beyond the VA, and unique resources including the National PTSD Brain Bank all uniquely position the National Center to contribute to the investigation of Precision Medicine approaches for the treatment of PTSD.

The National Center has investigators focused on treatment of PTSD as well as on the development of new or better treatments, whether they be biological, psychological, or other approaches. “We have an infrastructure in place that will let us look for potential markers—biological, clinical, and sociological,” Holtzheimer said.



**Research at NCPSTD spans from basic bench science to applied clinical and implementation science, and everything in between.**



**Effective PTSD treatment can look different for different patients at different times.**

“We’re the world leader in PTSD and the science of PTSD,” Kuhn said. “We have an incredibly talented, world-class workforce, sustained resources, multidisciplinary research programs—all divisions are working on this. We’re in the game of trying to translate science into practice. We have really strong academic partners. We’re uniquely positioned to advance this field. I think we’ve demonstrated as a Center that we can rise to the challenges.”

The National Center is committed to learning how to best use Precision Medicine for PTSD. “The desire to be able to predict up front who needs what, and which patient is more likely to benefit from a certain combination of individual treatments,” said Holtzheimer, “that’s our ultimate goal.”

---

## Getting help

---

If you are experiencing symptoms of PTSD, here is a list of resources that may be helpful:

<https://www.ptsd.va.gov/>

[https://www.ptsd.va.gov/understand\\_tx/tx\\_basics.asp](https://www.ptsd.va.gov/understand_tx/tx_basics.asp)

<https://www.veteranscrisisline.net/>

---

## Where to find us

---

Keep in touch with the National Center for PTSD on our [website](#) and social media:

[https://twitter.com/VA\\_PTSD\\_Info](https://twitter.com/VA_PTSD_Info)

<https://www.facebook.com/VAPTSD/>

<https://www.instagram.com/stepupforptsd/>

# Major Research Initiatives in 2022

National Center researchers work across the scientific spectrum, from examining the genetic and molecular underpinnings of PTSD to system-level implementation work. Fiscal year (FY) 2022 brought new advances across this spectrum and in each of NCPTSD’s [operational priorities](#). In addition, much of the work detailed below represents the base of the pyramid that will inform Precision Medicine for PTSD—understanding which treatments work best for which patients.

During FY 2022, researchers at the National Center led 158 funded studies, including research undertaken in collaboration with partner organizations in the government, academic institutions, and international agencies. Investigators published 590 peer-reviewed journal articles, book chapters, and books (see appendices C–G for a full list of grants, publications, and scientific presentations in FY 2022).


The National Center’s research and educational activities are driven by five operational priorities: Biomarkers, Treatment, Care Delivery, Implementation, and PTSD and Suicide. The following narrative highlights some of the FY 2022 research initiatives undertaken to address these five operational priorities. (Appendix C contains a more comprehensive listing of research projects conducted by investigators at each of the National Center’s six divisions.)

## Biomarkers

Work taking place under the Biomarkers Operational Priority aims to establish reliable and valid biomarkers to aid in predicting who develops PTSD, diagnosing PTSD, predicting treatment outcome, and measuring treatment response. Neurogenomics and neuroimaging guide biomarker development, including molecular, biochemical, structural, and functional approaches to better understand the sequence of pathological events associated with posttraumatic stress and PTSD treatment.

The [VA National PTSD Brain Bank](#) primarily studies gene expression in postmortem brain tissue of PTSD and major depressive disorder donors; this work aims to identify


biomarkers and potential novel pharmacologic targets. This year, researchers evaluated the role of orexigenic neuropeptides in modulating negative affective states, specifically in the context of trauma exposure. One study employed a gene co-expression analysis strategy to uncover PTSD-specific networks containing appetitive neuropeptides. Three PTSD-associated modules containing appetitive peptides *NPY*, *GHRL*, and *NPY2R* were uncovered, and differences in biological sex and body mass index were discovered.



The VA PTSD Brain Bank facilitates research that helps understand how the brains of people with PTSD are different.

Neuroimaging is another pillar of NCPTSD’s biomarkers work—using functional and structural magnetic resonance imaging, spectroscopy, and PET to understand the neural circuitry and activity involved in PTSD. In collaboration with the [Translational Research Center for Traumatic Brain Injury and Stress Disorders \(TRACTS\)](#), ongoing studies suggest distinct biotypes of PTSD characterized

by neurocognitive and network-based connectivity abnormalities, which may be associated with greater chronicity of PTSD. Center researchers have also used magnetic resonance spectroscopy to examine neurodegeneration and neuroinflammation. Novel work in an animal model of PTSD shows that the glutamatergic system (measured with PET technology) is altered as a function of stress—specifically, animals who developed PTSD symptoms showed changes in the glutamatergic system, whereas resilient animals did not, addressing a knowledge gap in the PTSD literature regarding whether observed brain alterations in patients are a consequence of or predisposition to the disorder.



In addition to research to understand treatment effectiveness, NCPTSD investigators also research how to communicate to patients and clinicians about effective research. Work published in 2022 explored how best to communicate the effectiveness of different PTSD treatments.

NCPTSD researchers also contribute to several large-scale genomic research programs. Data from the [Million Veteran Program \(MVP\)](#) have been paired with data from survey studies that provide longitudinal information to provide rich data on the biomarkers for PTSD. Using data from the [National Health and Resilience in Veterans Study \(NHRVS\)](#), which surveyed a nationally representative sample of 4,000 U.S. Veterans in the MVP, investigators found that polygenic risk scores for PTSD were associated with greater severity of PTSD symptoms. NHRVS data also showed that PTSD was linked to a two-fold greater likelihood of accelerated epigenetic aging.

Biomarkers can also be leveraged to better understand the mechanisms of effective PTSD treatments. A recently launched study is examining whether Prolonged Exposure (PE) is more efficacious during the morning hours when endogenous cortisol levels are at their highest, compared

with later in the day when cortisol levels are relatively low. Another ongoing study uses electroencephalogram (EEG) markers to predict response to transcranial magnetic stimulation treatment in depression and PTSD. Also, researchers are using genomic data to establish an analytic biomarker pipeline to predict ketamine treatment response via EEG patterns.

## Treatment Engagement, Efficiency, and Effectiveness

Several lines of work at the Center aim to increase the efficiency and effectiveness of existing PTSD treatments, and to develop strategies to enhance engagement in treatment. Several large-scale studies focus on the real-world effectiveness of PTSD treatments. CSP #591, conducted at 17 VA Medical Centers, published results showing that PE and Cognitive Processing Therapy (CPT) were both effective for PTSD in Veterans. Ongoing secondary analyses are examining which patients do best in PE and in CPT. CSP #2016 is being conducted at 34 VA Medical Centers and compares three commonly prescribed pharmacotherapies for insomnia: trazodone, gabapentin, and eszopiclone.

Other recently published work using large-scale medical record data, in conjunction with the Northeast Program Evaluation Center, has provided information about the relative effectiveness of PTSD treatments and treatment response patterns in VA PTSD specialty and residential care. This body of work supports existing evidence that first-line psychotherapies for PTSD are generally effective for Veterans, but also shows that Black Veterans have (on average) worse outcomes in VA specialty care than White Veterans.

Multiple lines of research examine ways to make effective treatment more efficient—e.g., delivered in fewer sessions or over less time. Written Exposure Therapy (WET), developed by NCPTSD investigators, is a five-session exposure-based treatment for PTSD that has been shown to be highly effective with non-Veteran patients. A recent DoD-funded study found that WET was non-inferior to CPT in the treatment of PTSD in service members. An ongoing VA-funded study is directly comparing the treatment efficacies of WET and PE among Veterans. Two recent studies examine the effectiveness of massed or intensive versions of PE and CPT. Additional efforts to improve the effectiveness of CPT include an ongoing, large-scale

study designed to test the impact of a case formulation enhanced version of CPT on treatment adherence, functioning, and PTSD symptoms.

Digital technologies, including telehealth, mobile apps, text messaging, and websites, can increase the engagement of effective treatment and supportive care for PTSD and commonly comorbid conditions. One study will compare an asynchronous messaging-based version of CPT for PTSD to messaging-based therapy as usual. Center investigators are also involved in trials to understand the efficacy of mobile mental health apps. Also, a series of naturalistic studies are examining how users engage with some of our most widely used apps: [Mindfulness Coach](#), [COVID Coach](#), [PTSD Coach](#), AIMS for Anger Management, and Beyond MST.

National Center research also targets the effectiveness of existing treatments by augmenting treatment with medication or psychotherapy. For example, studies are investigating ketamine plus PE, Cognitive Behavioral Therapy (CBT) for Insomnia, and CPT for Veterans with comorbid PTSD and insomnia, and buprenorphine plus CPT for patients diagnosed with PTSD and opiate use disorder.

## Care Delivery, Models of Care, and System Factors


The Center continues to engage in research to ensure that Veterans with PTSD nationwide receive access to VA mental health care. An ongoing VA-funded study is using a mixed methods approach to understand which Veterans who screen positive for PTSD in VA primary care clinics do not access follow-up VA mental health care. Results of this project, which leverages the Veterans Health Administration (VHA) Electronic Health Record, can inform the development and implementation of targeted access interventions nationally.

Survey data indicate that Veterans with PTSD are interested in family involvement in their care, but investigators have found that the number of Veterans with PTSD who receive a family-inclusive visit during VA care is relatively small. Investigators recently published outcomes from a systems-focused project examining factors that contribute to or inhibit family-inclusive care. Many providers described incorporating families into Veterans' care to provide psychoeducation, enhance the

Veteran's sense of social support and connection, and facilitate safety planning.

Additional activities include improving access to gold-standard medication for opioid use disorder (MOUD) and to counseling among VHA patients with opioid (OUD) and other co-occurring psychiatric disorders (e.g., PTSD). Ongoing analyses of VHA EHR and Commercial and Medicaid claims data highlight key gender and racial disparities regarding treatment utilization and health outcomes (e.g., opioid overdose), but also positive effects of receiving MOUD via telehealth and expansion of MOUD coverage among some existing patients, and other successes following VHA's swift response during the COVID-19 pandemic.

One area of work that bridges systems of care and implementation science is Modeling to Learn. This initiative trains frontline staff in participatory systems dynamics modeling (a collaborative quality improvement approach in which stakeholders identify specific system problems, use computer modeling to compare the likely outcomes of potential solutions, and select an optimal solution to implement). The third major release, Modeling to Learn 3.0, was distributed nationally in 2022. Two randomized trials are underway, testing whether Modeling to Learn is superior to other quality improvement approaches in increasing the number of VA patients who receive evidence-based psychotherapy and pharmacotherapy for mental and addictive disorders.



Apps like Beyond MST are being evaluated by NCPTSD researchers to understand how they are used, and how they can be effective for Veterans and others.

## Implementation

Facilitating implementation of best practices in PTSD care and studying barriers and facilitators of best practices is another Operational Priority. One study is underway evaluating how to simplify assessment of the quality of delivery of CBT for PTSD, depression, and anxiety disorders. A second study is comparing two different strategies intended to enhance and sustain the delivery of CPT; one strategy emphasizes fidelity to the protocol through expert consultation and online resources, and the



The Modeling to Learn dashboard is a quality improvement approach that provides feedback to clinics on potential solutions to VA clinic system problems.

is examining real world treatment outcomes among Veterans treated by VA mental health providers who are trained to deliver WET. Center investigators are also involved in studies comparing WET with medication and collaborative care to treat PTSD in both VA and non-VA primary care clinics, and are studying the effectiveness of different virtual training models and implementation support approaches for therapist delivery of treatment in WET and PE. Another study compares methods of assessing treatment quality and fidelity, two important implementation outcomes for CBTs, including CPT, and is finding that more scalable models of fidelity assessment have good agreement with the more labor-intensive observer method of assessing fidelity.

other uses continuous quality improvement strategies to improve fit and to address barriers to treatment delivery. Another trial on eight U.S. military bases tested whether a tailored approach that includes a guide for matching solutions to local problems and support from an external facilitator increases the use of PE more than does standard provider training alone.

Following the WET treatment development efforts detailed above, an implementation study

The Center also facilitates implementation efforts associated with Intimate Partner Violence (IPV) screening and intervention. Investigators are evaluating a national rollout of IPV screening programs within women's health primary care clinics to determine implementation outcomes and the clinical effectiveness of IPV screening programs. Findings from this trial demonstrated that a blended implementation facilitation strategy (an operations-funded external facilitator working for six months with a facility-funded internal facilitator) nearly tripled the reach of IPV screening programs in primary care compared with implementation as usual in VA care, resulting in a two-fold increase in IPV detection rates among patients. Researchers also published findings from a randomized clinical trial demonstrating the effectiveness of a brief counseling intervention, Recovering from IPV through Strength and Empowerment (RISE), for women who are experiencing violence in their intimate relationships. A collaboration with the national VHA IPV Assistance Program resulted in a rollout of RISE with IPV Assistance Program Coordinators across the country for implementation among Veterans of all gender identities. Published findings from an initial program evaluation support the effectiveness of RISE in routine VA care.

## PTSD and Suicide

Research under the PTSD and Suicide Operational Priority aims to investigate the relationship between PTSD and suicide and develop strategies to predict and prevent suicide among individuals with PTSD. To support our efforts, BSD investigators received funding for a new suicide prevention clinical resource center (SP-CRC). This SP-CRC will serve suicide prevention investigators by providing highly critical research resources to facilitate programmatic and scientific needs. The mission of the new SP-CRC, called the Center for Harmonizing and Improving Interventions to Prevent Suicide (CHIIPS), will be to advance a Precision Medicine approach to suicide prevention research.

Several lines of ongoing work examine risk factors for suicide. Center researchers have identified functional connectivity markers of suicide attempt history, compared categorical and dimensional approaches to understanding the association between PTSD and future suicide attempts, and identified distinct trajectories of suicidal ideation following psychiatric hospitalization discharge that were differentially related to future suicide attempts.

Recent research has identified insomnia as a risk factor for suicide, using newly developed innovative methods to accurately monitor sleep without requiring Veterans to come to a clinic-based sleep lab. A secondary analysis of data from [The Veterans Metrics Initiative Study](#), a longitudinal study of recently discharged male and female Veterans, identified post-separation life circumstances (e.g., vocation, finances, and social relationships) as predictors of change in suicidal ideation during the first three years after leaving military service.

Other research explores interventions to reduce the risk of suicide. In collaboration with the STRONG STAR Consortium, Center investigators have completed a study in which they tested a modified version of WET with a sample of Army soldiers and Veterans with PTSD symptoms who were hospitalized for suicide risk. A related study was recently funded to evaluate the efficacy of WET for Suicide Prevention (WET-SP) in reducing the incidence and severity of self-injurious thoughts and behaviors. Another project will be testing the feasibility and acceptability of Brief Cognitive Behavioral Therapy for suicide prevention in a sample of Veterans hospitalized for suicide risk. Center researchers are also investigating the use of medications to prevent suicide among individuals with PTSD. This work includes several projects that evaluate the anti-suicidal properties of ketamine in both treatment-resistant PTSD and depression.

Other research examines the prevalence of suicidal thoughts and behavior. Several studies using data from the 2019–2020 NHRVS wave examined suicidality and



**National Center researchers work to understand how best to implement effective treatments into real work settings.**

posttraumatic growth in Veterans. Investigators found that younger age, PTSD, depression, and adverse childhood experiences were the strongest correlates of suicidal thoughts and behaviors. NHRVS researchers also found that greater posttraumatic growth was associated with a 40% reduced likelihood of contemplating suicide, which suggests that interventions to help bolster posttraumatic growth may have utility in suicide prevention and treatment efforts.




# Promoting PTSD Education: Training, Dissemination, and Communication

The National Center for PTSD’s educational mission is to improve PTSD outcomes by developing and disseminating authoritative, culturally competent, equity-informed programs and information on PTSD and related conditions. Our stakeholders, including Veterans and other trauma survivors, the professionals who care for them, and the family and friends in their personal orbit, rely on NCPTSD to create products and programs that are rooted in science. From web-based resources to apps and training, our offerings innovate as they inform.

## PTSD Awareness and Public Education

This year’s PTSD Awareness Month campaign was our most ambitious effort yet. As in years past, we offered the public, providers, and medical centers an array of [resources](#) that could help them spread the word that PTSD treatment is available and that it works. This year, however, we also promoted June 27 as PTSD Screening Day. Thanks to an [interactive version of the Primary Care PTSD Screen](#) that we hosted on our website, Veterans and others who had experienced trauma could quickly learn whether symptoms that they have been experiencing following a trauma could be PTSD. Once they completed the screen, users received information about whether



PTSD Screening Day is part of June’s PTSD Awareness Month.

and more than 380,000 people viewed PTSD Screening Day promotions from agencies and organizations that partnered with NCPTSD. Thousands more participated in our Step Up for PTSD Awareness Virtual Walk, signed a

pledge to help raise PTSD awareness, or attended one of 20 PTSD Awareness Month presentations. In the month of June, 3.1 million people watched or listened to media interviews by National Center for PTSD experts that aired nationwide.

Another cornerstone of our awareness efforts is the [AboutFace website](#). This video gallery features hundreds of interviews with Veterans, family members, and clinicians delivering the message that PTSD treatment can turn lives around.

This year we continued an extensive redesign of the site that will allow visitors to access the content through a guided experience. With the continued ability to explore videos with robust search and filtering functions, plus a new, clearer path through the site, visitors will have more options for learning about PTSD treatment and experiencing compelling stories. We also continued to expand our featured topic pages on the site, developing the page “Race, Culture, and PTSD,” which focuses on how Veterans’ experiences of identity, bias, and discrimination intersect with trauma and PTSD. The revised site launches in FY 2023.

This year we continued an extensive redesign of the site that will allow visitors to access the content through a guided experience. With the continued ability to explore videos with robust search and filtering functions, plus a new, clearer path through the site, visitors will have more options for learning about PTSD treatment and experiencing compelling stories. We also continued to expand our featured topic pages on the site, developing the page “Race, Culture, and PTSD,” which focuses on how Veterans’ experiences of identity, bias, and discrimination intersect with trauma and PTSD. The revised site launches in FY 2023.

New content on the AboutFace website highlights the connection between race and culture and PTSD.




New content on the AboutFace website highlights the connection between race and culture and PTSD.



The *PTSD Bytes* podcast features innovative ways that technology is being used to support people with PTSD.

For those who prefer their information on PTSD in bite-sized portions, the Dissemination and Training Division’s Tech into Care initiative (see Support for Providers in the Field, below) has developed a podcast called *PTSD Bytes*. Clocking in at under 15 minutes, each episode of *PTSD Bytes* features an expert or innovator discussing how technology can support people with PTSD or related mental health concerns. Topics have included PTSD and emotions, specific treatments, military sexual trauma (MST),

and relationships. New episodes are released twice a month. Another podcast, *Talking Later: Veterans’ Stories of Late-Life PTSD*, focuses on recovery, resilience, and meaning-making in older Veterans who are grappling with PTSD in late life.




Hear about older Veterans’ experiences with recovery, resilience, and PTSD in the *Talking Later* podcast.

Each episode starts with a Veteran’s life story, told in their own words, followed by discussion of what the story can teach listeners about late-life PTSD and related experiences. This podcast was developed by researchers at the Behavioral Science Division and the New England Geriatric Research Education and Clinical Center.

The National Center for PTSD website continues to be perhaps our most important vehicle for information dissemination, with 6.5 million visits to the site in FY 2022. For the most part, new and extensively revised articles posted on the site for the public focused on evidence-based treatments—including an article on [recognizing good PTSD care](#)—and helping family members whose loved ones need or are in PTSD treatment. We also created new articles on coping with current events, including the [war in Ukraine](#) and [school shootings](#).

Staff at the Executive Division began laying the groundwork for a revision of our popular resource, the PTSD Treatment Decision Aid. Originally created in 2015 and updated two years later to reflect the 2017 VA/DoD Clinical Practice Guideline (CPG), the [PTSD Treatment Decision Aid](#) is an online resource that educates users on their PTSD treatment options and guides them through the process of making informed PTSD treatment decisions.

Both Veterans and civilians can use the Decision Aid on their own, with loved ones, or with their providers as part of a shared decision-making process.



The PTSD Decision Aid, with new content scheduled for FY 2024, can help educate Veterans and civilians about their PTSD treatment options.

The next revision of the website will be mobile-friendly and will incorporate new features that reflect updated treatment recommendations based on the 2023 CPG and changes in online technology. Redesign work will begin in earnest at the tail end of FY 2023.

## Support for Providers in the Field

For more than 10 years, the [PTSD Consultation Program](#), a program of NCPTSD’s Executive Division, has supported providers who treat Veterans with PTSD. Whether they



The PTSD Consultation Program provides expert consultation to any provider treating a Veteran with PTSD.

are experienced clinicians well-versed in evidence-based treatment, new providers who are just beginning to serve Veterans, or somewhere in between, any medical or mental

health professional can contact the PTSD Consultation Program for consultation on issues relating to care for Veterans with PTSD. This year, consultants responded to more than 2,100 requests on subjects as varied as disaster response, program development, diagnosis, and

medication. In addition to the tailored consultation it provides on demand, the PTSD Consultation Program also distributes a [monthly newsletter](#) that features articles and links for providers. The program also continued its popular monthly lecture series. These online webinars attracted an average of more than 600 learners each month; the archived sessions continue to draw learners accessing the lectures on their own schedules.

In addition, the PTSD Consultation Program has continued its partnership with the [Center for Deployment Psychology](#) and [VA's Suicide Risk Management Consultation Program](#), hosting trainings for rural community providers. This year, a total of 233 clinicians attended one of three live virtual sessions on military culture, suicide prevention, and PTSD assessment. The virtual format has allowed the trainings to reach more providers, drawing students from throughout the country who want to further their skills assessing and treating Veterans with PTSD.

With its focus on improving the reach of evidence-based PTSD treatment, supporting time-limited care, and making measurement-based care a standard practice throughout VA PTSD specialty care, the PTSD Mentoring Program had an active year. Staff worked closely with specialty care programs to identify areas of improvement and monitor progress on goals. In addition to providing standard levels of consultation (“Mentoring as Usual”), the program was able to offer more intensive levels of help across the nation. This included a continued effort to work with PTSD Clinical Teams (PCTs) to implement outpatient massed treatment programs. VISN mentors attended panels and flash talks that showcased PTSD Clinical Teams’ implementation work and best practices for clinical care and program management.

The [Tech into Care \(TIC\)](#) initiative, which operates out of the Dissemination and Training Division, facilitates the implementation of technology into clinical care for PTSD and other mental health issues in VA and beyond. The initiative unites practitioners, administrators, and researchers to improve the uptake of innovative best practices and evidence-based interventions for Veterans. TIC has created tools including [videos](#), [handouts](#), and [online courses](#) in support of these efforts. To capitalize on interest in the project from new sites within VA, the team is piloting Tech into Care+ (TIC+), an online, self-guided



**The Tech into Care program facilitates the implementation of technology into PTSD clinical care.**

implementation tool to help VA health care systems integrate apps for PTSD and other mental health concerns into care with minimal support from implementation facilitators. There are now 54 mobile health champions at 31 VA sites across the United States, with more than 1,200 VA staff trained on using NCPTSD apps and other technology in their work with Veterans. TIC continues to offer an [online lecture series](#) that is open to anyone interested in the intersection of technology and mental health care. The series offers free continuing education credits to learners. TIC also holds a monthly community of practice call for VA staff, addressing opportunities and barriers in implementation of mobile health.

Every year, thousands of providers turn to the NCPTSD website for access to assessment instruments for PTSD, trauma exposure, and other mental health concerns. In order to better serve that audience, this year we completed a full overhaul of the assessment section of the site. As has always been the case, the focus is on providing key NCPTSD measures, including the gold standard Clinician-Administered PTSD Scale for DSM-5, but the site also guides users in how to obtain other trauma- and PTSD-related instruments. The changes to the site, including the creation of a category that groups together measures that assess functioning and other outcomes, have streamlined the user experience.

## Working Toward an Inclusive Website for All Groups

Since the inception of the NCPTSD website, staff have worked hard to make sure that articles are free of biased language. This year we have deepened that commitment by embarking on an effort to make sure our site is not only bias-free but also uses inclusive language. In practice, this means reviewing our content—starting with articles for the public—and revising it as necessary so that it adheres to [principles suggested by the Centers for](#)



[Disease Control and Prevention \(CDC\)](#) and other authorities. We want to ensure that our content uses preferred terms for population groups and communities; employs person-first language; avoids words with violent connotations, such as “tackle,” “target,” or “combat” when talking about people; and does not use language that dehumanizes or blames individuals and communities. We have also made a commitment to develop new content for and about people who are disproportionately affected by trauma, such as transgender individuals, or have been previously left out of our resources, such as disabled people. We envision that this valuable work will be a multiyear effort.

## Self-Help and Treatment Companion Resources

Staff at the Behavioral Science Division are hard at work on their longstanding effort to have a provider-facilitated version of VetChange hosted on the VA network. VetChange is an intervention that addresses Veterans’ problematic drinking through a mix of online modules and provider assistance. By transitioning VetChange to a VA server, providers will be better able to integrate the program into care for Veterans who want to cut down on their drinking or stop drinking altogether.

The National Center for PTSD released [PTSD Coach](#)—VA’s first-ever app—in 2011. PTSD Coach made its debut in an era when owning a smartphone was hardly the norm. Fast-forward to today. NCPTSD continues to innovate, with the Dissemination and Training Division creating free, secure apps for an array of mental health and behavioral issues. Our [current portfolio](#) contains 16 apps that earn high user ratings in the app marketplaces and are featured in articles in the national press on a steady basis. Continuous improvement through ongoing user testing and programmatic enhancements keeps NCPTSD apps as cutting-edge today as the pioneering PTSD Coach was more than 10 years ago. Two completely new apps—Well Within (focused on women’s mental health) and Safety Plan—were in development in FY 2022, even as updates to existing apps were ongoing.

The [Women Veterans Network \(WoVeN\)](#) is now active in more than 200 cities with upwards of 4,000 women Veterans enrolled in the program to date. Staff at the Women’s Health Sciences Division established WoVeN to foster social support among women Veterans. Because of its peer-led structure, WoVeN thrives on the commitment of its members across the country. Members connect in person and online, creating a vibrant community for women Veterans of all eras and branches of service. An adaptation of WoVeN, called WoVeN in VA, is currently being piloted inside the VA health care system in collaboration with Women’s Mental Health and Peer Support Services. In addition to the work with Veterans, in FY 2022 WoVeN successfully completed a pilot of BRIDGES (Building Re-Integration from Dreams and Goals to Execution and Success), which pairs women about to transition out of military service with Veteran peers called “Guides.” These Guides provide ongoing support to women service members during the period of reintegration into civilian life.

## Educational Resources for Professionals

This year saw the completion of the final course in the [Clinician-Administered PTSD Scale for DSM-5 \(CAPS-5\) Training Curriculum](#). Staff at the Executive Division and the Behavioral Science Division have been collaborating

for four years, developing virtual patient courses that complement a traditional didactic course. In FY 2022, a third and final virtual patient made his debut. Robert Sheridan, like the prior virtual patients, Anthony Price and Kathy McKenna, is a Veteran who experienced trauma during military service. Working with Robert gives learners an immersive experience in administering and scoring the gold standard PTSD assessment measure. This year we also redesigned the evaluations that learners receive at the end of each virtual patient course and made some adjustments to the program interface. As with our other education courses, free continuing education credits are available to providers in VA and the community who complete each training.

Our ongoing commitment to providing continuing education opportunities on a variety of important topics related to PTSD treatment is evident in the addition of 12 new one-hour lectures to our website. Covering topics as disparate as PTSD and eating disorders, cultural considerations in the treatment and assessment of insomnia, and supported employment for Veterans with PTSD, these lectures were each originally presented in the Consultation Program Lecture Series. NCPTSD courses offer free continuing education credits for both the live and on-demand versions of lectures, which is not always the case when Veterans Health Administration (VHA) program offices make live lectures available as enduring content. We know from our contact with VA providers that having the ability to earn continuing education credits on their own schedules is an investment that is worth making.

## PTSD-Repository

The National Center for PTSD continues to expand the PTSD Trials Standardized Database Repository (PTSD-Repository), a web-based platform that hosts data from 389 randomized controlled trials (RCTs) of PTSD treatment. In 2022, the site began including standardized effect sizes and added a data story on medications. Efforts are underway to refine the categorization of treatment types so that users can work with the data in a more precise manner. Publicly available and free to use, the PTSD-Repository helps researchers, clinicians, Veterans, and family members better understand the treatment literature. The PTSD-Repository is included in [VA's Open Data Portal](#), which provides public access to VA data.

## PTSDpubs

In FY 2022, the Resource Center staff continued to develop its new content management system and to expand its indexing thesaurus, which will be updated in PTSDpubs in the first quarter of FY 2023. PTSDpubs currently holds nearly 67,000 records and remains the largest database of PTSD and traumatic stress literature in the world. Staff educated new PTSDpubs users through a national online training offered by the VA Library Network and will continue to make presentations to internal customers. During FY 2023, staff will focus on an overhaul of records templates and the implementation of auto-indexing capabilities.

### FY 2022 Communication Resources at a Glance

**Website:** 6,737,122 visits

**Facebook:** 162,536 followers and 184,582 likes

**Twitter:** 38,671 followers with 358,289 impressions

**PTSD Research Quarterly:** 68,571 subscribers

**Clinician's Trauma Update Online:** 58,844 subscribers

**PTSD Monthly Update Newsletter:** 460,015 subscribers

**Assessment Instruments:** 693,739 assessments downloaded

**Mobile Apps:** 16 mobile apps; downloaded 604,727 times in FY 2022.

**Professional Articles:** 508,006 unique views of professional articles on the NCPTSD website

**PTSDpubs articles:** 67,907 PTSD- and trauma-research articles available on PTSDpubs

**Educational items distributed free of charge:** 994,440 items printed

# About the National Center for PTSD

## History


The National Center for PTSD was created in 1989 within VA in response to a Congressional mandate (PL 98-528) to address the needs of Veterans and other trauma survivors with PTSD. The National Center was developed with the ultimate purpose of improving the well-being, status, and understanding of Veterans in American society.

The mandate called for a Center of Excellence (CoE) that would set the agenda for research and education on PTSD without direct responsibility for patient care. Convinced that no single VA site could adequately serve this unique mission, VA initially established the National Center as a consortium of five Divisions.

## Organization

The National Center now consists of six VA academic CoEs across the United States, with headquarters in White River Junction, Vermont. Two Divisions are in Boston, Massachusetts; two in West Haven, Connecticut; and one in Palo Alto, California. Each contributes to the overall NCPTSD mission through specific areas of focus. In fiscal year 2022, the National Center closed its Pacific Islands Division (PID) in Honolulu, HI, integrating PID's cross-cultural mission and focus on racial and ethnic disparities in PTSD care, telehealth and virtual care, and cultural factors in PTSD treatment, into each of the remaining six Divisions.

The National Center for PTSD is an integral and valued component of VA's OMHSP, which is part of VHA. OMHSP and NCPTSD receive budget support from VA, although NCPTSD also leverages this support through successful competition for extramural research funding.



## Quick Facts



The National Center for PTSD was formed in 1989.



It has six Divisions across the United States, each with a distinct area of focus.



The National Center for PTSD manages the largest PTSD brain bank in the world.

# Leadership in 2022



**Paula P. Schnurr, PhD**

Executive Director, [Executive Division](#), White River Junction, VT  
Professor of Psychiatry, Geisel School of Medicine at Dartmouth



**Jessica L. Hamblen, PhD**

Deputy for Education, [Executive Division](#), White River Junction, VT  
Associate Professor of Psychiatry, Geisel School of Medicine at Dartmouth



**Paul E. Holtzheimer, MD**

Deputy for Research, [Executive Division](#), White River Junction, VT  
Associate Professor of Psychiatry, Geisel School of Medicine at Dartmouth



**Terence M. Keane, PhD**

Division Director, [Behavioral Science Division](#), Boston, MA  
Professor of Psychiatry and Assistant Dean for Research, Boston University School of Medicine



**John H. Krystal, MD**

Division Director, [Clinical Neurosciences Division](#), West Haven, CT  
Robert L. McNeil, Jr. Professor of Translational Research and Chairman of the Department of Psychiatry, Yale University School of Medicine



**Craig S. Rosen, PhD**

Division Director, [Dissemination and Training Division](#), Menlo Park, CA  
Professor of Psychiatry and Behavioral Sciences, Stanford University School of Medicine



**Rani A. Hoff, PhD, MPH**

Division Director, [Evaluation Division](#), West Haven, CT  
Professor of Psychiatry, Yale University School of Medicine



**Tara E. Galovski, PhD**

Division Director, [Women's Health Sciences Division](#), Boston, MA  
Associate Professor of Psychiatry, Boston University School of Medicine

# Appendix A:

## Acronyms Used in Appendix B

<b>Acronym</b>	<b>Definition</b>
ACT	Acceptance and Commitment Therapy
bCBCT	brief Cognitive-Behavioral Conjoint Therapy
BEAMS	Boston Early Adversity and Mortality Study
BMI	Body Mass Index
BRIDGES	Building Re-Integration from Dreams and Goals to Execution and Success
BSD	Behavioral Science Division
CAP	Consortium to Alleviate PTSD
CAPS-5	Clinician Administered PTSD Scale for DSM-5
CBT	Cognitive-Behavioral Therapy
CBT-I	Cognitive-Behavioral Therapy for Insomnia
CERV-PTSD	Comparative Effectiveness Research in Veterans with PTSD
CES	Cranial Electrotherapy Stimulation
CHIIIPS	Center for Harmonizing and Improving Interventions to Prevent Suicide
CMARRS	Center for Mobile Applications Research Resources and Services
CND	Clinical Neurosciences Division
CoE	Center of Excellence
CPT	Cognitive Processing Therapy
COVID-19	Coronavirus Disease 2019
CRAFT	Community Reinforcement and Family Training
CSP	Cooperative Studies Program
DBS	Deep Brain Stimulation
DNA	Deoxyribonucleic Acid
DoD	Department of Defense
EBP	Evidence-Based Psychotherapy



**Acronym****Definition**

EEG	Electroencephalogram
EHR	Electronic Health Record
EMA	Ecological Momentary Assessment
ENIGMA	Enhancing Neuroimaging Genetics through Meta-Analysis
FY	Fiscal Year
GWAS	Genome-wide Association Studies
IOP	Intensive Outpatient Program
IPV	Intimate Partner Violence
LATR	Later Adulthood Trauma Reengagement
LC	Learning Collaborative
LGBT	Lesbian, Gay, Bisexual, and Transgender
LIGHT	Longitudinal Investigation of Gender, Health and Trauma
MAVERIC	Massachusetts Veterans Epidemiology Research and Information Center
MBC	Measurement-Based Care
MDD	Major Depressive Disorder
MDMA	3-4 methylenedioxymethamphetamine
MOUD	Medication for Opioid Use Disorder
MRI	Magnetic Resonance Imaging
mRNA	messenger Ribonucleic Acid
MST	Military Sexual Trauma
MVP	Million Veteran Program
NCPS	National Center for Patient Safety
NDHS	Neurocognition Deployment Health Study
NEPEC	Northeast Program Evaluation Center
NHRVS	National Health and Resilience in Veterans Study
NPY	Neuropeptide Y
OMHSP	Office of Mental Health and Suicide Prevention
ORH	Office of Rural Health
OD	Opioid Use Disorder
PCL-5	PTSD Checklist for DSM-5
PE	Prolonged Exposure
PET	Positron Emission Tomography

**Acronym****Definition**

PGC	Psychiatric Genomics Consortium
PHQ-9	Patient Health Questionnaire
PRS	Polygenic Risk Score
PTSD	Posttraumatic Stress Disorder
RCT	Randomized Controlled Trial
REACH VET	Recovery Engagement and Coordination for Health – Veterans Enhanced Treatment
RISE	Recovering from IPV through Strength and Empowerment
RRTP	Residential Rehabilitation Treatment Program
SERV	Survey of Experiences of Returning Veterans
SP-CRC	Suicide Prevention Clinical Resource Center
SPRINT	Suicide Prevention Research Impact Network
SSRI	Selective Serotonin Reuptake Inhibitor
STAIR	Skills Training in Affective and Interpersonal Regulation
STARRS	Study to Assess Risk and Resilience in Servicemembers
STRONG STAR	South Texas Research Organizational Network Guiding Studies on Trauma and Resilience
TBI	Traumatic Brain Injury
TMS	Transcranial Magnetic Stimulation
TRACTS	Translational Research Center for Traumatic Brain Injury and Stress Disorders
VA	Department of Veterans Affairs
Project VALOR	Veterans After-Discharge Longitudinal Registry
VHA	Veterans Health Administration
VNS	Vagus Nerve Stimulation
VOA	Veterans Outcome Assessment
WET	Written Exposure Therapy
WoVeN	Women Veterans Network

# Appendix B:

## Research Narratives by Division

### Behavioral Science Division

The Behavioral Science Division (BSD) in Boston, Massachusetts, conducts research on life adjustment after military deployment and other traumatic stressors, methods to assess trauma and PTSD, innovative approaches to clinical intervention and treatment delivery, and the potential neurobiological and genomic basis of PTSD and its comorbidities.

---

#### Biomarkers

---

The Division has an active portfolio of genetic and neuroimaging studies involving collaborations with investigators in the [Translational Research Center for Traumatic Brain Injury and Stress Disorders \(TRACTS\)](#), the Department of Veterans Affairs (VA) [National PTSD Brain Bank](#), the Psychiatric Genomics Consortium (PGC), and the PTSD Working Group of the ENIGMA (Enhancing Neuroimaging Genetics through Meta-Analysis) Consortium.

Ongoing studies that examine PTSD and blast-related traumatic brain injury (TBI) in Veterans of Iraq and Afghanistan war zones aim to clarify the relative contribution of mild TBI and psychiatric conditions to deficits in current functioning and health outcomes. Investigators are now in the process of expanding this work to an older longitudinal cohort to study how psychiatric stress, genetic risk, and peripheral biomarkers of inflammation are associated with subsequent health decline and neurodegeneration.

The biomarkers examined by Division studies include structural and functional brain features measured by neuroimaging, peripheral markers of inflammation, neuropathology, and metabolic pathology, including biomarkers obtained using Simoa® technology—which offers greater measurement sensitivity and precision relative to standard ELISA-based assays—as well as specific genes and polygenic risk scores. Also under investigation are epigenetic indicators drawn from both

blood and postmortem brain tissue, including epigenome-wide deoxyribonucleic acid (DNA) methylation levels and transcriptome-wide messenger ribonucleic acid (mRNA) (i.e., gene expression).

Division members are also contributing to a Million Veteran Program (MVP) project to examine genetic risk variants for Alzheimer’s disease and dementia and to evaluate how they interact with Veteran-relevant exposures such as TBI and combat to influence risk of dementia and early cognitive decline. In addition, this project examines how these same genetic markers and exposures interact to influence PTSD risk and symptoms in older Veterans.

Division researchers continued to use functional and structural magnetic resonance imaging (MRI) to identify neural circuitry involved in PTSD. In collaboration with TRACTS, current studies are examining evidence for neuroimaging subtypes of PTSD. These studies revealed two such biotypes of PTSD characterized by neurocognitive and network-based connectivity abnormalities, which may be associated with greater chronicity of PTSD. The studies also revealed impoverished recruitment of attention networks and hyper-recruitment of threat-related networks in PTSD. Additional studies are examining how genetic risk moderates the relationship between TBI, inflammation, and neurocognitive dysfunction in trauma-exposed Veterans. Division researchers have also used magnetic resonance spectroscopy to examine neurodegeneration and neuroinflammation.

---

## Treatment Efficiency, Effectiveness, and Engagement

---

The Division's pioneering research on treatments for PTSD is focused on overcoming barriers to seeking care, reducing dropout, and increasing the efficiency of care delivery. One example is the internet-based treatment [VetChange](#), which was originally designed for Iraq and Afghanistan combat Veterans who report both risky use of alcohol and PTSD-related distress. The initial clinical trial produced evidence that VetChange was effective in reducing both drinking and PTSD symptoms. VetChange was subsequently modified to include mobile-friendly features and was disseminated nationally; this later version, which is applicable to Veterans of all eras, has demonstrated successful nationwide reach and been shown to be effective as well.

A new and enhanced version of the [VetChange mobile app](#) was released and is now being disseminated and used nationally on both Android and iOS devices. In addition, a major extension of the VetChange web intervention platform features a provider-facing dashboard, which allows for virtual and synchronous clinical care between providers and Veterans. Efforts are underway to secure Authority to Operate to make this intervention available to VA clinicians and patients. Recent accomplishments include completion of 508 testing and remediation; the team is currently implementing two-factor authentication for providers and patients to ensure secure access to the intervention prior to Authority to Operate review.

Other Division efforts include developing and testing efficient, therapist-delivered interventions or treatment extenders, with the goals of finding approaches that require less professional staff time and that are easier for patients to complete. A prime example is Written Exposure Therapy (WET), a five-session exposure-based treatment for PTSD that has been shown to be highly effective with non-Veteran patients. Findings from a recently completed Department of Defense (DoD)-funded study indicate that WET is non-inferior to Cognitive Processing Therapy (CPT) in the treatment of PTSD among men and women service members. An ongoing VA-funded study is directly comparing the treatment efficacies of WET and Prolonged Exposure (PE) among Veterans, and initial findings indicate non-inferiority of WET compared with PE. An ongoing implementation study is examining real-world treatment outcomes among Veterans treated

by VA mental health providers who are trained to deliver WET. This implementation project is entering its fifth year. Given the high demand for training in the VA system and the positive results to date, VA Central Office has taken over the training effort. Division investigators are also involved in other studies comparing WET with medication and collaborative care to treat PTSD in both VA and non-VA primary care clinics.

Research on factors that link PTSD with aggression toward intimate partners has led to the development and evaluation of interventions that reduce or prevent aggression within at-risk military and Veteran families. Positive clinical trials have been published, and the interventions continue to be implemented/evaluated across the VA health care system via VA Central Office funding and on one military installation through two separate DoD grants. Separate funded pilot studies testing one of these programs in different underserved urban civilian settings have shown large effects in reducing intimate partner violence, and a recently funded study will entail a controlled trial of this program in a civilian Israeli sample. A new VA Merit grant will also examine a motivational alcohol-focused intervention as a pre-group preparation for this program in VA to better address Veterans entering the program with alcohol use problems.

Division investigators have launched a two-site randomized controlled trial (RCT) investigating the possible benefit of adding a brief family intervention for Veterans receiving individual CPT or PE. Pilot work indicated that adding this family intervention resulted in 50% less dropout from the Veterans' individual CPT/PE. This larger trial will enroll 100 dyads (Veterans and their chosen adult family member) and randomize the family members to receive or not receive the brief intervention. All Veterans will be receiving CPT/PE for PTSD. Enrollment is underway for this trial.

As part of the Consortium to Alleviate PTSD (CAP), Division investigators contributed to several RCTs on active-duty military and Veteran populations. Focusing on PTSD comorbidities in Veterans, a double-blind RCT of doxazosin versus placebo for Veterans with co-occurring PTSD and alcohol use disorder revealed that both groups demonstrated statistically significant reductions in the primary outcomes of Clinician Administered PTSD Scale for DSM-5 (CAPS-5), PTSD Checklist for DSM-5 (PCL-5), percent drinking days, and percent heavy drinking. Contrary to hypotheses, however, no significant differences were

observed between groups on these variables. Another CAP study involving Division investigators was an RCT evaluating two forms of PE in military personnel: massed versus intensive outpatient. There were no significant differences between the treatment arms. Across groups, 61% achieved clinically significant reductions in clinician-assessed PTSD symptoms, 74% had self-reported PTSD symptom reductions at the one-month follow-up, and over 50% maintained PTSD diagnostic remission at six-month follow-up.

A trial of comorbid sleep disorders and PTSD compared CPT with Cognitive Behavioral Therapy for Insomnia (CBT-I), and forthcoming results will provide important information about the best way to combine these two treatments for maximum benefit. Likewise, examination of treatments for posttraumatic headache compared treatment as usual with both CPT and Cognitive-Behavioral Therapy for Headache and found that both active treatments reduced PTSD symptoms on the PCL-5, but only Cognitive-Behavioral Therapy for Headache reduced headache disability symptoms.

In the area of complementary interventions, a continuing study examining the impact of two 12-week group treatments on chronic pain in Gulf War Illness was adapted to be a fully remote study, delivering synchronous video group interventions and allowing Gulf War Veterans from around the country to participate. A three-year development grant will examine similar interventions to Veterans with PTSD and chronic pain. In both studies, Tai Chi, a mind-body exercise that has been associated with physical and mental health benefits, is compared with a wellness promotion intervention that is based on an existing VA model of care entitled Whole Health.

Another study involving Division investigators was an RCT that examined the effectiveness of the Unified Protocol (UP) promising transdiagnostic treatment for emotional disorders. UP was compared with Present Centered Therapy in a pilot hybrid-1 effectiveness/pre-implementation study with trauma-exposed Veterans with one or more emotional disorder diagnoses presenting for routine care. Across the two conditions there were significant improvements with large effects, with the UP demonstrating the greatest change. Only the UP led to a decrease in the number of comorbid diagnoses.

Division investigators also are examining a developmental phenomenon termed later-adulthood trauma

reengagement (LATR). It involves efforts by older combat Veterans to actively re-engage with wartime memories with the aim of building coherence and finding meaning in past experiences. It is theorized that the LATR process has the potential to lead to either positive outcomes such as personal growth or negative outcomes such as increased PTSD symptoms. An ongoing study is examining the impact of a 10-week psychosocial discussion group for older combat Veterans who report experiences consistent with the LATR process. In addition, a group based on the LATR framework is being implemented and evaluated in the Geriatric Mental Health Clinic. In collaboration with the New England GRECC, Division researchers conducted an Office of Rural Health (ORH)-funded project that utilized focus groups with Home-Based Primary Care psychologists to better understand the unique presentations and challenges of treating PTSD in this population. Staff also recorded and disseminated Season 1 of a podcast called *Talking Later: Veterans' Stories of Late-Life PTSD*. ORH-supported work in the upcoming fiscal year (FY) will involve modifying and evaluating an individualized version of the LATR protocol, writing up and submitting a manuscript based on the focus group findings, and disseminating Season 2 of the podcast.

Division investigators continue to partner with researchers in the Women's Health Sciences Division, VINCI, Hunter College, and Boston Medical Center to examine the effects of trauma and other high-impact stressors on PTSD and related sequelae such as substance use disorders among lesbian, gay, bisexual, and transgender (LGBT) Veterans. Recent scholarship highlights interrelated psychiatric networks stemming from both criterion A trauma and non-criterion A trauma among transgender and gender-diverse individuals, as well as novel networks of preferred intervention strategies to address overlapping stressors and resulting symptoms. These interventions include the constituent parts of existing evidence-based treatments (e.g., CPT, PE, WET), but also novel intervention strategies, such as empowerment-based self-defense training, that both transgender individuals and providers who specialize in their care recommend to target trauma and minority stress. These data have also been used to support two recent CDA 2 submissions and a K23 proposal to NIMH, all to create adapted treatment to better target co-occurring PTSD and minority stress among LGBT Veterans.

---

## Care Delivery, Models of Care, and System Factors

---

The Division continues to engage in cutting-edge work to ensure that Veterans with PTSD nationwide receive access to VA mental health care. An ongoing VA-funded study is using a mixed methods approach to understand which Veterans who screen positive for PTSD in VA primary care clinics do not access follow-up VA mental health care, and the patient, provider, and system-level factors that may impede access. Results of this project, which leverages the Veterans Health Administration (VHA) Electronic Health Record (EHR), will directly inform the development and implementation of targeted access interventions nationally. This work builds on the results of a recently published VA-funded pilot study also spearheaded by Division investigators, which demonstrated that more than 61% of Veterans who screened positive for PTSD had evidence that the screen resulted in an action taken toward VA-based mental health care, and that certain Veteran subgroups were more likely to evidence an initial action toward VA mental health care than others.

Survey data indicate that Veterans with PTSD are interested in family involvement in their care, but Division investigators have found that the number of Veterans with PTSD who receive a family-inclusive visit in VA Medical Centers is relatively small. Investigators recently published outcomes from a systems-focused project examining factors that contribute to or inhibit the use of family-inclusive care. The research team conducted over 30 qualitative interviews with staff and administrators at VAs nationwide to identify their decision-making process and various barriers or facilitators for family involvement. Results confirmed that VA clinicians believe that families can impact, and are impacted by, the course of Veterans' PTSD. Many providers described incorporating families into Veterans' care to provide psychoeducation, enhance the Veteran's sense of social support and connection, and facilitate safety planning. Barriers to family-inclusive care included providers' lack of formal training in couples or family therapy, as well as staffing issues that made scheduling additional clinical contacts challenging.

Additional activities include improving access to gold-standard medication for opioid use disorder (MOUD) and therapy/counseling among VHA patients with opioid (OUD) and other co-occurring psychiatric disorders (e.g., PTSD). Completion of quantitative analyses highlights negative effects of Coronavirus Disease 2019 (COVID-19)

on treatment receipt among patients with OUD, despite telehealth expansion and federal and state policies expanding access to MOUD during the COVID-19 pandemic. Ongoing analyses of VHA EHR and Commercial and Medicaid claims data highlight key gender and racial disparities regarding treatment utilization and health outcomes (e.g., opioid overdose), but also positive effects of receiving MOUD via telehealth and expansion of MOUD coverage among some existing patients, and other successes following VHA's swift response during the pandemic. Analysis of qualitative data from policymaker, provider, and patient interviews highlights the benefits of federal and state MOUD policy leniencies during the public health emergency, with implications for future policy and practice.

---

## PTSD and Suicide

---

Division investigators received funding for a new suicide prevention clinical resource center (SP-CRC). This SP-CRC will serve suicide prevention investigators by providing highly critical research resources to facilitate programmatic and scientific needs. The mission of the new SP-CRC, called the Center for Harmonizing and Improving Interventions to Prevent Suicide (CHIIPS), will be to advance a Precision Medicine approach to suicide prevention research. CHIIPS content area hubs will include Predictive Analytics, Biomarkers, Identification, Screening, Assessment, Social Determinants/Disparities, Interventions, and Training and Education. By establishing a VA SP-CRC with an explicit focus on promoting Precision Medicine for suicide prevention, we will improve individual suicide prevention outcomes; address unsatisfactory response rates for standardized treatments; promote the incorporation of diverse patient presentations, characteristics, and needs into treatment plans and suicide prevention research; improve system and population-level outcomes; and increase efficient use of finite resources (staff, funds, infrastructure). CHIIPS will work closely with Health Services Research & Development's Suicide Prevention Research Impact Network (SPRINT) investigators and hubs to optimize synergies and avoid duplication of effort between the two centers. CHIIPS's goal is to enhance current SPRINT activities by leveraging their network and infrastructure to focus on Precision Medicine approaches. Together, SPRINT and CHIIPS will help VA Office of Research and Development build a

Precision Medicine suicide prevention research portfolio that will advance the state of the science and help VA achieve its mission of significantly reducing the number of Veteran suicides.

Division researchers are actively contributing to knowledge about PTSD and suicide, particularly in the domain of risk factors. Division researchers have identified functional connectivity markers of suicide attempt history, compared categorical and dimensional approaches to understanding the association between PTSD and future suicide attempts, and identified distinct trajectories of suicidal ideation following psychiatric hospitalization discharge that were differentially related to future suicide attempts. Collaboration with Army Study to Assess Risk and Resilience in Servicemembers (STARRS) developed and tested an ensemble machine learning algorithm to predict suicide attempts among service members who recently left active-duty service, using administrative, survey, and geospatial data collected while on active duty (including data regarding PTSD). Collaboration with NCPTSD Clinical Neurosciences Division (CND) investigators examined associations between non-response to a question assessing lifetime self-injurious thoughts and behaviors and proxy variables of suicide risk, such as PTSD, among a nationally representative sample of Veterans. Other collaborations have examined the association between PTSD symptoms and psychiatric hospitalizations for suicide-related concerns, and developed and tested an evidence-based suicide attempt risk checklist to aid clinicians in identifying those at risk for future suicide attempts. BSD investigators completed a Military Suicide Research Consortium-funded project titled, “Latent Profile-Based Psychopathology Phenotypes and Self-Injurious Thoughts and Behaviors,” which examined the intersection between permutations of PTSD and other psychiatric symptoms in the cross-sectional prediction of suicidal thoughts and behaviors.

In another project, in collaboration with the South Texas Research Organizational Network Guiding Studies on Trauma and Resilience (STRONG STAR) Consortium, Division investigators have completed a study in which they tested a modified version of WET with a sample of Army soldiers and Veterans with PTSD symptoms who have been hospitalized for suicide risk. A related study was just funded by the Congressionally Directed Medical Research Program. The primary objective of this study is to evaluate the efficacy of Written Exposure Therapy for

Suicide Prevention in reducing the incidence and severity of self-injurious thoughts and behaviors in active-duty military service members, Veterans, and adult military beneficiaries following a psychiatric hospitalization due to suicidal ideation, suicide plans, or a suicide attempt. One other project will be testing the feasibility and acceptability of Brief Cognitive Behavioral Therapy for suicide prevention in a sample of Veterans hospitalized for suicide risk. In addition, experience sampling will be used to explore granular fluctuations in suicide risk and related risk factors (e.g., hopelessness) during and after treatment.

---

### Other Important Research

---

BSD investigators are collaborating with infectious disease and neuroimaging experts on a “long-COVID” study designed to examine the long-term neurobiological and psychiatric sequelae of COVID-19. The goal of the project is to apply a multi-modal neuroimaging and biomarker assessment to patients with symptoms of long-COVID to further characterize the inflammatory, neurological, cerebrovascular, epigenetic, and structural brain alterations associated with long-COVID.

Ongoing work is examining telehealth delivery for patients with OUD and alcohol use disorders and other co-occurring disorders (e.g., PTSD). Recent analyses highlight the types of services that converted to telehealth delivery during the COVID-19 pandemic versus services that remained in person, and examine the impacts of receiving care via telehealth regarding subsequent risk of ED visits, inpatient hospitalizations, overdose, and death post-pandemic onset. These data already highlight positive effects of telehealth regarding utilization of therapy/counseling but also access to MOUD that would not have been possible without COVID-19-related telehealth expansion.

The Division has a great deal of expertise in longitudinal, observational studies that inform the understanding of the course of PTSD and associated conditions over time. Division researchers are working on two large prospective cohort studies that collect information from strategically selected Veteran and service member groups. The first, the Veterans After-Discharge Longitudinal Registry ([Project VALOR](#)), is working with a registry of 1,649 male and female combat Veterans who became users of VA services after 2002. The project collects data about health outcomes associated with PTSD, supplemented by

clinical information from VA electronic medical records. DNA has now been extracted from previously collected saliva samples from almost 1,000 participants, and those DNA have been sent to the Massachusetts Institute of Technology's Broad Institute for phenotyping. Division researchers are also collaborating with VA Boston's Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) on a project examining the association between PTSD and cardiovascular disease risk factors using Project VALOR data.

The second large investigation, the [Neurocognition Deployment Health Study \(NDHS\)](#), began data collection at the outset of the Iraq War in 2003. Military personnel were assessed before deployment and at several short- and long-term (funded as Cooperative Studies Program (CSP) #566) intervals afterward, making this the first prospective longitudinal study to address the psychological impact of war zone stress. The study design has allowed examination of long-term emotional and neuropsychological outcomes, as well as health-related quality of life and occupational functioning. The most recent papers have focused on long-term outcomes, examining bidirectional relationships between PTSD and neurocognitive functions, PTSD symptom and neurocognitive predictors of long-term functional outcomes, the long-term emotional outcomes of war zone TBI, and associations among stress exposures and social support with a range of long-term mental health outcomes. An associated study has examined the adjustment of both partners and children of the service members and Veterans in the cohort. Findings to date have suggested relationships between service member/Veteran depression and both partner mental health, and dyadic relationship dysfunction. Several additional papers examining family outcomes are currently under review.

Led by Division investigators, the Boston Early Adversity and Mortality Study (BEAMS) augments existing records of three of the longest running cohort studies of aging—the Veterans Affairs Normative Aging Study, and the Grant and Glueck studies (together forming the Harvard Study of Adult Development), with prospective early-life socioeconomic and

environmental information gathered from multiple large-scale administrative databases. In prior years of the study, Division investigators successfully identified early-life records, such as birth certificates and military enrollment records, belonging to 10,146 siblings of 3,005 original cohort members. In the past year, with support from the National Institute on Aging, the study team has begun to create linkages between BEAMS and administrative databases at the Census Bureau, the Centers for Medicare and Medicaid Services, and the National Death Index. Upon completion of data linkage, the team will begin to examine prospective associations linking early adversities in the socioeconomic, psychosocial, and environmental domains to later-life health and well-being.

BSD investigators are examining the longitudinal impact of lifestyle behaviors (e.g., physical activity and diet quality) on risk for cardiovascular and metabolic disease and poor functioning among Veterans with PTSD. The goal is to identify and characterize behaviors that if modified would have beneficial effects on cardiometabolic risk profile, mental health, and physical functioning. Data are being collected in partnership with the TRACTS. Currently, this study is in its second year.

Division investigators are making important contributions in the assessment and diagnosis of PTSD. Specifically, investigators are evaluating a computer adaptive test for PTSD. BSD investigators have also revised and are now testing a revised version of the CAPS-5. This new, improved version has simplified formatting to improve visual flow; revised prompts to better guide interviewers and increase respondent comprehension; expanded rating options to capture more variability; has more explicit, detailed scoring guidelines embedded within each symptom item; and uses a frequency response card to reduce respondent burden and increase accuracy of responses. Another study co-led by Division investigators aims to provide validation of CAPS-5 performance with a military sample. Finally, Division investigators are serving as the PTSD assessment experts and leading the assessment core for a VA-funded cooperative study and a DoD-funded adaptive platform for a series of trials that will test several new therapeutics for PTSD.



## Clinical Neurosciences Division

The Clinical Neurosciences Division (CND) in West Haven, Connecticut, focuses on research to establish novel treatments, uncover biomarkers of disease mechanisms related to traumatic stress, and investigate paradigms of risk and resilience. By leveraging an interdisciplinary approach that includes genetics, functional genomics, neuroimaging, treatment interventions, and epidemiologic studies, the CND maximizes efforts to translate discoveries into therapeutic targets for PTSD and associated comorbid conditions.

---

### Biomarkers

---

Neurogenomics and neuroimaging guide biomarker development, including molecular, biochemical, structural, and functional approaches to investigate stress-related phenotypes and to better understand the sequence of pathological events associated with posttraumatic stress. Integrating multiple markers into a comprehensive panel, combined with behavioral data, enables faster identification of biomarkers, earlier detection of at-risk individuals, and informed decisions regarding treatment planning.

Genome-wide association studies (GWAS) are used to screen for genetic variations across large numbers of research participants with the goal of uncovering markers associated with complex disease. CND researchers conducted a pioneering GWAS analysis of 250,000 U.S. Veterans from the [MVP](#) to identify genetic risk factors relevant to three PTSD symptom clusters: reexperiencing, hyperarousal, and avoidance—as well as total symptom score and diagnosis. Genomic structural equation modeling was used to determine genetic relationships between PTSD and clinically comorbid phenotypes from the internalizing spectrum (i.e., major depressive disorder, anxiety, and neuroticism). This work, published in *Nature Genetics*, identified numerous risk variants for each trait studied and showed a high level of genetic relatedness between them, including genome-wide associations with PTSD visible at the case-control level and numerous genome-wide associations with various dimensions of symptom severity. These results help to illuminate the neurobiology of PTSD and begin to uncover new avenues for therapeutic development.

Using data from the National Health and Resilience in Veterans Study ([NHRVS](#)), which surveyed a nationally representative sample of U.S. Veterans, and from the MVP, CND investigators found that polygenic risk scores (PRS) for PTSD were associated with greater severity of PTSD symptoms. This association was only observed among

Veterans who reported having an insecure attachment style, characterized by an inability to form meaningful relationships with others. Enrichment analyses further revealed an interaction between attachment style and a variant mapping to the *IGSF11* gene, which is implicated in regulating excitatory synaptic transmission and plasticity. A follow-up study examining the relationship between PRS for PTSD, environmental factors, and the development of PTSD over a seven-year period was recently published. Results revealed a strong gene-by-environment interaction for the rs4702 variant of the *FURIN* gene with cumulative trauma burden, and that genes implicated in the PTSD PRS are perturbed by the drug doxylamine. NHRVS data are also being used to examine epigenetic correlates of PTSD. A recently published epigenome-wide association study observed an association between PTSD and CpG sites mapping to genes involved in immune function, transcription regulation, and axonal guidance. PTSD was also linked to a two-fold greater likelihood of accelerated epigenetic aging.

The VA National PTSD Brain Bank studies postmortem brain tissue of PTSD and major depressive disorder (MDD) donors to characterize gene expression associated with stress and suicide. This year, researchers evaluated the role of orexigenic neuropeptides in modulating negative affective states, specifically in the context of trauma exposure. One study employed a gene co-expression analysis strategy to uncover PTSD-specific networks containing appetitive neuropeptides. Three PTSD-associated modules containing appetitive peptides *NPY*, *GHRL*, and *NPY2R* were uncovered. Two modules, specific to females, were enriched for inflammatory response genes with markers for endothelial cells and neurons. To disentangle the effect that neuropeptides may have in PTSD, cohorts were stratified (PTSD and neurotypical controls) by normal and high body mass index (BMI) for each sex. Numerous differentially expressed genes were identified across comparisons, including cytokine *IL1B*, as a putative upstream regulator of transcription in males

with a high BMI. Previous work has identified regulation of *IL1B*, a pro-inflammatory cytokine, as a peripheral marker in PTSD subjects. However, high BMI alone has not been shown to regulate *IL1B* levels in the human prefrontal cortex, suggesting a possible molecular intersection between PTSD and BMI in the human brain, and may also imply further functional implications, as genetic variations in *IL1B* has been linked to risk of PTSD in males.

Last year, our group published the largest genomics study of PTSD postmortem brain in *Nature Neuroscience*. We examined the gene expression changes in four primary prefrontal cortical regions and identified gene expression changes related to GABAergic signaling, glucocorticoids, and inflammatory cytokines. We also identified sex-specific molecular pathologies differentiating males and females with PTSD, and identified genetic control of PTSD gene expression by identifying *ELFN1* quantitative traits loci using the latest MVP GWAS for PTSD. Our work has moved toward single cell genomics of both the transcriptome and epigenome and has developed several tools that were recently published in the *Journal of Computational Biology and Genes*.

The CND uses multimodal neuroimaging, such as positron emission tomography (PET), MRI, and spectroscopy, to investigate functional activation patterns, neurotransmitters, the structure of brain regions, brain network connections, and energy demands throughout the brain. This year, CND researchers addressed a knowledge gap in the PTSD literature regarding whether observed brain alterations in patients are a consequence or predisposition to the disorder. Novel work done by CND researchers in an animal model of PTSD shows that the glutamatergic system (measured with PET technology) is altered as a function of stress—specifically, animals who developed PTSD symptoms showed changes, whereas resilient animals did not. A second PET study examined the glutamatergic system but as a function of nicotine effects in individuals with PTSD, MDD, and controls. This work shows that nicotine affects the glutamatergic system in PTSD and controls only, but the effects are opposing in nature, suggesting that aberrant glutamatergic processes in the brains of individuals with PTSD may make them more susceptible to the effects of drugs.

Investigators also use electroencephalogram (EEG) to evaluate changes in electrical activity in the brain pre/post pharmacotherapy treatment. Using genomic data, CND researchers are working to establish an analytic biomarker

pipeline to predict ketamine treatment response via EEG patterns, with promising results from validation samples.

Studies using MRI and computational modeling to examine PTSD-related brain dysfunction include: 1) a drug challenge to derive specific biomarkers of ketamine treatment via stimulation of the AMPAR neuroreceptor and to investigate how depression, PTSD, and suicidality are related to these biomarkers and how they co-occur; 2) a computational model to understand how cumulative stressful experiences may contribute to PTSD and to identify patient subgroups susceptible to PTSD; and 3) a study using novel pupillary biosensors to examine stress arousal via neuron firing in the locus coeruleus (i.e., this brain region controls changes in the pupil of the eye). Two recent publications utilizing MRI data—one in *Neuropsychopharmacology*—highlight a potential higher stress-induced analgesia in PTSD where amygdala response to pain was lower in individuals with PTSD and was associated with emotional numbing symptoms. Lower amygdala reactivity to mild pain may contribute to the “all-or-none” reaction to stressful situations often observed in PTSD. A second paper published in *Molecular Psychiatry*, in collaboration with investigators from Tel Aviv examining longitudinal volumetric changes in the hippocampus, suggests support to the “vulnerability trait” hypothesis, where lower initial volumes of specific hippocampus subregions are associated with non-remitting PTSD. The stable volume of all hippocampal and amygdala subregions over a year following a criterion A traumatic event does not support the idea of consequential, progressive, stress-related atrophy during the first critical year following trauma exposure.

---

## PTSD and Suicide

---

CND researchers are investigating the use of pharmacological agents that have an acute antidepressant effect as a strategy to prevent suicide among individuals with PTSD. This work includes several projects that evaluate the anti-suicidal properties of ketamine in both treatment-resistant PTSD and depression, and how neural alterations and changes in synaptic connectivity pre/post ketamine treatment may underlie behavioral changes. Other work includes investigation of suicide risk factors among Veterans in the general U.S. population as well as those who undergo VA specialty care in PTSD Clinical Teams and PTSD residential treatment programs.

Using data from the 2019–2020 NHRVS, which surveyed a nationally representative sample of more than 4,000 U.S. Veterans, CND investigators found that the prevalence of suicidal ideation, plans, and attempts was 9.0%, 7.3%, and 3.0%, respectively. Younger age, PTSD, depression, and adverse childhood experiences were the strongest correlates of suicidal thoughts and behaviors. Results further revealed that only 35% of Veterans with current suicidal ideation were engaged in mental health treatment, and that suicidal Veterans who used VA health care were more than twice as likely as non-VA users to be engaged in treatment. Collectively, these findings suggest that suicidal thoughts and behaviors are prevalent among U.S. Veterans, particularly among younger Veterans, and signal a need for enhanced suicide prevention and outreach efforts to engage suicidal Veterans in mental health treatment.

Additional analyses of NHRVS prospective data, collected before and during the COVID-19 pandemic, revealed that the prevalence of suicidal thinking decreased from 10.6% to 7.8%. However, 2.6%, or approximately 475,000 Veterans, developed suicidal thinking during the pandemic, and 0.3%, or approximately 55,000 Veterans, reported attempting suicide. Veterans who reported having been infected with COVID-19 were more than twice as likely as those without infection to develop suicidal thinking, thus underscoring the importance of COVID-19 infection as a potential risk factor for suicide in U.S. Veterans.

NHRVS researchers also found that more than 40% of U.S. Veterans reported experiencing positive psychological changes or posttraumatic growth during the pandemic, most notably a greater appreciation of life and improved interpersonal relationships. Further, greater posttraumatic growth was associated with a 40% reduced likelihood of contemplating suicide, which suggests that interventions to help bolster posttraumatic growth may have utility in suicide prevention and treatment efforts. A three-year follow-up of this NHRVS cohort was recently completed,

and studies evaluating pre-, peri-, and post-pandemic changes in PTSD and related outcomes are in progress.

---

### **Treatment Efficiency, Effectiveness, and Engagement**

---

CND researchers work to identify treatment strategies and contextual factors to optimize the design, delivery, and patient engagement of PTSD-based care. As part of this work, investigators completed the largest known efficacy study of repeated doses of ketamine in Veterans and active-duty service members diagnosed with treatment-resistant PTSD. Results of this work are currently under review.

CND researchers are also conducting the following treatment-based trials: 1) a seven-day trial of PE enhanced with a single infusion of ketamine; 2) a project examining Mindfulness Based Stress Reduction for anger and aggression in Veterans with PTSD; 3) a study examining non-suicidal self-harm in PTSD using ecological momentary assessment (EMA); 4) a trial of buprenorphine and CPT for patients diagnosed with PTSD and opiate use disorder; 5) a study that examines the effect of WET in Veterans diagnosed with PTSD and comorbid substance use disorder; and 6) studies of the neural and anti-suicidal effects of serotonin-releasing agent 3-4 methylenedioxyamphetamine (MDMA) in individuals with PTSD and obsessive compulsive disorder.

CND is also leading CSP #2016 conducted at 34 VA Medical Centers. This VA Cooperative Study compares three commonly prescribed pharmacotherapies for insomnia: trazodone, gabapentin, and eszopiclone. Insomnia is among the most common (>80%) persisting symptoms of PTSD among patients who are actively engaged in other behavioral and pharmacologic treatments. Currently, there are no medications approved for the treatment of PTSD-related insomnia.

## Dissemination and Training Division

The Dissemination and Training Division in Palo Alto, California, conducts research on patient needs and preferences, innovations to improve treatment outcomes or efficiency, technology-based delivery of treatment, and strategies for promoting wider use of best practices.

---

### Treatment Efficiency, Effectiveness, and Engagement

---

A key focus of Division researchers is increasing patient engagement in care. One area of research has been identifying people who are at high risk for mental health problems after trauma. Division researchers have developed tools for screening for mental health risk following sudden illness or injury. In a community sample, eight psychosocial risks accurately identified 80% of patients with elevated posttraumatic stress symptoms two months post-trauma. Among VA primary care patients, a 12-item screen correctly classified 86% of those who had elevated PTSD and/or depression symptoms (sensitivity) six months later, with good screening performance among members of ethnic/racial minority groups. Another study among racially and ethnically diverse patients hospitalized after sudden, severe illness or injury found that psychosocial risk factors largely explained racial/ethnic disparities in acute and longer-term posttraumatic stress symptoms.

Other studies are examining how to facilitate treatment engagement. Division investigators developed a brief measure of patient characteristics associated with effective engagement in care. This measure can help determine what types and amount of service resources are needed to engage Veterans. Another study on care for Veterans who screened positive for military sexual trauma (MST) found that most Veterans completed an initial appointment, but those with negative perceptions of care were less likely to complete three or more visits. A pilot study is exploring how Veterans' experiences of discrimination, harassment, or trauma, related to their race/ethnicity, gender, or sexual orientation during military service, impacts their identity as military Veterans and their engagement with mental health care.

VA has long been a leader in telehealth, and VA telemental health services to the home increased further during the COVID-19 pandemic. A study underway compares two treatments delivered to women Veterans in their homes via video teleconference: Skills Training in Affective and

Interpersonal Regulation (STAIR) and Present-Centered Therapy. The goals of the study are to assess the relative effectiveness of these treatments and to identify barriers and facilitators for using video-to-home delivery of treatment. Another study will compare an asynchronous messaging-based version of CPT for PTSD with messaging-based therapy as usual. It will also compare different strategies to increase engagement, including a unique incentive structure.

Additional studies are examining how online interventions can be combined with coaching and social support. A manuscript under review reports results of a pilot study using automated systems to recruit, screen, enroll, assess, and deliver a VA online version of Problem Solving Therapy ([Moving Forward](#)), with and without peer support. In collaboration with researchers from the Philadelphia and Minneapolis VAs, the Division launched a study to test a web-based intervention developed by the National Center called [VA Community Reinforcement and Family Training \(CRAFT\) for PTSD](#). This program is coupled with telephone coaching to help spouses and intimate partners of Veterans with untreated PTSD encourage their Veteran to seek mental health care.

Researchers are examining how to make exposure therapy, one of our best PTSD treatments, more effective and more readily accessible. Two recently published meta-analyses examined the effects of exposure therapy for PTSD among community and military populations. Two studies tested digital delivery of exposure-based interventions among Veterans who might not otherwise access traditional face-to-face care. One study tested written and verbal forms of exposure treatment delivered online with support from VA peer support specialists. Another study tested effects of an exposure therapy app delivered with and without coaching support.

Division investigators are involved in several other trials of mobile mental health apps. One trial compares the outcomes of [PTSD Coach](#) with clinician support versus usual mental health treatment in reducing PTSD symptoms among Veterans treated in primary care. A recently completed study tested whether a mobile

cognitive control training program for the treatment of alcohol use disorder and PTSD improved recovery outcomes. A manuscript under review reports results of a pilot study of [Insomnia Coach](#), an app to help Veterans self-manage insomnia symptoms. Another pilot study is assessing outcomes of the AIMS anger management app. Division staff are also collaborating on studies assessing whether [Mindfulness Coach](#) helps Veterans manage stress and recover from alcohol problems, and testing whether an app for tracking patient outcomes improves quality of care for Veterans who have both spinal cord injury and PTSD.

Division staff have developed procedures for collecting anonymous usage data from our apps while ensuring user privacy. These procedures can help us better understand how users experience our mental health apps in regular use, outside of clinical trials. A series of naturalistic studies are examining how users engage with some of our most widely used apps: [Mindfulness Coach](#), [COVID Coach](#), [PTSD Coach](#), AIMS for Anger Management, and Beyond MST. The Division is helping to advance the mobile and technology research of VA investigators around the nation through its Center for Mobile Applications Research Resources and Services (CMARRS).

Division investigators are collaborating on several studies testing a mindfulness-based intervention, Acceptance and Commitment Therapy (ACT). These trials are assessing whether ACT improves functioning of Veterans who experienced moral injury, whether adding ACT to brief inpatient treatment can reduce Veterans' suicidal behaviors after discharge, and whether an online version of ACT can help health care providers manage pandemic-related distress.

---

### Care Delivery, Models of Care, and System Factors

---

Division researchers are involved several other studies of stress related to the COVID-19 pandemic among health care workers. A recent paper identified risk and protective factors for burnout among VA mental health staff prior to and during the pandemic. A pilot study is examining effects of [COVID Coach](#), an app designed to help improve self-care and overall mental health during the pandemic, among VA health care providers. NCPTSD staff also collaborated with colleagues at five VA medical centers to develop and pilot a brief multi-session program based on Stress First Aid for VHA staff.

The COVID-19 pandemic also led to the expansion of remote supervision (telesupervision) of clinical trainees in VA training programs. Division staff are collaborating on an ORH-funded project investigating the impact of telesupervision on training of psychology interns, especially in rural sites.

One area of work that bridges systems of care and implementation science is Modeling to Learn. This initiative trains frontline staff in participatory systems dynamics modeling, a collaborative quality improvement approach in which stakeholders identify specific system problems, use computer modeling to compare the likely outcomes of different potential solutions, and then select an optimal solution to implement. The third major release, Modeling to Learn 3.0, was released nationally in 2022. Two randomized trials are now underway testing whether Modeling to Learn is superior to other quality improvement approaches in increasing the number of VA patients who receive evidence-based psychotherapies and pharmacotherapies for mental and addictive disorders.

---

### Implementation

---

A study is underway evaluating how to simplify assessment of the quality of delivery of CBT for PTSD, depression, and anxiety disorders. A second ongoing study is comparing two different strategies intended to enhance and sustain the delivery of CPT; one strategy emphasizes fidelity to the protocol through expert consultation and online resources, and the other focuses on using continuous quality improvement strategies to improve fit and to address barriers to treatment delivery. Another trial is underway in eight military bases testing whether a tailored approach that includes a guide for matching solutions to local problems and support from an external facilitator (coach) increases the use of PE more than does standard provider training alone. Based on initial results from that study, investigators proposed specific policy recommendations to enable wider use of evidence-based psychotherapies in military clinics.

Investigators involved in national rollouts of PE and WET are studying the effectiveness of different virtual training models and implementation support approaches on therapist delivery of the treatment. Another study compares methods of assessing treatment quality and fidelity, two important implementation outcomes for CBTs,

including CPT, and is finding that more scalable models of fidelity assessment have good agreement with the more labor-intensive observer method of assessing fidelity.

---

### PTSD and Suicide

---

Recent research has identified insomnia as a risk factor for suicide. Division investigators have developed innovative ways to accurately monitor sleep without requiring Veterans to come to a clinic-based sleep lab. A new study

leverages this technology to conduct in-home sleep monitoring to detect suicide risk in Veterans who have other risk factors for suicide.

Division staff also have developed participatory system dynamics modeling tools that clinic teams can use to optimize and allocate staff resources to different clinical activities. These tools have been expanded and employed to suicide management to help teams ensure effective management of Veteran patients at high risk for suicide, without compromising overall access to or quality of care.

---

## Evaluation Division

The Evaluation Division in West Haven, Connecticut, supports the National Center’s mission through a programmatic link with VA’s [Northeast Program Evaluation Center \(NEPEC\)](#). NEPEC has broad responsibilities within the VA Office of Mental Health and Suicide Prevention (OMHSP) to evaluate their treatment programs, including those for specialized treatment of PTSD. Researchers also work on independent research projects related to the treatment of PTSD.

---

### Treatment Efficiency, Effectiveness, and Engagement

---

NEPEC monitors and assesses PTSD treatment at VA, including residential and outpatient specialty treatment programs and PTSD treatment by trained providers not working within one of the specialty programs. The NCPTSD Evaluation Division continues to work closely with the NCPTSD mentoring team to address reporting and evaluation needs of VA PTSD treatment.

Other recently published work using large-scale medical record data, in conjunction with the NEPEC, has provided information about the relative effectiveness of PTSD treatments and treatment response patterns in VA PTSD specialty and residential care. This body of work supports existing evidence that first-line psychotherapies for PTSD (including PE and CPT) are generally effective and are associated with large improvements in PTSD for Veterans in residential programs. Additional findings include evidence that group CPT in VA residential care is as effective as individually delivered CPT.

The Evaluation Division also has a particular focus on barriers to effective PTSD treatment, and health disparities and differences in minoritized groups of Veterans. The effectiveness research above showed that Black Veterans have (on average) worse outcomes in VA specialty care than White Veterans. FY 2022 work from the Evaluation

Division also shows differential outcomes of VA PTSD residential treatment between men and women Veterans. The Division has active projects examining gender, race, military sexual trauma, and treatment disparities in the context of VA residential and specialty outpatient treatment for PTSD.

Other work uses neuroimaging to better understand the neural mechanisms that underlie PTSD. One publication examined the effects of intranasal oxytocin on threat- and reward-related functional connectivity in men and women with childhood abuse-related PTSD, finding differential alterations in amygdala-insula connectivity in men and women who were exposed to childhood abuse.

Finally, Evaluation Division investigators continued collaborations with investigators from the Clinical Neurosciences Division and from outside NCPTSD using data from the NHRVS longitudinal study, looking at a wide variety of research questions, including PTSD symptom worsening, attachment style and PTSD risk, and the characteristics of PTSD symptoms and diagnosis in older U.S. Veterans.

---

### Care Delivery, Models of Care, and System Factors

---

NEPEC staff support the national Psychotropic Drug Safety Initiative, which plays a major role in the monitoring of PTSD pharmacotherapy throughout VHA. This study has

been tracking data on changes in practice in prescribing for PTSD and has noted a continuing drop in the use of benzodiazepines among Veterans with PTSD. The Division continues its work with technical advisors at the PTSD Mentoring Program and at the OMHSP to provide technical assistance to this initiative. The Division also continues to respond to requests from specialized programs and staff in the field on policy, operations, handbook implementation, and the provision of evidence-based practices.

In FY 2022, the Evaluation Division continued to support the Measurement-Based Care (MBC) in Mental Health Initiative, which was formally launched by the OMHSP in June 2016. This initiative encourages the use of patient-reported information, collected as part of routine care, to inform clinical care and shared decision-making among clinicians and patients and to individualize ongoing treatment plans. Currently, every intensive substance abuse outpatient program and residential treatment program is required to implement MBC.

---

### PTSD and Suicide

---

The Evaluation Division has enhanced its evaluation and program monitoring products to better highlight suicide-related considerations. The system indicates whether a Veteran waiting to enter the Residential Rehabilitation Treatment Program (RRTP) has a high-risk flag or has a lifetime REACH VET (Recovery Engagement and Coordination for Health – Veterans Enhanced Treatment) status. This information is critical to determining priority RRTP admission status. The RRTP workload report also includes the prevalence of high-risk flags in the six months preceding admission and the six months following discharge. We are also currently developing and testing revised Screening and Status update templates that will pull in risk information so that clinicians can easily view different aspects of risk, such as recent suicide attempt, current inpatient hospitalization, overdoses, etc. In the PTSD outpatient treatment, a new dashboard to track all admissions to the PTSD Clinical Team was developed,

and it was linked to the MBC patient health questionnaire (PHQ-9) measure to track any suicidal death or ideation in this population. Each PTSD Clinical Team director who utilizes the PTSD Status Form template, which tracks MBC data at admission, has the capacity to pull its site data in real time and define the observed period they are interested in to best capture their site data. This dashboard allows for real-time and customizable data reports.

---

### Other Important Research

---

Evaluation Division staff were integrally involved in the development of a Quick Guide to Race and Ethnicity Analyses for the OMHSP and are currently developing a dashboard for PTSD specialty clinics to access and visualize data about differences in care between Veterans of different races, to be deployed in FY 2023.

The PTSD Evaluation team is currently analyzing Veterans Outcome Assessment (VOA) data to best model Veterans' experience when receiving PTSD specialty care to understand which demographic, clinical, and health care utilization factors are associated with better long-term outcomes. Another aim is to identify those Veterans who do not get better during the course of treatment or who experience worsening of PTSD symptoms while undergoing care at the VA.

Data analysis continues for the Survey of Experiences of Returning Veterans (SERV) study, which is a repeated panel study of gender differences in psychiatric status and functioning among Veterans of Iraq and Afghanistan. The study recruited 850 participants, with women making up more than 40% of the sample. Participants were interviewed at three-month intervals for at least a year, with follow-up rates of 80%–85%, and a sizeable subset continued interviewing for up to three years. Twenty-three manuscripts have been published, are in press, or are under review, and analyses on a variety of topics are still underway.

## Executive Division

The Executive Division in White River Junction, Vermont, provides leadership, directs program planning, and promotes collaboration to facilitate optimal functioning of the other Divisions both individually and collectively. The Executive Division specializes in the development and evaluation of innovative and authoritative educational resources, in programs that disseminate and implement best management and clinical practices, and in the use of technologies to reach a broad range of users. The Executive Division also oversees the administration of VA's National PTSD Brain Bank.

---

### Biomarkers

---

Predictors of treatment response, aimed at understanding why a treatment works (or does not work) for a particular patient, are an important facet of Executive Division biomarkers research. Transcranial magnetic stimulation (TMS) is a device-based, FDA-cleared intervention for depression that is being tested as a treatment for PTSD. Executive Division investigators are currently examining EEG and functional MRI predictive biomarkers of response to TMS among Veterans with treatment-resistant depression and PTSD.

The Executive Division continues to coordinate the operations of VA's [National PTSD Brain Bank](#). The PTSD Brain Bank supports the Presidential Executive Order of August 2012 on deployment health by enabling VA to lead the nation in unique research that will facilitate deeper understanding of the causes and consequences of PTSD, and advancing assessment and treatment techniques.

The VA National PTSD Brain Bank currently has over 200 living donors and approximately 330 frozen hemispheres (roughly one-third each from donors with PTSD, donors with major depression, and healthy controls). The PTSD Brain Bank is collaborating with PinkConcussions and the Vietnam Era Twin Registry to encourage donations from women with TBI and Vietnam Veterans. The Brain Bank's intramural research program has produced 18 published articles and has 7 active grants examining transcriptomic, synaptic, and neuroinflammatory alterations in key brain regions associated with PTSD.

Investigators are also evaluating the utility of other neuromodulatory therapies for PTSD and TBI in human and pre-clinical models, including deep brain stimulation (DBS), cranial electrotherapy stimulation (CES), and vagus nerve stimulation (VNS). DBS is an FDA-approved neuromodulatory treatment for movement disorders (Parkinson's disease, essential tremor, dystonia), epilepsy, and treatment-refractory obsessive-compulsive disorder,

with ongoing research into the utility of DBS for PTSD and brain injury. Executive Division investigators are evaluating the utility of DBS for neuropsychiatric consequences of shockwave-induced brain injury in rodents to inform clinical application. A pilot study investigating CES for PTSD found some evidence of improvement in PTSD, and that the treatment did not have adverse effects. Follow-up work is planned for FY 2023 and beyond. VNS, an FDA-approved treatment for epilepsy, depression, and migraine, with ongoing research on the treatment of inflammatory conditions, is being evaluated for inflammatory-mediated neuropsychiatric consequences of PTSD and brain injury in rodent models.

In addition to neuromodulatory therapies, Executive Division investigators are also evaluating novel small molecule therapies for immunomodulation, as immune dysfunction has been identified in PTSD and may mediate neuropsychiatric sequelae associated with brain injury. As part of this project, Executive Division investigators are characterizing neuroinflammatory consequences of shockwave-induced brain injury, including central nervous system barrier dysfunction that may perpetuate a chronic inflammatory state.

---

### Treatment Efficiency, Effectiveness, and Engagement

---

During FY 2022, Comparative Effectiveness Research in Veterans with PTSD (CERV-PTSD), a groundbreaking study comparing PE and CPT at 17 VA facilities across the country, continued data analysis and submitted results for publication. This study, conducted through the VA's CSP, enrolled 916 Veterans with PTSD, making it the largest study of psychotherapy for PTSD to date. In FY 2022, Executive Division researchers, in collaboration with CSP, published the main results showing that PE and CPT are both effective for Veterans with PTSD, and that PE has a slight advantage in rates of remission and loss of



diagnosis. These findings, along with ongoing secondary analyses examining predictors of PE and CPT treatment outcomes, will help VA leadership, clinicians, and Veterans make informed choices about the delivery of PTSD care in VA, and will also be broadly relevant to the scientific and clinical communities outside VA.

Ongoing work at the Executive Division is aimed at developing new treatments for PTSD and related conditions. A trial to evaluate Trauma Informed Guilt Reduction, a six-session protocol to reduce guilt and shame related to a traumatic event, among Veterans of Iraq and Afghanistan showed that this intervention reduced PTSD symptoms more than non-specific supportive therapy. Other work explores a potential new medication for PTSD discovered by retrospectively examining the medical records of Veterans with PTSD treated in VA and finding that several antivirals used to treat Hepatitis C were associated with improvement in PTSD symptoms. Data published in FY 2022 compared specific antivirals and found that a combination of glecaprevir and pibrentasvir was more effective in reducing PTSD symptoms than other commonly prescribed antiviral combinations. Novel work in couples treatment for PTSD is testing a brief Cognitive-Behavioral Conjoint Therapy for PTSD (bCBCT) and exploring oxytocin as a treatment adjunct for bCBCT. Further research aimed at understanding the effectiveness of these novel interventions is planned for FY 2023 and beyond.

Treatments for conditions and symptoms that frequently co-occur with PTSD is an ongoing focus of research for many investigators. A trial evaluating the combination of topiramate and PE for co-occurring PTSD and alcohol use disorder completed data collection. Another ongoing study is testing CBT for Insomnia versus sleep hygiene integrated with PE as a strategy for improving sleep problems in PTSD.

Finally, in addition to better understanding and maximizing PTSD treatment effectiveness, Executive Division investigators are also working on ways to better communicate the effectiveness of PTSD treatments with patients and providers. Work published in FY 2022 developed patient-friendly graphics that illustrate the effectiveness of several evidence-based treatments for PTSD, including PE, CPT, and medication.

---

## Care Delivery, Models of Care, and System Factors

---

Executive Division investigators are involved in several initiatives targeted at assessing models of care and improving evidence-based practice. Access to evidence-based treatments for Veterans with PTSD at rural facilities is a major continued area of focus. This work utilizes facilitation, academic detailing, and collaboration with the National Center's Mentoring Program. In FY 2022, a new Learning Collaborative (LC) within the Mentoring Program that includes monthly LC calls alongside implementation support, resources, and data feedback was extended to all Mentors. More information about the Mentoring Program can be found in the Education narrative on page 17.

---

## Implementation

---

The Executive Division continues to support quality improvement projects aimed at increasing access to effective treatments for PTSD within the VA. In previous years, quality improvement projects established thresholds for high and low evidence-based psychotherapy (EBP) reach (i.e., access to EBPs) and identified characteristics of PTSD Clinical Teams within VA contributing to higher reach. Investigators are in the middle of a five-year project to translate the findings of this series into practice through collaboration with the PTSD Mentoring Program. This program is sponsored by the Executive Division and serves as a dissemination network targeting best practices in the administration of PTSD Clinical Teams. The success of this work is reflected in an increase in high reach PTSD Clinical Teams, and a corresponding decrease in low reach PTSD Clinical Teams, from FY 2020 to the present.

The staff within the Executive Division are also studying the implementation of intensive models of PTSD care (defined as PTSD EBP protocol sessions three to five times per week, as compared with the more traditional once per week format) in four PTSD specialty programs. This work utilizes implementation facilitation to start new intensive outpatient programs (IOPs) and assesses the clinical innovations using the [Reach Effectiveness Adoption Implementation Maintenance evaluation framework](#).

---

## PTSD and Suicide

---

Executive Division researchers continue to advance the priority area of PTSD and suicide through collaborations with the National Center for Patient Safety (NCPS), OMHSP, and the Center of Excellence (CoE) for Prevention of Suicide. One key line of work focuses on developing and implementing an effective suicide prevention intervention for rural VA facilities to decrease suicide risk

in Veterans living in rural settings, especially around the time of care transitions. Other work investigates the time after discharge from psychiatric care as a risk period for death by suicide. Several publications describing this risk period, and a new intervention that targets patients after psychiatric discharge, were published in FY 2022. Future work will build on this work and continue to test the effectiveness of intervention in this risk period.

---

## Women’s Health Sciences Division

The Women’s Health Sciences Division in Boston, Massachusetts, specializes in the study of women Veterans and non-Veterans, with a particular focus on understanding sex and gender differences in trauma exposure and posttrauma psychopathology.

---

### Biomarkers

---

Research on biomarkers includes studies aimed at explaining the basic biological processes underlying PTSD, with particular relevance to women. A recently completed study is examining the role of neurobiological and psychosocial factors that affect negative pregnancy outcomes among women with PTSD. Results demonstrated that trauma-exposed women with any mental health condition (including PTSD) early in pregnancy were more likely to perceive their labor and delivery experience negatively and have increased depressive symptoms at six weeks postpartum compared with non-trauma-exposed healthy women. Trauma-exposed women with PTSD specifically were significantly more likely to have increased postpartum anxiety and an adverse baby outcome (e.g., preterm birth, low infant birthweight, NICU admission). Ongoing analyses are examining whether these differences are related to a deficiency in the capacity to synthesize pregnanolone and/or allopregnanolone (an anxiolytic metabolite of progesterone) in parallel with rising progesterone levels. A second study, currently in the data analysis phase, is examining the neurobiology and psychophysiology of PTSD across the menstrual cycle. Recently published results reveal that anxiety sensitivity moderated the relationship between conditioned physiological reactivity and PTSD symptoms among trauma-exposed women. Finally, investigators are examining methylation profiles of genes previously observed or posited to be

associated with PTSD and dysregulated neurosteroid, neurotransmitter, and inflammatory factor profiles while accounting for environmental exposures such as tobacco dependence and alcohol use disorder in the large longitudinal TRACTS cohort.

Efforts aimed at using biomarkers to improve treatments for PTSD and related disorders include a recently launched study examining whether PE therapy is more efficacious during the morning hours when endogenous cortisol levels are at their highest as compared with later in the day when cortisol levels are relatively low. A separate effort involves an ongoing study actively recruiting participants to investigate the impact of IV allopregnanolone on extinction retention and fear memory reconsolidation. Another ongoing study is investigating whether a specific electrophysiological response pattern to a series of loud tones is predictive of clinical responses to selective serotonin reuptake inhibitors (SSRIs).

Division researchers have also concluded a pioneering study in head injury in women suffering from PTSD secondary to intimate partner violence (IPV). The aim is to understand the interactive biological and psychological mechanisms that underlie comorbid PTSD and TBI. Recently published results of the study describe the multi-method approach to examining the psychiatric and neurological consequences of IPV in this sample and identify the neural correlates of TBI in women survivors of intimate partner violence.

---

## PTSD and Suicide

---

Division investigators are examining associations between trauma history, PTSD, and suicidal behavior among Veterans, particularly in regard to sex and gender differences. For example, the aims of a secondary analysis of data from [The Veterans Metrics Initiative Study](#), a longitudinal study of recently separated male and female Veterans, include identifying initial post-separation life circumstances (e.g., vocation, finances, and social relationships) as predictors of change in suicidal ideation during the first three years after leaving military service. Findings suggest that Veterans' initial well-being in each of these key life domains contributes to their risk for experiencing high-risk suicidal ideation trajectories, even after accounting for Veterans' experiences of PTSD and broader mental health. In addition, Division researchers are examining gender differences in suicide risk and behavior among older Veterans using data from two large-scale VA cooperative studies of Vietnam-era Veterans.

---

## Treatment Efficiency, Effectiveness, and Engagement

---

With an aim of improving treatment efficiency, investigators are testing the efficacy of CPT delivered in a massed trial outpatient format with active-duty service members. Additional efforts to improve the effectiveness of CPT include an ongoing, large-scale study designed to test the impact of a case formulation enhanced version of CPT on treatment adherence, functioning, and PTSD symptoms. Other intervention studies on traumatized populations include a 14-site comparative effectiveness study of trauma-focused versus non-trauma-focused therapy for the treatment of Veterans with PTSD and substance use disorders.

A recently completed pilot study used a hybrid effectiveness implementation design to examine WET for pregnant women with comorbid PTSD and substance use disorder engaged in prenatal care within a high-risk obstetrical and addiction recovery program. Results indicate that WET is feasible and acceptable to both patients and providers in quantitative and qualitative analyses. Furthermore, PTSD symptoms, depression symptoms, and substance use cravings decreased from pre-intervention to post-intervention and were sustained at the six-month postpartum follow-up. Findings from this study have

informed a large RCT on pregnant women with PTSD to examine the effectiveness of WET compared with a support intervention and the non-inferiority of delivery of WET by community health workers versus mental health clinicians.

The Division is also focused on intervention research among those who have not necessarily been diagnosed with PTSD. Ongoing work by Division investigators is examining whether pairing well-being assessment feedback with targeted resource recommendations, using a newly developed tool, is an effective strategy to promote Veterans' willingness to seek support for areas of relatively poorer well-being as they transition from military service. Investigators also published a description of the development and initial program evaluation of an innovative national network of peer-facilitated support groups for women Veterans, [WoVeN: The Women Veterans Network](#). WoVeN is intended to increase social connections and support and to improve well-being and quality of life among women Veterans. Ongoing efforts are evaluating the effectiveness of the program on these outcomes. Investigators also continued expanding WoVeN's sister program, BRIDGES (Building Re-Integration from Dreams and Goals to Execution and Success), which aims to engage women transitioning out of active-duty military service in a broader social support network of women Veterans.

---

## Care Delivery, Models of Care, and System Factors

---

Relevant research within the Women's Health Sciences Division has focused on understanding Veterans' experiences at the time they separate from service and their implications for Veterans' service use. Investigators continue to analyze data from a study of the effects of deployment stressors and resulting mental health conditions on Veterans' quality of life and health care needs. Recent findings indicate bi-directional relationships between mental health symptoms (PTSD and depression) and both psychosocial functioning (work, romantic relationships, and parenting) and physical health functioning, which were found to persist over several years following military separation, underscoring the need for models of care that support a holistic approach to addressing mental health and functioning.

The Division's focus on care delivery also emphasizes care for conditions with relevance to women Veterans.

Two studies are investigating VHA health care use related to eating disorders: a recently completed study with a nationally representative sample of male and female Veterans, and an ongoing study focused on a large cohort of post-9/11 male and female Veterans. These investigations are also examining barriers to mental health care use, both in general and specifically related to eating disorders. As part of this work, an examination of the impact of COVID-19 on mental health concerns among Veterans found that early pandemic depression, anxiety, stress, and PTSD symptoms were associated with peri-pandemic eating disorder diagnostic status.

Other key work has focused on research with important subpopulations within the Veteran community. A study examining a therapist-assisted self-management program for Veterans who successfully complete trauma-focused therapy (EMPOWER) was funded this year; the goal of the project is to improve Veteran outcomes while reducing mental health service utilization in moving toward an episodic model of care. An ongoing longitudinal study, the Longitudinal Investigation of Gender, Health and Trauma (LIGHT), in which investigators over-sampled for women, individuals in high crime communities, and racial and ethnic minority Veterans, seeks to assess the impact of community and gun violence on trajectories of mental health and in health care utilization. Data from this study have demonstrated that perceived neighborhood danger is associated with increased depression and PTSD, and that interpersonal social support or neighborhood cohesion mitigated the effect of neighborhood danger on Veterans' depression, but only among those without prior trauma. The health of older women Veterans is another area of focus, including a study examining gender differences in the impact of military service and mental health sequelae, with a focus on PTSD, depression, and

their comorbidity, on later-life health in Vietnam-era Veterans. Current analyses are targeting cardiometabolic and other chronic disease risks among this population.

---

## Implementation

---

The Division is also focused on implementation efforts associated with IPV screening and intervention. Investigators are evaluating a national rollout of IPV screening programs within women's health primary care clinics to determine implementation outcomes and the clinical effectiveness of IPV screening programs. Findings from this cluster-randomized, stepped-wedge, hybrid-II implementation-effectiveness trial demonstrate that a blended implementation facilitation strategy, consisting of an operations-funded external facilitator working for six months with a facility-funded internal facilitator, nearly tripled the reach of IPV screening programs in primary care compared with implementation as usual in VA. In turn, implementation facilitation was associated with a two-fold increase in IPV detection rates among the patient population and increased patients' post-screening uptake of psychosocial services. In the area of IPV interventions, researchers published findings from a randomized clinical trial demonstrating the effectiveness of a brief counseling intervention, Recovering from IPV through Strength and Empowerment (RISE), for women who are experiencing violence in their intimate relationships. A collaboration with the national VHA IPV Assistance Program resulted in a rollout of RISE with IPV Assistance Program Coordinators across the country for implementation with Veterans of all gender identities. Published findings from an initial program evaluation support the effectiveness of RISE in routine VA care.

# Appendix C:

## Fiscal Year 2022 Funding

### VA Cooperative Studies Program (CSP)

Principal Investigator	Research Title	Years	Current Funding	Total Funding
Clark & Bair (Scioli – Site PI)	Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response: The SCEPTER Trial	2019-2025	\$2,410,831	\$3,500,000
Krystal (Holtzheimer – Site PI)	CSP #2016: National Adaptive Trial for PTSD Related Insomnia	2018-2025	\$632,297	\$35,430,040

### Other VA Sources

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
Barnes (Walser – Site PI)	Thriving in the Midst of Moral Pain: The Acceptability and Feasibility of Acceptance and Commitment Therapy for Moral Injury among Warzone Veterans	RR&D	2019-2023	\$47,049	\$587,469
Bean & Scioli	The VA REAP Center for Rehabilitation Promoting Prevention and Improved Resilience	RR&D	2021-2025	\$440,000	\$2,200,000
Borges (Walser – Site PI)	Acceptance and Commitment Therapy Training Program for Health Care Providers	OMHSP	2022-2024	\$326,407	\$1,018,337
Bovin	Understanding Pathways to Care for Veterans Who Screen Positive for PTSD: The PTSD Access To Healthcare Study	HSR&D	2021-2025	\$288,057	\$1,074,207
Cloitre	Connecting Women to Care: Home-Based Psychotherapy for Women with MST Living in Rural Areas	HSR&D	2018-2022	\$241,497	\$1,095,979
DiSano	Neuroinflammation and Neuropsychiatric Consequences of Brain Injury: Determining the Role of Central Nervous System Barrier Integrity in Mediating Outcomes	CDA	2021-2025	\$92,834	\$182,673

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Esterman</b>	Defining Biotypes of PTSD with Resting-State Connectivity	CSR&D	2018-2022	\$324,822	\$1,008,084
<b>Esterman &amp; Lee, D.</b>	Identifying Neural Fingerprints of Suicidality	RR&D	2021-2023	\$66,582	\$201,324
<b>Galovski &amp; Kehle-Forbes</b>	Personalizing Cognitive Processing Therapy with a Case Formulation Approach to Intentionally Target Impairment in Psychosocial Functioning Associated with PTSD	RR&D	2020-2024	\$329,708	\$1,194,890
<b>Grubaugh &amp; Hamblen</b>	A Randomized Controlled Trial of AboutFace: A Novel Video Storytelling Resource to Improve Access, Engagement, and Utilization of Mental Health Treatment among Veterans with PTSD	HSR&D	2018-2022	\$216,735	\$1,001,900
<b>Hallenbeck</b>	Remote Monitoring of PTSD and MDD Symptoms in VA Mental Health Care	HSR&D	2022	\$12,470	\$12,470
<b>Hallenbeck</b>	Using Innovative mHealth Technology to Understand Real-World Psychosocial Functioning for Veterans with Comorbid PTSD and Depression Symptoms	VISN 21 Early Career Award Program	2023-2024	\$0	\$309,552
<b>Hallenbeck</b>	Active and Passive Monitoring of Symptoms of Posttraumatic Stress Disorder and Major Depressive Disorder and Psychosocial Functioning	RR&D	2022	\$17,920	\$17,920
<b>Hollifield (Holtzheimer – Site PI)</b>	Efficacy and Safety of Stellate Ganglion Block for Posttraumatic Stress Disorder in Veterans	CSR&D	2022-2025	\$1,028,639	\$3,964,679
<b>Holtzheimer</b>	Assessing an Electroencephalography Biomarker of Response to Transcranial Magnetic Stimulation for Major Depression	CSR&D	2020-2025	\$160,208	\$5,429,619
<b>Iverson</b>	Addressing Intimate Partner Violence among Women Veterans: Evaluating the Impact and Effectiveness of VHA's Response	HSR&D	2020-2024	\$329,000	\$1,140,000
<b>Jagger-Rickels</b>	Identifying Neural Signatures of Current and Future Suicidal Thoughts and Behaviors	CDA	2022-2024	\$36,492	\$291,929
<b>Kehle-Forbes</b>	Empowering Veterans to Self-Manage PTSD Symptoms Following Completion of Trauma-Focused Therapy	HSR&D	2023-2026	\$0	\$634,261
<b>Kehle-Forbes &amp; Galovski</b>	Empowering Veterans to Self-Manage PTSD Symptoms Following Completion of Trauma-Focused Therapy	HSR&D	2022-2025	\$0	\$574,245
<b>Kimerling</b>	Development of a Patient-Reported Measure to Assess Healthcare Engagement	HSR&D	2018-2023	\$165,877	\$941,352

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Kuhn</b>	A Randomized Controlled Trial of Coaching Into Care with VA-CRAFT to Promote Veteran Engagement in PTSD Care	HSR&D	2020-2024	\$345,285	\$1,193,618
<b>Kuhn &amp; Owen</b>	Mobile Apps Research Resources and Services	HSR&D	2018-2022	\$159,356	\$754,220
<b>Larsen</b>	Identifying Best Practices in How to Offer an Evidence-Based Treatment: A Pilot Feasibility Trial	HSR&D	2021-2022	\$87,397	\$87,397
<b>Logue</b>	Early Cognitive Impairment as a Function of Alzheimer's Disease and Trauma	BLR&D	2019-2022	\$160,478	\$946,330
<b>Macia</b>	Veteran Perspectives of a Trauma-Informed Intervention for VA Homeless Programs	HSR&D	2022	\$17,699	\$17,699
<b>Meshberg-Cohen</b>	Written Exposure Therapy as a Brief Trauma Treatment for Veterans with Co-Occurring Substance Use Disorders and PTSD	CSR&D	2022-2026	\$227,079	\$877,716
<b>Miller</b>	Magnetic Resonance Spectroscopy and Genetic Analysis of Oxidative Stress in OEF/OIF Veterans with PTSD and TBI	CSR&D	2018-2023	\$165,000	\$645,000
<b>Mitchell</b>	Eating Disorders in Veterans: Risk, Resilience, and Service Use	HSR&D	2019-2022	\$0	\$525,112
<b>Niles</b>	Novel Interventions for Gulf War Veterans' Illnesses	CSR&D	2016-2023	\$0	\$1,757,080
<b>Niles</b>	Barriers to CPAP Use in Veterans with Comorbid OSA and PTSD	RR&D	2021-2022	\$7,437	\$17,850
<b>Noller, C.</b>	Neuromodulation to Alter Acute Inflammation and Neuropsychiatric Deficits Following Traumatic Brain Injury	CDA	2021-2023	\$94,673	\$183,623
<b>Norman &amp; Galovski</b>	Non-Inferiority Trial of Trauma Informed Guilt Reduction Therapy to Prolonged Exposure	CSR&D	2022-2028	\$0	\$1,457,477
<b>Norman</b>	Topiramate and Prolonged Exposure for Alcohol Use Disorder and PTSD	RR&D	2018-2022	\$116,813	\$993,584
<b>Oslin (Gelernter – Site PI)</b>	PRIME Care (PRrecision medicine in MEntal health Care)	HSR&D	2017-2022	\$265,239	\$11,306,320
<b>Pineles</b>	An Electrophysiological Predictor of SSRI Response in Veterans with PTSD	CSR&D	2019-2022	\$163,238	\$1,158,051
<b>Pless Kaiser</b>	Improving Psychosocial Functioning in Older Veterans with PTSD	CDA	2017-2022	\$10,300	\$942,679
<b>Ranganathan</b>	VA PRIME Care	PRIME	2017-2022	\$82,067	\$329,363
<b>Shiner</b>	Patient Safety Center of Inquiry: Prevention of Suicide	NCPS	2019-2022	\$246,163	\$536,107

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Sloan</b>	An Efficient Exposure-Based Treatment for PTSD Compared to Prolonged Exposure: A Noninferiority Trial	CSR&D	2019-2023	\$414,987	\$1,762,404
<b>Smith</b>	Long-Term Health Impact of Vietnam Era Service: Examining Gender Differences in Risk of Mortality and Chronic Disease	CSR&D	2022-2024	\$182,478	\$383,456
<b>Sullivan</b>	Neural Metabolic Stress in mTBI and PTSD	CDA	2018-2023	\$245,154	\$877,915
<b>Taft</b>	Adjunctive Motivational Alcohol Intervention to Prevent Intimate Partner Violence	CSR&D	2021-2025	\$246,972	\$1,304,582
<b>Taft</b>	Strength at Home Implementation and Evaluation	VACO IPV Program	2021-2022	\$309,128	\$309,128
<b>Thompson-Hollands</b>	Family Involvement in Treatment for PTSD: A Brief, Feasible Method for Enhancing Outcomes, Retention, and Engagement	VA CSR&D	2022-2026	\$125,438	\$1,098,623
<b>Vogt</b>	Measurement-Based Transition Assistance: Evaluating the Promise of a Web-Based Approach to Promote Veterans' Support Seeking	HSR&D	2022-2024	\$150,915	\$195,515
<b>Vogt</b>	Risk and Resilience Factors Related to Suicidal Ideation during Transition from Military to Civilian Life: Secondary Analyses of the TVMI Cohort Study	HSR&D	2020-2022	\$156,627	\$356,266
<b>Whitworth</b>	Impact of Lifestyle on Cardiovascular and Metabolic Risk Factors in Trauma Exposed Post-9/11 Veterans	CDA	2021-2026	\$207,588	\$1,045,448
<b>Wiltsey Stirman</b>	Using the Multiphase Optimization Strategy to Adapt Cognitive Processing Therapy	HSR&D	2022-2026	\$138,474	\$1,063,822
<b>Zelkowitz</b>	Psychological Drivers of Self-Destructive Behaviors in PTSD	CSR&D	2022-2027	\$31,868	\$982,298
<b>Zimmerman</b>	Participatory System Dynamics vs Usual Quality Improvement: Is Staff Use of Simulation an Effective, Scalable and Affordable Way to Improve Timely Veteran Access to High-Quality Mental Health Care?	HSR&D	2020-2023	\$290,631	\$1,198,168

BLR&D Biomedical Laboratory Research & Development Service; CDA Career Development Award; CSR&D Clinical Science Research and Development Service; CPAP Continuous Positive Airway Pressure; HSR&D Health Services Research and Development Service; IPV Intimate Partner Violence; MDD Major Depressive Disorder; MST military sexual trauma; mHealth mobile health; mTBI mild traumatic brain injury; NCPS National Center for Patient Safety; OEF/OIF Operation Enduring Freedom/Operation Iraqi Freedom; OSA Obstructive Sleep Apnea; OMHSP Office of Mental Health and Suicide Prevention; PI Principal Investigator; PRIME Precision Medicine in Mental Health Care; PTSD Posttraumatic Stress Disorder; REAP Research Enhancement Award Program; RR&D Rehabilitation Research and Development Service; SSRI selective serotonin reuptake inhibitor; TBI Traumatic Brain Injury; TVMI The Veterans Metric Initiative; VACO VA Central Office; VA Department of Veterans Affairs; VA CRAFT Community Reinforcement and Family Training; VHA Veterans Health Administration; VISN Veterans Integrated Service Network



## National Institutes of Health (NIH)

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Abdallah</b>	Glial and Synaptic Functions in Major Depression	NIMH	2017-2022	\$130,963	\$2,493,229
Bohnert ( <b>Kuhn</b> – Site PI)	Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes	NIAAA	2020-2025	\$519,268	\$3,043,387
<b>Carlson</b>	Development of a Risk Factor Screen for Mental Health Problems after Sudden Illness or Injury	NIMHD	2018-2023	\$0	\$2,293,641
<b>Carpenter</b>	Enhancing Memory and Learning in Cognitive Processing Therapy for PTSD	K	2022-2027	\$189,216	\$946,080
<b>Cosgrove, Pietrzak &amp; Esterlis</b>	Imaging Microglial Activation in PTSD using PET	NIMH	2017-2022	\$0	\$825,495
<b>Davis</b>	Dysregulation in mGluR5 as a Marker of BPD and Suicide Related Endophenotypes	K	2018-2023	\$209,375	\$983,483
<b>Esterlis &amp; Pietrzak</b>	Depression and Accelerated Brain Aging: A PET Imaging Study	NIMH	2018-2023	\$1,246,108	\$4,051,532
<b>Esterlis</b>	In Vivo Imaging of a Neural Marker of Suicidal Behavior in Bipolar Disorder	NIMH	2018-2023	\$782,677	\$3,935,570
<b>Gradus &amp; Shiner</b>	Identification of Novel Agents to Treat PTSD Using Clinical Data	NIMH	2020-2024	\$554,790	\$2,459,226
Hayes ( <b>Miller</b> – Site PI)	Neuroimaging and Molecular Markers of AD and Neurodegenerative Disease after Concussion	NIA	2019-2023	\$239,414	\$1,205,642
<b>Kaffman</b>	Amygdala Hyper-Connectivity in a Mouse Model of Unpredictable Early Life Stress	NIMH	2019-2024	\$404,790	\$2,081,954
<b>Kaffman</b>	Role of Microglial IRF8 in the Developmental Consequences of Early Adversity	NIMH	2020-2025	\$250,000	\$1,250,000
<b>Kaye</b>	Determining the Role of Noradrenergic Heterogeneity in Innate Threat Response	K	2020-2025	\$194,940	\$974,700
<b>Kelmendi</b>	The Neural Correlates of the Effects of Psilocybin in OCD: Randomized Controlled Study	K	2020-2024	\$190,443	\$778,392
<b>Krystal</b>	Center for the Translational Neuroscience of Alcoholism CTNA-5	NIAAA	2021-2026	\$1,765,263	\$8,726,845
<b>Krystal &amp; Smith</b>	Yale Clinical and Translational Science Award Calhoun Diversity in Health-Related Research	NCATS	2022-2024	\$232,490	\$456,019
<b>Lee, L.</b>	Boston Early Adversity and Mortality Study: Linking Administrative Data to Long-Term Longitudinal Studies	NIA	2019-2024	\$696,953	\$3,528,185
<b>Levy</b>	Individual Differences in Decision Making Under Uncertainty	NIMH	2019-2024	\$393,090	\$3,337,954

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
Halko (Esterman – Site PI)	Non-Invasive Attentional Network Modulation	NIMH	2021-2022	\$763,833	\$763,833
Niles	Feasibility of Remote-Delivery Interventions: Tai Chi and Wellness for PTSD and Pain in Veterans	NCCIH	2022-2025	\$178,170	\$612,213
Nilani	PTSD-Related Neurobiological Mediators of Negative Pregnancy Outcomes	K	2017-2022	\$153,933	\$615,735
Nilani	A Non-Inferiority Trial Testing Delivery of Written Exposure Therapy by Community Health Workers for Treatment of PTSD during Pregnancy	NICHD	2022-2027	\$562,952	\$2,532,758
Owen	Development of a Mobile Mindfulness Intervention for Alcohol Use Disorder and PTSD among OEF/OIF Veterans	NIAAA	2021-2024	\$259,782	\$1,039,078
Pineles & Pace-Schott	Circadian Influence on Fear Extinction Resulting from Prolonged Exposure Therapy for PTSD	NIMH	2022-2024	\$198,748	\$320,956
Rasmusson	Facilitation of Reconsolidation Blockade and Extinction Retention in PTSD by Intravenous Allopregnanolone	NIMH	2021-2025	\$603,175	\$3,809,704
Sloan	Delivering Written Exposure Therapy for PTSD in Underserved Primary Care Settings	NIMH	2021-2026	\$123,470	\$4,958,744
Smith, S., Logue, Uddin & Nievergelt	The Impact of Traumatic Stress on the Methylome: Implications for PTSD	NIMH	2020-2025	\$702,411	\$3,589,840
Smith, A. (Kuhn – Site PI)	A SMART Design to Facilitate PTSD Symptom Management Strategies among Cancer Survivors	NCI	2020-2025	\$604,550	\$2,342,355
Stockman (Cloitre – Site PI)	Addressing Trauma from Interpersonal Violence through a Web-Based Peer Navigation-Social Support Intervention to Improve ART Adherence among Women	NIMH	2021-2026	\$798,490	\$3,992,450
Williams (Holtzheimer – Site PI)	Mechanistic Circuit Markers of Transcranial Magnetic Stimulation Outcomes in Pharmacoresistant Depression	NIMH	2020-2024	\$659,708	\$2,111,915
Wiltsey Stirman	Evaluating Effectiveness and Engagement Strategies for Asynchronous Texting Based Trauma Focused Therapy for PTSD	NIMH	2021-2024	\$806,007	\$2,510,190
Wiltsey Stirman	Leveraging Routine Clinical Materials and Mobile Technology to Assess CBT Quality	NIMH	2021-2022	\$556,814	\$2,607,817
Wiltsey Stirman	Telehealth 2.0: Evaluating Effectiveness and Engagement Strategies for CPT-Text for PTSD	NIMH	2021-2024	\$695,236	\$3,059,706
Wiltsey Stirman	Improving and Sustaining CPT for PTSD in Mental Health Systems	NIMH	2021-2022	\$0	\$1,615,257

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Wolf</b>	Longitudinal Neurometabolic Outcomes of Traumatic Stress-Related Accelerated Cellular Aging	NIA	2020-2025	\$423,508	\$1,694,033
<b>Wolf</b>	Neurobiological Correlates of Accelerated Cellular Aging	NIA	2019-2022	\$157,500	\$346,500
<b>Woodward &amp; Khan</b>	In-Home Sleep Monitoring to Detect Suicide Risk in Veterans	NIMH	2020-2022	\$53,802	\$416,632
<b>Zimmerman</b>	Participatory System Dynamics vs Audit and Feedback: A Cluster Randomized Trial of Mechanisms of Implementation Change to Expand Reach of Evidence-Based Addiction and Mental Health Care	NIDA	2019-2023	\$572,087	\$2,864,531

AD Alzheimer's Disease; ART Antiretroviral Therapy; BPD Borderline Personality Disorder; CBT Cognitive Behavioral Therapy; CPT Cognitive Processing Therapy; CTNA-5 Center for Translational Neuroscience of Alcoholism; IRF8 Interferon regulatory factor 8; K Research Career Development Award; mGluR5 Metabotropic glutamate receptor 5; m-Health mobile health; NCATS National Center for Advancing Translational Sciences; NCCIH National Center for Complementary and Integrative Health; NCI National Cancer Institute; NIA National Institute on Aging; NIAAA National Institute on Alcohol Abuse and Alcoholism; NICHD National Institute of Child and Human Development; NIDA National Institute on Drug Abuse; NIMH National Institute of Mental Health; NIMHD National Institute on Minority Health and Health Disparities; OCD Obsessive Compulsive Disorder; OEF/OIF Operation Enduring Freedom/Operation Iraqi Freedom; PET Positron Emission Tomography; PI Principal Investigator; PTSD Posttraumatic Stress Disorder; SMART Sequential Multiple Assignment Randomized Trial

## Department of Defense (DoD)

Principal Investigator	Research Title	Years	Current Funding	Total Funding
<b>Lee, D. &amp; Stanley</b>	Latent Profile-Based Psychopathology Phenotypes and Self-Injurious Thoughts and Behaviors: An Examination of the Military Suicide Research Consortium Common Data Elements	2021-2022	\$122,754	\$122,754
<b>Marx &amp; Chard</b>	Psychometric Evaluation of the Clinician Administered PTSD Scale for DSM-5 and the PTSD Symptom Scale Interview for DSM-5 (PSSI-5) in an Active Duty and Military Veteran Sample	2018-2023	\$1,681,050	\$6,354,218
<b>McLean &amp; Rosen</b>	Targeted Strategies to Accelerate Evidence-Based Psychotherapies Implementation in Military Settings	2017-2023	\$0	\$8,608,151
<b>Mitchell</b>	Eating Disorders in Veterans: Prevalence, Comorbidity, Risk, and Healthcare Use	2018-2023	\$525,112	\$1,067,200
<b>Norman (Wachen – Site PI)</b>	Trauma Informed Guilt Reduction Therapy for Guilt, Shame, and Moral Injury Resulting from Trauma: Rationale, Design, and Methodology of a Two-Site Randomized Controlled Trial	2015-2022	\$459,105	\$2,725,696

Principal Investigator	Research Title	Years	Current Funding	Total Funding
<b>Shiner</b>	Real World Effectiveness of Long-Acting Injectable versus Oral Naltrexone for Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder	2022-2024	\$315,250	\$616,716
<b>Taft</b>	Strength at Home Couples Program: Examining Sexual Aggression	2020-2022	\$137,075	\$274,149
<b>Wachen</b>	Massed Cognitive Processing Therapy for Combat-Related PTSD	2017-2022	\$0	\$3,282,395

## Other Non-VA Sources

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Bredemeier (McLean &amp; Larsen – Site PIs)</b>	A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD: What Works Best and for Whom	PCORI	2021-2025	\$224,434	\$905,205
<b>Cloitre</b>	Trauma-Focused Care in LGBTQ+ Communities: Building Capacity for Research	PCORI	2021-2023	\$125,000	\$250,000
<b>Davis</b>	In Vivo Investigation of the Relationship Between Kappa Opioid Receptor and Suicidal Behavior in PTSD	American Foundation for Suicide Prevention	2023-2024	\$0	\$88,058
<b>Davis</b>	Dysregulation in Kappa Opioid Receptor as a Marker of BPD and Suicide Related Endophenotypes	Robert Leet and Clara Guthrie Patterson Trust	2021-2022	\$22,500	\$45,000
<b>Driesen &amp; Street</b>	AMPA Components of the Ketamine Anti-Suicidal Response	American Foundation for Suicide Prevention	2022-2024	\$50,000	\$100,000
<b>Galovski &amp; Street</b>	Women Veterans Network (WoVeN) Continued Expansion	Bob Woodruff Foundation	2022	\$123,700	\$123,700
<b>Galovski &amp; Street</b>	Women Veterans Network (WoVeN)	May & Stanley Smith Charitable Trust	2021-2022	\$38,000	\$50,000
<b>Galovski &amp; Street</b>	Core Support - Women Veterans Network (WoVeN)	Oak Foundation	2020-2022	\$100,000	\$200,000
<b>Galovski &amp; Street</b>	Core Support - Women Veterans Network (WoVeN)	Oak Foundation	2022-2026	\$17,000	\$400,000

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Galovski &amp; Street</b>	Building Re-Integration from Dreams and Goals to Execution and Success (BRIDGES): A Peer Support Program for Transitioning Women Service Members	Walmart Foundation	2022-2024	\$125,000	\$250,000
<b>Gilbar &amp; Taft</b>	Social Information Processing and Intimate Partner Violence	United States-Israel Binational Science Foundation	2021-2025	\$54,000	\$216,000
<b>Girgenti</b>	Sex-Specific Molecular Mechanisms in PTSD	Brain and Behavior Research Foundation	2020-2022	\$1,780	\$70,000
<b>Goldfarb</b>	Neuroimaging Habit Learning in Posttraumatic Stress Disorder	NARSAD	2022-2024	\$35,000	\$70,000
<b>Kachadourian</b>	Non-Suicidal Self Injury in Military Veterans with PTSD: An Ecological Momentary Assessment Study	Yale Center for Clinical Investigation	2020-2022	\$20,000	\$40,000
<b>Kehle-Forbes (Norman – Site PI)</b>	Comparative Effectiveness of Trauma-Focused and Non-Trauma-Focused Treatment Strategies for PTSD among Those with Co-Occurring SUD	PCORI	2020-2025	\$1,621,492	\$5,635,307
<b>Kelmendi</b>	Cohen Foundation Research Grant	The Cohen Foundation	2021-2026	\$322,767	\$1,655,404
<b>Livingston &amp; Weisberg</b>	Impact of COVID-19-Related Medication-Assisted Treatment Policy Changes on Patients with Opioid Use Disorders	PCORI	2020-2022	\$1,129,612	\$2,494,203
<b>McCaslin</b>	Development of a Provider Tool to Increase Culturally Competent and Patient-Centered Care: The Military Culture and Experience Index	Ci2i - HSR&D Center of Excellence, VA Palo Alto HCS	2021-2022	\$20,379	\$20,379
<b>McLean</b>	An Efficient 2-Day Treatment for Posttraumatic Injury for Firefighters	FEMA	2021-2024	\$469,456	\$1,499,997
<b>Nillni</b>	A Pragmatic Effectiveness Trial of a Brief Exposure Therapy for PTSD on Substance Use and Mental Health Morbidity and Mortality during the Perinatal Period	Grayken Center for Addiction	2019-2022	\$75,000	\$150,000
<b>Noller</b>	Neuropsychiatric Consequences of Brain Injury: Determining How Neuroinflammation May Mediate Neurobehavioral Outcomes	Gary Tucker Junior Investigator Research Award	2022-2024	\$0	\$1,124,900

Principal Investigator	Research Title	Funding Source	Years	Current Funding	Total Funding
<b>Noller</b>	Vagus Nerve Stimulation as an Immunomodulatory Therapy for Acute Spinal Cord Injury	Wings for Life Spinal Cord Research Foundation	2021-2023	\$117,215	\$234,430
<b>Okamura &amp; Shimabukuro (Zimmerman – Site PI)</b>	Participatory System Dynamics Modeling	SAMHSA	2022-2026	\$449,016	\$1,868,991
<b>Sareen (Pietrzak – Site PI)</b>	Defining the Longitudinal Course, Outcomes, and Treatment Needs of Vulnerable Canadians with Posttraumatic Stress Disorder	Canadian Institutes of Health Research	2015-2022	\$0	\$2,386,073
<b>Taft</b>	Strength at Home: Promoting Healthy Relationships, Healing Trauma, Breaking the Cycle of Violence	Mother Cabrini Health Foundation	2021-2022	\$185,463	\$185,463
<b>Wiltsey Stirman</b>	Gavin Farrell Foundation CPT Training Initiative	Gavin Farrell Foundation	2019-2030	\$64,090	\$64,090
<b>Wiltsey Stirman &amp; Kaysen</b>	A Web-Based Intervention for Healthcare Workers Impacted by COVID-19	Huang Family Foundation	2021-2022	\$1,000,000	\$1,300,000
<b>Wiltsey Stirman</b>	Adaptive Digital Mental Health Tools to Improve COVID-19 Mental Health among Healthcare Workers	The Jen-Hsun and Lori Huang Foundation Digital Mental Health Platform Fund	2021-2022	\$500,000	\$1,000,000
<b>Wolf</b>	The Utility of MMPI-2 RF in Informing VA Pain Clinic Care	University of Minnesota Press, Test Division	2016-2022	\$0	\$24,000

BPD Borderline Personality Disorder; COVID-19 Coronavirus Disease 2019; Ci2i Center for Innovation to Implementation; CPT Cognitive Processing Therapy; DSM-5 Diagnostic and Statistical Manual - Version 5; HCS Health Care System; HSR&D Health Services Research and Development; FEMA Federal Emergency Management Agency; LGBTQ+ Lesbian Gay Bisexual Transgender Queer; MMPI-2 RF Minnesota Multiphasic Personality Inventory-2 Restructured Form; NARSAD National Alliance for Research on Schizophrenia & Depression; PCORI Patient-Centered Outcomes Research Institute; PI Principal Investigator; PSSI-5 PTSD Symptom Scale Interview for DSM-5; PTSD Posttraumatic Stress Disorder; SAMHSA Substance Abuse and Mental Health Services Administration; SUD substance use disorder; VA Department of Veterans Affairs

## Projects Pending Funding

Principal Investigator	Research Title	Funding Source	Years	Total Funding
Bean & Scioli	The VA REAP Center for Rehabilitative Care: Optimizing Mobility, the Mind, and Motivation	VA RR&D	2021-2025	\$1,570,721
Colvonen	Examining Early Intervention OSA PAP Treatment on Long-Term Outcomes in Veterans with SUD/PTSD in a Residential Treatment Program	VA RR&D	2022-2023	\$1,378,409
Forbush & Mitchell	Assessment of Eating Disorder and Comorbidity Risk and Resilience in a Nationally Representative Sample of Recent Military Enlistees	DoD	2023-2026	\$673,823
Forbush (Mitchell -Site PI)	Integrative Therapy for Veterans with Eating Disorders and Trauma	DoD	2023-2026	\$1,162,190
Hallenbeck	Virtual Care CORE Associate Investigator Funding	VA HSR&D	2023	\$23,500
Harpaz-Rotem	Using Ketamine to Enhance Memory Reconsolidation and Extinction of Overgeneralized Fear in Individuals Diagnosed with PTSD	NIH NIMH	2023-2028	\$8,322,871
Holtzheimer	Targeted Brain Stimulation to Enhance Recovery after Shockwave-Induced Blast TBI: Identifying Neural Biomarkers to Guide Treatment	VA BLR&D	2023-2027	\$1,200,000
Lee, D. & Esterman	Suicide Risk Interventions: A Comparison of Treatment Dose and Neural Markers of Treatment Outcome	VA CSR&D	2023-2027	\$1,195,952
Livingston & Simpson	Adapting and Evaluating a Web-Based Intervention for Women Veterans: Women's VetChange for Unsafe Drinking and PTSD Symptoms	NIH NIAAA	2022-2027	\$2,577,895
Macia	Implementation of a Trauma-Informed Skills Intervention to Improve Outcomes for Homeless Veterans	VA HSR&D	2023-2028	\$939,914
Miller	Post-Acute Sequelae of SARS-CoV-2 Infection and the Aging Brain	NIH Other	2023-2028	\$3,149,949
Mitchell	The Impact of Trained Provider Teams on Diagnosis and Treatment of Eating Disorders in the Veterans Healthcare Administration	DoD	2023-2026	\$793,109
Morey, Logue & Nievergelt	Genomic Architecture of Functional Brain Networks in PTSD	NIH NIMH	2023-2027	\$2,756,174
Noller	Harnessing the Cholinergic Inflammatory Reflex to Alter Neuroinflammation and Neuropsychiatric Consequences Following Traumatic Brain Injury	VA CDA	2023-2027	\$1,124,900

Principal Investigator	Research Title	Funding Source	Years	Total Funding
Rosenfeld	Virtual Care CORE Associate Investigator Funding: Expanding and Adapting webSTAIR-NT for LGBTQ+ Veterans	VA HSR&D	2022-2023	\$25,000
Sripada (Kuhn - Site PI)	Testing Adaptive Interventions to Improve PTSD Treatment Outcomes in Federally Qualified Health Centers	NIH NIMH	2022-2026	\$2,500,000

BLR&D Biomedical Laboratory Research and Development Service; CDA Career Development Award; CORE Consortium of Research; CSR&D Clinical Science Research and Development Service; DoD Department of Defense; HSR&D Health Services Research and Development Service; LGBTQ+ Lesbian Gay Bisexual Transgender Queer; NIAAA National Institute on Alcohol Abuse and Alcoholism; NIH National Institutes of Health; NIMH National Institute of Mental Health; OSA obstructive sleep apnea; PAP positive airway pressure; PI Principal Investigator; PTSD Posttraumatic Stress Disorder; REAP Research Enhancement Award Program; RR&D Rehabilitation Research and Development Service; SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2; SUD Substance Use Disorder; TBI traumatic brain injury; VA Department of Veterans Affairs; webSTAIR-NT web-based Skills Training in Affective and Interpersonal Regulation Narrative Therapy



# Appendix D: Publications

1. **Abdallah, C.**, Roache, J. D., Gueorguieva, R., **Averill, L.**, Young-McCaughan, S., Shiroma, P. R., **Purohit, P.**, Brundige, A., Murff, B., Ahn, K. H., Sherif, M. A., Baltutis, E. J., **Ranganathan, M.**, D'Souza, D., **Martini, B.**, Southwick, S. M., **Petrakis, I.**, Burson, R. R., ... **Keane, T. M.**, ... & **Krystal, J. H.** (2022). Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial. *Neuropsychopharmacology*, *47*, 1574-1581. doi:10.1038/s41386-022-01266-9
2. **Abdallah, C.**, Roache, J., Gueorguieva, R., Averill, L., Young-McCaughan, S., Shiroma, P., **Purohit, P.**, Brundige, A., Murff, W., Ahn, K., Sherif, M., Baltutis, E., **Ranganathan, M.**, D'Souza, D., **Martini, B.**, Southwick, S., **Petrakis, I.**, Burson, R., ... **Keane, T. M.**, ... & **Krystal, J. H.** (2022). Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial. *Neuropsychopharmacology*, *47*, 1583-1584. doi:10.1038/s41386-022-01339-9
3. Adams, T., Cisler, J., **Kelmendi, B.**, George, J., Kichuk, S., **Averill, C. L.**, **Anticevic, A.**, **Abdallah, C.**, & Pittenger, C. (2022). Transcranial direct current stimulation targeting the medial prefrontal cortex modulates functional connectivity and enhances safety learning in obsessive-compulsive disorder: Results from two pilot studies. *Depression and Anxiety*, *39*, 37-48. doi:10.1002/da.23212
4. Aljishi, A., Sandhu, M., Shaikh, N., Wise, T., **Krystal, J. H.**, **Kaye, A.**, & Damisah, E. (2022). Intracranial electrophysiology of amygdala-insula interactions in anxiety. *Biological Psychiatry*, *91*, S144-S145. doi:10.1016/j.biopsych.2022.02.377
5. Ameral, V., Hocking, E., **Leviyah, X.**, Newberger, N. G., Timko, C., & **Livingston, N.** (2022). Innovating for real-world care: A systematic review of interventions to improve post-detoxification outcomes for opioid use disorder. *Drug and Alcohol Dependence*, *233*, 109379. doi:10.1016/j.drugalcdep.2022.109379
6. Asch, R., **Esterlis, I.**, Wendt, F., **Kachadourian, L.**, Southwick, S., **Gelernter, J.**, Polimanti, R., & **Pietrzak, R. H.** (2021). Polygenic risk for traumatic loss-related PTSD in US military veterans: Protective effect of secure attachment style. *The World Journal of Biological Psychiatry*, *22*, 792-799. doi:10.1080/15622975.2021.1907721
7. Asch, R., **Holmes, S.**, Jastreboff, A., **Potenza, M.**, Baldassarri, S., Carson, R., **Pietrzak, R. H.**, & **Esterlis, I.** (2022). Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. *Neuropsychopharmacology*, *47*, 543-552. doi:10.1038/s41386-021-01111-5
8. Asch, R., **Kachadourian, L.**, Southwick, S., **Esterlis, I.**, & **Pietrzak, R. H.** (2021). Psychological resilience to the challenges of physical aging in older U.S. veterans: Results from the 2019-2020 National Health and Resilience in Veterans Study. *The American Journal of Geriatric Psychiatry*, *29*, 1280-1285. doi:10.1016/j.jagp.2021.04.013
9. Asch, R., Pothula, S., Toyonaga, T., Fowles, K., Groman, S., Garcia-Milian, R., DiLeone, R., Taylor, J., & **Esterlis, I.** (2022). Examining sex differences in responses to footshock stress and the role of the metabotropic glutamate receptor 5: An [18F]FPEB and positron emission tomography study in rats. *Neuropsychopharmacology*. doi:10.1038/s41386-022-01441-y
10. Atkinson, E., Bianchi, S., Ye, G., Martínez-Magaña, J., Tietz, G., **Montalvo-Ortiz, J. L.**, Giusti-Rodriguez, P., Palmer, A., & Sanchez-Roige, S. (2022). Cross-ancestry genomic research: Time to close the gap. *Neuropsychopharmacology*, *47*, 1737-1738. doi:10.1038/s41386-022-01365-7
11. Averill, L., Averill, C., Gueorguieva, R., **Fouda, S.**, Sherif, M., Ahn, K., Ranganathan, M., **D'Souza, D.**, Southwick, S., Sanacora, G., Duman, R., **Krystal, J. H.**, & Abdallah, C. (2022). mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. *Journal of Affective Disorders*, *303*, 91-97. doi:10.1016/j.jad.2022.01.104

12. Averill, L., Jiang, L., **Purohit, P.**, Coppoli, A., Averill, C., Roscoe, J., **Kelmendi, B.**, DeFeyter, H., de Graaf, R., Gueorguieva, R., Sanacora, G., **Krystal, J. H.**, Rothman, D., Mason, G., & **Abdallah, C.** (2022). Prefrontal glutamate neurotransmission in PTSD: A novel approach to estimate synaptic strength in vivo in humans. *Chronic Stress*. doi:10.1177/24705470221092734
13. **Azevedo, K. J.**, Kalvesmaki, A., Riendeau, R., Sweet, P., & Holmes, S. (2022). Leveraging anthropological expertise to respond to the Covid-19 global mental health syndemic. *American Anthropologist*, *124*, 622-627. doi:10.1111/aman.13747
14. Babcock, K., Abdolmohammadi, B., Kiernan, P., Mahar, I., Cherry, J., Alvarez, V., Goldstein, L., Stein, T., McKee, A., & **Huber, B.** (2022). Interface astrogliosis in contact sport head impacts and military blast exposure. *Acta Neuropathological Communications*. doi:10.1186/s40478-022-01358-z
15. **Banducci, A. N.** (2021). Prolonged Exposure therapy in the time of Covid-19: Modifying PTSD treatment for a military sexual trauma survivor who contracted Covid-19 mid-treatment. *Clinical Case Studies*, *20*, 331-349. doi:10.1177/1534650121993547
16. Bardeen, J., Gorday, J., & **Weathers, F. W.** (2022). Executive functioning deficits exacerbate posttraumatic stress symptoms: A longitudinal mediation model. *Journal of Anxiety Disorders*, *87*, 102556. doi:10.1016/j.janxdis.2022.102556
17. Barron, D., Heisig, S., Agurto, C., Norel, R., Quagan, B., Powers, A., Birnbaum, M., Constable, T., Cecchi, G., & **Krystal, J. H.** (2022). Feasibility analysis of phenotype quantification from unstructured clinical interactions. *Computational Psychiatry*. doi:10.5334/cpsy.78
18. Basu, A., Yu, A., Yang, J., Li, Y., & **Kaye, A.** (2022). Prefrontal cortex norepinephrine represents predictability of aversive events. *Biological Psychiatry*, *91*, S336. doi:10.1016/j.biopsych.2022.02.846
19. Bayley, P. J., Schulz-Heik, R. J., Tang, J. S., Mathersul, D. C., **Avery, T.**, Wong, M., Zeitzer, J., **Rosen, C. S.**, Burn, A. S., Hernandez, B., Lazzaroni, L., & Seppala, E. M. (2022). Randomised clinical non-inferiority trial of breathing-based meditation and Cognitive Processing Therapy for symptoms of post-traumatic stress disorder in military veterans. *BMJ Open*. doi:10.1136/bmjopen-2021-056609
20. Beidas, R. S., Dorsey, S., Lewis, C. C., Lyon, A. R., Powell, B. J., Purtle, J., Saldana, L., Shelton, R., **Wiltsey Stirman, S.**, & Lane-Fall, M. B. (2022). Promises and pitfalls in implementation science from the perspective of US-based researchers: Learning from a pre-mortem. *Implementation Science*. doi:10.1186/s13012-022-01226-3
21. Belon, K., **Serier, K.**, VanderJagt, H., & Smith, J. (2022). What is healthy eating? Exploring profiles of intuitive eating and nutritionally healthy eating in college women. *American Journal of Health Promotion*, *36*, 823-833. doi:10.1177/08901171211073870
22. Berke, D. S., Ruben, M. A., Liautaud, M. M., Meterko, M., Kauth, M. R., & **Shipherd, J. C.** (2022). Discrimination exposure based on race, gender, and sexual orientation of veterans healthcare administration patients. *Journal of Health Care for the Poor and Underserved*, *33*, 714-725. doi:10.1353/hpu.2022.0058
23. Bernstein, J. P., Stumps, A., Fortenbaugh, F., Fonda, J. R., McGlinchey, R. E., Milberg, W. P., **Esterman, M.**, & DeGutis, J. (2022). Associations between changes in somatic and psychiatric symptoms and disability alterations in recent-era U.S. veterans. *Journal of Traumatic Stress*, *35*, 1011-1024. doi:10.1002/jts.22809
24. Bhatt, S., Hillmer, A., Rusowicz, A., Nabulsi, N., Matuskey, D., Angarita, G., Najafzadeh, S., Kapinos, M., Southwick, S., **Krystal, J. H.**, Carson, R., **Huang, Y.**, & **Cosgrove, K.** (2021). Imaging brain cortisol regulation in PTSD with a target for 11 $\beta$ -hydroxysteroid dehydrogenase type 1. *Journal of Clinical Investigation*. doi:10.1172/JCI150452
25. Blonigen, D. M., Harris-Olenak, B., **Kuhn, E. R.**, Timko, C., Humphreys, K., & Dulin, P. (2021). Using peers to increase veterans' engagement in a smartphone application for unhealthy alcohol use: A pilot study of acceptability and utility. *Psychology of Addictive Behaviors*, *35*, 829-839. doi:10.1037/adb0000598
26. Bondar, J., Babich Morrow, C., Gueorguieva, R., Brown, M., Hawrilenko, M., **Krystal, J. H.**, Corlett, P., & Chekroud, A. (2022). Clinical and financial outcomes associated with a workplace mental health program before and during the Covid-19 pandemic. *JAMA Network Open*. doi:10.1001/jamanetworkopen.2022.16349

27. Bonomi, R., **Girgenti, M. J.**, **Krystal, J. H.**, & **Cosgrove, K.** (2022). A role for histone deacetylases in the biology and treatment of post-traumatic stress disorder: What do we know and where do we go from here? *Complex Psychiatry*, 8, 13-27. doi:10.1159/000524079
28. Borges, L. M., Barnes, S. M., Farnsworth, J., **Drescher, K.**, & **Walser, R. D.** (2022). Case conceptualizing in Acceptance and Commitment Therapy for moral injury: An active and ongoing approach to understanding and intervening on moral injury. *Frontiers in Psychiatry*. doi:10.3389/fpsy.2022.910414
29. Borges, L. M., Barnes, S. M., Farnsworth, J., Evans, W., Moon, Z., **Drescher, K.**, & **Walser, R. D.** (2022). Cultivating psychological flexibility to address religious and spiritual suffering in moral injury. *Journal of Health Care Chaplaincy*. doi:10.1080/08854726.2022.2031467
30. **Borowski, S.**, Rosellini, A. J., **Street, A. E.**, **Gradus, J. L.**, & **Vogt, D.** (2022). The first year after military service: Predictors of U.S. veterans' suicidal ideation. *American Journal of Preventive Medicine*, 63, 233-241. doi:10.1016/j.amepre.2022.03.017
31. Boyer, T. L., Rodriguez, K. L., Hruska, K. L., Klima, G. J., Vazzano, J. K., **Shipherd, J. C.**, Kauth, M. R., Montgomery, A. E., & Blossnich, J. R. (2021). Tailored recruitment strategies among transgender and non-transgender veterans: Participants' perceptions and response. *Military Behavioral Health*, 9, 181-189. doi:10.1080/21635781.2020.1837306
32. Boyer, T., Youk, A., Haas, A., Brown, G., **Shipherd, J. C.**, Kauth, M. R., Jasuja, G., & Blossnich, J. (2021). Suicide, homicide, and all-cause mortality among transgender and cisgender patients in the Veterans Health Administration. *LGBT Health*, 8, 173-180. doi:10.1089/lgbt.2020.0235
33. Bredemeier, K., **Larsen, S.**, Shivakumar, G., Grubbs, K., **McLean, C. P.**, Tress, C., Rosenfield, D., DeRubeis, R., Xu, C., Foa, E., **Morland, L. A.**, Pai, A., Tsao, C., Crawford, J., Weitz, E., Mayinja, L., Feler, B., Wachsmann, T., Lupo, M., . . . & Thase, M. E. (2022). A comparison of Prolonged Exposure therapy, pharmacotherapy, and their combination for PTSD: What works best and for whom; study protocol for a randomized trial. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2022.106850
34. Brennan, L. A., Brady, J. E., Drummond, K. L., **Wiltsey Stirman, S.**, Gutner, C. A., & **Iverson, K. M.** (2022). Mental health clinician perspectives regarding factors impacting implementation of evidence-based psychotherapies in Veterans Health Administration community-based outpatient clinics. *General Hospital Psychiatry*, 75, 54-60. doi:10.1016/j.genhosppsych.2022.01.001
35. Brienza, A., Suffoletto, B. P., **Kuhn, E. R.**, Germain, A., Jaramillo, S., Repine, M., Callaway, C. W., & Maria, L. (2021). The role of specific sources of social support on postinjury psychological symptoms. *Rehabilitation Psychology*, 66, 600-610. doi:10.1037/rep0000388
36. Brown, B., Goodman, F., **Pietrzak, R. H.**, & Rottenberg, J. (2022). Psychological well-being in US veterans with non-fatal suicide attempts: A multi-cohort population-based study. *Journal of Affective Disorders*, 314, 34-43. doi:10.1016/j.jad.2022.07.003
37. Brown, L. A., Bryan, C. J., Tabares, J. V., Young-McCaughan, S., Hale, W. J., Fina, B. A., Foa, E. B., Resick, P. A., Taylor, D. J., Coon, H., Williamson, D. E., Dondanville, K. A., Borah, E. V., **McLean, C. P.**, **Wachen, J. S.**, Pruiksma, K. E., Hernandez, A. M., Litz, B. T., Mintz, J., . . . & Peterson, A. L. (2021). Identifying suicidal subtypes and dynamic indicators of increasing and decreasing suicide risk in active duty military personnel: Study protocol. *Contemporary Clinical Trials Communications*. doi:10.1016/j.conctc.2021.100752
38. Browne, K., Leyva, Y., Malte, C., Lapham, G., & **Tiet, Q. Q.** (2022). Prevalence of medical and nonmedical cannabis use among veterans in primary care. *Psychology of Addictive Behaviors*, 36, 121-130. doi:10.1037/adb0000725
39. Bryant, R. A., Greenberg, N., Forbes, D., & **Schnurr, P. P.** as part of 5-Eyes Mental Health Research and Innovation Collaborative in Military and Veteran Mental Health Group (2021). The effect of the withdrawal from Afghanistan on military personnel's mental health. *The Lancet Psychiatry*, 8, 1026-1027. doi:10.1016/S2215-0366(21)00369-2
40. Bryant, R., **Schnurr, P. P.**, & Pedlar, D. (2022). Addressing the mental health needs of civilian combatants in Ukraine. *The Lancet Psychiatry*, 9, 346-347. doi:10.1016/s2215-0366(22)00097-9
41. Bryant, W. T., **Livingston, N.**, Choate, K. T., Harkness, A. R., & Brummel, B. J. (2021). Examining Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) scale scores in a transgender and gender diverse sample. *Psychological Assessment*, 33, 1239-1246. doi:10.1037/pas0001087

42. **Carpenter, J. K.**, Bragdon, L., & **Pineles, S. L.** (2022). Conditioned physiological reactivity and PTSD symptoms across the menstrual cycle: Anxiety sensitivity as a moderator. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, 453-461. doi:10.1037/tra0001129
43. **Carpenter, J.K.**, Moskow, D., & Hofmann, S. (2022). Enhanced mental reinstatement of exposure to improve extinction generalization: A study on claustrophobia and MRI fear. *Behavior Therapy*. doi:10.1016/j.beth.2022.08.002
44. Carr, M., Serowik, K., Na, P., **Potenza, M.**, Martino, S., Masheb, R., & **Pietrzak, R. H.** (2022). Co-occurring alcohol use disorder and obesity in U.S. military veterans: Prevalence, risk factors, and clinical features. *Journal of Psychiatric Research*, *150*, 64-70. doi:10.1016/j.jpsychires.2022.03.039
45. Cezard, T., Cunningham, F., Hunt, S., Koylass, B., Kumar, N., Saunders, G., Shen, A., Silva, A., Tsukanov, K., Venkataraman, S., Flicek, P., Parkinson, H., & **Keane, T. M.** (2022). The European variation archive: A FAIR resource of genomic variation for all species. *Nucleic Acids Research*, *50*, D1216-D1220. doi:10.1093/nar/gkab960
46. Cha, C., Robinaugh, D., Schacter, D., Alzheimer, G., **Marx, B. P.**, **Keane, T. M.**, **Kearns, J. C.**, & Nock, M. (2022). Examining multiple features of episodic future thinking and episodic memory among suicidal adults. *Suicide and Life-Threatening Behavior*, *52*, 356-372. doi:10.1111/slbt.12826
47. Chatzinakos, C., Schuler, H., Ressler, K., Snijders, C., **Girgenti, M. J.**, & Daskalakis, N. (2022). Approach to dissect PTSD systems biology across ancestries: From genetics to cell type-specific mechanisms. *Biological Psychiatry*, *91*, S2-S3. doi:10.1016/j.biopsych.2022.02.025
48. Chiu, C., **Gnall, K.**, **Pless Kaiser, A.**, **Taft, C. T.**, Franz, M. R., **Lee, L. O.**, & **Vasterling, J. J.** (2022). Neurocognitive performance predicts future partner violence among U.S. Iraq- and Afghanistan-deployed army soldiers and veterans. *Psychology of Violence*, *12*, 160-169. doi:10.1037/vio0000408
49. Clausen, A., Fercho, K., Monsour, M., Disner, S., Salminen, L., Haswell, C., Rubright, E., Watts, A., Buckley, M., Maron-Katz, A., Sierk, A., Manthey, A., Suarez-Jimenez, B., Olatunji, B., Averill, C., Hofmann, D., Veltman, D., Olson, E., Li, G., . . . **Krystal, J. H.**, . . . & Morey, R. (2022). Assessment of brain age in posttraumatic stress disorder: Findings from the ENIGMA PTSD and brain age working groups. *Brain and Behavior*. doi:10.1002/brb3.2413
50. **Cloitre, M.**, Amspoker, A., Fletcher, T. L., Hogan, J. B., Jackson, C., Jacobs, A., Shammet, R., Speicher, S., Wassef, M., & Lindsay, J. A. (2022). Comparing the ratio of therapist support to internet sessions in a blended therapy delivered to trauma-exposed veterans: Quasi-experimental comparison study. *JMIR Mental Health*. doi:10.2196/33080
51. **Cole, H. E.**, Gilbar, O., **Gnall, K.**, Eckhardt, C. I., & **Taft, C. T.** (2021). Examining executive functioning as a moderator of intimate partner violence risk in veterans. *Journal of Family Violence*, *10*, 22-35. doi:10.1007/s10896-021-00339-5
52. Coleman, J. N., Batchelder, A. W., Kirakosian, N., Choi, K. W., **Shipherd, J. C.**, Bedoya, C. A., Safren, S. A., Ironson, G., & O’Cleirigh, C. M. (2022). Indirect effects of dissociation on the relationship between lifetime PTSD symptoms and condomless sex among men who have sex with men with a history of childhood sexual abuse. *Journal of Trauma & Dissociation*, *23*, 279-295. doi:10.1080/15299732.2021.1989118
53. Comer, J., Conroy, K., Cornacchio, D., Furr, J., **Norman, S. B.**, & Stein, M. (2022). Psychometric evaluation of a caregiver-report adaptation of the Overall Anxiety Severity and Impairment Scale (OASIS) for use with youth populations. *Journal of Affective Disorders*, *300*, 341-348. doi:10.1016/j.jad.2021.12.113
54. Contractor, A., **Banducci, A. N.**, & Jin, L. (2022). The relationship between positive memory phenomenology and alcohol use among trauma-exposed individuals. *Substance Use & Misuse*, *57*, 929-939. doi:10.1080/10826084.2022.2052099
55. Contractor, A., **Banducci, A. N.**, & Weiss, N. (2022). Critical considerations for the positive memory-posttraumatic stress disorder model. *Clinical Psychology & Psychotherapy*, *29*, 81-91. doi:10.1002/cpp.2599
56. Contractor, A., Caldas, S., **Banducci, A. N.**, & Armour, C. (2022). A pilot study examining roles of cognitions and affect between positive memory processing and posttraumatic stress disorder symptom severity. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, 661-668. doi:10.1037/tra0000625
57. Cowlshaw, S., Freijah, I., Kartal, D., Sbisà, A., Mulligan, A., Notarianni, M., Couineau, A., Forbes, D., O’Donnell, M., Phelps, A., **Iverson, K. M.**, Heber, A., O’Dwyer, C., Smith, P., & Hosseiny, F. (2022). Intimate partner violence (IPV) in military and veteran populations: A systematic review of population-based surveys and population screening studies. *International Journal of Environmental Research and Public Health*, *19*, 8853. doi:10.3390/ijerph19148853

58. Creech, S. K., Pearson, R., Saenz, J., Braciszewski, J., Riggs, S., & Taft, C. T. (2022). Pilot trial of Strength at Home Parents: A trauma-informed parenting support treatment for veterans. *Couple and Family Psychology: Research and Practice, 11*, 205-216. doi:10.1037/cfp0000232
59. Cypel, Y., Schnurr, P. P., Schneiderman, A., Culpepper, W., Akhtar, F., Morley, S., Fried, D., Ishii, E., & Davey, V. (2022). The mental health of Vietnam theater veterans—the lasting effects of the war: 2016–2017 Vietnam Era Health Retrospective Observational Study. *Journal of Traumatic Stress, 35*, 605-618. doi:10.1002/jts.22775
60. Cyr, G., Godbout, N., Cloitre, M., & Bélanger, C. (2022). Distinguishing among symptoms of posttraumatic stress disorder, complex posttraumatic stress disorder, and borderline personality disorder in a community sample of women. *Journal of Traumatic Stress, 35*, 186-196. doi:10.1002/jts.22719
61. Dan, O., Wertheimer, E., & Levy, I. (2022). A neuroeconomics approach to obesity. *Biological Psychiatry, 91*, 860-868. doi:10.1016/j.biopsych.2021.09.019
62. Danan, E., Brunner, J., Bergman, A., Spoont, M., Chanfreau, C., Canelo, I., Krebs, E., & Yano, E. (2022). The relationship between sexual assault history and cervical cancer screening completion among women veterans in the Veterans Health Administration. *Journal of Women's Health, 31*, 1040-1047. doi:10.1089/jwh.2021.0237
63. Daphna-Tekoah, S., Harel-Shalev, A., & Harpaz-Rotem, I. (2021). Thank you for hearing my voice – listening to women combat veterans in the United States and Israeli militaries. *Frontiers in Psychology*. doi:10.3389/fpsyg.2021.769123
64. Davin, K., Dardis, C., Barth, M., & Iverson, K. M. (2022). Prospective mental health effects of intimate partner stalking among women veterans. *Psychological Trauma: Theory, Research, Practice, and Policy, 14*, 751-758. doi:10.1037/tra0001144
65. De Angelis, F., Wendt, F., Pathak, G., Tylee, D., Goswami, A., Gelernter, J., & Polimanti, R. (2021). Drinking and smoking polygenic risk is associated with childhood and early-adulthood psychiatric and behavioral traits independently of substance use and psychiatric genetic risk. *Translational Psychiatry*. doi:10.1038/s41398-021-01713-z
66. Deak, J., Zhou, H., Galimberti, M., Levey, D., Wendt, F., Sanchez-Roige, S., Hatoum, A., Johnson, E., Nunez, Y., Demontis, D., Børglum, A., Rajagopal, V., Jennings, M., Kember, R., Justice, A., Edenberg, H., Agrawal, A., Polimanti, R., Kranzler, H., & Gelernter, J. (2022). Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci. *Molecular Psychiatry*. doi:10.1038/s41380-022-01709-1
67. Dichter, M., Krishnamurti, L., Chhatre, S., Hoffmire, C., Monteith, L., Bellamy, S., Iverson, K. M., Montgomery, A., Agha, A., & McCoy, I. (2022). Gender differences in veterans' use of the Veterans Crisis Line (VCL): Findings from VCL call data. *General Hospital Psychiatry, 74*, 65-70. doi:10.1016/j.genhosppsych.2021.12.006
68. Dichter, M., Ogden, S., Tuepker, A., Iverson, K. M., & True, G. (2021). Survivors' input on health care-connected services for intimate partner violence. *Journal of Women's Health, 30*, 1744-1750. doi:10.1089/jwh.2020.8585
69. DiNardo, M., Greco, C., Phares, A., Beyer, N., Youk, A., Obrosky, D., Morone, N., Owen, J. E., Saba, S., Suss, S., & Siminerio, L. (2022). Effects of an integrated mindfulness intervention for veterans with diabetes distress: A randomized controlled trial. *BMJ Open Diabetes Research & Care*. doi:10.1136/bmjdr-2021-002631
70. Dong, L., Meredith, L., Farmer, C., Ahluwalia, S., Chen, P., Bouskill, K., Han, B., Qureshi, N., Dalton, S., Watson, P., Schnurr, P. P., Davis, K., Tobin, J., Cassells, A., & Gidengil, C. (2022). Protecting the mental and physical well-being of frontline health care workers during Covid-19: Study protocol of a cluster randomized controlled trial. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2022.106768
71. Doyle, K. W., Knetig, J. A., & Iverson, K. M. (2022). Practical implications of research on intimate partner violence experiences for the mental health clinician. *Current Treatment Options in Psychiatry, 9*, 280-300. doi:10.1007/s40501-022-00270-6
72. du Pont, A., Stanley, I. H., Pruitt, L., & Reger, M. A. (2021). Local implementation evaluation of a suicide prevention predictive model at a large VA health care system. *Suicide and Life-Threatening Behavior*. doi:10.1111/sltb.12810

73. **Duek, O.**, Spiller, T., Rubenstein, A., **Pietrzak, R. H.**, & **Harpaz-Rotem, I.** (2022). Exploration of a novel model of intrusive symptoms in posttraumatic stress disorder among US veterans. *JAMA Network Open*. doi:10.1001/jamanetworkopen.2022.3555
74. Edwards, E. R., Dichiara, A., Gromatsky, M., Tsai, J., Goodman, M., & **Pietrzak, R. H.** (2022). Understanding risk in younger veterans: Risk and protective factors associated with suicide attempt, homelessness, and arrest in a nationally representative veteran sample. *Military Psychology*, *34*, 175-186. doi:10.1080/08995605.2021.1982632
75. Eglit, G., Elman, J., Panizzon, M., Sanderson-Cimino, M., Williams, L. M., Dale, A., Eyler, L. T., Fennema-Notestine, C., Gillespie, N., Gustavson, D., Hatton, S., Hagler, D., Hauger, R. L., Jak, A. J., **Logue, M. W.**, McEvoy, L., McKenzie, R., Neale, M., Puckett, O, . . . & Kremen, W. S. (2022). Paradoxical cognitive trajectories in men from earlier to later adulthood. *Neurobiology of Aging*, *109*, 229-238. doi:10.1016/j.neurobiolaging.2021.10.002
76. **Eliacin, J.**, Burgess, D. J., Rollins, A. L., Patterson, S., Damush, T., Bair, M. J., Salyers, M. P., **Spoont, M.**, Slaven, J. E., O'Connor, C., Walker, K., Zou, D. S., Austin, E., Akins, J., Miller, J., Chinman, M., & Matthias, M. S. (2022). Proactive, recovery-oriented treatment navigation to engage racially diverse veterans in mental healthcare, a peer-led patient navigation intervention for racially and ethnically minoritized veterans. *JMIR Research Protocols*. doi:10.2196/37712
77. **Esterlis, I.**, DeBonne, S., Cool, R., **Holmes, S.**, Baldassari, S., Maruff, P., **Pietrzak, R. H.**, & **Davis, M.** (2022). Differential role of mGluR5 in cognitive processes in posttraumatic stress disorder and major depression. *Chronic Stress*. doi:10.1177/24705470221105804
78. Evans, T. C., DeGutis, J., **Rothlein, D.**, **Jagger-Rickels, A.**, Yamashita, A., Fortier, C. B., & **Esterman, M.** (2021). Punishment and reward normalize error-related cognitive control in PTSD by modulating salience network activation and connectivity. *Cortex*, *145*, 295-314. doi:10.1016/j.cortex.2021.09.004
79. **Evans, T.**, Alonso, M., **Jagger-Rickels, A.**, **Rothlein, D.**, Zuberer, A., Bernstein, J., Fortier, C., Fonda, J., Villalon, A., Jorge, R., Milberg, W., McGlinchey, R., DeGutis, J., & **Esterman, M.** (2022). PTSD symptomatology is selectively associated with impaired sustained attention ability and dorsal attention network synchronization. *NeuroImage: Clinical*. doi:10.1016/j.nicl.2022.103146
80. Fein-Schaffer, D., **Hawn, S. E.**, **Annunziata, A.**, Ryabchenko, K., **Miller, M. W.**, & **Wolf, E. J.** (2022). Premorbid traumatic stress and veteran responses to the Covid-19 pandemic. *Journal of Traumatic Stress*, *35*, 559-569. doi:10.1002/jts.22770
81. Flanagan, J., Nietert, P., **Sippel, L. M.**, Jarnecke, A., Kirby, C., Hogan, J., Massa, A., Brower, J., Back, S., & Parrott, D. (2022). A randomized controlled trial examining the effects of intranasal oxytocin on alcohol craving and intimate partner aggression among couples. *Journal of Psychiatric Research*, *152*, 14-24. doi:10.1016/j.jpsychires.2022.06.011
82. Fletcher, T. L., Wassef, M., Helm, A., Jackson, C., Jacobs, A., Speicher, R., Lindsay, S., & **Cloitre, M.** (2022). Increasing access to care for trauma-exposed rural veterans: A mixed methods outcome evaluation of a web-based skills training program with telehealth-delivered coaching. *The Journal of Rural Health*, *38*, 740-747. doi:10.1111/jrh.12628
83. Foa, E., Bredemeier, K., Acierno, R., Rosenfield, D., Muzzy, W., Tuerk, P., Zandberg, L., Hart, S., Young-McCaughan, S., Peterson, A., & **McLean, C. P.** (2022). The efficacy of 90-min versus 60-min sessions of Prolonged Exposure for PTSD: A randomized controlled trial in active-duty military personnel. *Journal of Consulting and Clinical Psychology*, *90*, 503-512. doi:10.1037/ccp0000739
84. Fondren, A., **Banducci, A. N.**, Cox, R., & Contractor, A. (2022). Processing of positive memories technique among clients reporting traumatic experiences: A case series. *Clinical Case Studies*, *21*, 61-81. doi:10.1177/15346501211035841
85. Forsberg, C., Estrada, S., Baraff, A., Magruder, K., Vaccarino, V., Litz, B., **Friedman, M. J.**, Goldberg, J., & Smith, N. (2022). Risk factors for suicide in the Vietnam-era twin registry. *Suicide and Life-Threatening Behavior*, *52*, 631-641. doi:10.1111/sltb.12848

86. Fortier, C., Beck, B., Werner, K., **Iverson, K. M.**, Kim, S., Currao, A., Fonda, J., & **Galovski, T. E.** (2021). The Boston assessment of traumatic brain injury-lifetime semistructured interview for assessment of TBI and subconcussive injury among female survivors of intimate partner violence. *Journal of Head Trauma Rehabilitation*. doi:10.1097/HTR.0000000000000700
87. Fortney, J. C., Bauer, A., Cerimele, J. M., Pyne, J. M., Pfeiffer, P., Heagerty, P. J., Hawrilenko, M., Zielinski, M. J., **Kaysen, D. L.**, Bowen, D. J., Moore, D. L., Ferro, L., Metzger, K., Shushan, S., Hafer, E., Nolan, J. P., Dalack, G. W., & Unützer, J. (2021). Comparison of teleintegrated care and telereferral care for treating complex psychiatric disorders in primary care. *JAMA Psychiatry*, *78*, 1189. doi:10.1001/jamapsychiatry.2021.2318
88. Fortney, J., Rajan, S., Reisinger, H., Moeckli, J., Nolan, J., Wong, E., Rise, P., Petrova, V., Sayre, G., Pyne, J. M., Grubaugh, A., Simsek-Duran, F., Grubbs, K., **Morland, L. A.**, Felker, B., & **Schnurr, P. P.** (2022). Deploying a telemedicine collaborative care intervention for posttraumatic stress disorder in the U.S. Department of Veterans Affairs: A stepped wedge evaluation of an adaptive implementation strategy. *General Hospital Psychiatry*, *77*, 109-117. doi:10.1016/j.genhosppsych.2022.03.009
89. Fox, A., **Vogt, D.**, Boyd, J., Earnshaw, V., Janio, E., Davis, K., Eikey, E., Schneider, M., Schueller, S., Stadnick, N., Zheng, K., Mukamel, D., & Sorkin, D. (2021). Mental illness, problem, disorder, distress: Does terminology matter when measuring stigma? *Stigma and Health*, *6*, 419-429. doi:10.1037/sah0000329
90. Fox, R., Hyland, P., Coogan, A., **Cloitre, M.**, & McHugh Power, J. (2022). Posttraumatic stress disorder, complex PTSD and subtypes of loneliness among older adults. *Journal of Clinical Psychology*, *78*, 321-342. doi:10.1002/jclp.23225
91. Franz, M. R., Sanders, W., **Nilni, Y. I.**, **Vogt, D.**, **Matteo, R.**, & **Galovski, T. E.** (2022). PTSD and parental functioning: The protective role of neighborhood cohesion among Black and White veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, S4-S12. doi:10.1037/tra0001123
92. **Froelich, J. M.**, Timko, C., & Woodhead, E. (2022). Motives for substance use and 6-month substance use outcomes among detoxification patients with a history of physical or sexual abuse or posttraumatic stress disorder. *Journal of Traumatic Stress*, *35*, 976-987. doi:10.1002/jts.22806
93. **Galovski, T. E.**, **Street, A. E.**, Creech, S. K., Lehavot, K., Kelly, U., & Yano, E. (2022). State of the knowledge of VA military sexual trauma research. *Journal of General Internal Medicine*, *37*, 825-832. doi:10.1007/s11606-022-07580-8
94. **Galovski, T. E.**, **Wachen, J. S.**, Chard, K. M., Monson, C. M., & Resick, P. A. (2022). Cognitive Processing Therapy. In U. Schnyder & M. Cloitre (Eds.), *Evidence based treatments for trauma-related psychological disorders: A practical guide for clinicians (2nd ed.)* (pp. 211-226). New York, NY: Springer.
95. **Galovski, T. E.**, Werner, K. B., Weaver, T. L., Morris, K. L., Dondanville, K. A., Nanney, J., Wamser-Nanney, R., McGlinchey, G., Fortier, C. B., & **Iverson, K. M.** (2022). Massed cognitive processing treatment for posttraumatic stress disorder in women survivors of intimate partner violence. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, 769-779. doi:10.1037/tra0001100
96. Ganesh, S., **Cortes-Briones, J.**, Schnakenberg Martin, A. M., Skosnik, P., **D'Souza, D.**, & **Ranganathan, M.** (2022). Delta-9-tetrahydrocannabinol, cannabidiol, and acute psychotomimetic states: A balancing act of the principal phyto-cannabinoids on human brain and behavior. *Cannabis and Cannabinoid Research*. doi:10.1089/can.2021.0166
97. **Gelernter, J.**, & Polimanti, R. (2021). Genetics of substance use disorders in the era of big data. *Nature Reviews Genetics*, *22*, 712-729. doi:10.1038/s41576-021-00377-1
98. Gelezelyte, O., Roberts, N., Kvedaraite, M., Bisson, J., Brewin, C., **Cloitre, M.**, Kairyte, A., Karatzias, T., Shevlin, M., & Kazlauskas, E. (2022). Validation of the International Trauma Interview (ITI) for the clinical assessment of ICD-11 posttraumatic stress disorder (PTSD) and complex PTSD (CPTSD) in a Lithuanian sample. *European Journal of Psychotraumatology*. doi:10.1080/20008198.2022.2037905
99. Germine, L., Joormann, J., Passell, E., Rutter, L., Scheuer, L., Martini, P., Hwang, I., Lee, S., Sampson, N., Barch, D., House, S., Beaudoin, F., An, X., Stevens, J., Zeng, D., Linnstaedt, S., Jovanovic, T., Clifford, G., . . . **Pietrzak, R. H.**, . . . & Kessler, R. (2022). Neurocognition after motor vehicle collision and adverse post-traumatic neuropsychiatric sequelae within 8 weeks: Initial findings from the AURORA study. *Journal of Affective Disorders*, *298*, 57-67. doi:10.1016/j.jad.2021.10.104

100. Gibson, R., **Whealin, J.**, Dasaro, C., Udasin, I., Crane, M., Moline, J., Harrison, D., Luft, B., Todd, A., Schechter, C., Lowe, S., Feder, A., & **Pietrzak, R. H.** (2022). Prevalence and correlates of suicidal ideation in World Trade Center responders: Results from a population-based health monitoring cohort. *Journal of Affective Disorders*, 306, 62-70. doi:10.1016/j.jad.2022.03.011
101. Gillespie, N., Hatton, S., Hagler, D., Dale, A., Elman, J., McEvoy, L., Eyler, L. T., Fennema-Notestine, C., **Logue, M. W.**, McKenzie, R., Puckett, O., Tu, X., Whitsel, N., Xian, H., Reynolds, C., Panizzon, M., Lyons, M., Neale, M., Kremen, W., & Franz, C. (2022). The impact of genes and environment on brain ageing in males aged 51 to 72 years. *Frontiers in Aging Neuroscience*. doi:10.3389/fnagi.2022.831002
102. **Girgenti, M. J.**, Pothula, S., & Newton, S. (2021). Stress and its impact on the transcriptome. *Biological Psychiatry*, 90, 102-108. doi:10.1016/j.biopsych.2020.12.011
103. **Goldfarb, E.**, Scheinost, D., Fogelman, N., Seo, D., & Sinha, R. (2022). High-risk drinkers engage distinct stress-predictive brain networks. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 7, 805-813. doi:10.1016/j.bpsc.2022.02.010
104. **Gorman, K. R.**, **Kearns, J. C.**, Pantalone, D. W., **Bovin, M. J.**, **Keane, T. M.**, & **Marx, B. P.** (2022). The impact of deployment-related stressors on the development of PTSD and depression among sexual minority and heterosexual female veterans. *Psychological Trauma: Theory, Research, Practice, and Policy*, 14, 747-750. doi:10.1037/tra0001102
105. **Gorman, K. R.**, **Shipherd, J. C.**, Collins, K., Gunn, H., Rubin, R., Rood, B., & Pantalone, D. (2022). Coping, resilience, and social support among transgender and gender diverse individuals experiencing gender-related stress. *Psychology of Sexual Orientation and Gender Diversity*, 9, 37-48. doi:10.1037/sgd0000455
106. Gottlieb, D., **Shiner, B.**, Hoyt, J., Riblet, N., Peltzman, T., Teja, N., & Watts, B. (2022). A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder. *Acta Psychiatrica Scandinavica*. doi:10.1111/acps.13477
107. **Gradus, J. L.**, Rosellini, A., Szentkúti, P., Horváth-Puhó, E., Smith, M., Galatzer-Levy, I., Lash, T., Galea, S., **Schnurr, P. P.**, & Sørensen, H. (2022). Using Danish national registry data to understand psychopathology following potentially traumatic experiences. *Journal of Traumatic Stress*, 35, 619-630. doi:10.1002/jts.22777
108. Gross, G. M., Smith, N., Holliday, R., Rozek, D. C., **Hoff, R.**, & **Harpaz-Rotem, I.** (2022). Racial disparities in clinical outcomes of Veterans Affairs residential PTSD treatment between Black and White veterans. *Psychiatric Services*, 73, 126-132. doi:10.1176/appi.ps.202000783.
109. Gross, G., **Pietrzak, R. H.**, **Hoff, R.**, Katz, I., & **Harpaz-Rotem, I.** (2022). Risk for PTSD symptom worsening during new PTSD treatment episode in a nationally representative sample of treatment-seeking U.S. veterans with subthreshold PTSD. *Journal of Psychiatric Research*, 151, 304-310. doi:10.1016/j.jpsychires.2022.04.040
110. Gujral, K., Van Campen, J., Jacobs, J., **Kimerling, R.**, Blonigen, D., & Zulman, D. (2022). Mental health service use, suicide behavior, and emergency department visits among rural US veterans who received video-enabled tablets during the Covid-19 pandemic. *JAMA Network Open*. doi:10.1001/jamanetworkopen.2022.6250
111. Hadlandsmyth, K., **Bernardy, N. C.**, & Lund, B. (2022). Central nervous system polytherapy among veterans with posttraumatic stress disorder: Changes across a decade. *General Hospital Psychiatry*, 74, 46-50. doi:10.1016/j.genhosppsych.2021.12.002
112. Haeny, A., Gueorguieva, R., Jackson, A., Morean, M., Krishnan-Sarin, S., DeMartini, K., Pearlson, G., Anticevic, A., **Krystal, J. H.**, & O'Malley, S. (2021). Individual differences in the associations between risk factors for alcohol use disorder and alcohol use-related outcomes. *Psychology of Addictive Behaviors*, 35, 501-513. doi:10.1037/adb0000733
113. **Hallenbeck, H. W.**, **Jaworski, B. K.**, **Wielgosz, J.**, **Kuhn, E. R.**, **Ramsey, K. M.**, Taylor, K., **Juhasz, K. M.**, **McGee-Vincent, P.**, **Mackintosh, M.**, & **Owen, J. E.** (2022). PTSD Coach version 3.1: A closer look at the reach, use, and potential impact of this updated mobile health app in the general public. *JMIR Mental Health*. doi:10.2196/34744
114. **Hamblen, J. L.**, Grubbs, K., Cole, B., **Schnurr, P. P.**, & Harik, J. (2022). "Will it work for me?" Developing patient-friendly graphical displays of posttraumatic stress disorder treatment effectiveness. *Journal of Traumatic Stress*, 35, 999-1010. doi:10.1002/jts.22808



115. Harnett, N., Finegold, K., Lebois, L., van Rooij, S., Ely, T., Murty, V., Jovanovic, T., Bruce, S., House, S., Beaudoin, F., An, X., Zeng, D., Neylan, T. C., Clifford, G., Linnstaedt, S., Germine, L., Bollen, K., . . . **Miller, M. W., Pietrzak, R. H., . . .** & Stevens, J. (2022). Structural covariance of the ventral visual stream predicts posttraumatic intrusion and nightmare symptoms: A multivariate data fusion analysis. *Translational Psychiatry*. doi:10.1038/s41398-022-02085-8
116. Harnett, N., van Rooij, S., Ely, T., Lebois, L., Murty, V., Jovanovic, T., Hill, S., Dumornay, N., Merker, J., Bruce, S., House, S., Beaudoin, F., **Ranganathan, M.**, Zeng, D., Neylan, T. C., Clifford, G., Linnstaedt, S., Germine, L., . . . **Pietrzak, R. H., . . .** & Stevens, J. (2021). Prognostic neuroimaging biomarkers of trauma-related psychopathology: Resting-state fMRI shortly after trauma predicts future PTSD and depression symptoms in the AURORA study. *Neuropsychopharmacology*, *46*, 1263-1271. doi:10.1038/s41386-020-00946-8
117. **Harper, K. L., Ellickson-Larew, S. A., Bovin, M. J., Keane, T. M., & Marx, B. P.** (2022). Discrepancies between electronic records and clinical interview diagnosis of PTSD: Differences in mental health care utilization. *Psychological Services*, *19*, 463-470. doi:10.1037/ser0000560
118. **Harper, K. L., Moshier, S. J., Ellickson-Larew, S. A., Andersen, M., Wisco, B., Mahoney, C. T., Keane, T. M., & Marx, B. P.** (2022). A prospective examination of health care costs associated with posttraumatic stress disorder diagnostic status and symptom severity among veterans. *Journal of Traumatic Stress*, *35*, 671-681. doi:10.1002/jts.22785
119. **Harper, K. L., Thompson-Hollands, J., Keane, T. M., & Marx, B. P.** (2022). Family-involved mental healthcare among OEF/OIF veterans using VHA administrative records. *Behavior Therapy*. doi:10.1016/j.beth.2022.01.006
120. **Harper, K. L., Thompson-Hollands, J., Keane, T. M., & Marx, B. P.** (2022). Mental health treatment utilization and relationship functioning among male and female OEF/OIF veterans. *Psychological Services*, *19*, 597-603. doi:10.1037/ser0000548
121. Harvanek, Z., Fogelman, N., **Xu, K.**, & Sinha, R. (2021). Psychological and biological resilience modulates the effects of stress on epigenetic aging. *Translational Psychiatry*. doi:10.1038/s41398-021-01735-7
122. Hatoum, A., Johnson, E., Colbert, S., Polimanti, R., Zhou, H., Walters, R., **Gelernter, J.**, Edenberg, H., Bogdan, R., & Agrawal, A. (2022). The addiction risk factor: A unitary genetic vulnerability characterizes substance use disorders and their associations with common correlates. *Neuropsychopharmacology*, *47*, 1739-1745. doi:10.1038/s41386-021-01209-w
123. Hatoum, A., Wendt, F., Galimberti, M., Polimanti, R., Neale, B., Kranzler, H., **Gelernter, J.**, Edenberg, H., & Agrawal, A. (2021). Ancestry may confound genetic machine learning: Candidate-gene prediction of opioid use disorder as an example. *Drug and Alcohol Dependence*, *229*, 109115. doi:10.1016/j.drugalcdep.2021.109115
124. **Hawn, S. E.**, Cusack, S., George, B., Sheerin, C., Dick, D., & Amstadter, A. (2022). Diagnostic validity of the PC-PTSD screen in college students. *Journal of American College Health*, *70*, 1909-1919. doi:10.1080/07448481.2020.1841768
125. **Hawn, S. E.**, Neale, Z., **Wolf, E. J.**, Zhao, X., Pierce, M., Fein-Schaffer, D., Milberg, W., McGlinchey, R., **Logue, M. W.**, & **Miller, M. W.** (2022). Methylation of the gene: An epigenetic mediator of PTSD-related inflammation and neuropathology plasma biomarkers. *Depression and Anxiety*, *39*, 323-333. doi:10.1002/da.23247
126. **Hawn, S. E.**, **Wolf, E. J.**, Neale, Z., & **Miller, M. W.** (2022). Conceptualizing traumatic stress and the structure of posttraumatic psychopathology through the lenses of RDoC and HiTOP. *Clinical Psychology Review*. doi:10.1016/j.cpr.2022.102177
127. **Hawn, S. E.**, Zhao, X., **Sullivan, D. R.**, **Logue, M. W.**, Fein-Schaffer, D., Milberg, W., McGlinchey, R., **Miller, M. W.**, & **Wolf, E. J.** (2022). For whom the bell tolls: Psychopathological and neurobiological correlates of a DNA methylation index of time-to-death. *Translational Psychiatry*. doi:10.1038/s41398-022-02164-w
128. **Hayes, J. P.**, Pierce, M. E., Valerio, K. E., **Miller, M. W.**, **Huber, B.**, Fortier, C. B., Fonda, J. R., Milberg, W., & McGlinchey, R. (2022). The association between blast exposure and transdiagnostic health symptoms on systemic inflammation. *Neuropsychopharmacology*, *47*, 1702-1709. doi:10.1038/s41386-021-01138-8
129. **Heinz, A. J.**, **Wiltsey Stirman, S.**, Sharin, T., **Loskot, T.**, Mason, D., Jaworski, B., & McGovern, M. (2022). Rising from the ashes by expanding access to community care after disaster: An origin story of the Wildfire Mental Health Collaborative and preliminary findings. *Psychological Services*, *19*, 58-66. doi:10.1037/ser0000553

130. Herzog, S., Nichter, B., Hill, M., **Norman, S. B.**, & **Pietrzak, R. H.** (2022). Factors associated with remission of suicidal thoughts and behaviors in U.S. military veterans with a history of suicide attempt. *Journal of Psychiatric Research*, *149*, 62-67. doi:10.1016/j.jpsychires.2022.02.021
131. Hien, D., Fitzpatrick, S., Saavedra, L., Ebrahimi, C., **Norman, S. B.**, Tripp, J., Ruglass, L., Lopez-Castro, T., Killeen, T., Back, S., & Morgan-López, A. (2022). What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders. *European Journal of Psychotraumatology*. doi:10.1080/20008198.2021.2001191
132. Highfill-McRoy, R. M., Levine, J. A., Larson, G. E., **Norman, S. B.**, Schmied, E. A., & Thomsen, C. J. (2022). Predictors of symptom increase in subsyndromal PTSD among previously deployed military personnel. *Military Medicine*, *187*, e711-e717. doi:10.1093/milmed/usab034
133. Hill, K., Gold, M., Nemeroff, C., McDonald, W., Grzenda, A., Widge, A., Rodriguez, C., Kraguljac, N., **Krystal, J. H.**, & Carpenter, L. (2022). Risks and benefits of cannabis and cannabinoids in psychiatry. *American Journal of Psychiatry*, *179*, 98-109. doi:10.1176/appi.ajp.2021.21030320
134. Hill, M., Loflin, M., Nichter, B., Na, P., Herzog, S., **Norman, S. B.**, & **Pietrzak, R. H.** (2022). Cannabis use among U.S. military veterans with subthreshold or threshold posttraumatic stress disorder: Psychiatric comorbidities, functioning, and strategies for coping with posttraumatic stress symptoms. *Journal of Traumatic Stress*, *35*, 1154-1166. doi:10.1002/jts.22823
135. Hocking, E., **Livingston, N.**, **Creech, S. K.**, & **Taft, C. T.** (2021). Moderator effects in a randomized controlled trial of the Common Elements Treatment Approach (CETA) for intimate partner violence and hazardous alcohol use in Zambia. *Drug and Alcohol Dependence*, *228*, 108995. doi:10.1016/j.drugalcdep.2021.108995
136. Hoffmire, C., **Borowski, S.**, Griffin, B., Maguen, S., & **Vogt, D.** (2022). Trajectories of suicidal ideation following separation from military service: Overall trends and group differences. *Suicide and Life-Threatening Behavior*, *52*, 413-426. doi:10.1111/sltb.12831
137. Holder, N., Batten, A., **Shiner, B.**, Li, Y., Madden, E., Neylan, T. C., Seal, K., Patterson, O., DuVall, S., & Maguen, S. (2022). Veterans receiving a second course of Cognitive Processing Therapy or Prolonged Exposure therapy: Is it better to switch or stay the same? *Cognitive Behaviour Therapy*, *51*, 456-469. doi:10.1080/16506073.2022.2058996
138. Holder, N., Maguen, S., Holliday, R., **Vogt, D.**, Bernhard, P., Hoffmire, C., Blossnich, J., & Schneiderman, A. (2022). Psychosocial outcomes among veteran and non-veteran survivors of sexual assault. *Journal of Interpersonal Violence*. doi:10.1177/08862605221090598
139. Holder, N., Woods, A., Neylan, T. C., Maguen, S., Seal, K., **Bernardy, N. C.**, Wiechers, I., Ryder, A., Urbietta, A., & Cohen, B. (2021). Trends in medication prescribing in patients with PTSD from 2009 to 2018. *The Journal of Clinical Psychiatry*. doi:10.4088/JCP.20m13522
140. Holliday, R., Nichter, B., Holder, N., Hill, M., Monteith, L., **Norman, S. B.**, & **Pietrzak, R. H.** (2022). Childhood sexual abuse and military sexual trauma interact to increase suicide risk: Results from a nationally representative veteran sample. *Journal of Interpersonal Violence*. doi:10.1177/08862605221120909
141. **Holmes, S.**, Finnema, S., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., **Davis, M.**, Ropchan, J., Emory, P., Ye, Y., Nabulsi, N., Matuskey, D., Angarita, G., **Pietrzak, R. H.**, Duman, R., Sanacora, G., **Krystal, J. H.**, Carson, R., & **Esterlis, I.** (2022). Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. *Molecular Psychiatry*, *27*, 2273-2281. doi:10.1038/s41380-022-01465-2
142. Homan, P., Lau, H., **Levy, I.**, Raio, C., Bach, D., Carmel, D., & Schiller, D. (2021). Evidence for a minimal role of stimulus awareness in reversal of threat learning. *Learning & Memory*, *28*, 95-103. doi:10.1101/lm.050997.119
143. **Iverson, K. M.**, Danitz, S. B., Driscoll, M., **Vogt, D.**, Hamilton, H. B., Gerber, M. R., **Wiltsey Stirman, S.**, Shayani, D. R., Suvak, M. K., & Dichter, M. E. (2022). Recovering from intimate partner violence through strengths and empowerment (RISE): Development, pilot testing, and refinement of a patient-centered brief counseling intervention for women. *Psychological Services*, *19*, 102-112. doi:10.1037/ser0000544
144. **Iverson, K. M.**, Danitz, S. B., Shayani, D. R., **Vogt, D.**, **Wiltsey Stirman, S.**, Hamilton, A., **Mahoney, C. T.**, Gerber, M. R., & Dichter, M. E. (2021). Recovering from intimate partner violence through strengths and empowerment. *The Journal of Clinical Psychiatry*. doi:10.4088/JCP.21m14041

145. **Iverson, K. M.**, Danitz, S., **Low, S.**, Knetig, J., Doyle, K., & Bruce, L. (2022). Recovering from intimate partner violence through strengths and empowerment (RISE): Initial evaluation of the clinical effects of RISE administered in routine care in the US Veterans Health Administration. *International Journal of Environmental Research and Public Health*, *19*, 8793. doi:10.3390/ijerph19148793
146. **Iverson, K. M.**, Dardis, C. M., Cowlishaw, S., Webermann, A. R., Shayani, D. R., Dichter, M. E., **Mitchell, K. S.**, Mattocks, K. M., Gerber, M. R., & Portnoy, G. A. (2022). Effects of intimate partner violence during Covid-19 and pandemic-related stress on the mental and physical health of women veterans. *Journal of General Internal Medicine*, *37*, 724-733. doi:10.1007/s11606-022-07589-z
147. **Iverson, K. M.**, Rossi, F. S., **Nilni, Y. I.**, **Fox, A. B.**, & **Galovski, T. E.** (2022). PTSD and depression symptoms increase women's risk for experiencing future intimate partner violence. *International Journal of Environmental Research and Public Health*, *19*, 12217. doi:10.3390/ijerph191912217
148. Jacoby, V., Straud, C., Bagley, J., Tyler, H., Baker, S., Denejkina, A., **Sippel, L. M.**, Kaya, R., Rozek, D., Fina, B., & Dondanville, K. (2022). Evidence-based posttraumatic stress disorder treatment in a community sample: Military-affiliated versus civilian patient outcomes. *Journal of Traumatic Stress*, *35*, 1072-1086. doi:10.1002/jts.22812
149. **Jagger-Rickels, A.**, **Rothlein, D.**, Stumps, A., Evans, T. C., Bernstein, J., Milberg, W., & **Esterman, M.** (2022). An executive function subtype of PTSD with unique neural markers and clinical trajectories. *Translational Psychiatry*. doi:10.1038/s41398-022-02011-y
150. **Jamison, A. L.**, Slightam, C., Bertram, F., Kim, S., & Roth, W. (2022). Randomized clinical trial of capnometry-assisted respiratory training in veterans with posttraumatic stress disorder hyperarousal. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, 883-893. doi:10.1037/tra0000525
151. **Jaworski, B. K.**, Taylor, K., **Ramsey, K. M.**, **Heinz, A. J.**, Steinmetz, S., **Owen, J. E.**, Tsai, J., & **Pietrzak, R. H.** (2022). Predicting uptake of the Covid Coach app among US military veterans: Funnel analysis using a probability-based panel. *JMIR Mental Health*. doi:10.2196/36217
152. Jaycox, L. H., Morral, A. R., **Street, A. E.**, Schell, T. L., Kilpatrick, D., & Cottrell, L. (2021). Gender differences in health among U.S. service members: Examining unwanted gender-based experiences as an explanatory factor. *RAND Corporation*. Retrieved from [https://www.rand.org/pubs/research\\_reports/RRA1848-1.html](https://www.rand.org/pubs/research_reports/RRA1848-1.html)
153. Jegede, O., Na, P., Haeny, A., **Krystal, J. H.**, & **Pietrzak, R. H.** (2022). Association of distress due to systemic racism and racial disparities with psychopathology and suicidal ideation among US veterans during the Covid-19 pandemic. *The Journal of Clinical Psychiatry*. doi:10.4088/JCP.22br14410
154. Jiang, T., Smith, M. L., **Street, A. E.**, Seegulam, V. L., Sampson, L., Murray, E. J., Fox, M. P., & **Gradus, J. L.** (2021). A comorbid mental disorder paradox: Using causal diagrams to understand associations between posttraumatic stress disorder and suicide. *Psychological Trauma: Theory, Research, Practice, and Policy*, *13*, 725-729. doi:10.1037/tra0001033
155. Johnson, E., Hatoum, A., Deak, J., Polimanti, R., Murray, R., Edenberg, H., **Gelernter, J.**, Di Forti, M., & Agrawal, A. (2021). The relationship between cannabis and schizophrenia: A genetically informed perspective. *Addiction*, *116*, 3227-3234. doi:10.1111/add.15534
156. Joormann, J., Ziobrowski, H. N., King, A., Lee, S., Sampson, N., House, S. L., Beaudoin, F. L., An, X., Stevens, J. S., Zeng, D., Neylan, T. C., Clifford, G. D., Linnstaedt, S. D., Germine, L. T., Bollen, K. A., Rauch, S. L., Haran, P., Storrow, A. B., . . . **Miller, M. W.**, **Pietrzak, R. H.**, . . . & Kessler, R. C. (2022). Prior histories of posttraumatic stress disorder and major depression and their onset and course in the three months after a motor vehicle collision in the AURORA study. *Depression and Anxiety*, *39*, 56-70. doi:10.1002/da.23223
157. **Kachadourian, L.**, **Harpaz-Rotem, I.**, Tsai, J., Southwick, S., & **Pietrzak, R. H.** (2021). Mindfulness as a mediator between trauma exposure and mental health outcomes: Results from the National Health and Resilience in Veterans Study. *Psychological Trauma: Theory, Research, Practice, and Policy*, *13*, 223-230. doi:10.1037/tra0000995
158. **Kachadourian, L.**, Lyons, R., Davis, B. C., **Haller, M.**, & **Norman, S. B.** (2021). Trauma-related guilt and posttraumatic stress disorder symptoms in military veterans: The role of psychological inflexibility. *Journal of Psychiatric Research*, *137*, 104-110. doi:10.1016/j.jpsychires.2021.02.022

159. **Kachadourian, L.**, Nichter, B., Herzog, S., **Norman, S. B.**, Sullivan, T., & **Pietrzak, R. H.** (2022). Non-suicidal self-injury in US military veterans: Results from the National Health and Resilience in Veterans Study. *Clinical Psychology & Psychotherapy*, 29, 941-949. doi:10.1002/cpp.2673
160. Kaniuka, A., Cramer, R., Wilsey, C., Langhinrichsen-Rohling, J., Mennicke, A., Patton, A., Zarwell, M., **McLean, C. P.**, Harris, Y., Sullivan, S., & Gray, G. (2022). Covid-19 exposure, stress, and mental health outcomes: Results from a needs assessment among low income adults in central North Carolina. *Frontiers in Psychiatry*. doi:10.3389/fpsyt.2021.790468
161. Kaplan, C., Chan, C., Feingold, J., Kaye-Kauderer, H., **Pietrzak, R. H.**, Peccoralo, L., Feder, A., Southwick, S., Charney, D., Burka, L., Basist, M., Ripp, J., & Akhtar, S. (2021). Psychological consequences among residents and fellows during the Covid-19 pandemic in New York City: Implications for targeted interventions. *Academic Medicine*, 96, 1722-1731. doi:10.1097/ACM.0000000000004362
162. Karatzias, T., Knefel, M., Maercker, A., **Cloitre, M.**, Reed, G., Bryant, R., Ben-Ezra, M., Kazlauskas, E., Jowett, S., Shevlin, M., & Hyland, P. (2022). The network structure of ICD-11 disorders specifically associated with stress: Adjustment disorder, prolonged grief disorder, posttraumatic stress disorder, and complex posttraumatic stress disorder. *Psychopathology*, 55, 226-234. doi:10.1159/000523825
163. Karatzias, T., Shevlin, M., Ford, J. D., Fyvie, C., Grandison, G., Hyland, P., & **Cloitre, M.** (2022). Childhood trauma, attachment orientation, and complex PTSD (CPTSD) symptoms in a clinical sample: Implications for treatment. *Development and Psychopathology*, 34, 1192-1197. doi:10.1017/S0954579420001509
164. Katrinli, S., Maihofer, A., Wani, A., Pfeiffer, J., Ketema, E., Ratanatharathorn, A., Baker, D. G., Boks, M., Geuze, E., Kessler, R., Risbrough, V. B., Rutten, B., Stein, M., Ursano, R., Vermetten, E., **Logue, M. W.**, Nievergelt, C., Smith, A., & Uddin, M. (2022). Epigenome-wide meta-analysis of PTSD symptom severity in three military cohorts implicates DNA methylation changes in genes involved in immune system and oxidative stress. *Molecular Psychiatry*, 27, 1720-1728. doi:10.1038/s41380-021-01398-2
165. Kaye-Kauderer, H., Loo, G., Murrrough, J. W., Feingold, J., Feder, A., Peccoralo, L., Ripp, J., & **Pietrzak, R. H.** (2022). Effects of sleep, exercise, and leadership support on resilience in frontline healthcare workers during the Covid-19 pandemic. *Journal of Occupational & Environmental Medicine*, 64, 416-420. doi:10.1097/JOM.0000000000002460
166. **Kaysen, D. L.**, Walton, T., Rhew, I., Jaffe, A., Pierce, A., & Walker, D. (2022). Development of StressCheck: A telehealth motivational enhancement therapy to improve voluntary engagement for PTSD treatment among active-duty service members. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2022.106841
167. **Keane, T. M.**, O'Donovan, C., & Vizcaíno, J. (2021). The growing need for controlled data access models in clinical proteomics and metabolomics. *Nature Communications*. doi:10.1038/s41467-021-26110-4
168. **Kearns, J. C.**, Brown, S., Cero, I., **Gorman, K. R.**, Nock, M., **Keane, T. M.**, & **Marx, B. P.** (2021). Temporal sequences of suicidal and nonsuicidal self-injurious thoughts and behaviors among inpatient and community-residing military veterans. *Journal of Affective Disorders*, 294, 430-440. doi:10.1016/j.jad.2021.07.088
169. Keefe, J., Hernandez, S., Johaneck, C., Landy, M. S. H., Sijercic, I., Shnaider, P., Wagner, A., Lane, J. E. M., Monson, C., & **Wiltsey Stirman, S.** (2022). Competence in delivering Cognitive Processing Therapy and the therapeutic alliance both predict PTSD symptom outcomes. *Behavior Therapy*, 53, 763-775. doi:10.1016/j.beth.2021.12.003
170. Kelly, K., O'Dell, R., Toyonaga, T., Barcelos, N., **Gelernter, J.**, Varma, P., Nabulsi, N., Huang, Y., Carson, R., van Dyck, C., & Mecca, A. (2022). Cortical amyloid burden is associated with basal forebrain but not medial temporal lobe atrophy in adults at varying APOE E4 risk for Alzheimer's Disease. *Biological Psychiatry*, 91, S125-S126. doi:10.1016/j.biopsych.2022.02.329
171. **Kelmendi, B.**, **Kaye, A.**, Pittenger, C., & Kwan, A. (2022). Psychedelics. *Current Biology*, 32, R63-R67. doi:10.1016/j.cub.2021.12.009
172. **Kelmendi, B.**, Pittenger, C., Ching, T., Farré, M., Mandell, B., Stogniew, M., Seelig, M., & **Averill, L.** (2022). Clinical evidence for the use of methylone in the treatment of PTSD: A case series with long-term follow-up. *Annals of Clinical Case Reports*, 7, 2209. Retrieved from <https://www.anncaserep.com/abstract.php?aid=8922>

173. Khalifian, C., **Bosch, J. O.**, Knopp, K., Delay, C., Sohn, M., & **Morland, L. A.** (2022). Adverse childhood experiences, mental health, and relationship satisfaction in military couples. *Journal of Family Psychology, 36*, 630-635. doi:10.1037/fam0000952
174. Khalifian, C., Leifker, F., Knopp, K., Wilks, C., Depp, C., Glynn, S., Bryan, C., & **Morland, L. A.** (2022). Utilizing the couple relationship to prevent suicide: A preliminary examination of treatment for relationships and safety together. *Journal of Clinical Psychology, 78*, 747-757. doi:10.1002/jclp.23251
175. Kizub, D., Melnitchouk, N., Beznosenko, A., Shabat, G., Semeniv, S., Nogueira, L., **Watson, P.**, Berg, K., Trapido, E., Espinel, Z., & Shultz, J. (2022). Resilience and perseverance under siege: Providing cancer care during the invasion of Ukraine. *The Lancet Oncology, 23*, 579-583. doi:10.1016/s1470-2045(22)00189-9
176. Kline, A., **Panza, K.**, Nichter, B., Tsai, J., **Harpaz-Rotem, I.**, **Norman, S. B.**, & **Pietrzak, R. H.** (2022). Mental health care use among U.S. military veterans: Results from the 2019–2020 National Health and Resilience in Veterans Study. *Psychiatric Services, 73*, 628-635. doi:10.1176/appi.ps.202100112
177. Kochunov, P., Hong, L., Dennis, E., Morey, R., Tate, D., Wilde, E., **Logue, M. W.**, Kelly, S., Donohoe, G., Favre, P., Houenou, J., Ching, C., Holleran, L., Andreassen, O., Velzen, L., Schmaal, L., Villalón-Reina, J., Bearden, C., Piras, F., . . . & Jahanshad, N. (2022). ENIGMA-DTI: Translating reproducible white matter deficits into personalized vulnerability metrics in cross-diagnostic psychiatric research. *Human Brain Mapping, 43*, 194-206. doi:10.1002/hbm.24998
178. **Korem, N.**, **Duek, O.**, Kaczurkin, A. N., Lissek, S., Orederu, T., Schiller, D., **Harpaz-Rotem, I.**, & **Levy, I.** (2022). Emotional numbing in PTSD is associated with lower amygdala reactivity to pain. *Neuropsychopharmacology, 47*, 1913-1921. doi:10.1038/s41386-022-01405-2
179. Kruger, E., **Serier, K.**, Pfund, R., McKay, J. R., & Witkiewitz, K. (2021). Integrative data analysis of self-efficacy in 4 clinical trials for alcohol use disorder. *Alcoholism: Clinical and Experimental Research, 45*, 2347-2356. doi:10.1111/acer.14713
180. **Krystal, J. H.**, Chow, B., Vessicchio, J., Henrie, A., Neylan, T. C., Krystal, A. D., **Marx, B. P.**, **Xu, K.**, Jindal, R., **Davis, L.**, **Schnurr, P. P.**, Stein, M., Thase, M., Ventura, B., Huang, G., & Shih, M. (2021). Design of the national adaptive trial for PTSD-related insomnia (NAP study), VA Cooperative Study Program (CSP) #2016. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2021.106540
181. **Krystal, J. H.**, Southwick, S., & **Girgenti, M. J.** (2022). Matthew J. Friedman, M.D., Ph.D. and his legacy of leadership in the field of posttraumatic stress disorder. *Psychiatry, 85*, 161-170. doi:10.1080/00332747.2022.2068931
182. **Kuhn, E. R.**, Hoffman, J. E., Ruzek, J. I., & **Owen, J. E.** (2022). Telemental health approaches for traumatic stress. In U. Schnyder & M. Cloitre (Eds.), *Evidence based treatment for trauma-related psychological disorders, 2nd ed* (pp. 533-550). New York, NY: Springer.
183. **Kuhn, E. R.**, **Miller, K. E.**, **Puran, D. N.**, **Wielgosz, J.**, York Williams, S. L., **Owen, J. E.**, **Jaworski, B. K.**, **Hallenbeck, H. W.**, **McCaslin, S. E.**, & Taylor, K. L. (2022). A pilot randomized controlled trial of the Insomnia Coach mobile app to assess its feasibility, acceptability, and potential efficacy. *Behavioral Therapy, 53*, 440-457. doi:10.1016/j.beth.2021.11.003
184. Lago, T. R., Brownstein, M. J., Beydler, E., Manbeck, A., Beale, A., Roberts, C., Balderston, N., Damiano, E., **Pineles, S. L.**, Simon, N., Ernst, M., & Grillon, C. (2021). The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: A randomized proof-of-concept study. *Psychopharmacology, 238*, 2393-2403. doi:10.1007/s00213-021-05861-4
185. Lawrence, K. A., **Vogt, D.**, Nigam, S., Dugan, A. J., & **Smith, B. N.** (2021). Temporal sequencing of mental health symptom severity and suicidal ideation in post-9/11 men and women veterans who recently separated from the military. *Chronic Stress*. doi:10.1177/24705470211061347
186. Lebois, L., Harnett, N., van Rooij, S., Ely, T., Jovanovic, T., Bruce, S., House, S., Ravichandran, C., Dumornay, N., Finegold, K., Hill, S., Merker, J., Phillips, K., Beaudoin, F., An, X., Neylan, T. C., Clifford, G., . . . **Miller, M. W.**, **Pietrzak, R. H.**, . . . & Ressler, K. (2022). Persistent dissociation and its neural correlates in predicting outcomes after trauma exposure. *American Journal of Psychiatry*. doi:10.1176/appi.ajp.21090911

187. Lee, B., Pothula, S., Wu, M., Kang, H., **Girgenti, M. J.**, Picciotto, M., DiLeone, R., Taylor, J., & Duman, R. (2022). Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear. *Molecular Psychiatry*, *27*, 2580-2589. doi:10.1038/s41380-022-01498-7
188. **Lee, D. J., Kearns, J. C., Stanley, I. H., Spitzer, E. G., Woodward, B., Keane, T. M., & Marx, B. P.** (2021). A comparison of dimensional and categorical approaches to characterizing the association between posttraumatic stress disorder and future suicide attempts. *Journal of Traumatic Stress*, *34*, 1099-1107. doi:10.1002/jts.22689
189. **Lee, D. J., Lee, J., Lee, J., Kim, C., & Jung, Y.** (2022). Insular activation and functional connectivity in firefighters with post-traumatic stress disorder. *BJPsych Open*. doi:10.1192/bjo.2022.32
190. **Lee, D. J., Weathers, F. W., Thompson-Hollands, J., Sloan, D. M., & Marx, B. P.** (2022). Concordance in PTSD symptom change between DSM-5 versions of the Clinician-Administered PTSD Scale (CAPS-5) and PTSD Checklist (PCL-5). *Psychological Assessment*. doi:10.1037/pas0001130
191. **Lee, L. O., Grodstein, F., Trudel-Fitzgerald, C., James, P., Okuzono, S. S., Koga, H. K., Schwartz, J., Spiro, A., Mroczek, D. K., & Kubzansky, L. D.** (2022). Optimism, daily stressors, and emotional well-being over two decades in a cohort of aging men. *The Journals of Gerontology: Series B*, *77*, 1373-1383. doi:10.1093/geronb/gbac025
192. **Levy, I., & Schiller, D.** (2021). Neural computations of threat. *Trends in Cognitive Sciences*, *25*, 151-171. doi:10.1016/j.tics.2020.11.007
193. Li, B., Aouizerat, B., Cheng, Y., Anastos, K., Justice, A., Zhao, H., & **Xu, K.** (2022). Incorporating local ancestry improves identification of ancestry-associated methylation signatures and meQTLs in African Americans. *Communications Biology*, *5*, 401. doi:10.1038/s42003-022-03353-5
194. Liang, X., Sinha, R., Justice, A., Cohen, M., Aouizerat, B., & **Xu, K.** (2022). A new monocyte epigenetic clock reveals nonlinear effects of alcohol consumption on biological aging in three independent cohorts (N = 2242). *Alcoholism: Clinical and Experimental Research*, *46*, 736-748. doi:10.1111/acer.14803
195. Lindsey, M., Sullivan, K., Chemtob, C., Ancharski, K., Jaccard, J., **Cloitre, M.**, Urquiza, A., Timmer, S., Okosi, M., & Kaplan, D. (2022). A randomized controlled trial to assess the efficacy of parenting-STAIR in treating maternal PTSD to reduce maltreatment recidivism: Protocol for the safe mothers, safe children study. *Trials*, *23*, 432. doi:10.1186/s13063-022-06354-1
196. Linzey, M., **DiSano, K. D.**, Welsh, N., Pachner, A., & Gilli, F. (2022). Divergent complement system activation in two clinically distinct murine models of multiple sclerosis. *Frontiers in Immunology*. doi:10.3389/fimmu.2022.924734
197. Litwack, S. D., Beck, J. G., & **Sloan, D. M.** (2022). Group treatment for trauma-related psychological disorders. In U. Schnyder & M. Cloitre (Eds.), *Evidence based treatments for trauma-related psychological disorders. A practical guide for clinicians (2nd ed)* (pp. 499-516). New York, NY: Springer.
198. **Livingston, N., Ameral, V., Hocking, E., Levijah, X., & Timko, C.** (2022). Interventions to improve post-detox treatment engagement and alcohol recovery: Systematic review of intervention types and effectiveness. *Alcohol and Alcoholism*, *57*, 136-150. doi:10.1093/alcalc/agab021
199. **Livingston, N., Farmer, S., Mahoney, C. T., Marx, B. P., & Keane, T. M.** (2022). Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. *Psychology of Addictive Behaviors*, *36*, 131-143. doi:10.1037/adb0000736
200. **Livingston, N., Farmer, S., Mahoney, C. T., Marx, B. P., & Keane, T. M.** (2022). The role of PTSD symptom clusters and criterion in predicting future high-risk drug and alcohol use among returning veteran men and women. *Psychological Services*, *19*, 386-395. doi:10.1037/ser0000538
201. **Livingston, N., Lynch, K., Hinds, Z., Gatsby, E., DuVall, S., & Shipherd, J. C.** (2022). Identifying posttraumatic stress disorder and disparity among transgender veterans using nationwide Veterans Health Administration electronic health record data. *LGBT Health*, *9*, 94-102. doi:10.1089/lgbt.2021.0246
202. **Logue, M. W., Zhou, Z., Morrison, F. G., Wolf, E. J., Daskalakis, N., Chatzinakos, C., Georgiadis, F., Labadorf, A., Girgenti, M. J., Young, K. A., Williamson, D., Zhao, X., Grenier, J., Huber, B., & Miller, M. W.** (2021). Gene expression in the dorsolateral and ventromedial prefrontal cortices implicates immune-related gene networks in PTSD. *Neurobiology of Stress*. doi:10.1016/j.ynstr.2021.100398

203. Long, K., Chao, L. L., Kazama, Y., An, A., Hu, K., Peretz, L., Muller, D., Roan, V., Misra, R., Toth, C., Breton, J., Casazza, W., Mostafavi, S., Huber, B., **Woodward, S. H.**, Neylan, T. C., & Kaufer, D. (2021). Regional gray matter oligodendrocyte- and myelin-related measures are associated with differential susceptibility to stress-induced behavior in rats and humans. *Translational Psychiatry*. doi:10.1038/s41398-021-01745-5
204. Love, T., Shabalin, A., Kember, R., Docherty, A., Zhou, H., Koppelmans, V., **Gelernter, J.**, Baker, A., Hartwell, E., Dubroff, J., Zubieta, J., & Kranzler, H. (2022). Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. *Neuropsychopharmacology*, *47*, 1784-1790. doi:10.1038/s41386-022-01325-1
205. Lynch, K. E., **Shipherd, J. C.**, Gatsby, E., Viernes, B., DuVall, S. L., & Blosnich, J. R. (2022). Sexual orientation-related disparities in health conditions that elevate Covid-19 severity. *Annals of Epidemiology*, *66*, 5-12. doi:10.1016/j.annepidem.2021.11
206. Ma, S., Skarica, M., Li, Q., Xu, C., Risgaard, R., Tebbenkamp, A., Mato-Blanco, X., Kovner, R., Krsnik, Ž., de Martin, X., Luria, V., Martí-Pérez, X., Liang, D., Karger, A., Schmidt, D., Gomez-Sanchez, Z., Qi, C., Gobeske, K., . . . **Girgenti, M. J.**, . . . & Sestan, N. (2022). Molecular and cellular evolution of the primate dorsolateral prefrontal cortex. *Science*. doi:10.1126/science.abo7257
207. Macdonald, A., Fredman, S., Taylor, D., Pruiksma, K., Blount, T., Hall-Clark, B., Fina, B., Dondanville, K., Mintz, J., Litz, B., Young-McCaughan, S., Le, Y., Jenkins, A., Monson, C., Yarvis, J., **Keane, T. M.**, & Peterson, A. (2022). Secondary individual outcomes following multicouple group therapy for posttraumatic stress disorder: An uncontrolled pilot study with military dyads. *Journal of Traumatic Stress*, *35*, 321-329. doi:10.1002/jts.22729
208. Madore, M., Kozel, F., Williams, L. M., Green, L., George, M., **Holtzheimer, P. E.**, Yesavage, J. A., & Philip, N. (2022). Prefrontal transcranial magnetic stimulation for depression in US military veterans – A naturalistic cohort study in the Veterans Health Administration. *Journal of Affective Disorders*, *297*, 671-678. doi:10.1016/j.jad.2021.10.025
209. Maguen, S., Griffin, B., Burkman, K., & **Norman, S. B.** (2021). Lessons from psychological first aid: Supporting healing of healthcare workers affected by Covid-19. *Psychiatry*, *84*, 378-385. doi:10.1080/00332747.2021.2005442
210. Maguen, S., Griffin, B., **Vogt, D.**, Hoffmire, C., Blosnich, J., Bernhard, P., Akhtar, F., Cypel, Y., & Schneiderman, A. (2022). Moral injury and peri- and post-military suicide attempts among post-9/11 veterans. *Psychological Medicine*. doi:10.1017/S0033291721005274
211. Maihofer, A. X., Choi, K. W., Coleman, J.R.I., Daskalakis, N. P., Denckla, C. A., Ketema, E., Morey, R. A., Polimanti, R., Ratanatharathorn, A., Torres, K., Wingo, A. P., Zai, C. C., Aiello, A. E., Almlil, L. M., Amstadter, A. B., Andersen, S. B., Andreassen, O. A., . . . **Logue, M. W.**, . . . **Miller, M. W.**, . . . & Nievergelt, C. M. (2022). Enhancing discovery of genetic variants for posttraumatic stress disorder through integration of quantitative phenotypes and trauma exposure information. *Biological Psychiatry*, *91*, 626-636. doi:10.1016/j.biopsych.2021.09.020
212. Malaktaris, A., **McLean, C. P.**, Mallavarapu, S., Herbert, M., Kelsven, S., Bormann, J., & Lang, A. J. (2022). Higher frequency of mantram repetition practice is associated with enhanced clinical benefits among United States veterans with posttraumatic stress disorder. *European Journal of Psychotraumatology*. doi:10.1080/20008198.2022.2078564
213. Maloney, G., **Kelmendi, B.**, & Pittenger, C. (2022). Imagery rescripting (ImRs) as an adjunctive treatment to exposure and response prevention (ERP)-resistant obsessive-compulsive disorder: A case study. *Clinical Case Studies*. doi:10.1177/15346501221123797
214. Mangini, P., **Averill, L.**, & Davis, A. (2022). Psychedelic treatment for co-occurring alcohol misuse and post-traumatic stress symptoms among United States Special Operations Forces Veterans. *Journal of Psychedelic Studies*, *5*, 149-155. doi:10.1556/2054.2021.00176
215. Marchese, S., Cancelmo, L., Diab, O., Cahn, L., Aaronson, C., Daskalakis, N., Schaffer, J., Horn, S., Johnson, J., Schechter, C., Desarnaud, F., Bierer, L., Makotkine, I., Flory, J., Crane, M., Moline, J., Udasin, I., Harrison, D., Roussos, P., Charney, D., Koenen, K., Southwick, S., Yehuda, R., **Pietrzak, R. H.**, Huckins, L., & Feder, A. (2022). Altered gene expression and PTSD symptom dimensions in World Trade Center responders. *Molecular Psychiatry*, *27*, 2225-2246. doi:10.1038/s41380-022-01457-2

216. **Marx, B. P., Fina, B. A., Sloan, D. M., Young-McCaughan, S., Dondanville, K. A., Tyler, H. C., Blankenship, A. E., Schrader, C. C., Kaplan, A. M., Greene, V. R., Bryan, B., Hale, W. J., Mintz, J., Peterson, A. L., & STRONG STAR Consortium (2021).** Written Exposure Therapy for posttraumatic stress symptoms and suicide risk: Design and methodology of a randomized controlled trial with patients on a military psychiatric inpatient unit. *Contemporary Clinical Trials, 110*, 106564. doi:10.1016/j.cct.2021.106564
217. **Marx, B. P., Lee, D. J., Norman, S. B., Bovin, M. J., Sloan, D. M., Weathers, F. W., Keane, T. M., & Schnurr, P. P. (2022).** Reliable and clinically significant change in the clinician-administered PTSD Scale for DSM-5 and PTSD Checklist for DSM-5 among male veterans. *Psychological Assessment, 34*, 197-203. doi:10.1037/pas0001098
218. Matarazzo, B. E., Eagan, A., **Landes, S. J.**, Mina, L., Clark, K., Gerard, G., McCarthy, J., Trafton, J., Bahraini, N. H., Brenner, L., Keen, A., Gamble, S., Lawson, W., Katz, I., & Reger, M. (2022). The Veterans Health Administration REACH VET Program: Suicide predictive modeling in practice. *Psychiatric Services*. doi:10.1176/appi.ps.202100629
219. Mathersul, D., Dixit, K., Schulz-Heik, R., **Avery, T.**, Zeitzer, J., & Bayley, P. (2022). Emotion dysregulation and heart rate variability improve in US veterans undergoing treatment for posttraumatic stress disorder: Secondary exploratory analyses from a randomised controlled trial. *BMC Psychiatry*. doi:10.1186/s12888-022-03886-3
220. **McCaslin, S. E., Becket-Davenport, C. M.,** Dinh, J. V., Lasher, B., Kim, M., Choucroun, G., & Herbst, E. (2021). Military acculturation and readjustment to the civilian context. *Psychological Trauma: Theory, Research, Practice, and Policy, 13*, 611-620. doi:10.1037/tra0000999
221. **McCaslin, S. E., Mackintosh, M., Chang, A.,** Sanborn, A., & **Rosen, C. S.** (2021). Serving veterans in their communities: Evaluation of an online resource for behavioral health care providers. *Community Mental Health Journal, 57*, 1499-1504. doi:10.1007/s10597-020-00766-6
222. **McCaslin, S. E.,** Turchik, J. A., & Hatzfeld, J. J. (2022). Considerations in the treatment of veterans with posttraumatic stress disorder. In U. Schnyder & M. Cloitre (Eds.), *Evidence based treatments for trauma-related psychological disorders (2nd ed.)* (pp. 475-495). New York, NY: Springer.
223. **McClendon, J.,** Kressin, N., Copeland, L. A., Finley, E. P., & **Vogt, D.** (2021). The impact of discriminatory stress on changes in posttraumatic stress severity at the intersection of race/ethnicity and gender. *Journal of Trauma & Dissociation, 22*, 170-187. doi:10.1080/15299732.2020.1869079
224. McCutchen, C., Hyland, P., Shevlin, M., & **Cloitre, M.** (2022). The occurrence and co-occurrence of ACEs and their relationship to mental health in the United States and Ireland. *Child Abuse & Neglect, 129*, 105681. doi:10.1016/j.chiabu.2022.105681
225. McGuire, A. P., Fagan, J., Tsai, J., Merians, A., Nichter, B., **Norman, S. B.,** Southwick, S., & **Pietrzak, R. H.** (2022). Dispositional gratitude predicts the development of psychopathology and suicidal behaviors: Results from a 7-year population-based study of U.S. military veterans. *Journal of Psychiatric Research, 149*, 168-176. doi:10.1016/j.jpsychires.2022.02.028
226. McLean, C. L., Turchik, J. A., & **Kimerling, R.** (2022). Mental health beliefs, access, and engagement with military sexual trauma-related mental health care. *Journal of General Internal Medicine, 37*, 742-750. doi:10.1007/s11606-022-07590-6
227. **McLean, C. P.,** Back, S. E., Capone, C., **Morland, L. A., Norman, S. B.,** Rauch, S., **Schnurr, P. P.,** Teng, E. J., & Acierno, R. (2022). The impact of Covid-19 on psychotherapy participation among individuals with posttraumatic stress disorder enrolled in treatment research. *Journal of Traumatic Stress, 35*, 308-313. doi:10.1002/jts.22718
228. **McLean, C. P.,** Foa, E., Dondanville, K., Haddock, C., Miller, M., Rauch, S., Yarvis, J., Wright, E., Hall-Clark, B., Fina, B., Litz, B., Mintz, J., Young-McCaughan, S., & Peterson, A. (2022). The effects of Web-Prolonged Exposure among military personnel and veterans with posttraumatic stress disorder: Correction. *Psychological Trauma: Theory, Research, Practice, and Policy, 14*, 804. doi:10.1037/tra0001251
229. **McLean, C. P.,** Levy, H., Miller, M., & Tolin, D. (2022). Exposure therapy for PTSD in military populations: A systematic review and meta-analysis of randomized clinical trials. *Journal of Anxiety Disorders, 90*, 102607. doi:10.1016/j.janxdis.2022.102607



230. Meis, L., Glynn, S., **Spoont, M., Kehle-Forbes, S.**, Nelson, D., Isenhardt, C., **Eftekhari, A.**, Ackland, P., Linden, E., Orazem, R., Cutting, A., Hagel Campbell, E., Astin, M., Porter, K., Smith, E., Chuick, C., Lamp, K., Vuper, T., Oakley, T., Khan, L., Keckeisen, S., & Polusny, M. (2022). Can families help veterans get more from PTSD treatment? A randomized clinical trial examining Prolonged Exposure with and without family involvement. *Trials*, *23*, 243. doi:10.1186/s13063-022-06183-2
231. **Meshberg-Cohen, S.**, Gross, G., **Kachadourian, L.**, & **Harpaz-Rotem, I.** (2021). Binge drinking following residential treatment for posttraumatic stress disorder among veterans with and without alcohol use disorder. *Journal of Psychiatric Research*, *143*, 202-208. doi:10.1016/j.jpsychires.2021.09.024
232. **Meshberg-Cohen, S.**, MacLean, R. R., Schnakenberg Martin, A. M., Sofuoglu, M., & **Petrakis, I.** (2021). Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and posttraumatic stress disorder: A review. *Addictive Behaviors*, *122*, 1-9. doi:10.1016/j.addbeh.2021.107026
233. Miles, S., Pruiksma, K., Slavish, D., Dietch, J., Wardle-Pinkston, S., Litz, B., Rodgers, M., Nicholson, K., Young-McCaughan, S., Dondanville, K., Nakase-Richardson, R., Mintz, J., **Keane, T. M.**, Peterson, A., Resick, P., & Taylor, D. (2022). Sleep disorder symptoms are associated with greater posttraumatic stress and anger symptoms in US Army service members seeking treatment for posttraumatic stress disorder. *Journal of Clinical Sleep Medicine*, *18*, 1617-1627. doi:10.5664/jcsm.9926
234. Mistler, L., & **Friedman, M. J.** (2022). Instruments for measuring violence on acute inpatient psychiatric units: Review and recommendations. *Psychiatric Services*, *73*, 650-657. doi:10.1176/appi.ps.202000297
235. **Mitchell, K. S.**, Masheb, B., **Smith, B. N.**, **Kehle-Forbes, S.**, Hardin, S., & **Vogt, D.** (2021). Eating disorder measures in a sample of military veterans: A focus on gender, age, and race/ethnicity. *Psychological Assessment*, *33*, 1226-1238. doi:10.1037/pas0001050
236. **Montalvo-Ortiz, J. L.**, **Gelernter, J.**, Cheng, Z., **Girgenti, M. J.**, **Xu, K.**, Zhang, X., Gopalan, S., Zhou, H., Duman, R., Southwick, S., **Krystal, J. H.**, Traumatic Stress Brain Research Study Group, & **Pietrzak, R. H.** (2022). Epigenome-wide association study of posttraumatic stress disorder identifies novel loci in U.S. military veterans. *Translational Psychiatry*. doi:10.1038/s41398-022-01822-3
237. Montena, A. L., Possemato, K., **Kuhn, E. R.**, **Carlson, E. B.**, McGovern, M., Smith, J., & Blonigen, D. (2021). Barriers and facilitators to peer-supported implementation of mental health mobile applications with veterans in primary care. *Journal of Technology in Behavioral Science*. doi:10.1007/s41347-021-00198-3
238. Morgan, N., Aronson, K., Perkins, W. S., Doucette, C., Bleser, J., Davenport, K., **Vogt, D.**, Copeland, L., Finley, E., & Gilman, C. (2022). The interaction of exposure to adverse childhood and combat experiences on the current mental health of new post-9/11 veterans. *Journal of Community Psychology*, *50*, 204-220. doi:10.1002/jcop.22523
239. Morgan-López, A., Hien, D., Saraiya, T., Saavedra, L., **Norman, S. B.**, Killeen, T., Simpson, T. L., Fitzpatrick, S., Mills, K., Ruglass, L., Back, S., & López-Castro, T. (2022). Estimating posttraumatic stress disorder severity in the presence of differential item functioning across populations, comorbidities, and interview measures: Introduction to Project Harmony. *Journal of Traumatic Stress*, *35*, 926-940. doi:10.1002/jts.22800
240. Moring, J., Straud, C., Penzien, D., Resick, P., Peterson, A., Jaramillo, C., Eapen, B., McGeary, C., Mintz, J., Litz, B., Young-McCaughan, S., **Keane, T. M.**, & McGeary, D. (2022). PTSD symptoms and tinnitus severity: An analysis of veterans with posttraumatic headaches. *Health Psychology*, *41*, 178-183. doi:10.1037/hea0001113
241. **Morland, L. A.**, Knopp, K., Khalifian, C., Macdonald, A., Grubbs, K., **Mackintosh, M.**, Becker-Cretu, J., Sautter, F., Buzzella, B., Wrape, E., Glassman, L., Webster, K., Sohn, M., Glynn, S., Acierno, R., & Monson, C. (2022). A randomized trial of brief couple therapy for PTSD and relationship satisfaction. *Journal of Consulting and Clinical Psychology*, *90*, 392-404. doi:10.1037/ccp0000731
242. **Morland, L. A.**, **Mackintosh, M.**, Glassman, L. H., & **Schnurr, P. P.** (2021). Clinical interventions for problematic anger. In A. B. Adler & D. Forbes (Eds.), *Anger at work: Advancing prevention, intervention, and treatment in high-risk occupations* (pp. 247-274). Washington, DC: American Psychiatric Association.
243. Mota, N., Bolton, S., Enns, M., Afifi, T., El-Gabalawy, R., Sommer, J., **Pietrzak, R. H.**, Stein, M., Asmundson, G., & Sareen, J. (2021). Course and predictors of posttraumatic stress disorder in the Canadian Armed Forces: A nationally representative, 16-year follow-up study: Cours et prédicteurs du trouble de stress post-traumatique dans les Forces Armées Canadiennes. *The Canadian Journal of Psychiatry*, *66*, 982-995. doi:10.1177/0706743721989167

244. Moyer, J., **Pless Kaiser, A., Cook, J., & Pietrzak, R. H.** (2022). Post-traumatic stress disorder in older U.S. military veterans: Prevalence, characteristics, and psychiatric and functional burden. *The American Journal of Geriatric Psychiatry, 30*, 606-618. doi:10.1016/j.jagp.2021.10.011
245. Mullins, N., Kang, J., Campos, A., Coleman, J., Edwards, A., Galfalvy, H., Levey, D., Lori, A., Shabalin, A., Starnawska, A., Su, M., Watson, H., Adams, M., Awasthi, S., Gandal, M., Hafferty, J., Hishimoto, A., . . . **Johnson, C. M., . . . Gelernter, J., . . . & Roussos, P.** (2022). Dissecting the shared genetic architecture of suicide attempt, psychiatric disorders, and known risk factors. *Biological Psychiatry, 91*, 313-327. doi:10.1016/j.biopsych.2021.05.029
246. Na, P., De Angelis, F., Nichter, B., Wendt, F., **Krystal, J. H., Southwick, S., Levey, D., Gelernter, J., Polimanti, R., & Pietrzak, R. H.** (2022). Psychosocial moderators of polygenic risk for suicidal ideation: Results from a 7-year population-based, prospective cohort study of U.S. veterans. *Molecular Psychiatry, 27*, 1068-1074. doi:10.1038/s41380-021-01352-2
247. Na, P., **Montalvo-Ortiz, J. L., Nagamatsu, S., Southwick, S., Krystal, J. H., Gelernter, J., & Pietrzak, R. H.** (2022). Association of symptoms of posttraumatic stress disorder and GrimAge, an epigenetic marker of mortality risk, in US military veterans. *The Journal of Clinical Psychiatry*. doi:10.4088/JCP.21br14309
248. Na, P., Nichter, B., Hill, M., Kim, B., **Norman, S. B., & Pietrzak, R. H.** (2021). Severity of substance use as an indicator of suicide risk among U.S. military veterans. *Addictive Behaviors*. doi:10.1016/j.addbeh.2021.107035
249. Na, P., **Ralevski, E., Jegede, O., Wolfgang, A., & Petrakis, I.** (2022). Depression and/or PTSD comorbidity affects response to antidepressants in those with alcohol use disorder. *Frontiers in Psychiatry*. doi:10.3389/fpsyt.2021.768318
250. Na, P., Straus, E., Tsai, J., **Norman, S. B., Southwick, S., & Pietrzak, R. H.** (2022). Loneliness in U.S. military veterans during the Covid-19 pandemic: A nationally representative, prospective cohort study. *Journal of Psychiatric Research, 151*, 546-553. doi:10.1016/j.jpsychires.2022.05.042
251. Na, P., Tsai, J., Harpaz-Rotem, I., & **Pietrzak, R. H.** (2022). Mental health and suicidal ideation in US military veterans with histories of Covid-19 infection. *BMJ Military Health, 168*, 15-19. doi:10.1136/bmjilitary-2021-001846
252. Nabity, P., Jaramillo, C., Resick, P., McGeary, C., Eapen, B., Straud, C., Hale, W., Houle, T., Litz, B., Mintz, J., Penzien, D., Young-McCaughan, S., **Keane, T. M., Peterson, A., & McGeary, D.** (2021). Persistent posttraumatic headaches and functioning in veterans: Injury type can matter. *Headache: The Journal of Head and Face Pain, 61*, 1334-1341. doi:10.1111/head.14210
253. Nagamatsu, S., **Pietrzak, R. H., Na, P., Krystal, J. H., Gelernter, J., & Montalvo-Ortiz, J. L.** (2022). Are positive psychosocial traits linked to epigenetic aging? Results from a national sample of U.S. Military veterans. *Biological Psychiatry, 91*, S119. doi:10.1016/j.biopsych.2022.02.313
254. Nason, E. E., Borah, E. V., Hale, W. J., **Wachen, J. S., Dondanville, K. A., Mintz, J., Litz, B. T., Yarvis, J. S., Young-McCaughan, S., Peterson, A. L., Resick, P. A., & STRONG STAR Consortium** (2021). The effects of interpersonal support on treatment outcomes using Cognitive Processing Therapy. *Cognitive Therapy and Research, 45*, 679-688. doi:10.1007/s10608-020-10181-6
255. Neppala, G., Terkuhle, I., Wagner, A., Lepow, L., Shaik, R., Freed, R., Kimhy, D., **Pietrzak, R. H., Velthorst, E., Feder, A., Ivanov, I., & Parvaz, M.** (2022). Social isolation-mediated exacerbation of negative affect in young drinkers during the Covid-19 pandemic. *Brain Sciences, 12*, 214. doi:10.3390/brainsci12020214
256. Newberger, N., Hinds, Z., **Mahoney, C. T., Bryant, W., Herbitter, C., & Livingston, N.** (2022). Real-time associations between discrimination, cannabis use, and mood among sexual and gender minority individuals. *Psychology of Addictive Behaviors, 36*, 491-498. doi:10.1037/adb0000836
257. Nichter, B., Holliday, R., Monteith, L., Na, P., Hill, M., Kline, A., **Norman, S. B., & Pietrzak, R. H.** (2022). Military sexual trauma in the United States: Results from a population-based study. *Journal of Affective Disorders, 306*, 19-27. doi:10.1016/j.jad.2022.03.016
258. Nichter, B., Na, P., Stanley, I., **Marx, B. P., Herzog, S., Moynahan, V., Hill, M., Norman, S. B., & Pietrzak, R. H.** (2022). Identifying factors associated with elevated suicidal intent among U.S. military veterans. *Journal of Psychiatric Research, 155*, 68-74. doi:10.1016/j.jpsychires.2022.08.001

259. Nichter, B., Stein, M., Monteith, L., Herzog, S., Holliday, R., Hill, M., **Norman, S. B., Krystal, J. H., & Pietrzak, R. H.** (2022). Risk factors for suicide attempts among U.S. military veterans: A 7-year population-based, longitudinal cohort study. *Suicide and Life-Threatening Behavior, 52*, 303-316. doi:10.1111/sltb.12822
260. Nikayin, S., Murphy, E., **Krystal, J. H., & Wilkinson, S.** (2022). Long-term safety of ketamine and esketamine in treatment of depression. *Expert Opinion on Drug Safety, 21*, 777-787. doi:10.1080/14740338.2022.2066651
261. **Nillni, Y. I.,** Crowe, H. M., Yland, J. Y., Wesselink, A. K., & Wise, L. A. (2022). The association between time-to-pregnancy and postpartum depressive symptoms in a North American prospective cohort study. *Annals of Epidemiology*. doi:10.1016/j.annepidem.2022.07.008
262. **Nillni, Y. I., Fox, A. B.,** Cox, K., Paul, E., **Vogt, D., & Galovski, T. E.** (2022). The impact of military sexual trauma and warfare exposure on women veterans' perinatal outcomes. *Psychological Trauma: Theory, Research, Practice, and Policy, 14*, 730-737. doi:10.1037/tra0001095
263. Nishimi, K., Borsari, B., **Marx, B. P.,** Tripp, P., Woodward, E., Rosen, R., Cohen, B., Maven, D., Jiha, A., Woolley, J., Neylan, T. C., & O'Donovan, A. (2022). Posttraumatic stress disorder symptoms associated with protective and risky behaviors for coronavirus disease 2019. *Health Psychology, 41*, 104-114. doi:10.1037/hea0001157
264. Nixon, R. D.V., **King, M. W., Smith, B. N., Gradus, J. L.,** Resick, P. A., & **Galovski, T. E.** (2021). Predicting response to Cognitive Processing Therapy for PTSD: A machine-learning approach. *Behaviour Research and Therapy*. doi:10.1016/j.brat.2021.103920
265. **Norman, S. B.** (2022). Effectiveness of currently available psychotherapies for post-traumatic stress disorder and future directions. *World Psychiatry, 21*, 309-310. doi:10.1002/wps.20974
266. **Norman, S. B.** (2022). Trauma-informed guilt reduction therapy: Overview of the treatment and research. *Current Treatment Options in Psychiatry, 9*, 115-125. doi:10.1007/s40501-022-00261-7
267. **Norman, S. B.,** Capone, C., **Panza, K., Haller, M.,** Davis, B. C., **Schnurr, P. P.,** Shea, M. T., Browne, K. C., Norman, G. J., Lang, A. J., Kline, A. C., Golshan, S., Allard, C. B., & Angkaw, A. C. (2022). A clinical trial comparing trauma-informed guilt reduction therapy (TriGR), a brief intervention for trauma-related guilt, to supportive care therapy. *Depression and Anxiety, 39*, 262-273. doi:10.1002/da.23244
268. **Norman, S. B.,** Nichter, B., Maguen, S., Na, P., **Schnurr, P. P., & Pietrzak, R. H.** (2022). Moral injury among U.S. combat veterans with and without PTSD and depression. *Journal of Psychiatric Research, 154*, 190-197. doi:10.1016/j.jpsychires.2022.07.033
269. Núñez-Rios, D., Martínez-Magaña, J., Nagamatsu, S., Andrade-Brito, D., Forero, D., Orozco-Castaño, C., & **Montalvo-Ortiz, J. L.** (2022). Central and peripheral immune dysregulation in posttraumatic stress disorder: Convergent multi-omics evidence. *Biomedicines, 10*, 1107. doi:10.3390/biomedicines10051107
270. Nunez-Rios, D., Rompala, G., Hurd, Y., Nagamatsu, S., Martinez-Magaña, J., **Krystal, J. H., Gelernter, J., & Traumatic Stress Brain Research Group, Janitza L. Montalvo-Ortiz.** (2022). Multiomics mapping of posttraumatic stress disorder in human cortical neurons. *Biological Psychiatry, 91*, S344. doi:10.1016/j.biopsych.2022.02.867
271. Olin, C. C., McDevitt-Murphy, M. E., Murphy, J. G., Zakarian, R. J., Roache, J. D., Young-McCaughan, S., Litz, B. T., **Keane, T. M., & Peterson, A. L.** (2022). The associations between posttraumatic stress disorder and delay discounting, future orientation, and reward availability: A behavioral economic model. *Journal of Traumatic Stress, 35*, 1252-1262. doi:10.1002/jts.22820
272. Olson, K., Fogelman, N., Maturo, L., Alvarado, J., Ball, S., Forray, A., Hu, M., Ivy, M., Kapo, J., **Krystal, J. H.,** Mayes, L., Rohrbaugh, R., Southwick, S., Tebes, J., Wassel, B., & Sinha, R. (2022). Covid-19 traumatic disaster appraisal and stress symptoms among healthcare workers: Insights from the Yale Stress Self-Assessment (YSSA). *Journal of Occupational & Environmental Medicine*. doi:10.1097/JOM.0000000000002673
273. Oslin, D. W., Lynch, K., Shih, M., Ingram, E., Wray, L. O., Chapman, S., Kranzler, H. R., **Gelernter, J.,** Pyne, J. M., Stone, A., DuVall, S., Lehmann, L., Thase, M. E., Aslam, M., Batki, S., Bjork, J. M., Blow, F., Brenner, L., . . . **Ranganathan, M., . . . & Wood, A.** (2022). Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder. *JAMA, 328*, 151-161. doi:10.1001/jama.2022.9805

274. Patel, K., Stevens, M., Dunlap, A., Gallagher, A., O'Malley, S., DeMartini, K., **Potenza, M., Krystal, J. H.,** & Pearson, G. (2022). Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial. *Neuropsychopharmacology*, *47*, 840-846. doi:10.1038/s41386-021-01157-5
275. Pathak, G., Singh, K., Wendt, F., Fleming, T., Overstreet, C., Koller, D., Tylee, D., De Angelis, D., Cabrera Mendoza, B., Levey, D., Koenen, K., **Krystal, J. H., Pietrzak, R. H.,** O'Donnell, C., Gaziano, J., Falcone, G., Stein, M., **Gelernter, J.,** Pasaniuc, B., Mancuso, N., Davis, L., & Polimanti, R. (2022). Genetically regulated multi-omics study for symptom clusters of posttraumatic stress disorder highlights pleiotropy with hematologic and cardio-metabolic traits. *Molecular Psychiatry*, *27*, 1394-1404. doi:10.1038/s41380-022-01488-9
276. Patt, V. M., Palombo, D. J., **Esterman, M.,** & Verfaellie, M. (2022). Hippocampal contribution to probabilistic feedback learning: Modeling observation- and reinforcement-based processes. *Journal of Cognitive Neuroscience*, *34*, 1429-1446. doi:10.1162/jocn\_a\_01873
277. Pavlacic, J., Buchanan, E., **McCaslin, S. E.,** Schulenberg, S., & Young, J. (2022). A systematic review of posttraumatic stress and resilience trajectories: Identifying predictors for future treatment of veterans and service members. *Professional Psychology: Research and Practice*, *53*, 266-275. doi:10.1037/pro0000451
278. Peccoralo, L., **Pietrzak, R. H.,** Feingold, J., Syed, S., Chan, C. C., Murrough, J. W., Kaplan, C., Verity, J., Feder, A., Charney, D., **Southwick, S.,** & Ripp, J. (2022). A prospective cohort study of the psychological consequences of the Covid-19 pandemic on frontline healthcare workers in New York City. *International Archives of Occupational and Environmental Health*, *95*, 1279-1291. doi:10.1007/s00420-022-01832-0
279. Peltzman, T., Gottlieb, D., Levis, M., & **Shiner, B.** (2022). The role of race in rural-urban suicide disparities. *The Journal of Rural Health*, *38*, 346-354. doi:10.1111/jrh.12603
280. Peltzman, T., **Rice, K.,** Jones, K., Washington, D., & **Shiner, B.** (2022). Optimizing data on race and ethnicity for Veterans Affairs patients. *Military Medicine*, *187*, e955-e962. doi:10.1093/milmed/usac066
281. Peterson, A. L., Young-McCaughan, S., Roache, J. D., Mintz, J., Litz, B. T., Williamson, D. E., Resick, P. A., Foa, E. B., McGeary, D. D., Dondanville, K. A., Taylor, D. J., **Wachen, J. S., . . . McLean, C. P., . . . Niles, B. L., Abdallah, C., Averill, L., . . . Krystal, J. H., . . . Marx, B. P., . . . Sloan, D. M., . . . & Keane, T. M.** (2021). STRONG STAR and the consortium to alleviate PTSD: Shaping the future of combat PTSD and related conditions in military and veteran populations. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2021.106583
282. **Pietrzak, R. H.,** Javier, F., **Krystal, J. H.,** & Southwick, S. (2021). Subthreshold post-traumatic stress disorder as a risk factor for post-traumatic stress disorder: Results from a sample of USA veterans. *The British Journal of Psychiatry*, *219*, 456-459. doi:10.1192/bjp.2021.17
283. **Pless Kaiser, A.,** O'Malley, K., Moye, J., Etchin, A., Korsun, L., Weiskittle, R., Bashian, H., Kemp, K., & Sager, Z. (2022). Hospice and palliative care clinicians' perceptions of posttraumatic stress disorder at end-of-life in military veterans. *Progress in Palliative Care*, *30*, 205-211. doi:10.1080/09699260.2021.1980649
284. Polimanti, R., Wendt, F., Pathak, G., Tylee, D., Tcheandjieu, C., Hilliard, A., Levey, D., Adhikari, K., Gaziano, J., O'Donnell, C., Assimes, T., Stein, M., & **Gelernter, J.** (2022). Understanding the comorbidity between posttraumatic stress severity and coronary artery disease using genome-wide information and electronic health records. *Molecular Psychiatry*. doi:10.1038/s41380-022-01735-z
285. Poole, V., Dawe, R., Lamar, M., **Esterman, M.,** Barnes, L., Leurgans, S., Bennett, D., Hausdorff, J., & Buchman, A. (2022). Dividing attention during the Timed Up and Go enhances associations of several subtask performances with MCI and cognition. *PLOS ONE*, *17*, e0269398. doi:10.1371/journal.pone.0269398
286. Possemato, K., Wu, J., Greene, C. J., MacQueen, R., Blonigen, D., Wade, M., **Owen, J. E., Keane, T. M.,** Brief, D., Lindley, S., **Prins, A., Mackintosh, M.,** & **Carlson, E. B.** (2022). Web-based problem-solving training with and without peer support in veterans with unmet mental health needs: Pilot study of feasibility, user acceptability, and participant engagement. *Journal of Medical Internet Research*. doi:10.2196/29559
287. **Rasmusson, A. M., Pineles, S. L.,** Brown, K., & Pinna, G. (2022). A role for deficits in GABAergic neurosteroids and their metabolites with NMDA receptor antagonist activity in the pathophysiology of posttraumatic stress disorder. *Journal of Neuroendocrinology*, *34*, 2. doi:10.1111/jne.13062

288. Rauch, S., Kim, H., Venners, M., Porter, K., **Norman, S. B.**, Simon, N., Rothbaum, B., Tuerk, P., Acierno, R., Bui, E., Powell, C., Smith, E., Goetter, E., & McSweeney, L. (2022). Change in posttraumatic stress disorder–related thoughts during treatment: Do thoughts drive change when pills are involved? *Journal of Traumatic Stress, 35*, 496-507. doi:10.1002/jts.22762
289. Redican, E., Hyland, P., **Cloitre, M.**, McBride, O., Karatzias, T., Murphy, J., Bunting, L., & Shevlin, M. (2022). Prevalence and predictors of ICD-11 PTSD and complex PTSD in young people. *Acta Psychiatrica Scandinavica*. doi:10.1111/acps.13442
290. Reed, G., First, M., Billieux, J., **Cloitre, M.**, Briken, P., Achab, S., Brewin, C., King, D., Kraus, S., & Bryant, R. (2022). Emerging experience with selected new categories in the ICD-11: Complex PTSD, prolonged grief disorder, gaming disorder, and compulsive sexual behaviour disorder. *World Psychiatry, 21*, 189-213. doi:10.1002/wps.20960
291. Rehm, H., Page, A., Smith, L., Adams, J., Alterovitz, G., Babb, L., Barkley, M., Baudis, M., Beauvais, M., Beck, T., Beckmann, J., Beltran, S., Bernick, D., Bernier, A., Bonfield, J., Boughtwood, T., Bourque, G., Bowers, S., . . . **Keane, T. M.**, . . . & Birney, E. (2021). GA4GH: International policies and standards for data sharing across genomic research and healthcare. *Cell Genomics*. doi:10.1016/j.xgen.2021.100029
292. Resick, P. A., **Wachen, J. S.**, LoSavio, S. T., Young-McCaughan, S., Pruiksma, K. E., Blankenship, A., Jacoby, V., Peterson, A. L., Mintz, J., & STRONG STAR Consortium (2021). Variable-length Cognitive Processing Therapy for posttraumatic stress disorder in active duty military: Outcomes and predictors. *Behaviour Research and Therapy*. doi:10.1016/j.brat.2021.103846
293. **Reuman, L.**, Solar, C., MacLean, R. R., Halat, A., Rajeevan, H., Williams, D., Heapy, A., Bair, M., Krein, S., Kerns, R., & Higgins, D. (2022). If you personalize it, will they use it?: Self-reported and observed use of a tailored, internet-based pain self-management program. *Translational Behavioral Medicine, 12*, 693-701. doi:10.1093/tbm/ibab165
294. Riblet, N., Gottlieb, D., Watts, B., Levis, M., Scott, R., & **Shiner, B.** (2022). Is it time for the mental health field to consider unplanned discharge a key metric of patient safety? *Journal of Nervous and Mental Disease, 210*, 227-230. doi:10.1097/nmd.0000000000001425
295. Riblet, N., Kenneally, L., Stevens, S., Watts, B., Gui, J., Forehand, J., **Cornelius, S. L.**, Rousseau, G., Schwartz, J., & **Shiner, B.** (2022). A virtual, pilot randomized trial of a brief intervention to prevent suicide in an integrated healthcare setting. *General Hospital Psychiatry, 75*, 68-74. doi:10.1016/j.genhosppsych.2022.02.002
296. Riblet, N., Varela, M., Ashby, W., Zubkoff, L., **Shiner, B.**, Pogue, J., Stevens, S., Wasserman, D., & Watts, B. (2022). Spreading a strategy to prevent suicide after psychiatric hospitalization: Results of a quality improvement spread initiative. *The Joint Commission Journal on Quality and Patient Safety, 48*, 503-512. doi:10.1016/j.jcjq.2022.02.009
297. Richards, A., Inslicht, S., Huie, J. R., Straus, L., Dukes, C., Hubachek, S., Felmingham, K., Mathalon, D., **Woodward, S. H.**, & Neylan, T. C. (2022). The relationship of fear-potentiated startle and polysomnography-measured sleep in trauma-exposed men and women with and without PTSD: Testing REM sleep effects and exploring the roles of an integrative measure of sleep, PTSD symptoms, and biological sex. *Sleep*. doi:10.1093/sleep/zsab271
298. Rippey, C., **Pietrzak, R. H.**, Maruff, P., & Adams, T. (2022). Interactive effects of the BDNF Val66Met polymorphism and posttraumatic stress disorder on cognition in U.S. military veterans. *Psychoneuroendocrinology, 142*, 1-8. doi:10.1016/j.psyneuen.2022.105820
299. Rozek, D., Baker, S., Rugo, K., Steigerwald, V., **Sippel, L. M.**, Holliday, R., Roberge, E., Held, P., Mota, N., & Smith, N. (2022). Addressing co-occurring suicidal thoughts and behaviors and posttraumatic stress disorder in evidence-based psychotherapies for adults: A systematic review. *Journal of Traumatic Stress, 35*, 729-745. doi:10.1002/jts.22774
300. Rubenstein, A., Koenig, H., Marin, D., Sharma, V., Harpaz-Rotem, I., & **Pietrzak, R. H.** (2021). Religion, spirituality, and risk for incident posttraumatic stress disorder, suicidal ideation, and hazardous drinking in U.S. military veterans: A 7-year, nationally representative, prospective cohort study. *Journal of Affective Disorders, 295*, 1110-1117. doi:10.1016/j.jad.2021.08.128
301. Saavedra, L., Morgan-López, A., Back, S., Patel, S., Hien, D., Killeen, T., **Norman, S. B.**, Fitzpatrick, S., Ebrahimi, C., & Ruglass, L. (2022). Measurement error-corrected estimation of clinically significant change trajectories for interventions targeting comorbid PTSD and substance use disorders in OEF/OIF veterans. *Behavior Therapy, 53*, 1009-1023. doi:10.1016/j.beth.2022.04.007

302. Saavedra, L., Morgan-López, A., Hien, D., López-Castro, T., Ruglass, L., Back, S., Fitzpatrick, S., **Norman, S. B.**, Killeen, T., Ebrahimi, C., & **Hamblen, J. L.** (2021). Evaluating treatments for posttraumatic stress disorder, alcohol and other drug use disorders using meta-analysis of individual patient data: Design and methodology of a virtual clinical trial. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2021.106479
303. Salas, J., Gebauer, S., Gillis, A., van den Berk-Clark, C., Schneider, F., **Schnurr, P. P.**, **Friedman, M. J.**, **Norman, S. B.**, Tuerk, P., Cohen, B., Lustman, P., & Scherrer, J. (2022). Increased smoking cessation among veterans with large decreases in posttraumatic stress disorder severity. *Nicotine & Tobacco Research*, *24*, 178-185. doi:10.1093/ntr/ntab179
304. Sarnowski, C., Ghanbari, M., Bis, J., **Logue, M. W.**, Fornage, M., Mishra, A., Ahmad, S., Beiser, A., Boerwinkle, E., Bouteloup, V., Chouraki, V., Cupples, L., Damotte, V., DeCarli, C., DeStefano, A., Djoussé, L., Fohner, A., Franz, C., Kautz, T., . . . & Seshadri, S. (2022). Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels. *Communications Biology*. doi:10.1038/s42003-022-03287-y
305. Sayer, N. A., **Wiltsey Stirman, S.**, **Bernardy, N. C.**, **Rosen, C. S.**, **Kehle-Forbes, S.**, **Spoont, M.**, Chard, K., Eftekhari, A., & Nelson, D. B. (2022). Investigation of therapist effects on patient engagement in evidence-based psychotherapies for posttraumatic stress disorder in the Veterans Health Administration. *Journal of Traumatic Stress*, *35*, 66-77. doi:10.1002/jts.22679
306. Schlienzy, N., Scalsky, R., Martin, E., Jackson, H., Munson, J., Strickland, J., Bonn-Miller, M., **Loflin, M. J.**, & Vandrey, R. (2021). A cross-sectional and prospective comparison of medicinal cannabis users and controls on self-reported health. *Cannabis and Cannabinoid Research*, *6*, 548-558. doi:10.1089/can.2019.0096
307. **Schnurr, P. P.** (2022). Understanding pathways from traumatic exposure to physical health. In U. Schnyder & M. Cloitre (Eds.), *Evidence based treatments for trauma-related psychological disorders - A practical guide for clinicians*, (2nd ed.) (pp. 87-103). New York, NY: Springer.
308. **Schnurr, P. P.**, Chard, K., Ruzek, J. I., Chow, B., Resick, P., Foa, E., **Marx, B. P.**, **Friedman, M. J.**, **Bovin, M. J.**, **Caudle, K. L.**, Castillo, D., Curry, K., Hollifield, M., Huang, G., Chee, C., Astin, M., Dickstein, B., Renner, K., . . . **Maieritsch, K. P.**, . . . & Shih, M. (2022). Comparison of Prolonged Exposure vs Cognitive Processing Therapy for treatment of posttraumatic stress disorder among US veterans. *JAMA Network Open*. doi:10.1001/jamanetworkopen.2021.36921
309. Schulz-Heik, R. J., Lazzeroni, L., Hernandez, B., **Avery, T.**, Mathersul, D. C., Tang, J. S., Hugo, E., & Bayley, P. J. (2022). Valued living among veterans in breath-based meditation treatment or Cognitive Processing Therapy for posttraumatic stress disorder: Exploratory outcome of a randomized controlled trial. *Global Advances in Health and Medicine*. doi:10.1177/2164957X221108376
310. Scott, J., Lynch, K., Cenkner, D., **Kehle-Forbes, S.**, Polusny, M., Gur, R., Chen, S., Foa, E., & Oslin, D. W. (2021). Neurocognitive predictors of treatment outcomes in psychotherapy for comorbid PTSD and substance use disorders. *Journal of Consulting and Clinical Psychology*, *89*, 937-946. doi:10.1037/ccp0000693
311. Seligowski, A. V., Steuber, E. R., Hinrichs, R., Reda, M. H., Wiltshire, C. N., Wanna, C. P., Winters, S. J., Phillips, K. A., House, S. L., Beaudoin, F. L., An, X., Stevens, J. S., Zeng, D., Neylan, T. C., Clifford, G. D., Linnstaedt, S. D., Germine, L. T., . . . **Miller, M. W.**, **Pietrzak, R. H.**, . . . & Jovanovic, T. (2021). A prospective examination of sex differences in posttraumatic autonomic functioning. *Neurobiology of Stress*. doi:10.1016/j.ynstr.2021.100384
312. Sellinger, J., Martino, S., Lazar, C., Mattocks, K., Rando, K., Serowik, K., Ablondi, K., Fenton, B., Gilstad-Hayden, K., Brummett, B., **Holtzheimer, P. E.**, Higgins, D., Reznik, T., Semiatin, A., Stapley, T., Ngo, T., & Rosen, M. I. (2022). The acceptability and feasibility of screening, brief intervention, and referral to treatment for pain management among New England veterans with chronic pain: A pilot study. *Pain Practice*, *22*, 28-38. doi:10.1111/papr.13023
313. Selloni, A., Bhatia, G., **Ranganathan, M.**, & De Aquino, J. P. (2022). Multimodal correlates of cannabis use among U.S. veterans with bipolar disorder: An integrated study of clinical, cognitive, and functional outcomes. *Journal of Dual Diagnosis*, *18*, 81-91. doi:10.1080/15504263.2022.2053264
314. **Serier, K. N.**, **Smith, B. N.**, Cooper, Z., **Vogt, D.**, & **Mitchell, K. S.** (2022). Disordered eating in sexual minority post-9/11 United States veterans. *International Journal of Eating Disorders*, *55*, 470-480. doi:10.1002/eat.23680
315. **Serier, K.**, Peterson, K., VanderJagt, H., Sebastian, R., Mullins, C., Medici, J., Smith, J., & Smith, J. (2022). Factor analytic support for the EDE-Q7 among American Indian/Alaska Native undergraduate women. *Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity*, *27*, 2011-2018. doi:10.1007/s40519-021-01335-w

316. **Serier, K., Vogt, D., Pandey, S., & Smith, B. N.** (2022). Analysis of the bidirectional relationships between posttraumatic stress and depression symptoms with physical health functioning in post-9/11 veteran men and women deployed to a war zone. *Journal of Psychosomatic Research*, *162*, 111034. doi:10.1016/j.jpsychores.2022.111034
317. Shaikh, N., Sandhu, M., Aljishi, A., Obaid, S., Gu, B., **Krystal, J. H., Kaye, A., & Damisah, E.** (2022). Neural correlates of bodily feedback during spatial threat avoidance. *Biological Psychiatry*, *91*, S144. doi:10.1016/j.biopsych.2022.02.376
318. Shayani, D. R., Danitz, S. B., **Low, S.,** Hamilton, A., & **Iverson, K. M.** (2022). Women tell all: A comparative thematic analysis of women's perspectives on two brief counseling interventions for intimate partner violence. *International Journal of Environmental Research and Public Health*, *19*, 2513. doi:10.3390/ijerph19052513
319. Shea, T., Krupnick, J. L., Sautter, F. J., Mete, M., Finley, S. L., **Norman, S. B., & Green, B. L.** (2021). Rationale, design, and methods of a two-site randomized controlled trial: Comparative effectiveness of two treatments for posttraumatic stress disorder in veterans. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2021.106408
320. **Shiner, B.,** Forehand, J., Rozema, L., Kulldorff, M., Watts, B., Trefethen, M., Jiang, T., Huybrechts, K., **Schnurr, P. P.,** Vincenti, M., Gui, J., & **Gradus, J. L.** (2022). Mining clinical data for novel posttraumatic stress disorder medications. *Biological Psychiatry*, *91*, 647-657. doi:10.1016/j.biopsych.2021.10.008
321. **Shiner, B.,** Gottlieb, D., Levis, M., Peltzman, T., Riblet, N., **Cornelius, S. L.,** Russ, C., & Watts, B. (2022). National cross-sectional cohort study of the relationship between quality of mental healthcare and death by suicide. *BMJ Quality & Safety*, *31*, 434-440. doi:10.1136/bmjqs-2020-012944
322. **Shiner, B.,** Gottlieb, D., **Rice, K.,** Forehand, J., Snitkin, M., & Watts, B. (2022). Evaluating policies to improve access to mental health services in rural areas. *The Journal of Rural Health*, *38*, 805-816. doi:10.1111/jrh.12674
323. **Shiner, B.,** Huybrechts, K., Gui, J., Rozema, L., Forehand, J., Watts, B., Jiang, T., Hoyt, J., Esteves, J., **Schnurr, P. P.,** Ray, K., & **Gradus, J. L.** (2022). Comparative effectiveness of direct-acting antivirals for posttraumatic stress disorder in Veterans Affairs patients with hepatitis C virus infection. *American Journal of Epidemiology*, *191*, 1614-1625. doi:10.1093/aje/kwac104
324. **Shiner, B.,** Levis, M., Dufort, V., Patterson, O., Watts, B., DuVall, S., Russ, C., & Maguen, S. (2022). Improvements to PTSD quality metrics with natural language processing. *Journal of Evaluation in Clinical Practice*, *28*, 520-530. doi:10.1111/jep.13587
325. **Shiner, B.,** Peltzman, T., **Cornelius, S. L.,** Gui, J., Jiang, T., Riblet, N., Gottlieb, D., & Watts, B. (2022). Influence of contextual factors on death by suicide in rural and urban settings. *The Journal of Rural Health*, *38*, 336-345. doi:10.1111/jrh.12579
326. Shinohara, R., Aghajanian, G., & **Abdallah, C.** (2021). Neurobiology of the rapid-acting antidepressant effects of ketamine: Impact and opportunities. *Biological Psychiatry*, *90*, 85-95. doi:10.1016/j.biopsych.2020.12.006
327. **Shor, R., Lee, D. J., Thompson-Hollands, J., & Sloan, D. M.** (2022). Psychometric properties of the Posttraumatic Avoidance Behaviour Questionnaire among a treatment-seeking adult sample. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, 393-398. doi:10.1037/tra0001060
328. Silvia, P., Eddington, K., Maloney, K., Lunsford, J., **Harper, K. L., & Kwapil, T.** (2021). Self-report measures of anhedonia and approach motivation weakly correspond to anhedonia and depression assessed via clinical interviews. *Personality and Individual Differences*. doi:10.1016/j.paid.2021.110963
329. Simpson, T. L., Goldberg, S., Loudon, D., Blakey, S., Hawn, S., Lott, A., Browne, K., Lehavot, K., & **Kaysen, D. L.** (2021). Efficacy and acceptability of interventions for co-occurring PTSD and SUD: A meta-analysis. *Journal of Anxiety Disorders*. doi:10.1016/j.janxdis.2021.102490
330. Singh, R. S., Landes, S. J., Resnick, S., Abraham, T. H., **Maieritsch, K. P.,** Pollack, S., & Kirchner, J. E. (2022). Engaging frontline workers in policy development to support the implementation of measurement-based care: Lessons learned from a field-based workgroup. *Frontiers in Health Services*. doi:10.3389/frhs.2022.929438
331. **Sloan, D. M.** (2022). Vision statement from the new Editor in Chief. *Journal of Traumatic Stress*, *35*, 5-6. doi:10.1002/jts.22805

332. **Sloan, D. M., Marx, B. P.**, Resick, P., Young-McCaughan, S., Dondanville, K., Straud, C., Mintz, J., Litz, B., & Peterson, A. (2022). Effect of Written Exposure Therapy vs Cognitive Processing Therapy on increasing treatment efficiency among military service members with posttraumatic stress disorder. *JAMA Network Open*. doi:10.1001/jamanetworkopen.2021.40911
333. **Sloan, D. M.**, Sloan, C., & Litwack, S. D. (2021). Flexibility with PTSD treatment. In P. Kendall (Ed.), *Flexibility within fidelity: Breathing life into a treatment manual* (pp. 42-60). New York, NY: Oxford University Press.
334. **Sloan, D. M., Thompson-Hollands, J.**, Hayes, A., **Lee, D. J.**, Alpert, E., & **Marx, B. P.** (2022). Sudden gains in two trauma-focused treatments for posttraumatic stress disorder. *Behavior Therapy*, 53, 255-266. doi:10.1016/j.beth.2021.08.003
335. Smith, A., Shoji, K., Griffin, B., **Sippel, L. M.**, Dworkin, E., Wright, H., Morrow, E., Locke, A., Love, T., Harris, J. I., Kaniasty, K., Langenecker, S., & Benight, C. (2022). Correction to: Social cognitive mechanisms in healthcare worker resilience across time during the pandemic. *Social Psychiatry and Psychiatric Epidemiology*, 57, 1469-1469. doi:10.1007/s00127-022-02275-1
336. Smith, A., Shoji, K., Griffin, B., **Sippel, L. M.**, Dworkin, E., Wright, H., Morrow, E., Locke, A., Love, T., Harris, J. I., Kaniasty, K., Langenecker, S., & Benight, C. (2022). Social cognitive mechanisms in healthcare worker resilience across time during the pandemic. *Social Psychiatry and Psychiatric Epidemiology*, 57, 1457-1468. doi:10.1007/s00127-022-02247-5
337. Smith, S. K., Somers, T. J., **Kuhn, E. R.**, Laber, E., Syrjala, K., Kelleher, S. A., Majestic, C., Gebert, R., LeBlanc, M., **Owen, J. E.**, Applebaum, A., Sung, A. D., & Feger, B. (2021). A SMART approach to optimizing delivery of an mHealth intervention among cancer survivors with posttraumatic stress symptoms. *Contemporary Clinical Trials*. doi:10.1016/j.cct.2021.106569
338. Sofouli, E., **Wiltsey Stirman, S.**, Groleau, D., Perreault, M., & Piat, M. (2022). Identifying and exploring sustainability determinants of mental health recovery-oriented interventions: A mixed methods study protocol. *Global Implementation Research and Applications*, 2, 249-261. doi:10.1007/s43477-022-00052-5
339. Sorrentino, A. E., **Iverson, K. M.**, Tuepker, A., True, G., Cusack, M., Newell, S., & Ditcher, M. E. (2021). Mental health care in the context of intimate partner violence: Survivor perspectives. *Psychological Services*, 18, 512-522. doi:10.1037/ser0000427
340. Spiller, T., **Duek, O.**, Buta, E., Gross, G., Smith, N., & **Harpaz-Rotem, I.** (2022). Comparative effectiveness of group v. individual trauma-focused treatment for posttraumatic stress disorder in veterans. *Psychological Medicine*. doi:10.1017/S0033291722001441
341. **Stanley, I. H.** (2021). Advancements in the understanding of PTSD and suicide risk: Introduction to a Special Section. *Psychological Trauma: Theory, Research, Practice, and Policy*, 13, 7. doi:10.1037/tra0001121
342. **Stanley, I. H.**, & **Marx, B. P.** (2022). When a patient dies by suicide: A consideration of PTSD Criterion A and disentangling self-blame from medicolegal blame. *Clinical Psychology: Science and Practice*, 29, 121-123. doi:10.1037/cps0000087
343. **Stanley, I. H., Marx, B. P.**, Nichter, B., & **Pietrzak, R. H.** (2022). Non-response to questions about suicide ideation and attempts among veterans: Results from the National Health and Resilience in Veterans Study. *Suicide and Life-Threatening Behavior*, 52, 763-772. doi:10.1111/sltb.12860
344. **Stanley, I. H.**, Ravindran, C., Morley, S. W., Stephens, B., & Reger, M. A. (2022). Analysis of methods of suicide among US military veterans recently separated from military service. *JAMA Network Open*. doi:10.1001/jamanetworkopen.2022.10731
345. Steers, M. L. N., **Macia, K. S.**, Young, C. M., Neighbors, C., & Pedersen, E. R. (2021). Self in the service: Self-identification moderates the association between perceived drinking norms and own drinking among veterans. *Substance Use & Misuse*, 56, 1428-1438. doi:10.1080/10826084.2021.1928216
346. Stellman, J. M., Stellman, S., **Spiro, A.**, **Pless Kaiser, A.**, & **Smith, B. N.** (2022). The impact of military service in Vietnam on coping and health behaviors during the Covid-19 pandemic. *Frontiers in Public Health*. doi:10.3389/fpubh.2021.809357



347. Stone, L., **Girgenti, M. J.**, Wang, J., Ji, D., Zhao, H., **Krystal, J. H.**, & **Duman, R.** (2021). Cortical transcriptomic alterations in association with appetitive neuropeptides and body mass index in posttraumatic stress disorder. *International Journal of Neuropsychopharmacology*, *24*, 118-129. doi:10.1093/ijnp/pyaa072
348. Stout, D., Harlé, K. M., **Norman, S. B.**, Simmons, A. N., & Spadoni-Townsend, A. (2021). Resting-state connectivity subtype of comorbid PTSD and alcohol use disorder moderates improvement from integrated Prolonged Exposure therapy in veterans. *Psychological Medicine*. doi:10.1017/S0033291721001513
349. Straud, C. L., Blount, T. H., Foa, E. B., Brown, L. A., **McLean, C. P.**, McGeary, C. A., Koch, L. M., Schobitz, R. P., & Peterson, A. L. (2022). Intensive outpatient program using Prolonged Exposure for combat-related PTSD: A case study. *Cognitive and Behavioral Practice*, *29*, 710-721. doi:10.1016/j.cbpra.2021.06.001
350. Straud, C., Resick, P., Foa, E., Back, S., Monson, C., **McLean, C. P.**, Flanagan, J., **Wachen, J. S.**, McMahon, C., Schuhman, B., Zwetzig, S., Yarvis, J., Borah, A., Schrader, C., Sharrieff, A., Schobitz, R., Roache, J., Litz, B., Young-McCaughan, S., Mintz, J., **Keane, T. M.**, & Peterson, A. (2022). Aggression and violent behavior in the military: Self-reported conflict tactics in a sample of service members and veterans seeking treatment for posttraumatic stress disorder. *Aggression and Violent Behavior*, *66*, 101734. doi:10.1016/j.avb.2022.101734
351. Sullivan, G., Gendreau, R., Gendreau, J., Peters, P., Peters, A., Engels, J., Daugherty, B., Vaughn, B., **Weathers, F. W.**, & Lederman, S. (2021). Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. *Psychiatry Research*, *301*, 113974. doi:10.1016/j.psychres.2021.113974
352. Sun, D., Rakesh, G., Haswell, C., **Logue, M. W.**, Baird, C., O'Leary, E., Cotton, A., Xie, H., Tamburrino, M., Chen, T., Dennis, E., Jahanshad, N., Salminen, L., Thomopoulos, S., Rashid, F., . . . **Krystal, J. H.**, **Levy, I.**, . . . **Abdallah, C.**, . . . **Harpaz-Rotem, I.**, . . . & Morey, R. (2022). A comparison of methods to harmonize cortical thickness measurements across scanners and sites. *NeuroImage*. doi:10.1016/j.neuroimage.2022.119509
353. **Swanson, K. N.**, Song, J., **Beristianos, M.**, Lane, J., Landy, M., Shields, N., Monson, C. M., & **Wiltsey Stirman, S.** (2021). A glimpse into the “Black Box”: Which elements of consultation in an EBP are associated with client symptom change and therapist fidelity? *Implementation Research and Practice*. doi:10.1177/26334895211051791
354. **Taft, C. T.**, Gallagher, M. W., Hoffman, A., **Cole, H. E.**, & Creech, S. K. (2022). Does Strength at Home for Couples prevent sexual aggression in returning veterans? Examining randomized controlled trial findings. *Psychological Trauma: Theory, Research, Practice, and Policy*, *14*, 431-436. doi:10.1037/tra0001034
355. Tamman, A., Wendt, F., Pathak, G., **Krystal, J. H.**, Southwick, S., **Sippel, L. M.**, **Gelernter, J.**, Polimanti, R., & **Pietrzak, R. H.** (2022). Attachment style moderates polygenic risk for incident posttraumatic stress in U.S. military veterans: A 7-year, nationally representative, prospective cohort study. *Biological Psychiatry*, *91*, 637-646. doi:10.1016/j.biopsych.2021.09.025
356. Tanriverdi, B., Gregory, D., Olino, T., Ely, T., Harnett, N., van Rooij, S., Lebois, L., Seligowski, A., Jovanovic, T., Ressler, K., House, S., Beaudoin, F., An, X., Neylan, T. C., Clifford, G., Linnstaedt, S., Germine, L., . . . **Miller, M. W.**, **Pietrzak, R. H.**, . . . & Murty, V. (2022). Hippocampal threat reactivity interacts with physiological arousal to predict PTSD symptoms. *The Journal of Neuroscience*, *42*, 6593-6604. doi:10.1523/JNEUROSCI.0911-21.2022
357. Tebes, J., Awad, M., Connors, E., Fineberg, S., Gordon, D., Jordan, A., Kravitz, R., Li, L., Ponce, A., Prabhu, M., Rubman, S., Silva, M., Steinfeld, M., Tate, D., **Xu, K.**, & **Krystal, J. H.** (2022). The Stress and Resilience Town Hall: A systems response to support the health workforce during Covid-19 and beyond. *General Hospital Psychiatry*, *77*, 80-87. doi:10.1016/j.genhosppsych.2022.04.009
358. Than, C., Washington, D., **Vogt, D.**, Chuang, E., Needleman, J., Canelo, I., Meredith, L., & Yano, E. (2022). Discontinuity of women veterans' care in patient-centered medical homes: Does workforce gender sensitivity matter? *Women's Health Issues*, *32*, 173-181. doi:10.1016/j.whi.2021.11.008
359. **Thompson-Hollands, J.**, **Marx, B. P.**, **Lee, D. J.**, & **Sloan, D. M.** (2021). Longitudinal change in self-reported peritraumatic dissociation during and after a course of PTSD treatment: Contributions of symptom severity and time. *Psychological Trauma: Theory, Research, Practice, and Policy*, *13*, 665-672. doi:10.1037/tra0000951
360. Tkachuck, M. A., Pavlacic, J. M., Raley, M. J., **McCaslin, S. E.**, & Schulenberg, S. E. (2022). Validating military culture: The factor analysis of a military-related adaptation of acculturation in veterans. *Psychological Services*, *19*, 585-596. doi:10.1037/ser0000558

361. Toikumo, S., Xu, H., **Gelernter, J.**, Kember, R., & Kranzler, H. (2022). Integrating human brain proteomic data with genome-wide association study findings identifies novel brain proteins in substance use traits. *Neuropsychopharmacology*. doi:10.1038/s41386-022-01406-1
362. Toomey, R., Alpern, R., Reda, D., Baker, D., **Vasterling, J. J.**, Blanchard, M., & Eisen, S. (2021). A cohort study of neuropsychological functioning in spouses of U.S. Gulf War veterans. *Life Sciences*. doi:10.1016/j.lfs.2021.119894
363. Topiwala, A., Taschler, B., Ebmeier, K., Smith, S., Zhou, H., Levey, D., Codd, V., Samani, N., **Gelernter, J.**, Nichols, T., & Burgess, S. (2022). Alcohol consumption and telomere length: Mendelian randomization clarifies alcohol's effects. *Molecular Psychiatry*. doi:10.1038/s41380-022-01690-9
364. Tylee, D., Lee, Y., Wendt, F., Pathak, G., Levey, D., De Angelis, F., **Gelernter, J.**, & Polimanti, R. (2022). An atlas of genetic correlations and genetically informed associations linking psychiatric and immune-related phenotypes. *JAMA Psychiatry*, 79, 667. doi:10.1001/jamapsychiatry.2022.0914
365. Tylee, D., Lee, Y., Wendt, F., Pathak, G., Levey, D., De Angelis, F., **Gelernter, J.**, & Polimanti, R. (2022). Characterizing the genetic effects linking psychiatric and immune-related phenotypes. *Biological Psychiatry*, 91, S72-S73. doi:10.1016/j.biopsych.2022.02.200
366. Tynan, M., Wooldridge, J., Rossi, F., **McLean, C. P.**, Gasperi, M., **Bosch, J. O.**, Timko, C., Herbert, M., & Afari, N. (2022). Latent class patterns of adverse childhood experiences and their relationship to veteran status and sex in the national epidemiologic survey of alcohol and related conditions wave III. *Military Medicine*, 187, 304-312. doi:10.1093/milmed/usab536
367. Upchurch, D., Wong, M., Yuan, A., Haderlein, T., **McClendon, J.**, Christy, A., & Washington, D. (2022). Covid-19 infection in the Veterans Health Administration: Gender-specific racial and ethnic differences. *Women's Health Issues*, 32, 41-50. doi:10.1016/j.whi.2021.09.006
368. **Vasterling, J. J.**, Lafleche, G. C., Patt, V., & Verfaellie, M. (2022). Episodic future thinking and anticipatory emotions: Effects on delay discounting and preventive behaviors during Covid-19. *Applied Psychology: Health and Well-Being*, 14, 842-861. doi:10.1111/aphw.12350
369. Verma, A., Minnier, J., Wan, E., Huffman, J., Gao, L., Joseph, J., Ho, Y., Wu, W., Cho, K., Gorman, B., Rajeevan, N., Pyarajan, S., Garcon, H., Meigs, J., Sun, Y., Reaven, P., McGeary, J., Suzuki, A., **Gelernter, J.**, . . . & Luoh, S. (2022). A MUC5B gene polymorphism, rs35705950-T confers protective effects against Covid-19 hospitalization but not severe disease or mortality. *American Journal of Respiratory and Critical Care Medicine*. doi:10.1164/rccm.202109-2166OC
370. Viet, C., Zhang, X., **Xu, K.**, Yu, G., Asam, K., Thomas, C., Callahan, N., Doan, C., Walker, P., Nguyen, K., Kidd, S., Lee, S., Grandhi, A., Allen, C., Young, S., Melville, J., Shum, J., Viet, D., Herford, A., Roden, D., Gonzalez, M., Zhong, J., & Aouizerat, B. (2021). Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer. *Biomarker Research*, 9, 90. doi:10.1186/s40364-021-00349-x
371. **Vogt, D.**, **Borowski, S.**, Maguen, S., Blosnich, J., Hoffmire, C., Bernhard, P., **Iverson, K. M.**, & Schneiderman, A. (2022). Strengths and vulnerabilities: Comparing post-9/11 U.S. veterans' and non-veterans' perceptions of health and broader well-being. *SSM - Population Health*. doi:10.1016/j.ssmph.2022.101201
372. Wang, J., Zhao, H., & **Girgenti, M. J.** (2022). Posttraumatic stress disorder brain transcriptomics: Convergent genomic signatures across biological sex. *Biological Psychiatry*, 91, 6-13. doi:10.1016/j.biopsych.2021.02.012
373. Watanabe, K., Jansen, P., Savage, J., Nandakumar, P., Wang, X., Agee, M., Aslibekyan, S., Auton, A., Bryc, K., Clark, S., Elson, S., Fletez-Brant, K., Fontanillas, P., Furlotte, N., Gandhi, P., Heilbron, K., Hicks, B., . . . **Gelernter, J.**, . . . & Posthuma, D. (2022). Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. *Nature Genetics*, 54, 1125-1132. doi:10.1038/s41588-022-01124-w
374. **Watson, P.** (2021). Application of the five elements framework to the Covid pandemic. *Psychiatry*, 84, 415-429. doi:10.1080/00332747.2021.2005446
375. **Watson, P.** (2022). Stress, PTSD, and Covid-19: The utility of disaster mental health interventions during the Covid-19 pandemic. *Current Treatment Options in Psychiatry*, 9, 14-40. doi:10.1007/s40501-021-00253-z
376. Watts, B., Gottlieb, D., Riblet, N., Gui, J., & **Shiner, B.** (2022). Association of medication treatment for opioid use disorder with suicide mortality. *American Journal of Psychiatry*, 179, 298-304. doi:10.1176/appi.ajp.2021.21070700

377. Webermann, A., Dardis, C., & Iverson, K. M. (2022). The role of general self-efficacy in intimate partner violence and symptoms of posttraumatic stress disorder among women veterans. *Journal of Traumatic Stress, 35*, 868-878. doi:10.1002/jts.22794
378. Wells, S. Y., Walter, K. H., Dedert, E., Strasshofer, D., Schnitzer, J., Thorp, S., Morland, L. A., & Glassman, L. H. (2022). Do older veterans experience change in posttraumatic cognitions following treatment for posttraumatic stress disorder? *Psychological Trauma: Theory, Research, Practice, and Policy, 14*, 605-614. doi:10.1037/tra0001119
379. Wendt, F., Garcia-Argibay, M., Cabrera-Mendoza, B., Valdimarsdóttir, U., Gelernter, J., Stein, M., Nivard, M., Maihofer, A., Nievergelt, C., Larsson, H., Mattheisen, M., Polimanti, R., & Meier, S. (2022). The relationship of attention-deficit/hyperactivity disorder with post-traumatic stress disorder: A two-sample mendelian randomization and population-based sibling comparison study. *Biological Psychiatry*. doi:10.1016/j.biopsych.2022.08.012
380. Wendt, F., Pathak, G., Deak, J., De Angelis, F., Koller, D., Cabrera-Mendoza, B., Lebovitch, D., Levey, D., Stein, M., Kranzler, H., Koenen, K., Gelernter, J., Huckins, L., & Polimanti, R. (2022). Using phenotype risk scores to enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder. *Molecular Psychiatry, 27*, 2206-2215. doi:10.1038/s41380-022-01469-y
381. Wendt, F., Pathak, G., Singh, K., Stein, M., Koenen, K., Krystal, J. H., Gelernter, J., Davis, L., & Polimanti, R. (2022). Sex-specific genetic and transcriptomic liability to neuroticism. *Biological Psychiatry*. doi:10.1016/j.biopsych.2022.07.019
382. Wendt, F., Warrier, V., Pathak, G., Koenen, K., Stein, M., Krystal, J. H., Pietrzak, R. H., Gelernter, J., Goldfarb, E., Baron-Cohen, S., & Polimanti, R. (2022). Polygenic scores for empathy associate with posttraumatic stress severity in response to certain traumatic events. *Neurobiology of Stress*. doi:10.1016/j.ynstr.2022.100439
383. Whealin, J., Ciro, D., Dasaro, C., Udasin, I., Crane, M., Moline, J., Harrison, D., Luft, B., Todd, A., Feder, A., & Pietrzak, R. H. (2022). Race/ethnic differences in prevalence and correlates of posttraumatic stress disorder in World Trade Center responders: Results from a population-based, health monitoring cohort. *Psychological Trauma: Theory, Research, Practice, and Policy, 14*, 199-208. doi:10.1037/tra0001081
384. Whiteman, S., Kramer, L., Silverstein, M., Witte, T., & Weathers, F. W. (2022). Evaluating the factor structure of the Posttraumatic Cognitions Inventory. *Assessment, 29*, 128-135. doi:10.1177/1073191120954915
385. Whiteman, S., Witte, T., Cero, I., Kramer, L., & Weathers, F. W. (2021). Posttraumatic stress disorder and suicidal ideation: The moderating effect of posttraumatic cognitions. *Journal of Traumatic Stress, 34*, 1178-1187. doi:10.1002/jts.22598
386. Whitworth, J., Scioli, E. R., Keane, T. M., & Marx, B. P. (2022). Physical inactivity, cigarette smoking, and psychiatric comorbidity among veterans with posttraumatic stress disorder. *Health Psychology, 41*, 169-177. doi:10.1037/hea0001174
387. Williams, A., Baier, A., Woolley, M., & Galovski, T. E. (2022). Integrating social determinants of health within cognitive therapy. *Current Treatment Options in Psychiatry, 9*, 215-228. doi:10.1007/s40501-022-00268-0
388. Wingo, T., Gerasimov, E., Liu, Y., Duong, D., Vattathil, S., Lori, A., Gockley, J., Breen, M., Maihofer, A., Nievergelt, C., Koenen, K., Levey, D., Gelernter, J., Stein, M., Ressler, K., Bennett, D., Levey, A., Seyfried, N., & Wingo, A. (2022). Integrating human brain proteomes with genome-wide association data implicates novel proteins in post-traumatic stress disorder. *Molecular Psychiatry, 27*, 3075-3084. doi:10.1038/s41380-022-01544-4
389. Wisco, B., Nomamiukor, F., Marx, B. P., Krystal, J. H., Southwick, S., & Pietrzak, R. H. (2022). Posttraumatic stress disorder in US military veterans. *The Journal of Clinical Psychiatry*. doi:10.4088/JCP.20m14029
390. Woodward, S. H. (2022). Autonomic regulation during sleep in PTSD. *Neurobiology of Stress*. doi:10.1016/j.ynstr.2022.100483
391. Xu, K., Hu, Y., Zhang, X., Aouizerat, B., Yan, C., & Xu, K. (2022). A novel graph-based k-partitioning approach improves the detection of gene-gene correlations by single-cell RNA sequencing. *BMC Genomics*. doi:10.1186/s12864-021-08235-4

392. **Xu, K.**, Skarica, M., Hwang, A., Dai, Y., Lee, C., **Girgenti, M. J.**, & Zhang, J. (2022). A transfer learning approach to facilitate single-cell ATAC-seq data analysis from reference dataset. *Journal of Computational Biology*, *29*, 619-633. doi:10.1089/cmb.2021.0596
393. Yang, M. S., Quach, L., **Lee, L. O.**, **Spiro, A.**, & Burr, J. A. (2022). Subjective well-being among male veterans in later life: The enduring effects of early life adversity. *Aging & Mental Health*, *26*, 107-115. doi:10.1080/13607863.2020.1842999
394. Zakiniaeiz, Y., Hoyer, J., Ryan Petrulli, J., LeVasseur, B., Stanley, G., Gao, H., Najafzadeh, S., Ropchan, J., Nabulsi, N., **Huang, Y.**, Chen, M., Matuskey, D., Barron, D., **Kelmendi, B.**, Fulbright, R., Hampson, M., **Cosgrove, K.**, & Morris, E. (2022). Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers. *Brain, Behavior, and Immunity*, *106*, 262-269. doi:10.1016/j.bbi.2022.08.016
395. Zhang, J., **Kaye, A.**, Wang, J., & **Girgenti, M. J.** (2021). Transcriptomics of the depressed and PTSD brain. *Neurobiology of Stress*. doi:10.1016/j.ynstr.2021.100408
396. Zheng, Y., Garrett, M., Sun, D., Clarke-Rubright, E., Haswell, C., Maihofer, A., Elman, J., Franz, C., Lyons, M., Kremen, W. S., Peverill, M., Sambrook, K., McLaughlin, K., Davenport, N., . . . **D. R.**, **Miller, M. W.**, . . . **Wolf, E. J.**, **Salat, D.**, . . . **Logue, M. W.**, & Morey, R. (2021). Trauma and posttraumatic stress disorder modulate polygenic predictors of hippocampal and amygdala volume. *Translational Psychiatry*. doi:10.1038/s41398-021-01707-x
397. Zuberer, A., Kucyi, A., Yamashita, A., Wu, C. M., Walter, M., Valera, E. M., & **Esterman, M.** (2021). Integration and segregation across large-scale intrinsic brain networks as a marker of sustained attention and task-unrelated thought. *NeuroImage*. doi:10.1016/j.neuroimage.2020.117610

# Appendix E:

## Publications in Press

1. Allard, C. B., **Norman, S. B.**, Straus, E., Kim, H. M., Stein, M., Simon, N. M., Rauch, S., & the PROGrESS Study Team (2021). Reductions in guilt cognitions following Prolonged Exposure and/or sertraline predict subsequent improvements in PTSD and depression. *Journal of Behavior Therapy and Experimental Psychiatry*. Advance online publication. doi:10.1016/j.jbtep.2021.101666
2. Alosco, M., Mian, A., Buch, K., Farris, C., Uretsky, M., Tripodis, Y., Baucom, Z., Martin, B., Palmisano, J., Puzo, C., Ang, T., Joshi, P., Goldstein, L., Au, R., Katz, D., Dwyer, B., Daneshvar, D., Nowinski, C., . . . **Huber, B.**, . . . & Mez, J. (2021). Structural MRI profiles and tau correlates of atrophy in autopsy-confirmed CTE. *Alzheimer's Research & Therapy*. Advance online publication. doi:10.1186/s13195-021-00928-y
3. Alosco, M., Su, Y., Stein, T., Protas, H., Cherry, J., Adler, C., Balcer, L., Bernick, C., Pulukuri, S., Abdolmohammadi, B., Coleman, M., Palmisano, J., Tripodis, Y., Mez, J., Rabinovici, G., Marek, K., Beach, T., Johnson, K., **Huber, B.**, . . . & Johnson, K. (2022). Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players. *European Journal of Nuclear Medicine and Molecular Imaging*. Advance online publication. doi:10.1007/s00259-022-05963-x
4. **Alpert, E.**, Hayes, A., Ben Barnes, J., & **Sloan, D. M.** (2022). Using client narratives to identify predictors of outcome in Written Exposure Therapy and Cognitive Processing Therapy. *Behavior Therapy*. Advance online publication. doi:10.1016/j.beth.2022.09.002
5. Arditte-Hall, K., Werner, K., Griffin, M., & **Galovski, T. E.** (2022). Exploring predictors of sleep state misperceptions in women with posttraumatic stress disorder. *Behavior Therapy*. Advance online publication. doi:10.1080/15402002.2021.2024193
6. **Banducci, A. N.**, Cooper, B. N., Betts, J. M., & **Serier, K. N.** (in press). Exposure-based and behavioral theory. In F. Leong (Ed.), *APA handbook of psychotherapy*. Washington, DC: American Psychological Association Publishing.
7. **Banducci, A. N.**, **Mahoney, C. T.**, & **Street, A. E.** (in press). Military sexual trauma. In C. H. Warner & C. Castro (Eds.), *Veteran and military mental health: The psychiatrist's role*. Washington, DC: American Psychiatric Association.
8. Barnes, S. M., Borges, L. M., Sorensen, D., Smith, G., Bahraini, N. H., & **Walser, R. D.** (2022). Safety planning within Acceptance and Commitment Therapy. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2022.01.002
9. Beck, J., & **Keane, T. M.** (2022). Representing all of us: Methodological and conceptual issues in the PTSD treatment literature, with a scoop of reality. *Clinical Psychology: Science and Practice*. Advance online publication. doi:10.1037/cps0000081
10. Blonigen, D. M., Montena, A. L., Smith, J., Hedges, J., **Kuhn, E. R.**, **Carlson, E. B.**, **Owen, J. E.**, **Wielgosz, J.**, & Possemato, K. (2022). Peer-supported mobile mental health for veterans in primary care: A pilot study. *Psychological Services*. Advance online publication. doi:10.1037/ser0000709
11. Bountress, K., Brick, L., Sheerin, C., Grotzinger, A., Bustamante, D., **Hawn, S. E.**, Gillespie, N., Kirkpatrick, R., Kranzler, H. R., Morey, R., Edenberg, H., Maihofer, A., Disner, S., Ashley-Koch, A., Peterson, R., Lori, A., Stein, D., Kimbrel, N. A., Nievergelt, C., . . . & Amstadter, A. (2022). Alcohol use and alcohol use disorder differ in their genetic relationships with PTSD: A genomic structural equation modelling approach. *Drug and Alcohol Dependence*. Advance online publication. doi:10.1016/j.drugalcdep.2022.109430

12. **Bovin, M. J.**, Resnik, J., Linsky, A. M., Stolzmann, K., Mull, H. J., **Schnurr, P. P.**, Post, E. P., Pleasants, E. A., & Miller, C. J. (2022). Does screening for PTSD lead to VA mental health care? Identifying the spectrum of initial VA screening actions. *Psychological Services*. Advance online publication. doi:10.1037/ser0000651
13. **Bovin, M. J.**, Schneiderman, A., Bernhard, P., Maguen, S., Hoffmire, C., Blosnich, J., **Smith, B. N.**, Kulka, R., & **Vogt, D.** (2022). Development and validation of a brief warfare exposure measure among U.S. Iraq and Afghanistan war veterans: The Deployment Risk and Resilience Inventory-2 Warfare Exposure-Short Form (DRRI-2 WE-SF): Correction. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001340
14. **Brady, C. B.**, Robey, I., Stein, T., **Huber, B.**, Riley, J., Abdul Rauf, N., Spencer, K., Walt, G., Adams, L., Averill, J., Walker, S., McKee, A., Thomson, S., & Kowall, N. (2021). The Department of Veterans Affairs Gulf War Veterans' Illnesses Biorepository: Supporting research on Gulf War veterans' illnesses. *Brain Sciences*. Advance online publication. doi:10.3390/brainsci11101349
15. Brau, J., Sugarman, A., **Rothlein, D.**, DeGutis, J., **Esterman, M.**, & Fortenbaugh, F. (2022). The impact of image degradation and temporal dynamics on sustained attention. *Journal of Vision*. Advance online publication. doi:10.1167/jov.22.4.8
16. **Carlson, E. B.**, Palmieri, P. A., **Vogt, D.**, **Macia, K. S.**, & Lindley, S. E. (in press). Development and cross-validation of a veterans mental health risk factor screen. *PLOS ONE*.
17. Cherry, J., Esnault, C., Baucom, Z., Tripodis, Y., **Huber, B.**, Alvarez, V., Stein, T., Dickson, D., & McKee, A. (2021). Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease. *Acta Neuropathologica Communications*. Advance online publication. doi:10.1186/s40478-021-01189-4
18. Chu, C., **Stanley, I. H.**, **Marx, B. P.**, King, A. J., **Vogt, D.**, Gildea, S. M., Hwang, I. H., Sampson, N. A., O'Brien, R., Stein, M. B., Ursano, R. J., & Kessler, R. C. (2022). Associations of vulnerability to stressful life events with suicide attempts after active duty among high-risk soldiers: Results from the study to assess risk and resilience in servicemembers-longitudinal study (STARRS-LS). *Psychological Medicine*. Advance online publication. doi:10.1017/S0033291722000915
19. Ciccolo, J., Louie, M., SantaBarbara, N., Webster, C., **Whitworth, J.**, Nosrat, S., Chrastek, M., Dunsiger, S., Carey, M., & Busch, A. (2022). Resistance training for Black men with depressive symptoms: A pilot randomized controlled trial to assess acceptability, feasibility, and preliminary efficacy. *BMC Psychiatry*. Advance online publication. doi:10.1186/s12888-022-03935-x
20. Cole, T. A., **Reuman, L.**, **Lee, D. J.**, **Shotwell-Tabke, C. D.**, **Marx, B. P.**, & **Sloan, D. M.** (2022). The effect of time since index trauma on trauma-related beliefs. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001249
21. Convertino, A., **Morland, L. A.**, & Blashill, A. (2022). Trauma exposure and eating disorders: Results from a United States nationally representative sample. *International Journal of Eating Disorders*. Advance online publication. doi:10.1002/eat.23757
22. Cowlshaw, S., Sbisá, A., Freijah, I., Kartal, D., Mulligan, A., Notarianni, M., **Iverson, K. M.**, Couineau, A., Forbes, D., O'Donnell, M., Phelps, A., Smith, P., & Hosseiny, F. (2022). Health service interventions for intimate partner violence among military personnel and veterans: A framework and scoping review. *International Journal of Environmental Research and Public Health*. Advance online publication. doi:10.3390/ijerph19063551
23. Creech, S. K., Hamilton, E. G., Garza, A., Benzer, J., & **Taft, C. T.** (in press). Change in implementation strategy increases adoption of Strength at Home for Intimate Partner Violence within the VA Healthcare System. *Journal of Aggression*.
24. **Crowe, M. L.**, **Harper, K. L.**, **Moshier, S. J.**, **Keane, T. M.**, & **Marx, B. P.** (2022). Longitudinal PTSD network structure: Measuring PTSD symptom networks over 5 years. *Psychological Medicine*. Advance online publication. doi:10.1017/s0033291722000095
25. Cruz-Gonzalez, M., Alegría, M., Palmieri, P., Spain, D., Barlow, M., Shieh, L., Williams, M., Srirangam, P., & **Carlson, E. B.** (2022). Racial/ethnic differences in acute and longer-term posttraumatic symptoms following traumatic injury or illness. *Psychological Medicine*. Advance online publication. doi:10.1017/S0033291722002112

26. DeLaney, E., Williams, C., Mosley, D., **Hawn, S. E.**, & Dick, D. (2022). The associations between sexual victimization and health outcomes among LGBTQA college students: Examining the moderating role of social support. *Journal of Interpersonal Violence*. Advance online publication. doi:10.1177/0886260520978179
27. DeViva, J., **McCarthy, E.**, **Southwick, S.**, Tsai, J., & **Pietrzak, R. H.** (2021). The impact of sleep quality on the incidence of PTSD: Results from a 7-year, nationally representative, prospective cohort of U.S. military veterans. *Journal of Anxiety Disorders*. Advance online publication. doi:10.1016/j.janxdis.2021.102413
28. Dichter, M., **Iverson, K. M.**, Montgomery, A., & Sorrentino, A. (2021). Clinical response to positive screens for intimate partner violence in the Veterans Health Administration: Findings from review of medical records. *Journal of Aggression, Maltreatment & Trauma*. Advance online publication. doi:10.1080/10926771.2021.2013380
29. Elbogen, E., Zeber, J. E., **Vogt, D.**, Perkins, D., Finley, E., & Copeland, L. (2022). Financial status and well-being in recently separated military veterans. *Military Medicine*. Advance online publication. doi:10.1093/milmed/usac030
30. **Eliacin, J.**, & Cameron, K. (in press). Patient navigation. In E. Y. Ho, C. L. Bylund, & J. C. M. Van Weert (Eds.), *The international encyclopedia of health communication*. West Sussex: Wiley-Blackwell.
31. Fikretoglu, D., Sharp, M., Adler, A., Bélanger, S., Benassi, H., Bennett, C., Bryant, R., Busuttill, W., Cramm, H., Fear, N., Greenberg, N., Heber, A., Hosseiny, F., Hoge, C., Jetly, R., McFarlane, A., Morganstein, J., Murphy, D., O'Donnell, M., Phelps, A., Richardson, D., Sadler, N., **Schnurr, P. P.**, Smith, P., Ursano, R., Van Hooff, M., Wessely, S., Forbes, D., & Pedlar, D. (2022). Pathways to mental health care in active military populations across the Five-Eyes nations: An integrated perspective. *Clinical Psychology Review*. Advance online publication. doi:10.1016/j.cpr.2021.102100
32. Fonda, J. R., **Crowe, M. L.**, Levin, L. K., **Jagger-Rickels, A.**, **Marx, B. P.**, Milberg, W. P., McGlinchey, R. E., & Fortier, C. B. (in press). Mild traumatic brain injury, persistent neurobehavioral and psychiatric symptoms, and functional disability in post-9/11 veterans: Network analysis of a transdiagnostic sample. *Journal of Traumatic Stress*.
33. Forehand, J., Dufort, V., Gradus, J., Maguen, S., Watts, B., Jiang, T., Holder, N., & **Shiner, B.** (2022). Association between post-traumatic stress disorder severity and death by suicide in US military veterans: Retrospective cohort study. *The British Journal of Psychiatry*. Advance online publication. doi:10.1192/bjp.2022.110
34. Fowles, T., Moore, C., **Alpert, E.**, Beveridge, R., & Carlsen, A. (2022). Using simulated patients to train interpersonal skills with clinical psychology doctoral students. *Training and Education in Professional Psychology*. Advance online publication. doi:10.1037/tep0000396
35. **Friedman, M. J.**, Kilpatrick, D., Pynoos, R., **Schnurr, P. P.**, Ursano, R., & **Weathers, F. W.** (in press). Trauma- and stressor-related disorders. In American Psychiatric Association (Ed.), *Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR)*. Washington, DC: American Psychiatric Publishing.
36. **Galovski, T. E.**, **Street, A. E.**, **McCaughey, V.**, **Archibald, E.**, **Wachen, J. S.**, & **Chan, A. C.** (in press). WoVeN, the Women Veterans Network: An innovative peer support program for women veterans. *Journal of General Internal Medicine*.
37. **Gradus, J. L.**, Rosellini, A., Szentkúti, P., Horváth-Puhó, E., Smith, M., Galatzer-Levy, I., Lash, T., Galea, S., **Schnurr, P. P.**, & Sørensen, H. (2022). Pre-trauma predictors of severe psychiatric comorbidity 5 years following traumatic experiences. *International Journal of Epidemiology*. Advance online publication. doi:10.1093/ije/dyac030
38. Gray, C., **Azevedo, K. J.**, Urech, T., Lerner, B., Charns, M., & Vashi, A. (2022). Engaging patients in the Veterans Health Administration's lean enterprise transformation: A qualitative study. *Quality Management in Health Care*. Advance online publication. doi:10.1097/QMH.0000000000000371
39. Gurewich, D., Kressin, N., Dichter, M., Hunt, K., Linsky, A., Bokhour, B., Fix, G., & **Niles, B. L.** (in press). Protocol for a randomized controlled trial evaluating the effects of screening and referral for social determinants of health on veterans' outcomes. *BMJ Open*.
40. Gustavson, D., Reynolds, C., Hohman, T., Jefferson, A., Elman, J., Panizzon, M., Neale, M., **Logue, M. W.**, Lyons, M., Franz, C., & Kremen, W. S. (2022). Alzheimer's disease polygenic scores predict changes in episodic memory and executive function across 12 years in late middle age. *Journal of the International Neuropsychological Society*. Advance online publication. doi:10.1017/s1355617722000108
41. Hardin, S., **Vogt, D.**, **Smith, B. N.**, **Kehle-Forbes, S.**, Masheb, R., **Iverson, K. M.**, & **Mitchell, K. S.** (in press). Male and female veterans' preferences for eating disorders screening. *Journal of General Internal Medicine*.

42. **Harper, K. L., Vogt, D., Fox, A. B., Nillni, Y. I., & Galovski, T. E.** (in press). The impact of PTSD symptom severity, trauma type, and relationship functioning on mental health service use. *Psychological Trauma: Theory, Research, Practice, and Policy*.
43. **Heinz, A. J., Wiltsey Stirman, S., Jaworski, B. K.,** Sharin, T., Rhodes, L., Taylor, K., Gorman, B., Mason, D., Markios, S., & McGovern, M. (2021). Feasibility and preliminary efficacy of a public mobile app to reduce symptoms of post-disaster distress in adolescent wildfire survivors: Sonoma rises. *Psychological Services*. Advance online publication. doi:10.1037/ser0000576
44. Herzog, S., Nichter, B., Hill, M., Na, P., **Norman, S. B., & Pietrzak, R. H.** (2022). Factors associated with remission of suicidal ideation during the Covid-19 pandemic: A population-based, longitudinal study in US military veterans. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.21br14341
45. Hessinger, J. D., Etingen, B., **Larsen, S.,** Hunley, H. A., Goldstein, D. A., Day, A. M., Mayberry, M., Weber, D. J., Dolgin, R., Beyer, J. A., & **Maieritsch, K. P.** (2022). Improving engagement and retention to treatment within VHA PTSD specialty care: Evolution of an outpatient program design. *Psychological Services*. Advance online publication. doi:10.1037/ser0000705
46. Hinds, Z., **Herbitter, C.,** Bryant, W. T., Newberger, N. G., & **Livingston, N. A.** (2022). Hazardous substance use among SGM adults: A deeper look into distal minority stressors. *Psychology of Sexual Orientation and Gender Diversity*. Advance online publication. doi:10.1037/sgd0000583
47. Hoffman, S., Lyons, R., Stein, M., Taylor, C., & **Norman, S. B.** (2022). Changes in positive and negative affect following Prolonged Exposure for PTSD comorbid with alcohol use disorder: Secondary analysis of a randomized clinical trial. *Behaviour Research and Therapy*. Advance online publication. doi:10.1016/j.brat.2022.104097
48. **Holmes, S., Abdallah, C., & Esterlis, I.** (2022). Imaging synaptic density in depression. *Neuropsychopharmacology*. Advance online publication. doi:10.1038/s41386-022-01368-4
49. Hoyt, J., Teja, N., Jiang, T., Rozema, L., Gui, J., Watts, B., **Shiner, B.,** & Gradus, J. (2022). Changes in alcohol consumption following direct-acting antiviral treatment for hepatitis C in VA patients with comorbid alcohol use disorder and PTSD. *Journal of Dual Diagnosis*. Advance online publication. doi:10.1080/15504263.2022.2123119
50. Huckins, L. M., Signer, R., Johnson, J., Wu, Y.-K., **Mitchell, K. S.,** & Bulik, C. M. (2022). What next for eating disorder genetics? Replacing myths with facts to sharpen our understanding. *Molecular Psychiatry*. Advance online publication. doi:10.1038/s41380-022-01601-y
51. **Jagger-Rickels, A.,** Stumps, A., **Rothlein, D.,** Park, H., Fortenbaugh, F., Zuberer, A., Fonda, J., Fortier, C., DeGutis, J., Milberg, W., McGlinchey, R., & **Esterman, M.** (2021). Impaired executive function exacerbates neural markers of posttraumatic stress disorder. *Psychological Medicine*. Advance online publication. doi:10.1017/S0033291721000842
52. **Johnson, C. M., La Bash, H.,** Song, J., **Dunlap, K. L., Lagdamen, J. M.,** Suvak, M., Shields, N., Monson, C. M., & **Wiltsey Stirman, S.** (2021). The role of the consultant in consultation for an evidence-based treatment for PTSD. *Psychological Services*. Advance online publication. doi:10.1037/ser0000592
53. Jones, W. C., An, X., Ji, Y., Liu, M., Zeng, D., House, S. L., Beaudoin, F. L., Stevens, J. S., Neylan, T. C., Clifford, G. D., Jovanovic, J., Linnstaedt, S. D., Germine, G. T., Bollen, K. A., Rauch, S. L., Haran, J. P., Storrow, A. B., . . . **Miller, M. W., Pietrzak, R. H.,** . . . & McLean, S. A. (in press). Derivation and validation of a brief ED-based prediction tool for posttraumatic stress after motor vehicle collision. *Annals of Emergency Medicine*.
54. **Kachadourian, L.,** Tsai, J., Na, P., **Krystal, J. H.,** Southwick, S. M., & **Pietrzak, R. H.** (in press). Resilience to Covid-19 pandemic-related stressors in U.S. *Primary Care Companion for CNS Disorders*.
55. **Kehle-Forbes, S.,** Ackland, P., **Spoont, M., Meis, L.,** Orazem, R., Lyon, A., Valenstein-Mah, H., **Schnurr, P. P.,** Zickmund, S., Foa, E., Chard, K., Alpert, E., & Polusny, M. (2022). Divergent experiences of U.S. veterans who did and did not complete trauma-focused therapies for PTSD: A national qualitative study of treatment dropout. *Behaviour Research and Therapy*. Advance online publication. doi:10.1016/j.brat.2022.104123



56. **Kehle-Forbes, S.**, Nelson, D., **Norman, S. B.**, **Schnurr, P. P.**, Shea, M. T., Ackland, P. E., **Meis, L.**, Possemato, K., Polusny, M. A., Oslin, D. W., **Hamblen, J. L.**, **Galovski, T. E.**, Kenny, M., Babajide, N., & Hagedorn, H. (2022). Comparative effectiveness of trauma-focused and non-trauma-focused psychotherapy for PTSD among veterans with comorbid substance use disorders: Protocol & rationale for a randomized clinical trial. *Contemporary Clinical Trials*. Advance online publication. doi:10.1016/j.cct.2022.106876
57. **Kelmendi, B.**, Kitchuk, S., DePalmer, G., Maloney, G., Ching, T., Belser, A., & Pittenger, C. (in press). Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. *Heliyon*.
58. Khoo, S., Stasik-O'Brien, S., **Ellickson-Larew, S. A.**, Stanton, K., Clark, L., & Watson, D. (2022). The predictive validity of consensual and unique facets of neuroticism, conscientiousness, and agreeableness in five personality inventories. *Assessment*. Advance online publication. doi:10.1177/10731911221089037
59. Kim, S., Currao, A., Fonda, J. R., **Iverson, K. M.**, Kenna, A., Pierce, M. E., Beck, B. M., Jorge, R. E., & Fortier, C. B. (2022). Experience of intimate partner violence and associated psychiatric, neurobehavioral, and functional burden in male and female veterans: Implications for treatment. *Journal of Aggression, Maltreatment and Trauma*. Advance online publication. doi:10.1080/10926771.2022.2038756
60. Kline, A. C., Panza, K. E., Harlé, K. M., Angkaw, A. C., Trim, R. S., Back, S. E., & **Norman, S. B.** (2021). Within-treatment clinical markers of dropout risk in integrated treatments for comorbid PTSD and alcohol use disorder. *Drug and Alcohol Dependence*. Advance online publication. doi:10.1016/j.drugalcdep.2021.108592
61. Kline, A. C., Straus, E., Lyons, R. C., Angkaw, A. C., Davis, B. C., Haller, M., Hien, D., & **Norman, S. B.** (2021). Substance use predictors of attendance among veterans in integrated PTSD and alcohol use disorder treatment. *Journal of Substance Abuse Treatment*. Advance online publication. doi:10.1016/j.jsat.2021.108278
62. Koga, H., Trudel-Fitzgerald, C., **Lee, L. O.**, James, P., Kroenke, C., Garcia, L., Shadyab, A., Salmoirago-Blotcher, E., Manson, J., Grodstein, F., & Kubzansky, L. (2022). Optimism, lifestyle, and longevity in a racially diverse cohort of women. *Journal of the American Geriatrics Society*. Advance online publication. doi:10.1111/jgs.17897
63. Kramer, L., Whiteman, S., Petri, J., Spitzer, E., & **Weathers, F. W.** (2022). Self-rated versus clinician-rated assessment of PTSD: An evaluation of discrepancies between the PTSD Checklist and the Clinician-Administered PTSD Scale. *Assessment*. Advance online publication. doi:10.1177/10731911221113571
64. Krishnamurti, L., Agha, A., **Iverson, K. M.**, Monteith, L., & Dichter, M. (2022). Outreach to the Veterans Crisis Line during the Covid-19 pandemic: A mixed-methods analysis. *Psychiatric Services*. Advance online publication. doi:10.1176/appi.ps.202200044
65. **Kuhn, E. R.**, Reger, G., & Gratzler, D. (in press). Online consumer tools and support for mental health disorders. In A. Tasman (Ed.), *Tasman's psychiatry, 5th edition*. New York, NY: Springer.
66. Landes, S. J., Jaffe, A. E., McBain, S. A., Feinstein, B. A., Rhew, I. C., & **Kaysen, D. L.** (2021). Prospective predictors of work limitations in young adult lesbian and bisexual women: An examination of minority stress, trauma exposure, and mental health. *Stigma and Health*. Advance online publication. doi:10.1037/sah0000292
67. Landy, M.S.H., Vezer, E., Bance, S., **Loskot, T.**, Ip, J., Lenton-Brym, A. P., Mutschler, C., Thomas, F. C., McShane, K., Monson, C. M., & **Wiltsey Stirman, S.** (in press). Elucidating the elements of clinical case consultation in Cognitive Processing Therapy. *The Counseling Psychologist*.
68. Lawrence, K. A., **Vogt, D.**, Dugan, A. J., Nigam, S., Slade, E., & **Smith, B. N.** (in press). Psychosocial functioning deficits impact and are impacted by suicidal ideation in post-9/11 women veterans. *Journal of Affective Disorders Reports*.
69. **Lee, L. O.**, Grimm, K., **Spiro, A.**, & Kubzansky, L. (2022). Neuroticism, worry, and cardiometabolic risk trajectories: Findings from a 40-year study of men. *Journal of the American Heart Association*. Advance online publication. doi:10.1161/JAHA.121.022006
70. Lehavot, K., Beaver, K., Rhew, I., Dashtestani, K., Upham, M., **Shipherd, J. C.**, Kauth, M. R., **Kaysen, D. L.**, & Simpson, T. L. (in press). Disparities in mental health and health risk behaviors for LGBT veteran subgroups in a national U.S. survey. *LGBT Health*. doi:10.1089/lgbt.2022.0039

71. Levis, M., Levy, J., Dufort, V., Gobbel, G., Watts, B., & **Shiner, B.** (2022). Leveraging unstructured electronic medical record notes to derive population-specific suicide risk models. *Psychiatry Research*. Advance online publication. doi:10.1016/j.psychres.2022.114703
72. Levis, M., Ludmer, D., & **Shiner, B.** (2022). Self-guided online therapeutic assessment in substance abuse care: A conflict analysis implementation and feasibility case study. *Computers in Human Behavior Reports*. Advance online publication. doi:10.1016/j.chbr.2022.100178
73. Levis, M., Ludmer, D., **Cornelius, S. L.**, Scott, R., Watts, B., & **Shiner, B.** (2022). An implementation and effectiveness study evaluating conflict analysis in VA residential substance abuse services: Whole health informed self-guided online care. *Explore*. Advance online publication. doi:10.1016/j.explore.2022.02.005
74. Lewis, C., Tafur, J., Spencer, S., Green, J. G., Harrison, C., **Kelmendi, B.**, Rabin, D., Yehuda, R., Yazar-Klosinski, B., & Cahn, R. (in press). Pilot study suggests DNA methylation of NR3C1 is associated with MDMA-assisted therapy treatment response for severe PTSD. *Frontiers*.
75. Likitlersuang, J., Brown, E., **Salat, D.**, **Iverson, K. M.**, Werner, K., McGlinchey, R., **Galovski, T. E.**, & Fortier, C. (2022). Neural correlates of traumatic brain injury in women survivors of intimate partner violence: A structural and functional connectivity neuroimaging study. *Journal of Head Trauma Rehabilitation*. Advance online publication. doi:10.1097/HTR.0000000000000758
76. Lindgren, K. P., Jaffe, A. E., Kaysen, D., Teachman, B. A., Young-McCaughan, S., Peterson, A. L., Resick, P. A., & **Wachen, J. S.** (in press). Implicit trauma identity associations in treatment-seeking U.S. military personnel do not predict or change in response to Cognitive Processing Therapy for PTSD. *Psychological Trauma: Theory, Research, Practice, and Policy*.
77. Lippe, M., Eyer, J., Rosa, W., McKinney, R., Patterson, B., **Matteo, R.**, Townsend, H., & Halli-Tierney, A. (2021). Caring for an unconscious transgender patient at the end of life. *Journal of Hospice & Palliative Nursing*. Advance online publication. doi:10.1097/NJH.0000000000000765
78. **Livingston, N.**, **Levyiah, X.**, Ameral, V., Hocking, E., & Timko, C. (in press). Scoping review of intervention studies to improve opioid and alcohol use outcomes and links to care following inpatient detoxification. *Addiction Research & Theory*.
79. LoSavio, S. T., Straud, C. L., Dondanville, K. A., Fridling, N. R., **Wachen, J. S.**, McMahon, C. J., Mintz, J., Young-McCaughan, S., Yarvis, J. S., Peterson, A. L., Resick, P. A., & STRONG STAR Consortium (2022). Treatment responder status and time to response as a function of hazardous drinking among active-duty military receiving variable-length Cognitive Processing Therapy for posttraumatic stress disorder. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001268
80. LoSavio, S. T., Worley, C. B., Aajmain, S., **Rosen, C. S.**, **Wiltsey Stirman, S.**, & **Sloan, D. M.** (2021). Effectiveness of Written Exposure Therapy for posttraumatic stress disorder in the Department of Veterans Affairs Healthcare System. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001148
81. Lowe, S., Hennein, R., Feingold, J., Peccoralo, L., Ripp, J., Mazure, C., & **Pietrzak, R. H.** (2021). Are women less psychologically resilient than men? Background stressors underlying gender differences in reports of stress-related psychological sequelae. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.21br14098
82. Lynch, K. E., **Livingston, N.**, Gatsby, E., **Shipherd, J. C.**, DuVall, S. L., & Williams, E. C. (2022). Alcohol-attributable deaths and years of potential life lost due to alcohol among veterans: Overall and between persons with minoritized and non-minoritized sexual orientations. *Drug and Alcohol Dependence*. Advance online publication. doi:10.1016/j.drugalcdep.2022.109534
83. **Macia, K. S.**, **Carlson, E. B.**, Palmieri, P. A., Smith, S. R., Anglin, D. M., Ippen, C. G., Lieberman, A. F., Wong, E. C., Schell, T. L., & Waelde, L. C. (in press). Development of a brief version of the Dissociative Symptoms Scale (DSS-B) and the reliability and validity of DSS-B scores in diverse clinical and community samples. *Assessment*.
84. **Mackintosh, M.**, Greene, C. J., Glassman, L. H., Willis, E. A., Schaper, K. M., & **Morland, L. A.** (2022). Delivering anger management treatment through a web-based intervention supplemented with brief coaching: A pilot study. *JMIR Formative Research*. Advance online publication. doi:10.2196/17694

85. **Mahoney, C. T., Moshier, S. J., Keane, T. M., & Marx, B. P.** (2021). Heightened healthcare utilization & risk of mental disorders among veterans with comorbid opioid use disorder & posttraumatic stress disorder. *Addictive Behaviors*. Advance online publication. doi:10.1016/j.addbeh.2020.106572
86. **Mahoney, C. T., Shayani, D. R., & Iverson, K. M.** (2022). Longing for sleep after violence: The impact of PTSD symptoms, avoidance, and pain on insomnia among female veterans. *Psychiatry Research*. Advance online publication. doi:10.1016/j.psychres.2022.114641
87. Martins, B., Rutland, W., De Aquino, J. P., Kazer, B., Funaro, M., **Potenza, M.**, & Angarita, G. (2022). Helpful or harmful? The therapeutic potential of medications with varying degrees of abuse liability in the treatment of substance use disorders. *Current Addiction Reports*. Advance online publication. doi:10.1007/s40429-022-00432-9
88. Mattocks, K., Kroll-Desrosiers, A., Vance, V., **Vogt, D., Iverson, K. M., & Bastien, L.** (2022). Veterans' perinatal care and mental health experiences during the Covid-19 pandemic: An examination of the role of prior trauma and pandemic-related stress. *Journal of Women's Health*. Advance online publication. doi:10.1089/jwh.2021.0209
89. May, C., Wisco, B., Fox, V., **Marx, B. P., & Keane, T. M.** (2022). Posttraumatic stress disorder-related anhedonia as a predictor of psychosocial functional impairment among United States veterans. *Journal of Traumatic Stress*. Advance online publication. doi:10.1002/jts.22832
90. **McCarthy, E., DeViva, J., Ranganathan, M., & Pietrzak, R. H.** (2021). New-onset and exacerbated insomnia symptoms during the Covid-19 pandemic in U.S. military veterans: A nationally representative, prospective cohort study. *Journal of Sleep Research*. Advance online publication. doi:10.1111/jsr.13450
91. **McCarthy, E., DeViva, J., Southwick, S., & Pietrzak, R. H.** (2022). Self-rated sleep quality predicts incident suicide ideation in US military veterans: Results from a 7-year, nationally representative, prospective cohort study. *Journal of Sleep Research*. Advance online publication. doi:10.1111/jsr.13447
92. McGeary, D., Resick, P., Penzien, D., McGeary, C., Houle, T., Eapen, B., Jaramillo, C., Nability, P., Reed, D., Moring, J., Bira, L., Hansen, H., Young-McCaughan, S., Cobos, B., Mintz, J., **Keane, T. M., & Peterson, A.** (2022). Cognitive behavioral therapy for veterans with comorbid posttraumatic headache and posttraumatic stress disorder symptoms: A randomized clinical trial. *JAMA Neurology*. Advance online publication. doi:10.1001/jamaneurol.2022.1567
93. **McLean, C. P., Cook, J., Riggs, D., Peterson, A. L., Young-McCaughan, S., Borah, E. V., Comtois, K. A., Dondanville, K. A., Frick, E., Mann, J., Reynolds, D., Mistretta, M., Neitzer, A., Brzuchalski, A., Clayton, S. P., Conforte, A. M., DuMars, T. D., Ekundayo, K., Flores, A., . . . & Rosen, C. S.** (2022). Barriers and potential solutions to implementing evidence-based PTSD treatment in military treatment facilities. *Military Medicine*. Advance online publication. doi:10.1093/milmed/usac240
94. **McLean, C. P., Levy, H., & Tolin, D.** (2022). Exposure therapy for PTSD: A meta-analysis. *Clinical Psychology Review*. Advance online publication. doi:10.1016/j.cpr.2021.102115
95. **McLean, C. P., Miller, M. L., Dondanville, K. A., Yarvis, J. S., Wright, E. C., Hall-Clark, B. N., Fina, B. A., Litz, B. T., Mintz, J., Young-McCaughan, S., Peterson, A. L., & Foa, E. B.** (2022). Perceptions and experiences of Web-Prolonged Exposure for PTSD: A mixed methods study. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001124
96. **McLean, C. P., Wachsman, T., Morland, L. A., Norman, S. B., Hooper, V., & Cloitre, M.** (2022). The mental health impact of Covid-19-related stressors among treatment-seeking trauma-exposed veterans. *Journal of Traumatic Stress*. Advance online publication. doi:10.1002/jts.22874
97. Meis, L., Polusny, M., **Kehle-Forbes, S.**, Erbes, C., O'Dougherty, M., Erickson, E., Orazem, R., Burmeister, L., & **Spoont, M.** (2022). Making sense of poor adherence in PTSD treatment from the perspectives of veterans and their therapists. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001199
98. Miles, S. R., Hale, W. J., Mintz, J., **Wachen, J. S., Litz, B. T., Dondanville, K. A., Yarvis, J., Hembree, E. A., Young-McCaughan, P., & Resick, P. A.** (2022). Hyperarousal symptoms linger after successful PTSD treatment in active duty military. *Psychological Trauma: Theory, Research, Practice and Policy*. Advance online publication. doi:10.1037/tra0001292

99. Miller, C. J., Adjogon, O. L., Brady, J. E., Dichter, M. E., & **Iverson, K. M.** (2021). Screening for intimate partner violence in healthcare settings: An implementation-oriented systematic review. *Implementation Research and Practice*. Advance online publication. doi:10.1177/26334895211039
100. Miller, C., Stolzmann, K., Dichter, M., Adjogon, O., Brady, J., Portnoy, G., Gerber, M., Iqbal, S., & **Iverson, K. M.** (2022). Intimate partner violence screening for women in the Veterans Health Administration: Temporal trends from the early years of implementation 2014-2020. *Journal of Aggression, Maltreatment & Trauma*. Advance online publication. doi:10.1080/10926771.2021.2019160
101. **Mitchell, K. S.**, Sienkiewicz, M., **Smith, B. N.**, **Vogt, D.**, **Kehle-Forbes, S.**, & Cooper, Z. (in press). Associations between eating disorders and healthcare use among male and female post-9/11 veterans. *Journal of Psychosomatic Research*.
102. **Mitchell, K. S.**, Sienkiewicz, M., **Smith, B. N.**, **Vogt, D.**, **Kehle-Forbes, S.**, & Cooper, Z. (in press). Associations between eating disorders and healthcare use among male and female post-9/11 veterans. *Medical Care*.
103. **Mitchell, K. S.**, **Smith, B. N.**, Masheb, R., & **Vogt, D.** (in press). The impact of the Covid-19 pandemic on eating disorders in U.S. military veterans. *International Journal of Eating Disorders*.
104. Morissette, S. B., Ryan-Gonzalez, C., Blessing, A., Judkins, J., Crabtree, M., Hernandez, M., **Wiltsey Stirman, S.**, & **Sloan, D. M.** (2022). Delivery of Written Exposure Therapy for PTSD in a university counseling center. *Psychological Services*. Advance online publication. doi:10.1037/ser0000608
105. Morris, K., Schwartz, C., **Galovski, T. E.**, Dondanville, K., & **Wachen, J. S.** (2022). Massed Cognitive Processing Therapy in active-duty military: A case series. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2022.04.004
106. **Moshier, S. J.**, **Harper, K. L.**, **Keane, T. M.**, & **Marx, B. P.** (2022). Using electronic medical record diagnostic codes to identify veterans with posttraumatic stress disorder. *Journal of Traumatic Stress*. Advance online publication. doi:10.1002/jts.22844
107. Na, P., Tsai, J., Southwick, S., & **Pietrzak, R. H.** (2021). Factors associated with post-traumatic growth in response to the Covid-19 pandemic: Results from a national sample of U.S. military veterans. *Social Science & Medicine*. Advance online publication. doi:10.1016/j.socscimed.2021.114409
108. Naeser, M. A., Martin, P. I., Ho, M. D., Kregel, M. H., Bogdanova, Y., **Knight, J. A.**, Hamblin, M. R., Fedoruk, A., Poole, L. G., Cheng, C. H., & Koo, B. B. (in press). Transcranial photobiomodulation for ex-football players possibly developing CTE: Four case reports with cognitive and behavioral improvements, MRI changes. *Journal of Alzheimer's Research*.
109. Newberger, N. G., Yeager, S., **Livingston, N.**, Enggasser, J., Brief, D., Litwack, S., **Helmuth, E.**, Roy, M., Rosenbloom, D., & **Keane, T. M.** (2022). Life satisfaction following treatment-related reductions in alcohol use and PTSD symptoms: Results from VetChange. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001234
110. Nichter, B., Hill, M. L., Na, P. J., Kline, A. C., **Norman, S. B.**, **Krystal, J. H.**, Southwick, S. M., & **Pietrzak, R. H.** (2021). Prevalence and trends in suicidal behavior among US military veterans during the Covid-19 pandemic. *JAMA Psychiatry*. Advance online publication. doi:10.1001/jamapsychiatry.2021.2332
111. Nichter, B., Stein, M., **Norman, S. B.**, Hill, M., Straus, E., **Haller, M.**, & **Pietrzak, R. H.** (2021). Prevalence, correlates, and treatment of suicidal behavior in US military veterans. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.20m13714
112. Nichter, B., Tsai, J., & **Pietrzak, R. H.** (2022). Prevalence, correlates, and mental health burden associated with homelessness in U.S. military veterans. *Psychological Medicine*. Advance online publication. doi:10.1017/s0033291722000617
113. **Niles, B. L.**, Reid, K., **Whitworth, J.**, Alligood, E., Williston, S. K., Grossman, D. H., McQuade, M., & Mori, D. L. (2022). Tai Chi and Qigong for trauma exposed populations: A systematic review. *Mental Health and Physical Activity*. Advance online publication. doi:10.1016/j.mhpa.2022.100449

114. Nishimi, K., Borsari, B., **Marx, B. P.**, Rosen, R., Cohen, B., Woodward, E. N., Maven, D., Tripp, P., Jiha, A., Woolley, J., Neylan, T. C., & O'Donovan, A. (2022). Clusters of Covid-19 protective and risky behaviors and their associations with pandemic, socio-demographic, and mental health factors in the United States. *Preventive Medicine Reports*. Advance online publication. doi:10.1016/j.pmedr.2021.101671
115. O'Malley, K., Etchin, A., **Pless Kaiser, A.**, Korsun, L., Weiskittle, R., Bashian, H., Sager, Z., & Moye, J. (2021). Advancing trauma-informed care education for hospice and palliative staff. *Journal of Hospice & Palliative Nursing*. Advance online publication. doi:10.1097/NJH.0000000000000804
116. Palmisano, A., **Norman, S. B.**, **Panza, K.**, **Petrakis, I.**, & **Pietrzak, R. H.** (2022). PTSD symptom heterogeneity and alcohol-related outcomes in U.S. military veterans: Indirect associations with coping strategies. *Journal of Anxiety Disorders*. Advance online publication. doi:10.1016/j.janxdis.2021.102496
117. Panelli, D. M., Chan, C. S., Shaw, J. G., Shankar, M., **Kimerling, R.**, Frayne, S. M., Herrero, T. C., Lyell, D. J., & Phibbs, C. S. (in press). An exploratory analysis of factors associated with spontaneous preterm birth among pregnant people with post-traumatic stress disorder. *Women's Health Issues*.
118. **Panza, K.**, Kline, A., Na, P., **Potenza, M.**, **Norman, S. B.**, & **Pietrzak, R. H.** (2022). Epidemiology of DSM-5 alcohol use disorder in U.S. military veterans: Results from the National Health and Resilience in Veterans Study. *Drug and Alcohol Dependence*. Advance online publication. doi:10.1016/j.drugalcdep.2021.109240
119. Park, C. L., **Pless Kaiser, A.**, Finkelstein-Fox, L., **Spiro, A.**, & **Wachen, J. S.** (in press). Risk and resilience factors for traumatic stress disorders. In J. G. Beck & D. Sloan (Eds.), *Oxford handbook of traumatic stress disorders*. New York, NY: Oxford University Press.
120. Peccoralo, L., Depierro, J., Feingold, J., Feder, A., Charney, D., Southwick, S., Ripp, J., & **Pietrzak, R. H.** (2021). Building resilience and well-being in health care workers in the Covid-19 era. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.21r14035b
121. Peltzman, T., Forehand, J., Freytes, I., & **Shiner, B.** (2022). Rural and urban Hispanic patients of the Veterans Health Administration. *Journal of Racial and Ethnic Health Disparities*. Advance online publication. doi:10.1007/s40615-022-01406-3
122. Perkins, D., Davenport, K., Morgan, N., Aronson, K., Bleser, J., McCarthy, K., **Vogt, D.**, Finley, E., Copeland, L., & Gilman, C. (2022). The influence of employment program components upon job attainment during a time of identity and career transition. *International Journal for Educational and Vocational Guidance*. Advance online publication. doi:10.1007/s10775-022-09527-1
123. **Pineles, S. L.**, Pandey, S., **Shor, R.**, Abi-Raad, R. F., Kimble, M. O., & Orr, S. P. (in press). Loudness Dependence of Auditory Evoked Potentials (LDAEP): A promising pre-treatment predictor of selective serotonin reuptake inhibitor (SSRI) response. In G. Pinna (Ed.), *Translational methods for PTSD research*. New York, NY: Springer.
124. Price, R., Kissel, N., Baumeister, A., Rohac, R., Woody, M., Ballard, E., Zarate, C., Deakin, W., **Abdallah, C.**, Feder, A., Charney, D., Grunebaum, M., Mann, J., Mathew, S., Gallagher, B., McLoughlin, D., Murrough, J. W., Muthukumaraswamy, S., McMillan, R., . . . & Wallace, M. (2022). International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. *Molecular Psychiatry*. Advance online publication. doi:10.1038/s41380-022-01757-7
125. Rando, A. A., & **Thompson-Hollands, J.** (in press). Veteran and family member goals for family involvement in PTSD treatment: A qualitative study of dyads. *Couple and Family Psychology: Research and Practice*.
126. **Ranganathan, M.**, **Norman, S. B.**, Nichter, B., Hill, M., Rosen, M., **Petrakis, I.**, & **Pietrzak, R. H.** (2021). Prevalence, risk and protective factors of alcohol use disorder during the Covid-19 pandemic in U.S. military veterans. *Drug and Alcohol Dependence*. Advance online publication. doi:10.1016/j.drugalcdep.2021.108818
127. Ranney, R., Maguen, S., Bernhard, P., Holder, N., **Vogt, D.**, Blossnich, J., & Schneiderman, A. (2022). Moral injury and chronic pain in veterans. *Journal of Psychiatric Research*. Advance online publication. doi:10.1016/j.jpsychires.2022.08.009
128. Rashid, B., Poole, V. N., Fortenbaugh, F. C., **Esterman, M.**, Milberg, W. P., McGlinchey, R. E., & Leritz, E. C. (2021). Association between metabolic syndrome and resting-state functional brain connectivity. *Neurobiology of Aging*. Advance online publication. doi:10.1016/j.neurobiolaging.2021.03.012

129. **Rasmusson, A. M.**, Novikov, O., Brown, K. D., Pinna, G., & Pineles, S. (2022). Pleiotropic endophenotypic and phenotype effects of GABAergic neurosteroid synthesis deficiency in posttraumatic stress disorder. *Current Opinion in Endocrine and Metabolic Research*. Advance online publication. doi:10.1016/j.coemr.2022.100359
130. Rauch, S. A. M., Kim, H. M., Lederman, S., Sullivan, G., Acierno, R., Tuerk, P. W., Simon, N., Venners, M., **Norman, S. B.**, & PTSD Study Team (2021). Predictors of response to Prolonged Exposure, sertraline, and their combination for the treatment of military PTSD. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.20m13752
131. Reinhardt, K. M., **McCaughey, V.**, Vento, S. A., & **Street, A. E.** (in press). In their own words: Women veterans identify the personal consequences of military sexual trauma victimization. *Violence Against Women*.
132. Reise, S., Hubbard, A., Wong, E., Schalet, B., Haviland, M., & **Kimerling, R.** (2021). Response category functioning on the health care engagement measure using the nominal response model. *Assessment*. Advance online publication. doi:10.1177/10731911211052682
133. **Reuman, L.**, & **Thompson-Hollands, J.** (2022). Family accommodation in PTSD: Proposed considerations and distinctions from the established transdiagnostic literature. *Clinical Psychology: Science and Practice*. Advance online publication. doi:10.1111/CPSP.12375
134. **Reuman, L.**, & **Thompson-Hollands, J.** (in press). Women veterans' attitudes toward family involvement in PTSD treatment: A mixed methods examination. *Psychological Services*.
135. Riblet, N. B. V., Matsunaga, S., Lee, Y., Young-Xu, Y., **Shiner, B.**, **Schnurr, P. P.**, Levis, M., & Watts, B. V. (in press). Tools to detect risk of death by suicide: A systematic review and meta-analysis. *Journal of Clinical Psychiatry*.
136. Richards, A., **Woodward, S. H.**, Baquirin, D., Yack, L., Metzler, T., Udupa, N., Staggs, E., & Neylan, T. C. (2022). The sleep physiology of nightmares in veterans with psychological trauma: Evaluation of a dominant model using participant-applied electroencephalography in the home environment. *Journal of Sleep Research*. Advance online publication. doi:10.1111/jsr.13639
137. Rose, A. J., Hughto, J. M. W., Dunbar, M. S., Quinn, E. K., Deutsch, M., Feldman, J., Radix, A., Safer, J. D., **Shipherd, J. C.**, Thompson, J., & Jasuja, G. K. (2021). Trends in feminizing hormone therapy for transgender patients, 2006–2017. *Transgender Health*. Advance online publication. doi:10.1089/trgh.2021.0041
138. **Rosen, C. S.**, Kaplan, A., Nelson, D. B., **La Bash, H.**, Chard, K. M., **Eftekhari, A.**, **Kehle-Forbes, S.**, **Wiltsey Stirman, S.**, & Sayer, N. A. (2022). Implementation context and burnout among Department of Veterans Affairs psychotherapists prior to and during the Covid-19 pandemic. *Journal of Affective Disorders*. Advance online publication. doi:10.1016/j.jad.2022.09.141
139. **Rosenfeld, E. A.**, Lyman, C., & Roberts, J. E. (2022). Introducing RuminAid: The development and focus group testing of a mobile health app for depression. *JMIR Formative Research*. Advance online publication. doi:10.2196/preprints.40045
140. Ruben, M. A., Kauth, M. R., Meterko, M., Norton, A. M., **Matza, A.**, & **Shipherd, J. C.** (2021). Veterans' reported comfort in disclosing sexual orientation and gender identity. *Medical Care*. Advance online publication. doi:10.1097/MLR.0000000000001543
141. Sager, Z., Nathan, S., Doherty, K., **Pless Kaiser, A.**, King, K., Topor, D., Morrison, N., & Moye, J. (2022). Traumatic disclosures in the life stories of older Vietnam era veterans. *Journal of the American Geriatrics Society*. Advance online publication. doi:10.1111/jgs.17918
142. Salas, J., **Norman, S. B.**, Tuerk, P. W., van den Berk-Clark, C., Cohen, B. E., Schneider, F. D., Chard, K. M., Lustman, P. J., **Schnurr, P. P.**, **Friedman, M. J.**, Grucza, R., & Scherrer, J. F. (2021). PTSD improvement and substance use disorder treatment utilization in veterans: Evidence from medical record data. *Drug and Alcohol Dependence*. Advance online publication. doi:10.1016/j.drugalcdep.2020.108365
143. Salomaa, A., **Livingston, N.**, Bryant, W., Herbitter, C., **Harper, K. L.**, Sloan, C., Hinds, Z., **Gyuro, L.**, Valentine, S., & **Shipherd, J. C.** (2022). A bottom-up approach to developing a unified trauma-minority stress model for transgender and gender diverse people. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001373

144. **Schnurr, P. P., & Hamblen, J. L.** (in press). PTSD treatment research: An overview and evaluation. In J. G. Beck & D. M. Slone (Eds.), *The Oxford handbook of traumatic stress disorders, 2nd ed.* New York, NY: Oxford University Press.
145. Serier, K. N., **Vogt, D.**, Pandey, S., & **Smith, B. N.** (in press). Analysis of the bidirectional relationships between posttraumatic stress and depressive symptoms with physical health functioning in post-9/11 veteran men and women deployed to a war-zone. *Journal of Psychosomatic Research.*
146. Serier, K. N., **Zelkowitz, R., Smith, B. N., Vogt, D., & Mitchell, K. S.** (in press). The Posttraumatic Cognitions Inventory (PTCI): Psychometric validity in male and female veterans with trauma exposure. *Psychological Assessment.*
147. **Shiner, B.**, Gui, J., Rozema, L., **Cornelius, S. L.**, Dufort, V., **Schnurr, P. P.**, & Watts, B. (2021). Patient and clinical factors associated with response to medications for posttraumatic stress disorder. *The Journal of Clinical Psychiatry.* Advance online publication. doi:10.4088/JCP.21m13913
148. **Shiner, B.**, Peltzman, T., Forehand, J., Gui, J., Freytes, I., & Watts, B. (2022). Examination of increasing suicide rates among rural Hispanic VA patients. *The Journal of Rural Health.* Advance online publication. doi:10.1111/jrh.12714
149. **Shor, R., Borowski, S., Zelkowitz, R., Pineles, S. L., Copeland, L. A., Finley, E. P., Perkins, D. F., & Vogt, D.** (2022). The transition to civilian life: Impact of comorbid PTSD, chronic pain, and sleep disturbance on veterans' social functioning and suicidal ideation. *Psychological Trauma: Theory, Research, Practice, and Policy.* Advance online publication. doi:10.1037/tra0001271
150. Silvia, P., Eddington, K., **Harper, K. L.**, & Kwapil, T. (2022). Self-reflection, insight, and mood disorder symptoms: Evaluating the short form of the self-reflection and insight scale with clinical interviews and self-reports. *Current Psychology.* Advance online publication. doi:10.1007/s12144-021-02619-1
151. **Sippel, L. M.**, Flanagan, J., **Holtzheimer, P. E.**, Moran-Santa-Maria, D., Brady, K., & Joseph, J. (2021). Effects of intranasal oxytocin on threat- and reward-related functional connectivity in men and women with and without childhood abuse-related PTSD. *Psychiatry Research: Neuroimaging.* Advance online publication. doi:10.1016/j.psychresns.2021.111368
152. **Sippel, L. M.**, Myers, A. L., Brooks, J. M., Storm, M., Mois, G., & Fortuna, K. L. (in press). Risk and protective factors in relation to early mortality among people with serious mental illness: Perspectives of peer support specialists and service users. *Psychiatric Rehabilitation Journal.*
153. **Sippel, L. M.**, Taverna, E., & Marshall, A. (2022). In vivo defensive behaviors, fear, and attention bias to physical and negative evaluation threats. *Behaviour Research and Therapy.* Advance online publication. doi:10.1016/j.brat.2022.104108
154. Smith, A., Hunt, R., Grunewald, W., Jeon, M., **Stanley, I. H.**, Levinson, C., & Joiner, T. (2021). Identifying central symptoms and bridge pathways between Autism Spectrum Disorder traits and suicidality within an active duty sample. *Archives of Suicide Research.* Advance online publication. doi:10.1080/13811118.2021.1993398
155. Sottile, J., **Macia, K. S.**, Wickham, R., & Haug, N. (2022). Development and initial validation of an MDMA/Ecstasy motives assessment. *Addictive Behaviors.* Advance online publication. doi:10.1016/j.addbeh.2022.107494
156. **Stanley, I. H.**, Chu, C., Gildea, S., Hwang, I., King, A., Kennedy, C., Luedtke, A., **Marx, B. P.**, O'Brien, R., Petukhova, M., Sampson, N., **Vogt, D.**, Stein, M., Ursano, R., & Kessler, R. (2022). Predicting suicide attempts among U.S. Army soldiers after leaving active duty using information available before leaving active duty: Results from the Study to Assess Risk and Resilience in Servicemembers-Longitudinal Study (STARRS-LS). *Molecular Psychiatry.* Advance online publication. doi:10.1038/s41380-021-01423-4
157. **Stanley, I. H., Marx, B. P., Keane, T. M., & Anestis, M. D.** (2021). Firearm storage practices among military service members with suspected traumatic brain injury. *Journal of Clinical Psychiatry.* Advance online publication. doi:10.4088/JCP.21br13951
158. Straus, E., Worley, M. J., Lyons, R., Kline, A. C., Tripp, J. C., Davis, B. C., **Haller, M.**, Angkaw, A. C., Trim, R. S., & **Norman, S. B.** (2022). Examining attendance patterns across integrated therapies for posttraumatic stress disorder and alcohol use disorder. *Journal of Anxiety Disorders.* Advance online publication. doi:10.1016/j.janxdis.2021.102498

159. **Street, A. E., Bell, M. E.,** & Ready, C. B. (in press). Sexual assault. In J. West, J. Morganstein, M. Vance, & D. Benedek (Eds.), *Clinical manual for the management of PTSD*. Washington, DC: American Psychiatric Press.
160. Sun, D., Rakesh, G., Clarke-Rubright, E., Haswell, C., **Logue, M. W.,** O’Leary, E., Cotton, A., Xie, H., Dennis, E., Jahanshad, N., Salminen, L., Thomopoulos, S., Rashid, F., Ching, C., Koch, S., Frijling, J., Nawijn, L., . . . **Krystal, J. H., Levy, I., . . . Harpaz-Rotem, I., . . .** & Morey, R. (2022). Remodeling of the cortical structural connectome in posttraumatic stress disorder: Results from the ENIGMA-PGC PTSD consortium. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. Advance online publication. doi:10.1016/j.bpsc.2022.02.008
161. Thomas, F. C., **Loskot, T.,** Landy, M.S.H., Mutschler, C., Lane, M.E.P., Burdo, J., **Lagdamen, J. M.,** Sijercic, I., Liebman, R., Finley, E., Monson, C. M., & **Wiltsey Stirman, S.** (in press). Initiating Cognitive Processing Therapy (CPT) in community settings: A qualitative investigation of therapist decision-making. *Administration and Policy in Mental Health and Mental Health Services Research*.
162. **Thompson-Hollands, J., Lee, L. O., & Schnurr, P. P.** (in press). Military PTSD. In C. Castro & C. Warner (Eds.), *Mental healthcare for military and veteran personnel*. Washington, DC: American Psychiatric Association.
163. **Thompson-Hollands, J.,** Rando, A. A., Stoycos, S. A., **Meis, L., & Iverson, K. M.** (2022). Family involvement in PTSD treatment: Perspectives from a nationwide sample of Veterans Health Administration clinicians. *Administration and Policy in Mental Health and Mental Health Services Research*. Advance online publication. doi:10.1007/s10488-022-01214-1
164. Tsai, J., Peltzman, T., Watts, B., & **Shiner, B.** (2021). Effects of electroconvulsive therapy on suicidal behavior and emergency department use among homeless veterans. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.21m13935
165. Tsai, J., Szymkowiak, D., Wilkinson, S., & **Holtzheimer, P. E.** (2022). Twenty-year trends in use of electroconvulsive therapy among homeless and domiciled veterans with mental illness. *CNS Spectrums*. Advance online publication. doi:10.1017/S1092852921001061
166. Tyler, H., Fina, B. A., **Marx, B. P.,** Young-McCaughan, S., **Sloan, D. M.,** Kaplan, A. M., Green, V. R., Blankenship, A., Bryan, C. J., Peterson, A. L., & the STRONG STAR Consortium (2021). Written Exposure Therapy for suicide in a psychiatric inpatient unit: A case series. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2021.06.011
167. Valenstein-Mah, H., Polusny, M. A., **Spoont, M.,** Ackland, P., **Meis, L.,** Orazem, R. J., **Schnurr, P. P.,** Zickmund, S., Chard, K., & **Kehle-Forbes, S.** (in press). Provider perceptions of their patients’ dropout from trauma focused therapy for PTSD in the U.S. Veterans Health Administration. *Psychological Trauma: Theory, Research, Practice, & Policy*.
168. Vandiver, R. A., **Wachen, J. S., Spiro, A., Pless Kaiser, A.,** Tyzik, A. L., & **Smith, B. N.** (2022). PTSD symptom severity mediates the impact of war zone stress exposure on post-deployment physical health: The Ft. Devens Gulf War Veterans Cohort. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001286
169. **Vogt, D., Borowski, S.,** Godier-McBard, L. R., Fossey, M. J., Copeland, L. A., Perkins, D. F., & Finley, E. P. (2022). Changes in the health and broader well-being of U.S. veterans in the first three years after leaving military service: Overall trends and group differences. *Social Science & Medicine*. Advance online publication. doi:10.1016/j.socscimed.2022.114702
170. **Vogt, D.,** Merker, V. L., **Borowski, S.,** Bokhour, B., & Kligler, B. (in press). Beyond disease and dysfunction: Asking patients about their psychosocial well-being. *Health Affairs Forefront*.
171. **Wachen, J. S.,** & Held, P. (2022). Special series: Intensive delivery of cognitive behavioral therapies for anxiety, mood, and trauma-related disorders. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2022.06.004
172. **Wachen, J. S.,** Mintz, J., LoSavio, S. T., Kennedy, J. E., Hale, W. J., Straud, C. L., Dondanville, K. A., Moring, J., Blankenship, A. E., Vandiver, R., Young-McCaughan, S., Yarvis, J. S., Peterson, A. L., Resick, P. A., & for the STRONG STAR Consortium (in press). The effect of prior head injury on outcomes in group and individual Cognitive Processing Therapy with military personnel. *Journal of Traumatic Stress*.



173. **Walser, R. D., & McGee-Vincent, P.** (in press). How to develop your abilities as an ACT therapist. In P. Lucena-Santos, S. A. Carvalho, J. Pinto-Gouveia, M. S. Oliveira, & J. Pistorello (Eds.), *Manual prático internacional de Terapia de Aceitação e Compromisso [International practical handbook of Acceptance and Commitment Therapy]*. Novo Hamburgo, RS: Sinopsys.
174. Watts, B., Peltzman, T., & **Shiner, B.** (2022). Electroconvulsive therapy and death by suicide. *The Journal of Clinical Psychiatry*. Advance online publication. doi:10.4088/JCP.21m13886
175. Webermann, A., Dardis, C., **Shipherd, J. C., & Iverson, K. M.** (2022). A two-year examination of intimate partner violence and associated mental and physical health among sexual minority and heterosexual women veterans. *Journal of Aggression, Maltreatment, & Trauma*. Advance online publication. doi:10.1080/10926771.2022.2053260
176. Weiss, J., Calvi, R., Naganawa, M., Toyonaga, T., Farhadian, S., Chintanaphol, M., Chiarella, J., Zheng, M., Ropchan, J., **Huang, Y., Pietrzak, R. H.,** Carson, R., & Spudich, S. (2021). Preliminary in vivo evidence of reduced synaptic density in HIV despite antiretroviral therapy. *Clinical Infectious Diseases*. Advance online publication. doi:10.1093/cid/ciab484
177. **Wielgosz, J.,** Perlman, D. M., Mumford, J. A., Wager, T. D., Lutz, A., & Davidson, R. J. (2022). Neural signatures of pain modulation in short-term and long-term mindfulness training: A randomized active-control trial. *American Journal of Psychiatry*. Advance online publication. doi:10.1176/appi.ajp.21020145
178. Williston, S. K., Kruepke, M., Grossman, D., Litwack, S., & **Niles, B. L.** (2022). Exploring modifications to individual trauma-focused PTSD treatments in a routine care setting: An examination of medical records at a Veterans Health Administration PTSD clinic. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2021.06.002
179. Williston, S., & **Vogt, D.** (2022). Mental health literacy in veterans: What do U.S. military veterans know about PTSD and its treatment? *Psychological Services*. Advance online publication. doi:10.1037/ser0000501
180. Wohleb, E. S., & **Duman, R.** (in press). Disruption of mTORC1 signaling contributes to synaptic deficits caused by chronic stress: Reversal by rapid-acting antidepressants. *Neurobiology of Stress*.
181. **Wolf, E. J., Hawn, S. E., Sullivan, D. R., Miller, M. W.,** Sanborn, V., Brown, E., Neale, Z., Fein-Schaffer, D., Zhao, X., **Logue, M. W.,** Fortier, C. B., McGlinchey, R. E., & Milberg, W. P. (in press). Neurobiological and genetic correlates of the dissociative subtype of PTSD. *Journal of Psychopathology and Clinical Science*.
182. Wolfe, H. L., Boyer, T. B., Rodriguez, K. L., Klima, G. J., **Shipherd, J. C.,** Kauth, M. R., & Blosnich, J. R. (2021). Exploring research engagement and priorities of transgender and gender diverse veterans. *Military Medicine*. Advance online publication. doi:10.1093/milmed/usab460
183. **Woodward, S. H., Jamison, A. L.,** Kahn, C. T., **Gala, S. M., Bhowmick, C. P.,** Villasenor, D., **Tamayo, G. C.,** Puckett, M., & Parker, K. J. (in press). Reading the mind in the eyes in PTSD: Limited moderation by the presence of a service dog. *Journal of Psychiatry Research*.
184. Wooldridge, J., Tynan, M., Rossi, F., Gasperi, M., **McLean, C. P., Bosch, J. O.,** Trivedi, R., Herbert, M., & Afari, N. (2022). Patterns of adverse childhood experiences and cardiovascular risk factors in U.S. adults. *Stress and Health*. Advance online publication. doi:10.1002/smi.3167
185. Worley, C. B., **Rosen, C. S.,** LoSavio, S. T., Aajmain, S., **Wiltsey Stirman, S., & Sloan, D. M.** (2022). An examination of individual and organizational theory in a pilot virtual facilitated learning collaborative to implement Written Exposure Therapy. *Psychological Services*. Advance online publication. doi:10.1037/ser0000698
186. Wright, E. C., **Wachen, J. S., Yamokoski, C. A., Galovski, T. E.,** Morris, K., Goetter, E. M., Klassen, B. J., Jacoby, V., Zweibach, L., Sornborger, J., Dondanville, K. A., & Fina, B. A. (2022). Clinical and administrative insights from delivering massed trauma-focused therapy to service members and veterans. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2022.06.005
187. Yahalom, J., Yarns, B., Clair, K., **Cloitre, M.,** Lang, A. J., & Hamilton, A. (2022). Patient experiences and reported effectiveness of a multimodal short-term pilot therapy group for veteran men with military sexual trauma. *Journal of Clinical Psychology*. Advance online publication. doi:10.1002/jclp.23353

188. **Yamokoski, C. A.**, Barron, S., Fowler, J., Fast, E., & Flores, H. (2022). Barriers and facilitators to the implementation of intensive treatments for PTSD: Early lessons learned from the field. *Cognitive and Behavioral Practice*. Advance online publication. doi:10.1016/j.cbpra.2022.04.003
189. **Yamokoski, C. A.**, Flores, H., Facemire, V., **Maieritsch, K. P.**, Perez, S., & Fedynich, A. (2022). Feasibility of an intensive outpatient treatment program for posttraumatic stress disorder within the Veterans Health Care administration. *Psychological Services*. Advance online publication. doi:10.1037/ser0000628
190. Yip, S., Lichenstein, S., Garrison, K., **Averill, C. L.**, Viswanath, H., Salas, R., & **Abdallah, C.** (2021). Effects of smoking status and state on intrinsic connectivity. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. Advance online publication. doi:10.1016/j.bpsc.2021.02.004
191. Yland, J., McKinnon, C., Hatch, E., Eisenberg, M., **Nillni, Y. I.**, Rothman, K., & Wise, L. (2022). A prospective study of male depression, psychotropic medication use, and fecundability. *American Journal of Men's Health*. Advance online publication. doi:10.1177/15579883221075520
192. You, Y., Hersh, S., Aslebagh, R., Shaffer, S., Ikezu, S., Mez, J., Lunetta, K., **Logue, M. W.**, Farrer, L., & Ikezu, T. (2022). Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells. *Aging Cell*. Advance online publication. doi:10.1111/accel.13617
193. **Zelkowitz, R.**, **Archibald, E.**, **Gradus, J. L.**, & **Street, A. E.** (2022). Postdeployment mental health concerns and family functioning in veteran men and women. *Psychological Trauma: Theory, Research, Practice, and Policy*. Advance online publication. doi:10.1037/tra0001237
194. **Zelkowitz, R.**, Jiang, T., Horváth-Puhó, E., **Street, A. E.**, Lash, T., Sørensen, H., Rosellini, A., & **Gradus, J. L.** (2022). Predictors of nonfatal suicide attempts within 30 days of discharge from psychiatric hospitalization: Sex-specific models developed using population-based registries. *Journal of Affective Disorders*. Advance online publication. doi:10.1016/j.jad.2022.03.034
195. **Zelkowitz, R.**, Sienkiewicz, M. E., **Vogt, D.**, **Smith, B. N.**, & **Mitchell, K. S.** (in press). Gender differences in direct and indirect associations of trauma types with disordered eating in a national US veteran sample. *Psychological Trauma: Theory, Research, Practice, and Policy*.
196. Zheng, Y., Lunetta, K. L., Liu, C., Katrinli, S., Smith, A. K., **Miller, M. W.**, & **Logue, M. W.** (2022). An evaluation of the genome-wide false positive rates of common methods for identifying differentially methylated regions using Illumina methylation arrays. *Epigenetics*. Advance online publication. doi:10.1080/15592294.2022.2115600

# Appendix F: Scientific Presentations by National Center Staff

## AcademyHealth Annual Research Meeting | Washington, DC | June 2022

1. Benzer, J., **Bovin, M. J.**, Bryant, C., Charns, M., Copeland, L., MacCarthy, A., Mignogna, J., Miller, C., Pearson, R., Post, E., & Kum, H. *Measuring patterns of health services with set-based sequence analysis: A preliminary test of replicability.*
2. Brady, J. E., Miller, C. J., Adjognon, O., Stolzmann, K., Dichter, M., Portnoy, G., Gerber, M., Iqbal, S., & **Iverson, K. M.** *IPV screening in women's health primary care: Evaluating implementation facilitation efforts in the Veterans Health Administration.*
3. Gibson, T., **Livingston, N.**, Head, M., Davenport, M., Meng, F., Chen, M., Stein, M., Henke, R., & Weisberg, R. *Examination of the effects of a rapid policy shift in access to medication for opioid use disorders (MOUD) among the commercially insured.*
4. **Kimerling, R.**, Zulman, D., Lewis, E., Schalet, B., & Riese, S. The return on engagement: Better healthcare engagement predicts quality of care over 1 year. In J. Mittler (Chair), *Patient engagement and access to high quality care.*
5. **Livingston, N.**, Davenport, M., Meng, F., Head, M., Gibson, T., Henke, R., Chen, D., Stein, M., & Weisberg, R. *Access and utilization of medication for opioid use disorder (MOUD) among veterans during Covid-19: An observational cohort study using Veterans Health Administration data from 2019-2021.*
6. White, M., LeBeau, L., Cubanski, L., Henke, R., Hyde, J., Weisberg, R., **Livingston, N.**, & Mulvaney-Day, N. *A qualitative examination of the opioid use disorder treatment policymaker's impression of Covid-19-related medication-assisted treatment policy changes.*
7. Wolfe, H. L., Reisman, J. I., Blosnich, J. R., Vimalananda, V. G., Rao, S. R., **Shipherd, J. C.**, **Livingston, N.**, & Jasuja, G. K. *Examining guideline concordance of gender-affirming hormone therapy initiation in transgender and gender diverse patients.*

## Association for Behavioral and Cognitive Therapies | Virtual | November 2021

8. Benevides, E., Herbitter, C., Newberger, N. G., Bryant, W. T., Hinds, Z., & **Livingston, N.** *The role of specific identity components in understanding the relationship between real-time sexual and gender minority (SGM) discrimination and mood.*
9. Danitz, S. B., Shayani, D. R., Mahoney, C. T., & **Iverson, K. M.** *How brief is too brief? A mixed method examination of outcomes in a counseling intervention for IPV.*
10. Gumport, N. B., Aajmain, S., **Wiltsey Stirman, S.**, **Sloan, D. M.**, LoSavio, S., Worley, C., & **Rosen, C. S.** *An evaluation of a clinician-rated measure of fidelity to Written Exposure Therapy [Webinar].*
11. **Hallenbeck, H. W.**, **Jaworski, B. K.**, **Wielgosz, J.**, **Kuhn, E. R.**, **Ramsey, K. M.**, Taylor, K., **Juhasz, K. M.**, **McGee-Vincent, P.**, **Mackintosh, M.**, & **Owen, J. E.** *PTSD Coach version 3.1: A closer look at the reach, use, and clinical impact of this updated mobile health app in the U.S. population. In H. W. Hallenbeck (Chair), *Disseminating CBT principles through mobile mental health apps: An evaluation of self-management apps from VA's National Center for PTSD.**

12. Hernandez-Vallant, A., **Serier, K.**, Solis, I., Mullins, C. R., Gomez, I., Medici, I., & Smith, J. E. *A pilot study of the Body Project as an adjunctive to a behavioral weight loss intervention in Latinx women with overweight/obesity.*
13. **Livingston, N.**, Lynch, K. E., Gatsby, E., **Shipherd, J. C.**, DuVall, S. L., & Williams, E. C. Alcohol-attributable deaths and years of life lost among veteran men and women: Overall and across minoritized and non-minoritized sexual orientations. In J. Scheer (Chair), *Innovative approaches to studying unequal mental, behavioral, and physical health burdens on diverse sexual and gender minority populations.*
14. Martin, W. B., Holliday, R., Hoffmire, C., **Hoff, R.**, & Monteith, L. *Suicide risk & psychiatric symptoms among post-9/11 justice-involved veterans.*
15. **Serier, K.**, Sebastian, R. M., Solis, I., Hernandez-Vallant, A., Mullins, C., Medici, J., & Smith, J. E. *Adherence and weight loss outcomes from a pilot study testing the efficacy of the Body Project as an adjunctive to an online self-monitoring intervention in Hispanic/Latinx women with overweight/obesity.*
16. **Sloan, D. M.** *Treatment length and outcomes in Written Exposure Therapy.*
17. Smethurst, M. A., Franz, M. R., **Taft, C. T.**, & Barry, R. A. *Women's disengagement behaviors prospectively predict physical and psychological partner violence.*
18. **Wielgosz, J.**, **Walser, R. D.**, **Jaworski, B. K.**, **Rosen, C. S.**, **Kuhn, E. R.**, & **Owen, J. E.** Mobile-based self-guided mindfulness training for veterans with PTSD: Preliminary findings from a pilot randomized trial. In H. W. Hallenbeck (Chair), *Disseminating CBT principles through mobile mental health apps: An evaluation of self-management apps from VA's National Center for PTSD.*
19. **Wiltsey Stirman, S.**, Hernandez, S., Song, J., **Johnson, C. M.**, Calloway, A., Dean, K., **Loskot, T.**, Aajmain, S., **Lagdamen, J. M.**, Luana, M., & Creed, T. Identifying scalable strategies to assess fidelity: The innovative methods of assessing psychotherapy practice (imAPP) study. In S. Wiltsey Stirman (Chair), *Assessing and understanding fidelity to interventions for individuals with PTSD or trauma exposure in public mental health settings.*
20. **Wiltsey Stirman, S.**, **Lagdamen, J. M.**, Song, J., **Mallard, K. N.**, Aajmain, S., **La Bash, H.**, Suvak, M., Thomas, F., Ramirez, V., Masina, T., Lane, J., Finley, E., Shields, N., & Monson, C. Sustainment of Cognitive Processing Therapy: Fidelity across mental health systems. In S. Wiltsey Stirman (Chair), *Assessing and understanding fidelity to interventions for individuals with PTSD or trauma exposure in public mental health settings.*

## International Society for Traumatic Stress Studies | Virtual | November 2021

21. **Alpert, E.** Making sense of trauma memories: Characteristics and responses to trauma narratives as predictors of PTSD outcomes. In **J. K. Carpenter** (Chair), *Examining cognitions and emotions during recounting and processing of the trauma memory as predictors of symptom change in Prolonged Exposure.*
22. **Archibald, E.**, **Chan, A. C.**, **McCaughey, V.**, **Wachen, J. S.**, **Street, A. E.**, & **Galovski, T. E.** *Online peer support groups for women veterans are an effective tool during Covid-19.*
23. Arulpragasam, A. R., **Holtzheimer, P. E.**, Collier, E., Wheatley, T., **Sippel, L. M.**, & Meyer, M. L. *Neural mechanisms underlying social-emotional processing in posttraumatic stress disorder.*
24. **Banducci, A. N.** *Recovery from PTSD, secondary to military sexual trauma, during a global pandemic: Adapting Prolonged Exposure therapy for a veteran who acquired Covid-19 mid-therapy [Webinar]. A case study.*
25. Benevides, E., McQuade, M., Grossman, D., Grossman, S., Mori, D., & **Niles, B. L.** *Recruitment success of telehealth treatments for Gulf War veterans and qualitative findings for a randomized trial.*
26. **Borowski, S.**, Rosellini, A., **Street, A. E.**, & **Vogt, D.** *Application of a machine learning approach to identify predictors of U.S. military veterans' suicidal ideation in the first year after leaving service [Webinar].*
27. **Bovin, M. J.**, **Caudle, K. L.**, **Weathers, F. W.**, Hollifield, M., **Schnurr, P. P.**, & **Marx, B. P.** Development of a training protocol for the Clinician Administered PTSD Scale for DSM-5 (CAPS-5). In J. Hamblen (Chair), *Advances in face-to-face training and virtual technology.*
28. **Bovin, M. J.**, Resnik, J., Linsky, A., Stolzmann, K., Mull, H., **Schnurr, P. P.**, Post, E. P., & Miller, C. J. *Does PTSD screening in VA primary care lead to mental health treatment? Identifying the spectrum of veterans' initial access steps.*

29. Bowen, M., **Cuccurullo, L. J.**, Fast, E., & **Bernardy, N. C.** *Increasing VA/DoD clinical practice guideline PTSD care at a rural VA Medical Center.*
30. **Carpenter, J.K.**, Griffin, M. G., **Pineles, S. L.**, Werner, K., Kecala, N. M., Resick, P. A., & **Galovski, T. E.** *Physiological reactivity to trauma memories as a predictor of PTSD treatment response.*
31. **Chan, A. C.**, **Archibald, E.**, **McCaughey, V.**, **Nillni, Y. I.**, & **Galovski, T. E.** *The moderating influence of social support on the relationship between PTSD and quality of life.*
32. **Cuccurullo, L. J.**, Bowen, M., **Breen, K.**, & **Bernardy, N. C.** *Developing PTSD teams at three rural VA medical centers: Movement toward team-based care.*
33. **Cuccurullo, L. J.**, Bowen, M., **Breen, K.**, & **Maieritsch, K. P.** Supporting PTSD evidence-based care at rural VA Medical Centers during the Covid-19 pandemic. In L. Cuccurullo (Chair), *Supporting EBP practice during the Covid-19 pandemic for veterans and active duty military: Working together for the field during challenging times.*
34. Fein-Schaffer, D., **Hawn, S. E.**, **Annunziata, A.**, Ryabchenko, K., **Miller, M. W.**, & **Wolf, E. J.** *Pre-existing PTSD and related comorbidities as predictors of responses to the Covid-19 pandemic.*
35. **Galovski, T. E.**, **Nillni, Y. I.**, **Fox, A. B.**, & Duke, C. The impact of covid-19 criterion a trauma and stress on the course of veterans' PTSD and depression. In B. Marx (Chair), *Trauma exposure and PTSD in the context of the covid-19 pandemic.*
36. **Galovski, T. E.**, **Street, A. E.**, **Wachen, J. S.**, **McCaughey, V.**, **Archibald, E.**, & **Chan, A. C.** *The effectiveness of peer support as a first step in recovery from posttraumatic stress and depression in veterans.*
37. Griffin, B., **Vogt, D.**, Hoffmire, C., Blossnich, J. R., & Schneiderman, A. *The role of moral injury in veteran suicide: An overlooked risk factor?*
38. **Hamblen, J. L.**, **Bovin, M. J.**, **Merrick, C.**, & **Marx, B. P.** Pilot evaluation of the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) virtual trainer. In J. Hamblen (Chair), *Advances in face-to-face training and virtual technology.*
39. **Hawn, S. E.**, Zhao, X., **Miller, M. W.**, **Logue, M. W.**, Milberg, W., McGlinchey, R., & **Wolf, E. J.** *Traumatic stress and mortality risk as indexed by DNA methylation.*
40. **Iverson, K. M.** (2021, November). Recovering from IPV through strengths and empowerment (RISE): Findings from a randomized clinical trial. In C. Mahoney (Chair), *New directions of gender-based violence research and practice.*
41. LoSavio, S. T., Worley, C. B., Aajmain, S., **Wiltsey Stirman, S.**, **Rosen, C. S.**, & **Sloan, D. M.** *Effectiveness of Written Exposure Therapy for posttraumatic stress disorder in the Department of Veterans Affairs Healthcare System.*
42. **Macdonald, A.**, Fredman, S. J., Meis, L. A., **Thompson-Hollands, J.**, & Monson, C. Maximizing the healing power of partners: Different models for involving loved ones in PTSD treatment. In A. Macdonald (Chair), *Maximizing the healing power of partners: Different models for involving loved ones in PTSD treatment.*
43. **Mackintosh, M.** *This might sting a bit: Symptom spikes and treatment benefits related to including trauma narratives in Cognitive Processing Therapy.*
44. Mazzulo, N. N., Cole, A., Morris, K., **Galovski, T. E.**, Dondanville, K., Schwartz, C., & **Wachen, J. S.** *The relationship between moral injury and well-being in active-duty service members.*
45. **McCarthy, E.**, Angkaw, A., **Cuccurullo, L. J.**, Hall-Clark, B., **Larsen, S.**, **McKee, T. A.**, Silva, M., **Watson, P.**, & **Norman, S. B.** PTSD consultation during the first year of the Covid-19 pandemic: What were the needs of providers. In L. Cuccurullo (Chair), *Supporting EBP practice during the Covid-19 pandemic for veterans and active-duty military: Working together for the field during challenging times.*
46. **McCarthy, E.**, DeViva, J. C., Na, P. J., Southwick, S. M., & **Pietrzak, R. H.** *Pre- and peri-pandemic-related factors associated with new-onset and exacerbated insomnia symptoms in U.S. military veterans: Results from the 2019-2020 National Health and Resilience in Veterans Study.* Flash talk.
47. McQuade, M., Benevides, E., Wilson, E., O'Donnell, S., Mori, D., & **Niles, B. L.** *PTSD and chronic pain: Comorbidity and symptom severity among Gulf War veterans.*
48. **Mitchell, K. S.**, Singh, S., Hardin, S., & Thompson-Brenner, H. *The impact of comorbid posttraumatic stress disorder on eating disorder treatment outcomes: Investigating the Unified Treatment Model.*

49. **Nillni, Y. I.**, Paul, E., Clark, C., Giovannini, K., **Sloan, D. M.**, & Valentine, S. E. Results from a pilot effectiveness-implementation trial of a brief exposure-based treatment for PTSD among pregnant women with comorbid PTSD and substance use disorder. In Y. I. Nillni (Chair), *Implementing and sustaining effective PTSD treatments in real-world settings*.
50. Pandey, S., **Shor, R.**, **Spiro, A.**, Magruder, K. M., & **Smith, B. N.** *Comorbid PTSD and depression is associated with increased cardiovascular disease risk among Vietnam era women veterans*.
51. Paul, E., Borba, C. P., & **Nillni, Y. I.** *A thematic analysis of the impact of past trauma exposure on women's labor and delivery experiences*.
52. **Pless Kaiser, A.** *Interpersonal perspectives: Concordance of military veteran PTSD status based on first-person and close informant assessment methods*.
53. Pruiksma, K. E., Taylor, D. J., Mintz, J., Slavish, D. C., Wardle-Pinkston, S., Dondanville, K. A., Young-McCaughan, S., Nicholson, K. L., Litz, B. T., Dietch, J. R., **Keane, T. M.**, Peterson, A. L., & Resick, P. A. Treatment of comorbid insomnia, nightmares and posttraumatic stress disorder in active-duty military: A pilot study. In N. Holder (Chair), *When standard treatment is not enough: Augmenting and sequencing care for posttraumatic stress disorder*.
54. **Schnurr, P. P.** Discussant. In B. Marx (Chair), *Trauma exposure and PTSD in the context of the Covid-19 pandemic*.
55. **Serier, K.**, **Zelkowitz, R.**, & **Mitchell, K. S.** *Factor structure of the Posttraumatic Cognitions Inventory (PTCI) in post-9/11 female veterans and relation to mental health outcomes*.
56. Shayani, D. R., Danitz, S. B., **Mahoney, C. T.**, & **Iverson, K. M.** *Finding the right dose: A mixed method examination of a brief counseling intervention for IPV*.
57. **Shiner, B.** *When standard treatment is not enough: Augmenting and sequencing care for posttraumatic stress disorder* [Webinar].
58. **Sloan, D. M.**, **Marx, B. P.**, Resick, P. A., Dondanville, K. A., Young-McCaughan, S., Mintz, J., Litz, B. T., Peterson, A. L., & STRONG STAR Consortium. *Is Written Exposure Therapy non-inferior to Cognitive Processing Therapy in the treatment of military service members?*
59. **Sloan, D. M.**, **Thompson-Hollands, J.**, Hayes, A., **Lee, D. J.**, Alpert, E., & **Marx, B. P.** *Using trauma narratives to predict sudden gains in trauma-focused treatment*.
60. **Sullivan, D. R.**, **Wolf, E. J.**, Merugumala, S., **Logue, M. W.**, Fein-Schaffer, D., Zhao, X., Liao, H. J., Fortier, C. B., Fonda, J. R., Milberg, W., McGlinchey, R. E., Lin, A. P., & **Miller, M. W.** *PTSD is associated with increased myo-inositol in the aging brain: A magnetic resonance spectroscopy study*.
61. **Vogt, D.** Relationship and community functioning of warfare-exposed U.S. Veterans. In D. Vogt (Chair), *Expanding stress and trauma research to consider associations with relationship and community functioning*.
62. Webermann, A. R., Dardis, C. M., **Shipherd, J. C.**, & **Iverson, K. M.** *A two-year examination of intimate partner violence and associated mental and physical health among sexual minority and heterosexual women veterans*.
63. Welch, K., **Vogt, D.**, & **Smith, B. N.** *Direct and indirect effects of family stressors during deployment on post-military interpersonal functioning in female and male post-9/11 veterans: Examining the role of social support*.
64. **Whitworth, J.**, **Scioli, E. R.**, **Keane, T. M.**, & **Marx, B. P.** *Comorbid depression, anxiety, alcohol, and substance use are associated with increased odds of physical inactivity and cigarette smoking among veterans with PTSD*.
65. **Woodward, B.**, **Lee, D. J.**, **Livingston, N.**, **Marx, B. P.**, & **Keane, T. M.** *Race and sex differences in PTSD and somatic symptoms among OEF/OIF veterans*.
66. Woolley, M. G., **Smith, B. N.**, & **Galovski, T. E.** *Evaluating the contribution of homework in reducing PTSD during a course of Cognitive Processing Therapy*.

## Other

67. **Abdallah, C.** (2021, November). *The effects of ketamine on the brain connectivity networks*. Invited speaker at Gulf Coast Consortia (GCC), Houston, TX.
68. **Abdallah, C.** (2021, October). *Serendipity and clinical neuroscience: Rapamycin prolongs the antidepressant effects of ketamine*. Presented for the European College of Neuropsychopharmacology, Lisbon, Portugal.
69. **Abdallah, C.** (2022, April). *Brain networks as target for successful antidepressant treatments*. Grand Rounds, Stony Brook University, Stony Brook, NY.
70. **Abdallah, C.** (2022, April). *Ketamine mechanisms and efficacy: A tale of two clinical trials with unexpected results*. Presented for the Ketamine & Related Compounds International Conference, University of Oxford, Oxford, UK.
71. **Abdallah, C.** (2022, April). *Reduced prefrontal synaptic strength in posttraumatic stress disorder (PTSD)*. Symposium presented for the Society of Biological Psychiatry, New Orleans, LA.
72. **Abdallah, C.** (2022, January). *Challenges and opportunities in our search for a robust and reproducible biomarker of ketamine*. Core for Advanced MRI (CAMRI), Houston, TX.
73. **Abdallah, C.** (2022, March). *Connectome fingerprints of behavioral symptoms and treatments*. Presented for the Computational and Molecular Psychiatry Seminar, University of Iowa, Iowa City, IA.
74. **Azevedo, K. J.** (2022, March). *Leveraging anthropology to address the Covid-19 global mental health syndemic*. Society for Applied Anthropology, Salt Lake City, UT.
75. **Bernardy, N. C., & Cuccurullo, L. J.** (2022, February). *Supporting PTSD clinical practice guideline consistent care at rural VA medical centers*. Presentation to the National Clinical Resource Hubs, Virtual.
76. **Blonigen, D., Montena, A., Smith, J., Hedges, J., Kuhn, E. R., Carlson, E. B., Owen, J. E., Wielgosz, J., & Possemato, K.** (2022, June). *Evaluating the feasibility, acceptability, and utility of peer-supported mobile mental health for veterans in primary care*. Presentation for the Society for Digital Mental Health, Virtual.
77. **Borges, L. M., Farnsworth, J. K., Drescher, K., Barnes, S. M., & Walser, R. D.** (2022, June). *Connecting with meaning while living with moral pain: a workshop on ACT for moral injury (ACT-MI)*. Presentation at the Association for Contextual Behavioral Science (ACBS), San Francisco, CA.
78. **Cuccurullo, L. J.** (2022, July). *Assessing PTSD*. Virtual Presentation to the Amarillo Veterans Health Care System Mental Health Service Line, Virtual.
79. **Cuccurullo, L. J.** (2022, June). *Ethical considerations in shared decision making for PTSD treatment*. Virtual Presentation for the National Center for PTSD Consultation Program, Virtual.
80. **Danböck, S., Duek, O., Ben-Zion, Z., Korem, N., Amen, S., Kelmendi, B., Wilhelm, F., Levy, I., & Harpaz-Rotem, I.** (2022, July). *Ketamine-induced dissociation does not increase fronto-limbic functional connectivity in individuals with posttraumatic stress disorder*. Presentation at the Salzburg Mind-Brain Annual Meeting (SAMBA), Salzburg, Austria.
81. **DiSano, K. D., Aronson, J. P., Zanazzi, G., French, J., Gilli, F., Holtzheimer, P. E., & Noller, C.** (2022, May). *Vagus nerve stimulation as an immunomodulatory therapy for acute spinal cord injury*. Presentation at Wings for Life Annual Scientific Meeting, Virtual.
82. **Esterman, M.** (2021, November). *Evidence for a specific association between sustained attention and gait speed in middle-to-older-aged adults*. Presentation at the 2021 Gerontological Society of America Annual Meeting, Virtual.
83. **Esterman, M.** (2022, April). *Aberrant connectivity in the right middle temporal gyrus before and after a suicide*. Presentation at the 2022 SOBP Annual Meeting, Society of Biological Psychiatry, New Orleans, LA.
84. **Esterman, M.** (2022, May). *Neurocognitive models of sustained attention and their clinical application* [Webinar]. Center for Neuromodulation in Depression and Stress, University of Pennsylvania.
85. **Faerman, A., Schulte, T., Woodward, S. H., & Richards, A. M.** (2022, July). *Sleep misperception in insomnia is associated with verbal memory erroring*. Presentation at the Association for Scientific Study of Consciousness (ASSC), Amsterdam, Netherlands.

86. Flanagan, J. C., Massa, A. A., Young-McCaughan, S., Mintz, J., Litz, B. T., Roache, J. D., **Keane, T. M.**, Peterson, A. L., & Back, S. E. (2022, June). Examining the direct and indirect effects of posttraumatic stress disorder symptom severity and alcohol use on aggression among dually diagnosed veterans. In N. Mastroleo (Chair), *Hazardous alcohol use among veterans with co-occurring mental health concerns: mechanisms, consequences, and novel treatment effects*. Symposium presented at the Annual Meeting of the Research Society on Alcoholism, Orlando, FL.
87. Funderburk, J. S., Cigrang, J., **Livingston, N.**, Pigeon, W., Shepardson, R. L., Wade, M., Maisto, S. A., Cordova, J., Gray, T., Fedynich, A., Maher, E., Hawrilenko, M., Zhou, S., Bickmore, T., Rubin, A., & Simon, S. (2022). *Hot off the presses: RCTs of interventions for integrated primary care for depression, relationship distress, and at-risk alcohol use*. Oral presentation at the 2022 Annual Collaborative Family Healthcare Association Conference, Boise, ID.
88. **Galovski, T. E.** (2022, January). *The role of peer support in reducing risk of negative outcomes for women veterans* [Webinar]. VA HSR&D Cyberseminar Series.
89. **Galovski, T. E.**, Kelly, U. A., **Street, A. E.**, Lehavot, K., Creech, S. K., **Bell, M. E.**, & Yano E. M. (2021, October). *Prevalence, consequences, and care of veterans with military sexual trauma* [Webinar]. Presented for the National VA HSR&D Cyberseminar Series.
90. **Gelernter, J.** (2021, December). *Using large samples to investigate the human genetics of substance use disorders*. National Institutes of Health NIAAA Fall Seminar Series, Bethesda, MD.
91. **Gelernter, J.** (2022, July). *Substance use disorder genetics in Thailand and the U.S.* Presented for the International Neuro HIV Cure Consortium, Montreal, Canada.
92. **Gelernter, J.** (2022, May). *Genetics of SSRI antidepressant use and implications for Covid 19 risk*. In HGM 2022: The 25th Human Genome Meeting, Tel Aviv, Israel.
93. Gibson, T., Head, M., **Livingston, N.**, Henke, R., Pack, K., Davenport, M., LeBeau, L., White, M., Hyde, J., Chen, D., Stein, M., Meng, F., & Weisberg, R. (2022). *Changes in health care utilization among enrollees with opioid use disorder after Covid-19 onset*. Poster presentation at the 150th Annual Conference for the American Public Health Association, Boston, MA.
94. Grunthal, B., Benfer, N., Dondanville, K. A., Young-McCaughan, S., Blankenship, A., **Abdallah, C.**, Back, S. E., Flanagan, J., Foa, E. B., Fox, P. T., **Krystal, J. H.**, **Marx, B. P.**, McGeary, D., **McLean, C. P.**, Pruiksma, K. E., Resick, P. A., Roache, J. D., Shiroma, P., **Sloan, D. M.**, & Taylor, D. J. (2022, May). *DSM-5 criterion-A-based trauma types in service members seeking treatment for posttraumatic stress disorder*. Presented at the Association for Psychological Science, Chicago, IL.
95. **Hallenbeck, H. W.**, **Wielgosz, J.**, **Cohen, Z. D.**, **Kuhn, E. R.**, & **Cloitre, M.** (2022, June). *Using machine learning to identify prognostic predictors of outcomes in a coached web-based intervention (webSTAIR) for diverse trauma-exposed veterans*. Society for Digital Mental Health, Virtual conference.
96. **Hawn, S. E.**, Neale, Z., **Wolf, E. J.**, Zhao, X., Pierce, M., Fein-Schaffer, D., Milberg, W., McGlinchey, R., **Logue, M. W.**, & **Miller, M. W.** (2022, March). *Methylation of the AIM2 gene: An epigenetic mediator of PTSD-related inflammation and neuropathology plasma biomarkers*. Poster presented at the 2022 Anxiety and Depression Association of America Conference, Denver, CO.
97. Herbitter, C., Newberger, N., Hinds, Z., Benevides, E., Bryant, W., & **Livingston, N.** (2022, August). *Associations between discrimination, sexual and gender minority identity, and substance use*. 130th Annual Convention of the American Psychological Association, Minneapolis, MN.
98. Hoffmire, C., **Borowski, S.**, & **Vogt, D.** (2022, June). *Veterans well-being at the time of military separation uniquely predicts trajectories of suicidal ideation following separation from military service*. Poster presentation at the Society for Epidemiologic Research Conference, Chicago, IL.
99. **Iverson, K. M.**, Stolzmann, K., Adjognon, O., Brady, J. E., Dichter, M., Lew, R., Gerber, M., Iqbal, S., Portnoy, G., & Miller, C. J. (2022, September). *Evaluating VHA's response to intimate partner violence among women primary care patients*. Society of Implementation Research Collaboration (SIRC) Bi-annual Research Meeting, San Diego, CA.
100. **Kelmendi, B.**, Pittenger, C., Farre, T., & **Averill, L.** (2022, June). *Clinical evidence for the use of methylone in the treatment of PTSD: A case series with long-term follow-up*. Presentation at the CINP Hybrid World Congress of Neuropsychopharmacology, Taipei, Taiwan.



101. Kram Mendelsohn, A., Orr, S. P., Ivkovic, V., Fortier, E. P., Kelly, A. M., Cetinkaya, D., Martinez, U., Bazer, O., Tanev, K. S., Lasko, N. B., **Pineles, S. L.**, & Pace-Schott, E. (2022, April). *Physiological reactivity to script-driven imagery of past trauma compared with imagery of trauma-related nightmares in patients with PTSD*. Poster presented at the 77th annual conference of the Society of Biological Psychiatry, New Orleans, LA.
102. **Krystal, J. H.** (2022, January). *Rapidly acting antidepressants: New treatments, new hope and new insights into the brain*. Presented for the Duke Psychiatry and Behavioral Sciences Grand Rounds, Durham, NC.
103. **Krystal, J. H.** (2022, March). *Rapidly acting antidepressants: New treatments, new hope and new insights into the brain*. Presented for the Detroit Medical Center at Wayne State University Elliot Luby Endowed Lectureship, Detroit, MI.
104. **Krystal, J. H.** (2022, March). *Rapidly acting antidepressants: New treatments, new hope and new insights into the brain*. Presented for the Montefiore Psychiatry and Behavioral Sciences Grand Rounds, Bronx, NY.
105. **Krystal, J. H.** (2022, September). *Ketamine and depression*. Presented for the University of California at San Diego's Innovation in Psychiatric Clinical Practice: Novel Treatments for Depression, San Diego, CA.
106. **Kuhn, E. R., Owen, J. E., Stanley, L. M., Hallenbeck, H. W., Blonigen, D., & Wielgosz, J.** (2022, April). VA mHealth resources for addressing and researching behavioral health issues of veterans. In J. D. Piette (Chair), *Supporting veterans through virtual communication between in-person visits: Opportunities and challenges*. Symposium conducted at the 43rd Annual Meeting and Scientific Session of the Society of Behavioral Medicine, Baltimore, MD.
107. **Kuhn, E. R., Possemato, K., & Beehler, G. P.** (2022, June). *Using the PTSD Coach mobile app with clinician support in VA primary care: A pragmatic randomized controlled trial*. Presentation for the Society for Digital Mental Health, Virtual.
108. Lawrence, K. A., & **Smith, B. N.** (2021, December). *Mental health and psychosocial functioning in recently separated U.S. women Veterans: Trajectories, bi-directional relationships, and implications for reintegration* [Webinar]. Department of Defense Military-Civilian Transition Office national webinar series.
109. Lawrence, K. A., **Vogt, D., Dugan, A. J., Nigam, S., Slade, E. M., & Smith, B. N.** (2021, December). *Gender differences in post-traumatic stress disorder symptom cluster trajectories in United States Iraq and Afghanistan war veterans who recently separated from the military*. Presentation at the Annual Meeting of the Building Interdisciplinary Research Careers in Women's Health Program, Virtual Conference.
110. **Lee, L. O.** (2021, November). *The long arm of childhood experiences on longevity*. Presented for the Rush Alzheimer's Disease Center, Virtual.
111. **Levy, I.** (2021, November). *Individual differences in decision-making under uncertainty*. Current Issues in Neuroscience, Trinity College, West Hartford, CT.
112. **Levy, I.** (2022, May). *Decision-making and learning under uncertainty in aging*. Growing Up in Aging Neuroscience, Brown University, Providence, RI.
113. **Logue, M. W., Sherva, R. M., Zhang, R., Harrington, K. M., Fonda, J. R., Merritt, V., Panizzon, M., Hauger, R. L., Wolf, E. J., & Miller, M. W.** (2022, August). *A genetically informed examination of posttraumatic stress disorder and traumatic brain injury's impact on dementia risk in U.S. veterans*. Presentation at Alzheimer's Association International Conference, San Diego, CA.
114. Lyman, C., **Rosenfeld, E. A., & Roberts, J.** (2022, June). *A new method for assessing naturally occurring episodes of rumination in daily life: the day reconstruction method for rumination (DRM-R)*. Presented at the Multidisciplinary Conference on Reinforcement Learning and Decision Making, Providence, RI.
115. **Mackintosh, M., Greene, C. J., Jamison, A. L., & McGee-Vincent, P.** (2021, November). *Predictors of multidisciplinary staffs' use of mobile mental health apps with veterans*. Presentation at the Technology, Mind & Society Conference, Virtual.
116. **McGee-Vincent, P., Jamison, A. L., Juhasz, K. M., & Mackintosh, M.** (2021, November). *Fostering technology-supported self-care: Expanding the reach of VA mobile mental health apps during the Covid-19 pandemic*. Presentation at the Technology, Mind & Society Conference, Virtual.
117. McQuade, M., Wilson, E., O'Donnell, S., Mori, D., & **Niles, B. L.** (2022, April). *A 12-week wellness intervention reduces insomnia severity in veterans with Gulf War illness*. Poster accepted for the annual meeting of the Society of Behavioral Medicine, Baltimore, MD.

118. Merritt, V., Maihofer, A., Gasperi, M., Katema, E., Chanfreau-Coffinier, C., Stein, M. B., Panizzon, M., Hauger, R. L., **Logue, M. W.**, Dealano-Wood, L., & Nivergelt., C. M. (2022, September). *Genome-wide association study of traumatic brain injury risk in U.S. military veterans enrolled in the Million Veteran Program*. Accepted for the Annual Million Veteran Program Science Meeting, Virtual.
119. **Mitchell, K. S.** (2022, June). Treating comorbid eating disorders and PTSD. In K. Claudat (Chair), *Treating common comorbidities in eating disorders*. SIG panel presentation conducted at the annual meeting of the Academy for Eating Disorders International Conference, Virtual.
120. **Niles, B. L.** (2022, March). Mind-body interventions for PTSD and chronic pain: Breaking the cycle of mutual maintenance. In A. Lott (Chair), *Mind-body interventions in trauma-exposed populations: Exploring treatment response predictors, mechanisms of change, and outcomes*. Symposium conducted at the 2022 Annual Meeting of the Anxiety Disorders Association of America, Denver, CO.
121. **Nillni, Y. I.** (2022, March). *Trauma, PTSD, and perinatal health* [Webinar]. Presented for VISN 20 MIRECC Presents. Retrieved from <https://www.mirecc.va.gov/visn20/Education/past-webinars-mirecc-presents.asp#WomenVeteransPerinatalHealth>.
122. **Nillni, Y. I.**, Paul, E., Lee-Parritz, A., **Vogt, D.**, Epperson, N., & **Rasmusson, A. M.** (2022, September). Impact of trauma and PTSD on perinatal mental health and pregnancy outcomes. In M. Bublitz (Chair), *Trauma exposure, PTSD, and maternal wellbeing: Identifying treatment targets in the perinatal period*. Symposium conducted at the International Marcé Society for Perinatal Mental Health Biennial Meeting, London, England.
123. **Pless Kaiser, A.** (2021, October). *Veteran PTSD-related distress at end of life: Results from the bereaved family survey*. Presentation at the National Palliative Care Research Center, Jackson Hole, WY.
124. **Rosenfeld, E. A.** (2022, May). *RuminAid: a new mHealth app for depression and rumination* [Webinar]. Presentation at Stanford TechHub Grand Rounds.
125. **Rosenfeld, E. A.**, & Malek, N. (2022, June). *Digital tools that say gay: a scoping review of digital mental health tools for sexual and gender minority stress and PTSD*. Presented for the Society for Digital Mental Health, Virtual.
126. Schmidt-Warner, J., Pittenger, C., Olmstead, S., & **Kelmendi, B.** (2022, May). *Methylone, a rapid acting entactogen with robust antidepressant-like activity in the forced swim test*. Presentation at the Psychedelic Therapeutics Conference, Washington, DC.
127. **Schnurr, P. P.** (2022, March). *Physical health effects of PTSD*. Posttraumatic Stress and Related Disorders Conference, Virtual.
128. **Skidmore, C.**, & **Street, A. E.** (2022, April). *The Beyond MST mobile app: Strategies and lessons learned for supporting military sexual trauma survivors* [Webinar]. Invited address for the Tech Into Care Practice Based Implementation Network Lecture Series, Department of Veterans Affairs.
129. **Sloan, D. M.** (2022, April). *Written Exposure Therapy for PTSD: A 5 session, evidence-based, manualized intervention*. Annual meeting of North American Society for Psychosocial Obstetrics & Gynecology, University of Michigan, Ann Arbor, MI.
130. **Sloan, D. M.** (2022, March). *Written Exposure Therapy for PTSD: A brief PTSD treatment approach*. Virtual presentation - Grand Rounds, Department of Psychiatry, Medical University of South Carolina, Charleston, SC.
131. **Spoont, M.** (2022, May). *Thinking about inequity in mental health treatment for PTSD: What do we do now?* PTSD Mentoring Program Annual Meeting, Virtual.
132. **Stanley, I. H.** (2021, October). *Firearm ownership, access, and storage practices among individuals with PTSD: Implications for suicide risk*. Presentation at the San Antonio Combat PTSD Conference, Virtual.
133. Stolzmann, K., Miller, C. J., Brady, J. E., Adjognon, O., Dichter, M. E., & **Iverson, K. M.** (2022, September). *Implementation facilitation efforts on intimate partner violence screening and subsequent psychosocial service utilization*. Society of Implementation Research Collaboration (SIRC) Bi-annual Research Meeting, San Diego, CA.
134. **Street, A. E.**, Lehavot, K., & Strauss, J. (2022, February). *Emerging evidence on technology-based treatment of women veterans' mental health* [Webinar]. Invited address for VA HSR&D Spotlight on Women's Health Cyberseminar Series.

135. **Taft, C. T.** (2022, March). *Strength at Home: An introduction to a trauma-informed, evidence-based intervention for those who use intimate partner violence*. Talk presented at 19th Hawai'i International Summit, Honolulu, HI.
136. **Taft, C. T.** (2022, March). *Trauma among military personnel, veterans, and their families*. Talk presented at 19th Hawai'i International Summit, Honolulu, HI.
137. Thomas, K., Beattie, E., Smith, J., Coe, E., **Knight, J. A.**, Meyer, E. C., & Gulliver, S. B. (2022, May). *The interaction of impulsivity and drinking behavior in fire service*. 34th Annual Meeting of the Association for Psychological Science, Chicago, IL.
138. Thompson, A., Kaplan, A., **Spoont, M.**, & Diem, S. (2022, August). *Racial disparities in the reporting of disruptive behavior*. Presentation at the VA Quality Scholars Summer Institute, Houston, TX.
139. **Thompson-Hollands, J.** (2022, September). *Involving family members in PTSD treatment: Enhancing retention through social support* [Webinar]. Presented to the Department of Psychology, University of Kentucky, Lexington, KY.
140. Tsemekhin, R., **Pless Kaiser, A.**, & Wang, C. (2022, April). *A remote-delivered mind-body intervention for knee osteoarthritis patients during the pandemic: A qualitative study*. Poster presented at the OARSI Hybrid World Conference on Osteoarthritis, Berlin, Germany, Virtual.
141. **Vasterling, J. J.** (2021, November). *Neuropsychology of PTSD and mild TBI*. Presented to Postgraduate Program in Neuropsychology, University of Bristol, UK, Virtual.
142. **Vogt, D.** (2021, November). *Women's experiences during and after U.S. military service: Part II*. Invited Presentation for Canadian NATO Advanced Research Workshop: A Gendered Lens Approach to Military to Civilian Transition (MCT) and Reintegration for Ukraine Joint Forces Operation Women Combatants, Virtual.
143. **Vogt, D.** (2022, May). *Risk and resilience factors related to suicidal ideation during transition from military to civilian life: Secondary analyses of the TVMI cohort study*. Invited presentation for the VA Women's Health Research Network (WHRN) Women Veteran's Suicide Prevention Research Meeting, Virtual.
144. **Whitworth, J.** (2022, January). *Impact of lifestyle on cardiovascular and metabolic risk factors among trauma exposed post-9/11 veterans* [Webinar]. Presented for the National Center for PTSD: Research Lecture Series.
145. **Wielgosz, J., Kuhn, E. R.,** Possemato, K., & Blonigen, D. (2022, June). *Temporal associations between peer coaching and mobile mental health engagement for veterans in primary care*. Society for Digital Mental Health, Virtual.
146. **Wolf, E. J.** (2022, August). *Traumatic stress-related accelerated cellular aging*. Paper presentation to the 2022 Butler-Williams Scholars Program at the National Institute on Aging, Virtual.
147. **Wolf, E. J.,** Zhao, X., **Logue, M. W.,** **Hawn, S. E.,** Neale, Z. E., Zhou, Z., **Huber, B.,** Traumatic Stress Brain Research Group, & **Miller, M. W.** (2022, September). *Traumatic stress and advanced transcriptomic aging in the human prefrontal cortex*. Poster presented at the annual meeting of the World Congress of Psychiatric Genetics, Florence, Italy.
148. Wolfe, H. L., Boyer, T. L., **Shipherd, J. C.,** Kauth, M. R., & Blosnich, J. R. (2021, November). *Structural barriers and facilitators to hormone therapy in the U.S. Veterans Affairs Healthcare System*. Oral presentation at the 2021 World Endocrine & Obesity Conference, Virtual.
149. Zhao, X., **Logue, M. W.,** Neale, Z. E., **Hawn, S. E.,** **Huber, B.,** Traumatic Stress Brain Research Group, **Miller, M. W.,** & **Wolf, E. J.** (2021, October). *PTSD, major depression, and advanced transcriptomic age in neural tissue*. Poster presented at the 71st Annual Meeting of the American Society of Human Genetics, Virtual.
150. **Zimmerman, L. E.** (2021, November). *The how and why of Modeling to Learn: Participatory system dynamics to improve evidence-based addiction and mental health care* [Webinar]. Virtual Grand Rounds presentation for the Prevention Science Methodology Research Group at Northwestern University Feinberg School of Medicine. Retrieved from <https://cepim.northwestern.edu/calendar-events/2021-10-12-zimmerman>.
151. **Zimmerman, L. E.** (2021, October). *Modeling to learn: Test. Don't guess* [Webinar]. Methods Lecture for the Implementation Research Institute at Washington University.
152. **Zimmerman, L. E.** (2021, October). *Modeling to learn: Test. Don't guess*. Presentation at the Institute for Operations Research and the Management Sciences (INFORMS), Anaheim, CA.

# Appendix G: Education Presentations by National Center Staff

## International Society for Traumatic Stress Studies | Virtual | November 2021

1. **Bippart, V., McCarthy, E., & Hamblen, J. L.** *AboutFace: PTSD treatment can turn your life around - A peer education campaign from the National Center for PTSD.*
2. **Davis, J., & Sloan, D. M.** *Navigating peer review and editorial roles.*
3. **Hamblen, J. L., & Symon, K.** *An introduction to cognitive behavior therapy for postdisaster distress: A transdiagnostic treatment.* Pre Meeting Institute.
4. **Livingston, N., Harper, K. L., & Kassing, F.** (2022). *Trauma and minority stress among transgender and gender diverse (TGD) communities.*
5. **Merrick, C.** Building the Clinician-Administered PTSD Scale for DSM-5 training simulator, a virtual patient course. In J. Hamblen (Chair), *Strategies to improve PTSD assessment: Advances in face-to-face training and virtual technology.*

## Other

6. **Aaen, T., Krebs, K., Watson, C., & Cuccurullo, L. J.** (2022, May). *Using data to work with leadership and teams.* Presented at the 2022 National Mentor Conference, Virtual.
7. **Barnes, S. M., Borges, L. M., Walser, R. D., & Bahraini, N. H.** (2021, November). *ACT for life: Using acceptance and commitment therapy to prevent suicide and build meaningful lives* [Webinar]. Presentation for the Association of Behavioral and Cognitive Therapies.
8. **Becket-Davenport, C. M.** (2022, January). *Mobile mental health apps for self-care* [Webinar]. Presented for VA Clinical Informatics.
9. **Becket-Davenport, C. M.** (2022, March). *Stay Quit Coach and other tools for smoking cessation* [Webinar]. Presented for the Office of Connected Care Discussion Series.
10. **Becket-Davenport, C. M.** (2022, May). *Recognizing and responding to employee mental health needs* [Webinar]. Presented to Department of Homeland Security.
11. **Becket-Davenport, C. M.** (2022, May). *VA mental health apps for wellness and recovery* [Webinar]. Presented for the National Mental Health Recovery & Wellness webinar series.
12. **Becket-Davenport, C. M.** (2022, September). *Incorporating VA mental health applications into care* [Webinar]. Presented to Readjustment Counseling Service Grand Rounds.
13. **Becket-Davenport, C. M., & Bosch, J. O.** (2021, October). *Mental health apps for self-care* [Webinar]. Presented for the VHA Procurement Office.
14. **Becket-Davenport, C. M., Bosch, J. O., McGee-Vincent, P., Juhasz, K. M., & Jamison, A. L.** (2021, December). *VA Mobile Mental Health Apps* [Webinar]. Presentation at the Mobile Mental Health Conference, Virtual.

15. **Bippart, V., McCarthy, E., & Hamblen, J. L.** (2022, February). *AboutFace: PTSD treatment can turn your life around - a peer education campaign from the National Center for PTSD* [Webinar]. Tech into Care Series.
16. **Bippart, V., McCarthy, E., & Hamblen, J. L.** (2022, March). *AboutFace: PTSD treatment can turn your life around - a peer education campaign from the National Center for PTSD* [Webinar]. PTSD Consultation Lecture Series.
17. **Bosch, J. O.** (2022, March). *Integrating mobile mental health apps into care* [Webinar]. Mental Health Grand Rounds: Overton VA Medical Center.
18. **Bosch, J. O.** (2022, May). *Mental health in May* [Webinar]. Connected Care Discussion Series: VHA Office of Connected Care.
19. **Bosch, J. O.** (2022, September). *Mental Health Apps Overview* [Webinar]. VISN 8 InnoVAtion Showcase: Suicide Prevention.
20. **Bosch, J. O., & Becket-Davenport, C. M.** (2022, April). *Clinical integration of mobile mental health apps into psychotherapy* [Webinar]. Presented for the VA Central Texas HCS MHBM Training Day 2022.
21. **Bosch, J. O., & Becket-Davenport, C. M.** (2022, April). *Integration of mobile mental health apps across the continuum of care* [Webinar]. VA Central Texas HCS MHBM Training Day 2022.
22. **Bosch, J. O., & Becket-Davenport, C. M.** (2022, August). *Meet them where they are: Hands-on skills for using mobile apps to support mental health*. Presentation at the American Psychological Association, Minneapolis, MN.
23. **Bosch, J. O., & Walsh, N.** (2022, June). *Integration of Mobile Mental Health Apps Along the Continuum of Care* [Webinar]. Santa Barbara County Psychological Association.
24. **Bovin, M. J.** (2022, January). *PTSD assessment: What, how, when and why*. Mental Health Grand Rounds. Harvard Medical School, Department of Psychiatry, Boston, MA.
25. **Cuccurullo, L. J., & Matteo, R.** (2022, July). *Supporting those you love with PTSD*. Presentation to Voices Center for Resilience, Virtual.
26. **Cuccurullo, L. J., & Matteo, R.** (2022, June). *Understanding PTSD treatment* [Webinar]. Presentation to Voices Center for Resilience, Virtual.
27. **Cuccurullo, L. J., & Matteo, R.** (2022, June). *What is PTSD?* [Webinar]. Presentation to Voices Center for Resilience, Virtual.
28. Decker, S. E., Matthieu, M. M., **Smith, B. N.**, & Landes, S. J. (2021, November). Facilitators to dialectical behavior therapy skills groups in the Veterans Health Administration. In M. Harned (Chair), *Implementing dialectical behavior therapy in the Department of Veterans Affairs*. Challenges and successes symposium, National Harbor, MD.
29. **Esterman, M.** (2021, December). *Sustained attention: Consequences for age-related health and functioning* [Webinar]. Presentation at the Mobility and Falls Center Meeting, Marcus Institute for Aging Research, Hebrew Senior Life, Virtual.
30. **Galovski, T. E.** (2021, October). *Enhancing approaches to PTSD care to achieve optimal outcomes* [Webinar]. Orama Institute for Mental Health and Well-Being at University of Flinders, Adelaide, Australia.
31. **Galovski, T. E.** (2021, October). *The importance of social support in veterans' well-being and mental health* [Webinar]. Presented to Move United.
32. **Galovski, T. E.** (2022, February). *Appreciating common factors while administering manualized therapy: Complimentary or mutually exclusive?* [Webinar]. Clinical Grand Rounds, Ryerson University.
33. **Galovski, T. E.** (2022, June). *Voices of nexus: The climate of trauma* [Webinar]. Nexus podcast series.
34. **Galovski, T. E.** (2022, March). *Treating PTSD with a personalized approach to an evidence-based therapy* [Webinar]. University of Bath and Royal United Hospitals.
35. **Galovski, T. E.** (2022, May). *Coping with stress, trauma, and loss* [Webinar]. The Sandberg Goldberg Bernthal Family Foundation.
36. Gross, D., **Niles, B. L.**, Unger, W. S., & Wattenberg, M. (2022, March). *Embracing today; Present Centered Group Therapy*. Workshop presented at the annual meeting of the American Group Psychotherapy Association, Virtual.

37. Hall-Clark, B., **Cuccurullo, L. J.**, & **Watson, P.** (2022, June). *Too tired to care: How providers can recognize and overcome compassion fatigue*. Association of VA Leadership Conference, San Antonio, TX.
38. **Harper, K. L.**, Hinds, Z., & **Livingston, N.** (2022). *Research and practice at the intersection of trauma and minority stress among sexual and gender minority individuals*. Invited lecture, National Center for PTSD, Women's Health Sciences Division, Boston, MA.
39. Hessinger, J., **Larsen, S.**, Larson, E., Melka, S., & Smith, H. (2022, June). "Paper in a day": A model to encourage psychology collaboration and participation in research/program evaluation. Poster presented at the 2022 VA Psychology Leadership Conference, San Antonio, TX.
40. Holloway, K. M., & **Cuccurullo, L. J.** (2022, July). *Assessing military and veteran clients for trauma and posttraumatic stress disorder* [Webinar].
41. Holloway, K. M., & **Cuccurullo, L. J.** (2022, March). *Assessing military and veteran clients for trauma and posttraumatic stress disorder* [Webinar].
42. **Iverson, K. M.**, & Knetig, J. (2022, January). *Intimate partner violence among women veterans: New research and clinical practices*. VA Women's Mental Health Monthly Teleconference, Virtual.
43. Joyce, J., Steiger, S., Friedman, N., Allen, S., & **Cuccurullo, L. J.** (2022, May). *Strategies to engage and support mentees and teams*. Presented at the 2022 National Mentor Conference, Virtual.
44. **Juhasz, K. M.** (2022, February). *Mobile apps to support self-care and relationships* [Webinar]. Support the Ones You Love campaign for the Department of Homeland Security, Customs and Border Patrol, & US Citizenship and Immigration Services.
45. **Keane, T. M.** (2021, October). *The remarkable past, present and future of the study of psychological trauma*. San Antonio Combat Related PTSD Conference, San Antonio, TX.
46. **Keane, T. M.** (2022, March). *Current models of PTSD treatment*. Boston Vietnam Veteran Recognition Ceremony, Charlestown, MA.
47. **Keane, T. M.** (2022, March). *Current models of PTSD treatment*. Presented at Boston College School of Nursing, Chestnut Hill, MA.
48. **Keane, T. M.** (2022, March). *PTSD in military and veteran populations*. Harvard Medical School Conference, Virtual.
49. **Livingston, N.** (2022, April). *LGBTQ+ disparities in addiction*. Presentation at the VA Pittsburgh Healthcare System's WPH/VAPHS Addiction Psychiatry Fellowship Didactic Series, Virtual.
50. **Livingston, N.** (2022, January). *Research and practice at the intersection of trauma and minority stress among sexual and gender minority individuals*. Presentation at the VA Palo Alto Healthcare System, Virtual.
51. **Livingston, N.** (2022, January). *Technology-based interventions to improve prevention and treatment of substance use and posttraumatic stress disorder*. Presentation at the Citrus Health Network/Florida International University, Herbert Wertheim College of Medicine's Psychiatry, Behavioral Health, & Psychology Integrated Grand Rounds, Virtual.
52. **Livingston, N.** (2022, March). *VA interprofessional advanced addiction treatment fellowship conference* [Webinar]. VA Interprofessional Advanced Addiction Treatment Fellowship Conference.
53. **McCarthy, E.** (2021, October). *Sleep as a privilege: Delivering cognitive behavioral therapy for insomnia (CBT-I)* [Webinar]. Veterans Health Administration National CBT-I Advanced Quarterly Didactic.
54. **McCarthy, E.**, & **Cuccurullo, L. J.** (2022, March). *We can help! National Center for PTSD resources and consultation*. Presentation to SonderMind, Virtual.
55. **McCarthy, E.**, DeViva, J. C., Heckler, A., Martin, J., DeBeer, C., & Runnals, J. (2021, October). *Cognitive behavioral therapy for insomnia consultant training* [Webinar]. Veterans Health Administration National Evidence-Based Psychotherapy Rollout.
56. **McCarthy, E.**, DeViva, J. C., Hekler, A., Martin, J., DeBeer, C., & Runnals, J. (2022, January). *Cognitive behavioral therapy for insomnia: Provider training* [Webinar]. Veterans Health Administration National Evidence-Based Psychotherapy Rollout training.

57. **Meshberg-Cohen, S.** (2022, March). *Bringing evidence-based trauma care into substance use disorder (SUD) treatment*. Invited presentation at The VCU Opioid ECHO Series, Richmond, VA.
58. **Meshberg-Cohen, S., & Wolkowicz, N. R.** (2021, November). *Addressing posttraumatic stress disorder within SUD specialty care: Written Exposure Therapy (WET)*. Invited presentation at The National Mental Health & Suicide Prevention ECHO Series of the US Department of Veterans Affairs, Office of Rural Health, West Haven, CT.
59. **Pineles, S. L.** (2022, July). *Gender differences in recovery from PTSD* [Webinar]. Presented for the VISN2 MIRECC Webinar Series.
60. **Pless Kaiser, A.** (2022, January). *Understanding late life PTSD* [Webinar]. Presentation for the Geriatric Scholars webinar series, Virtual.
61. **Romero, E., & Cuccurullo, L. J.** (2021, December). *Best practices in PTSD care: How to optimize recovery after trauma* [Webinar]. Presentation to Shephard Pratt Health Care, Virtual.
62. **Rosenfeld, E. A.** (2021, November). *Spreading the word: How graduate students can leverage social media for #SciComm and professional development*. Member of panel discussion at the Association for Behavioral and Cognitive Therapies Annual Conference, Virtual.
63. **Rosenfeld, E. A.** (2022, June). *Implementing PTSD interventions for transgender, gender diverse, and non-binary clients* [Webinar]. Presented at the VAPAHCS Clinical Psychology Internship Training Program Didactic Seminar Series. Palo Alto, CA.
64. **Schnurr, P. P.** (2021, October). *An update on the treatment of PTSD*. Research Advisory Committee on Veterans Readjustment, Department of Veterans Affairs, Virtual.
65. **Schnurr, P. P.** (2022, March). *Grand rounds: An update on psychotherapy for PTSD* [Webinar]. Geisel School of Medicine at Dartmouth.
66. **Schnurr, P. P., & Norman, S. B.** (2022, June). *PTSD: Posttraumatic stress disorder*. Meta, Virtual.
67. **Skidmore, C., & Street, A. E.** (2022, May). *Beyond MST: Using the mobile app to support individuals who experienced military sexual trauma* [Webinar]. Invited address for the National Community Based Outpatient Care Mental Health Grand Rounds, Department of Veterans Affairs.
68. **Sloan, D. M.** (2021, October). *Implementing Written Exposure Therapy* [Webinar]. Workshop presented for the Children and Family Services.
69. **Sloan, D. M.** (2022, February). *Delivering Written Exposure Therapy to clients diagnosed with PTSD*. Workshop presentation for Philadelphia Cognitive Behavioral Association, Philadelphia, PA.
70. **Sloan, D. M.** (2022, February). *Development and efficacy data for Written Exposure Therapy for PTSD*. Presentation for clinical brown bag series, Department of Psychology, University of Southern California, Los Angeles, CA, Virtual.
71. **Sloan, D. M.** (2022, July). *Written Exposure Therapy for PTSD: A brief treatment approach*. Invited presentation to Madison VA Medical Center, Madison, WI.
72. **Sloan, D. M.** (2022, March). *Written Exposure Therapy for PTSD: A brief PTSD treatment approach* [Webinar]. Grand Rounds, Department of Psychiatry, Medical University of South Carolina.
73. **Street, A. E.** (2021, December). *WoVeN, the Women Veterans Network: An innovative peer support program for women veterans* [Webinar]. Invited address for the Office of Women's Health, Veterans Health Administration, Women's Health National Call.
74. **Street, A. E.** (2021, October). *Providing care for survivors of military sexual trauma* [Webinar]. Invited keynote speaker for the Canadian Institute for Military and Veteran Health Research (CIMVHR) Annual Military and Veteran Health Research Forum.
75. **Street, A. E.** (2022, March). *Sexual assault and PTSD* [Webinar]. Invited address for Posttraumatic Stress and Related Disorders Conference, sponsored by Harvard Medical School and Massachusetts General Hospital, Virtual.
76. **Taft, C. T.** (2021, November). *Strength at Home Couples program training*. Presented at Invited half-day training at Veterans Health Administration, Virtual.

77. **Taft, C. T.** (2021, November). *Strength at Home: Reviewing the evidence for a trauma informed IPV intervention*. Presentation at Ann Arbor VA Grand Rounds, Virtual.
78. **Taft, C. T.** (2021, October). *Strength at Home: A trauma informed intervention to prevent violence in veterans*. Presented at the Rocky Mountain Intimate Partner Violence Summit, Virtual.
79. **Taft, C. T.** (2021, October). *Strength at Home: A trauma-informed IPV intervention*. Presentation at the Association of Domestic Violence Intervention Providers, Virtual.
80. **Taft, C. T.** (2022, January). *Reviewing the evidence for a trauma informed IPV intervention*. Presented at VA Central Ohio HCS's Mental Health Department's EBP meeting, Virtual.
81. **Thompson-Hollands, J.** (2022, February). *The role of family members in PTSD treatment* [Webinar]. Presented for the PTSD Consultation Program Monthly Lecture. Retrieved from [https://www.ptsd.va.gov/professional/consult/lecture\\_series.asp](https://www.ptsd.va.gov/professional/consult/lecture_series.asp).
82. **Wielgosz, J.** (2022, May). *What can VA mobile mental health apps do for you?* [Webinar]. VA Palo Alto Healthcare System Research Week.
83. **Zimmerman, L. E.** (2022, March). *Modeling to learn: Test. Don't guess* [Webinar]. Presentation on the Office of Mental Health and Suicide Prevention Mental Health Access call. Veterans Health Administration.



# Appendix H:

## Editorial Board Activities

Activity	Board Member(s)
Administration and Policy in Mental Health Services and Mental Health Services Research	Wiltsey Stirman
Annals of LGBTQ Public and Population Health	Livingston
Asian Biomedicine (Research, Reviews and News)	Gelernter
The Behavior Therapist	Wiltsey Stirman (Associate Editor)
Behavior Therapy	Thompson-Hollands, Wiltsey Stirman
Behavioral Medicine	Livingston (Associate Editor)
Behaviour Research and Therapy	Sloan
Biological Psychiatry	Gelernter, Krystal (Editor)
British Journal of Psychiatry Open	Cloitre (Associate Editor)
Cerebral Cortex	Esterman (Associate Editor)
Chinese Journal of Psychology	Keane
Chronic Stress	Averill (Deputy Editor), Esterlis, Krystal (Associate Editor), Pietrzak, Woodward
Clinical Psychology Review	Pineles
Clinical Psychology: Science and Practice	Marx
Cognitive and Behavioral Practice	Livingston, McLean (Associate Editor), Norman, Wachen
Contemporary Clinical Trials	McLean, Schnurr, Wachen (Associate Editor)
Depression and Anxiety	Holtzheimer, Schnurr, Tiet, Wolf
Eating Behaviors	Mitchell (Associate Editor)
European Journal of Psychotraumatology	Cloitre (Associate Editor), Pineles
Frontiers in Neurology – Multiple Sclerosis and Neuroimmunology	DiSano, Noller
Frontiers in Psychiatry	Whitworth (Guest Associate Editor)
International Journal of Emergency Mental Health	Keane
Journal of Anxiety Disorders	McLean (Associate Editor), Pietrzak
Journal of Clinical Psychology	Nazem (Associate Editor), Sloan

Activity	Board Member(s)
Journal of Consulting and Clinical Psychology	Marx, Sloan, Taft
Journal of Contemporary Psychotherapy	Sloan
Journal of Family Psychology	Taft
Journal of Family Violence	Taft
Journal of General Internal Medicine	Galovski (Guest Editor)
Journal of Gerontology: Medical Sciences	Esterman (Editor)
Journal of Neuroscience	Levy (Associate Editor)
Journal of Obsessive-Compulsive and Related Disorders	Thompson-Hollands
Journal of Psychopathology and Clinical Science	Miller (Associate Editor), Wolf
Journal of Trauma and Dissociation	Barlow, Carlson, Marx
Journal of Traumatic Stress	Bovin, Galovski (Associate Editor), Marx, Miller, McLean, Morland, Sloan (Editor), Larsen, Lee, D., Thompson-Hollands, Wolf
Neuropsychology	Vasterling
Neuropsychopharmacology	Gelernter (Associate Editor)
Psychiatric Genetics	Gelernter
Psychological Assessment	Mitchell, Vasterling
Psychological Services	Norman
Psychological Trauma: Theory, Research, Practice and Policy	Barlow, Carlson, Keane, Larsen, Marx, Miller, Smith, Stanley, Vogt, Wachen
Psychology Injury and Law	Pietrzak, Wolf
Psychosomatic Medicine	Lee, L., Sloan
Suicide and Life-Threatening Behavior	Stanley
Trauma, Violence & Abuse	Keane

**Executive Division**

VA Medical Center (116D)  
215 North Main Street  
White River Junction, VT 05009

**Behavioral Science Division**

VA Boston Healthcare System (116B-2)  
150 South Huntington Avenue  
Boston, MA 02130

**Clinical Neurosciences Division**

Psychiatry Service (116A)  
VA Medical Center  
950 Campbell Avenue  
West Haven, CT 06516

**Dissemination and Training Division**

VA Palo Alto Health Care System  
Building 334-PTSD  
795 Willow Road  
Menlo Park, CA 94025

**Evaluation Division (NEPEC)**

VA Connecticut Healthcare System (182)  
950 Campbell Avenue  
West Haven, CT 06516

**Women's Health Sciences Division**

VA Boston Healthcare System (116B-3)  
150 South Huntington Avenue  
Boston, MA 02130

